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Chapter 1 
General overview 
7 
Percutaneous coronary intervention is widely used in the treatment of coronaty 
artery disease but currently limited by restenosis in a proportion of cases. We 
investigated the restenosis problem using complimentary experimental, clinical 
and epidemiological approaches. 
In the first part of this thesis laboratory models and techniques are evaluated 
which may provide an insight into the undelying pathological processes involved. 
For example extracellular matrix synthesis by vascular smooth muscle cells 
(vsmc) may be an important pathophysiological mechanism for restenosis. In 
chapter 2 we assessed the ability of vsmc to produce extracellular matrix in-vitro 
using vsmc cultivated from primary and restenotic tissue samples obtained, in-
vivo, by directional coronary atherectomy. In chapter 3 we investigated the rela-
tionship between the clinical and histopathological substrate of tissue retrieved 
during directional coronary atherectomy and the proliferative and migratory 
potential of smooth muscle cells as judged from successful outgrowth during cell 
culture. Cell culture however, does not take into account the normal anatomical 
relationships of the different cellular components of the vessel wall or the cell to 
cell interactions which may modulate growth. Therefore in Chapter 4 we develo-
ped an organ culture of human coronary artery subjected to balloon angioplasty in 
order to investigate the cellular and molecular basis of intimal proliferation in a 
preparation which maintained the anatomical relationships of the vessel wall. In 
chapter 5 we used a serum free adaptation of the organ culture technique in con-
junction with an in vivo porcine model of restenosis to assess whether the release 
of growth factors from cells intrinsic to the vessel wall is implicated in the deve-
lopment of restenosis. One of the ways it is hoped to reduce restenosis is with 
local drug delivery, perhaps with growth factor antagonists, by perfusion catheters. 
Pressure mediated trauma and duration of balloon inflation are however key limi-
tations of these devices. In Chapter 6 we evaluated a new delivery catheter which 
promises to overcome both these restrictions. 
Although experimental models can provide insight into the pathophysiology of 
restenosis they can never however replace the clinical situation. Intracoronary 
ultrasound imaging allows direct visualisation of the vessel wall in vivo. In the 
second part of this thesis we looked at what role this may play in our understan-
ding of the pathophysiological mechanisms involved in the mechanism of acute 
luminal gain and subsequent restenosis after coronary intervention. Chapter 7 
provides an introduction and a succinct overview of the subject whilst chapter 8 
compares the luminal dimensions measured by intra coronary ultrasound with the 
hitherto gold standard, quantitative coronary angiography. Chapter 9 summarises 
our initial clinical experience with a new device combining intravascular ultra-
sound imaging with balloon angioplasty thus allowing on line imaging during the 
procedure and obviating the need for repeated catheter exchanges. In chapter 10 
we used intracoronaty ultrasound to assess the influence of vascular remodeling 
on the mechanisms of acute luminal gain and long term restenosis following both 
coronary balloon angioplasty and directional atherectomy. 
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In the third part of this thesis data from four major European and American trials 
were used to examine the influence of clinical angiographic and procedural varia-
bles on subsequent restenosis. Chapter II examines the role of cholesterol and 
cholesterol subfractions whilst chapter 12 examines the influence of past and pre-
sent smoking habits on post angioplasty restenosis. Chapter 13 expands on some 
of our previous findings and assessess the role of local t1n'ombus formation and 
incorporation on subsequent restenosis. Chapter 14 looks as total occlusion and 
what influence these lesions may have on subsequent restenosis whilst chapter 15 
examines the role of favourable arterial remodeling on outcome after coronary 
angioplasty. Chapter 16 reviews critically the large multicentre trials on which the 
previous studies were based and defines ways in which some of their limitations 
may be minimised in future shldies. 
In the final part of tltis thesis we look at coronary stenting, the only technique 
demonstrated to date to reduce restenosis and sUlrnnarise the current and fuhlre 
stent technology available to the interventional cardiologist in his fight against 
restenosis. 
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Chapter 2 
Increased extracellular matrix synthesis by smooth muscle 
cells obtained from in-vivo restenotic lesions by directional 
coronary atherectomy 
Vio\aris AG, de Jong M, MacLeod DC, Umans VA, Vcrdouw PD, 
Serruys PW. 
Am Heart J 1996; 131 (3): 613-615 
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Increased extracellular matrix synthesis 
by smooth-muscle cells obtained from 
in vivo restenotlc lesions by directional 
coronary atherectomy 
Andonis G. Violaris, 10m, MRCP (UK),a 
Marcel de Jong, B Eng,b 
Donald C. MacU!od, PhD, :MRCP (UK),a 
Victor A. Umans, 1ID, PhD,a 
Pieter D. Verdollw, PhD,b and 
Patrick W. Serruys, 1ID, PhOa 
Rotterdam, The Netherlands 
Coronary angiopiasty continues to be limited by a 30% 
rostenosis rate within 6 months. Postmortem histopatho-
logic studies suggest that the intimally directed migration 
and proliferation of vascular smooth-mu.scle cells (VSMC) 
may playa critical role in this problem. These studies, 
however, can provide only limited static infonnation re-
garding a specific moment in the disease process. To O\'ef-
C{)me this limitation and to look at the underlying mecha-
nisms involved, we used directional coronary atherectomy 
to percutaneously retrieve tissue from patients with clin-
ically and angiographically documented coronary artery 
disease and examined the hypothesis that VSl\IO cultured 
from restenotic lesions differ in extracellular matrix syn-
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thesis from primary atherosclerotic cells. Our experimen-
tal strategy was first to culture the tissue segment. and 
confinn the identity of the explant cells and then to com-
pare extracellular matrix synthesis between primary and 
restenotic cells. 
Methods. A total of98 in vivo plaque spedmens were ob-
tained from 98 patients undergoing dire<:tional coronary 
atherectomy with a previously described standard tech-
nique.! Tissue specimens were cultured with standard ex-
plant. techniques. Smooth-muscle cell outgrowth was as-
sessed by light microscopy with morphologic criteria rein-
forced by eleetron microscopy and positive immunostaining 
against specific smooth-muscle cell a-actin. E;rlracellular 
matrix synthesis was assessed by studying the synthosis 
of collagen and sulfated aminogiycans, the principal com-
ponents ofthe extracellular matrix. To determine collagen 
synthesis growth, arrested cells of passage 2 to 4 were in-
cubated for 48 hours at 370 0 in culture medium contain-
ing 2 J.1mollL ascorbic acid and 10 J.1CLml-1 3H-proline 
(speeific activity 23 mOi.mg-l). To determine sulfated gIy-
cosaminoglycans synthesis growth, arrested cells were 
incubated for 48 hours at 370 0 in culture medium 
containing 0.5 ml 35'S-sulfate (speeific activity 20 mOi-
.mg-1). Subsequent analyses were performed with previ-
ously described techniques.! Measurements are expressed 
as mean ± SEM. Mean values were compared by the Stu-
dent's t test for unpaired data. Data were considered sig-
nificant if p < 0.05. 
Results. Initial cell outgrowth and successful secondary 
culture (up t.o seven serial passages) was achieved in 11 
patients, 7 with primary and 4 ,vith restenotic lesions. 
Cells started to grow out from explants after 4 to 8 days 
(Fig. 1), and confluent multilayer primary cultures from 
the 11 patients were established after 4 to 6 weeks. Sub-
confluent cultures took the form of a network ofmultilay-
erad elongated cells, whereas in confluent multilayer 
structures the cells appeared as whorls, producing the "hill 
and valley" pattern typical of vascular smooth-muscle cells 
in culture (Fig. 1). Immunostaining ofthe cells for o:-dctin 
was positive and confirmed them to be of smooth-muscle 
origin. Electron microscopy revealed features consistent 
with the synthetic phenotype. Collagen synthesis, re-
fleeted by the incorporation of3H-proline, was significantly 
greater for cells of restenotic than primary origin 
(0.034 ±. 0.002 vs 0.024 ±. 0.001 nmol [3m-proline. J.1g to-
tal cell protein-I, n = ll,p < 0.05) (Fig. 1). Similarly, pro-
duction of sulfated aminoglycans as assessed by the incor-
poration of 35S-sulfate was significantly greater for rest-
enotic than primary ceIls (7.49 ±. 0.58 vs 5.11 ± 0.48n'mol 
[3HJ-sulphate· J.1g total cell protein-I, n = 11, p < 0.05) 
(Fig. 1). 
Commenis. Our study has demonstrated that restenotic 
cells synthesize significantly more collagen and sulfated 
aminoglycans than do primary cells, suggesting that ex-
tracellular matrix synthesis may playa significant role in 
postangioplasty restenosis. This finding is in contrast to 
our previous study,! in which we found that restenotic and 
primary cells synthesized more extracellular matrix pro-
Fig. 1. Upper left panel, Fragment of retrieved atherectomy tissue in culture showing dense population 
ofVSMC migrating out of explant (Original magnification x60). Upper right panel, "Hill and valley" pat-
tern typical of vascular smooth·muscle cells in culture. Lol/.!er left panel, Production of extracellular rna· 
trix collagen. Lower right panel, Production of extracellular matrix sulfated aminoglycans. *p < 0.05. 
tein than did human umbilical vein cells, but no differences 
were seen between the two. This finding is likely to have 
occurred because of the significantly higher proliferation 
rate in restenotic cells during those experiments. In this 
study, in which we looked for differences in extracellular 
matrix synthesis during growth arrest, we found that re-
stenotic cells synthesize significantly more extracellular 
matrix than do primary cells. 
Be<:ause the difference in extracellular matrix synthesis 
between primary and restenotic cell lines occurred under 
identical culture conditions, we believe that the secretory 
behavior of the restenotic cells in vitro reflects a previous 
phenomenon of phenotypic modulation and selection in 
vivo rather than some effect of the culture process itself.2 
In support of this belief are histopathologic studies that 
suggest that smooth-muscle cells in both primary athero· 
sclerotic and restenotic lesions are frequently of the syn-
thetic phenotype. Additionally, coronary smooth·muscle 
cells in tissue excised at atherectomy have been recently 
shown to express messenger RNA for nonmuscle myosin 
heavy chain, which is associated with the syntheticsmooth-
muscle cell phenotype.3 
Our data suggest that restenotic cells are fundamentally 
different from primary atherosclerotic cells in the produc-
tion of extracellular matrix, in keeping with previous 
studies suggesting that restenotic cells differ from primary 
ce~s in teons of their migratory activity,4 growth regula-
tion,l and motility.5 This finding may be a reflection ofa 
more spedalized function of the VSMC situated in the res-
tenotic lesion, which may have been activated as a result 
of the angioplasty procedure itselfin the response to injury 
hypothesis. Alternatively, it may signify a selected popu-
lation of already activated VSMC in lesions that have sub-
sequently undergone restenosis. The small numbers in-
volyed preclude us from commenting on ,yhich of the two 
mechanisms is most likely, but both are likely to involve 
the induction of growth factors such as traruforming 
growth factor·p, the expression of which has been shown 
to be increased in restenotic lesions.s This finding is in 
keeping with our data and would suggest that the in-
creased expression of transforming growth factor-p may 
result in increased production of extracellular matrix. This 
study has demonstrated that coronary smooth-muscle cells 
obtained from in vivo restenotic lesions synthesize signif-
icantly more extracellular matrix than do cells from 
primary lesions, suggesting that increased extracellular 
matrix production may playa fundamental role in rest-
Mosis after angioplasty. 
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PATHOPHYSIOLOGY AND NATURAL HISTORY 
Clinical and histological determinants of 
smooth-muscle cell outgrowth in 
cultured atherectomy specimens: 
Importance of thrombus organization 
Javier Escaned, MD, Marcel de Jong*, SEng, 
Andonis G. Violaris, MRCP, Donald C. Macleod, MRCP, 
Victor A. Umans, MD, Robert J. van Suylent , MD, 
Pim J. de Feyter, MD, PhD, Pieter D. Verdouw*, PhD, 
and Patrick W. Serruys, MD, PhD 
Background: Coronary alhereclomy provides a unique opportunity 10 obtain plaque 
tissue from a wide variety of clinical syndromes. We Investigated the relation between 
the clinical status and histopathological substrate of tissue retrieved during directional 
coronary alherectomy and the proliferative and migratory potential of smooth-muscle 
cells judged from successful outgrowth during cell culture. 
Methods: After directional coronary alhereclomy, tissue samples were examined 
macroscopIcally, divided Into two equal pieces, and separately subjected to eel[ culture 
and histopathological study. Cell culture was performed using an explant technique. 
In-vitro smooth-muscle cell outgrowth was related to clinical and hIstologIcal variables. 
Results: Atherosclerotic tissue was obtained from 98 consecutive athereclomy 
procedures. HIstological examInation revealed a broad spectrum of appearances, 
ranging from complex atheroma containing dense fibrous tissue, calcium deposits, 
macrophages, and necrotic debris to neointimal proliferation and organized thrombI. 
Smooth-muscle cell outgrowth was obsel'Ved in 43 of the 98 samples (44%). Although 
not affected by any of the clinical variables, cell outgrowth was influenced by histological 
variables, In particular the presence of organizing thrombI. Outgrowth was successful 
in eight out of 10 samples with thrombus (80%) and In only 35 out of 88 (40%) without 
(P=O.03). 
Conclusion: The presence of organizing thrombI in the retrieved tissue facilitates 
smooth-muscle ce!! outgrowth and suggests an enhanced proliferative and mIgratory 
potential. These findings maybe relevant to the understanding of neolntimal proliferatJon 
in coronary syndromes where mural thrombosis Is likely to occur. 
Coronary Artery Disease 1993, 4:863-890 
Keywords: atherosclerosis, directional coronary atherectomy, Intimal prOliferation, 
thrombus organization, smooth muscle, cell culture 
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Smooth-muscle cell proliferation plays a key role in 
the development of typical and accelerated forms 
of atherosclerosis [IJ. Cell culture of atheromatous 
tissue retrieved during directional coronary atherec-
tomy allows us to study smooth-muscle cells from 
the pathological substrate of a variety of human 
coronary syndromes. In shtdying the palhobio!ogy 
of coronary atheroma, the use of coronary atherec-
tomy specimens for cell culture offers several dis-
tinct methodological advantages over other sources 
of atheromatous material, such as peripheral aihe-
reclomy, carotid endarterectomy, or animal mod-
els of atherosclerosis. Vascular smooth-muscle cells 
are embryologically derived from local mesoderm 
[2.3J. Those found in the coronary arteries are likely 
to have biological differences from those located 
in other vessels. likewise, the development of the 
atheromatous plaque is strongly affected by local 
factors [41 that may influence cell populations, extra-
cellular matrix composition, and plaque architecture. 
The use of human coronary material also makes it 
possible to avoid some of the pitfalls associated with 
animal models of atherosclerosis [5,6]. 
Nevertheless, cell culture studies using human coro-
nary smooth-muscle cells have some technical lim-
itations. Once in culture, these cells undergo a 
progressive phenotypic modulation that is time-
dependent and enhanced by successive cell pas-
sages [7-9]. This process may facilitate the selection 
of cell clones with a higher proliferative capacity. 
FurthemlOre, although isolated cell studies provide 
information regarding cellular function and patho-
physiological conditions, their extrapolation to the 
clinical situation is limited because they ignore the 
complex cell-cell and cell-extracellular-matrix inter-
actions that modulate smooth-muscle cell growth ill 
vivo [lO], 
In order to minimize these limitations, in the 
present study we used an explant culture technique 
[11,12], This maintains a representative section of the 
atherosclerotic plaque in the culture medium, thus 
retaining the intrinsic distribution and anatomical 
relations of the participating cells, cell-cell interac-
tions, the correct chemical configuration of the ex-
tracellular matrix, and the general in-vivo milieu of 
the atherosclerotic plaque, Only coronary material 
was used. The initial outgrowth of smooth·muscle 
cells was then used as a surrogate index for their 
in-vivo migratory and proliferative potential while 
still under the influence of other histological and 
humoral variables that were present in the athero-
matous plaque at the time of atherectomy. 
Methods 
Percutaneous diredional coronary atherectomy was per-
formed on 98 lesions in 98 patients. Informed consent was 
obtained from all patients before the procedUre, in accor-
dance with the protocol approved by the Thoraxcenter 
Institutional Review Board. Atherectomy was performed 
using Simpson's Atherocath (Devices for Cardiovascular 
Intervention, Redwood City, CA, USA) and a conven-
tional technique [t3}. Multiple cuts in different sectors of 
the vessel were routinely performed. Under sterile condi-
tions, the specimens were removed from the housing of 
the atherocatheter, washed with 0.9% saline, and placed 
in Ml99 HEPES buffered culture medium (Gibeo Labo· 
ratories, USA) with antibiotics (lOOrn/ml penicillin and 
O.tmg/ml streptomycin). They were immediately trans-
ferred to the laboratory where they were flushed with 
fresh culture medium and examined with a dissecting 
microscope. A representative section was then fixed in 
3.6% buffered formalin for histopathological examination 
and the remainder placed in culture. 
Clinical variables 
A number of clinical variables were recorded for each pa-
tient. These included age, sex, previous myocardial infarc-
tion, stable or unstable angina pectoris, previous coronary 
intervention, and risk factors for coronary artery disease 
(hypercholesterolaemia, diabetes meilltus, cigarette smok-
ing, hypertension, and family history of coronary artery 
disease). Unstable angina was defined as continuous or 
intermittent chest pain at rest requiring hospitalization, as-
sociated with electrocardiographic evidence of myocardial 
ischaemia and no increase in cardiac enzyme levels. 
Tissue analysis 
Specimens for histopathological study were routinely pro-
cessed for light microscopy and stained with haemalo-
xylin-azophloxin and Verhoeff-van Giesson stains. All 
specimens were reviewed independently by two ob-
servers, who were blinded to the clinical data. If they 
disagreed, the opinion of a third pathologist was sought 
and a consensus reached. 
For the analysis of intimal constituents, the re<:ommenda-
tions of the American Heart Association Medical/Scientific 
statement on the definitions of the intima of human ar-
teries and of its atherosclerosis-prone regions were fol-
lowed [141, Fibrous tissue was classified as 'dense' when 
composed of acellular or poorly cellular connective tis· 
sue formed predominantly by dense collagen, and 'loose' 
when the tissue fragments showed moderate cellularity 
and collagen bundles separated by accumulations of ex-
tracellular matrix. Fibromuscular hyperplasia was defined 
as fibrous connective tissue showing a random orien· 
tation of spindle-shaped and stellate cells embedded in 
abundant extracellular matrix. Thrombus was identified 
as amorphous material, often in close apposition with 
atheromatous material, and frequently showing collec-
tions of leukocytes between layers of fibrin. Discrimina· 
tion between fibrin and dense collagen was achieved us-
ing Verhoefl-van Giesson staining. The thrombus was re-
garded as organizing when infiltrated by cellular elements 
such as smooth·muscle cells or fibroblasts. Cholesterol 
crystal defts, necrotic debris, and calcium deposits were 
recorded independently. The presence of macrophages 
was recorded only when these fomled dusters or when 
they were pr('5ent in unusually high numbers. Medial 
tissue was identified on the basis of ,1 parallel arrange-
ment of smooth·muscle cells, embedded in collagen, and 
frequently associated with a fragment of the internal or ex· 
ternal elastic lamina. The adventitia was recognized by 
the presenC(! of coarse bundles of dense collagen inter-
mingled with elastin fibres, sometimes in association with 
fragments of the external elastic lamina and media. 
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Cell culture 
The atheromatous tissue was cultured by a cell biolo-
gist (MdJ) blinded to the clinical data. An explant tech-
nique was us«l. Tissue explants were placed on human 
fibronectin-coatoo (lOJlg/cm2) glass cover slips in 2cm2 
wells (Four-well plates, Nunc) and cultured in 300 pi cul-
ture medium IMI99 with NaHCOJ (Gibeo Laboratories) 
supplemented with glutamine, 10% human serum, 10% 
fetal calf St'rum, 100 IV/ml penicillin and 0.1 mg/ml strep-
tomycin, and mixed in a ratio of 1: 1 with conditioned 
medium from established smooth-musdecell lines actively 
growing in our laboratoryl. Cultures were maintained in a 
CO2 incubator at 37'C in a humidified atmosphere equili-
brated with 5% (vol/vol) CO2 in air. The culture mooium 
was changed every 3-4 days_ Smooth-muscle cell out-
growth was identified using inverted light microscopy 
and morphological criteria. These included a characteris-
tic growth pattern of multiple layers of spindJe-shap&l 
or stellate cells showing stress fibres and lameIlipodia 
(Fig. 1). These morphological criteria were reinforced by 
positive immunostaining for smooth-muscle-cell specific 
«-actin (DAKO, Denmark) with human skin fibroblasts as 
negative controls. 
Statistical analysis 
Mean values and standard deviations were calculated for 
all continuous variables. Comparison of mean values was 
made using the tw'o·tailed unpaired t-,test. Discrete vari-
ables were compared using the chi-squared test, and con-
tinuitycorrection was applied when indicated, P<O.05 was 
considered statistically Significant. 
Results 
Clinical 
Of the 98 patients in the study, 49 presented with 
stable and 47 with unstable angina pectoris. The re-
maining two were post-cardiac transplantation pa-
tients with cardiac aUograph vasculopathy (Table 1). 
Twenty-four of the patients had a previous history 
of coronary intervention (14 of balloon angioplasty, 
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Fig. 1. Fragment of retrieved tissue 
examined under phase-contrast mi-
croscopy after 12 days of culture. A 
dense population of cells migrating 
out of the atherectomy explant Is 
evident. These cells fulfil the mor-
phological criteria of myofibrob!asls 
discussed in detail in the text. (Orig-
Inal magnification x 60.) 
six of stent implantation, three of atherectomy proce-
dures, and one of excimer laser angioplasty) and had 
restenosis at the site of this intervention. The mean 
time interval between the previous revasculariza-
tion procedure and the atherectomy was 147±108 
days. The target lesion was located in the left an-
terior descending coronary artery in 62 patients, in 
the circumflex'in 12, in the right coronary in 20, and 
in saphenous vein grafts in four. An average of 6±3 
passes in different directions were made across each 
lesion. 
In the study population, seven patients had a his-
tory of hypercholesterolaemia (serum cholesterol Ie--
vel ~8mmql/dl), 27 had systemic hypertension, 36 
were smokers, and 18 had a family history of coro-
nary artery disease; none of the patients had a his-
tory of diabetes mellitus. None of these risk factors 
appeared to influence smooth-muscle cell outgrowth 
(Table 1). Likewise, none of the other clinical vari-
ables discussed above could be related to enhanced 
cell outgrowth. 
Histological 
Thrombus was presel1t in 10 out of 97 sections ex-
amined, predominantly in unstable angina patients; 
nine out of 49 (18%), compared with one out of 
49 (2%) stable patients, P = 0.019. Some degree of 
organization was present in all of the thrombotic 
specimens examined (Fig. 2). This ranged from the 
presence of endothelial-like cells in lacunar spaces 
or capillaries and the presence of scarce myofibro-
blasts infiltrating the thrombotic mass from the ad-
jacent fibrous tissue, to infiltration by high numbers 
of myofibroblasts with the production of extracellu-
Jar matrix. the thrombotic material appeared to be 
embedded in the fibrocellular tissue, suggesting that 
areas of fibrin and platelets derived from an episode 
of Ihrombosis or plaque haemorrhage were being in-
tegrated into the atheromatous plaque. In four cases, 
Table 1. Clinical variables and outcome of smooth muscle cell culture. 
Successful 
cell cullure 
Clinical variables 
Age (years, mean ±SD) 57±10 
Previous MI 14/43 
Syndrome 
Stable angina 20/49 (41%) 
Unstable angina 23147 (49%) 
Transplant vasculopathy 0/2 
Risk factors fOf CAD 
Male sex 34/43 (79%) 
Hypercholesterolemia 3f39 (8%) 
Hypertension 10/40 (26%) 
Smoking 17/42 (400/0) 
Family history of CAD 8143 (19%) 
Previous intervention 11143 (26%) 
Hislologlcal variables 
Neolntimal hyperplasia 14/30 (47%) 
Thrombus (organizing) 8/10 (800/0) 
Dense fibrous tissue 32fl9 (41%) 
loose fibrous tissue 10/16 (62%) 
Cholesterol defts 4/8 {500/0} 
Calcium deposits 13/27 (48%) 
Necrotic debris 619 (67%) 
Macrophage dusters 7/16 (47%) 
Media 11123 (48%) 
MI, myocardial Infarction; CAD. coronary artery disease. 
this process was seen in conjunction with extensive 
fibromuscular proliferation. 
Neointimal hyperplasia was observed in 31 samples, 
predominantly in restenotic (17 out of 24, 71 %) rather 
than de-novo (14 out of 69,20%) lesions (P""O.OOOl). 
Failed 
cell culture Significance (P) 
57±11 NS 
21/55 NS 
29149 (59%) NS 
24f47 (51%) NS 
212 
46/66 (84%) NS 
4/69 (7%) NS 
17/68 (290/0) NS 
19/56 (34%) NS 
10155 (18%) NS 
13/56 (24%) NS 
29/68 (43%) NS 
35188 (40%) 0.03 
11/19 (58%) NS 
33/82 (40%) NS 
39/90 (43%) NS 
3Dnl (42%) NS 
37/89 (42%) NS 
36/83 (43%) NS 
32175 (43%) NS 
In seven of the 31 samples, (22%), a neovasculariza-
tion network was found in the interphase between 
neointimal hyperplasia and surrounding dense fi-
brous or loose fibrous tissue (four in primary and 
·three in restenotic lesions). In secondary lesions, 
Fig. 2. Histological cross-section 
showing thrombus partially infiltrated 
by myofibroblasts (arrows) In close 
association with newly formed fibro-
muscular tissue (FM). (Original mag-
nification x 30.) 
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neointimal proliferation showed identical character-
istics irrespective of the nature of the previous inter-
vention. Dense and loose fibrous tissue was found 
in 79 and 17 samples, respectively. Calcium de-
posits were observed in 27 samples. Macrophages 
were identified in 15 samples, predominantly in 
those with necrotic debris. Media and adventitia 
were found in 23 (23%) and 7 (7%) specimens, re-
spectively. 
Smooth·muscle cell outgrowth 
Depending on the volume of the retrieved tissue, an 
average of 4.5 fragments (range 2-8), each measuring 
approximately 1 rum3, were placed in culture. Cells 
started to grow out from explants after 4-14 days 
(Fig. 1), reaching a steady state within 4-6 weeks. 
The samples were discarded if no outgrowth was ob-
served after 3--4 weeks. Despite the use of antibiotics 
in the culture medium, six of the cultured specimens 
developed infections and were discarded. TIle infec-
tions tended to develop after 3--4 weeks, by which 
time cell outgrowth should have occurred but did 
not. 
Primary cell outgrowth was observed in 43 out of 98 
samples (44%). When primary outgrowth occurred, 
light microscopy showed that the majority of cells 
tended to form multiple layers and were polygo-
nal or spindle-shaped, with multiple stress fibres 
extending to lamellipodia. These appearances are 
characteristic of smooth-muscle cells. The cells were 
confirmed to be smooth-muscle cells using positive 
immunocytochemical staining with an a-actin-spe-
dfic monoclonal antibody. In addition to smooth-
muscle cells, a second cell type, oval in shape with 
eccentrically placed small indented nuclei, was iden-
tified in six cultures. Irumunoperoxidase staining 
with macrophage-specific HAM 56 confirmed these 
cells to be macrophages; typically, they disappeared 
after 10-14 days of culture. 
Cell outgrowth was not significantly influenced by 
any of the clinical variables recorded (Table 1), in-
cluding the age or sex of the patient, coronary syn-
drome (stable or unstable angina), type of coro-
nary lesion (de-novo or secondary). or risk factors 
for coronary artery disease (hypercholesterolaemia, 
hypertension, smoking, family history). Although 
cell culture failed in samples obtained from the 
two cardiac transplant patients, the small number 
involved precludes any conclusions about the sta-
tistical significance of this finding. Smooth-muscle 
cell outgrowth was significantly influenced, how-
ever, by the presence of organizing thrombus doc-
umented during histological examination. Smooth-
muscIe cell outgrowth was documented in eight out 
of 10 (80%) samples with and only 35 out of 88 
(40%) without thrombus (P=0.03, Table 1). None 
of the other histological variables analysed, includ-
ing the presence of neointimal hyperplasia, fibrous 
tissue (dense or loose), lipid deposits, necrotic de-
bris, macrophages, media, or adventitia, influenced 
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Day 1 
Edematous wall 
Thrombus retraction 
DayS 
0_-4;::-""--./''--,11- Endothelial celts 
Capi!!ary sprouts 
Smooth muscle cells 
Day 20 Endothelial cells 
CaplHary sproUlS 
Fig. 3, The sequence of events leading (0 thrombus orga-
nization, based on observations In experimental animal 
models (15-17). After the IniUal episode of thrombosis, a 
Significant retraction of the thrombotic mass occurs, with 
the formation of lacunar spaces. These, like the throm-
botic surface, become quickly endothelized. A granulation 
reaction with capillary Ingrowth from the vessel wall occurs 
simultaneously. By day 20, smooth·muscle cells that may 
have migrated from the vascular wall during the granulation 
reaction or thaI are derived ((om circulating cells that have 
Infiltrated the thrombus are seen along newly formed capil-
laries. Some of the endothellzed lacunar spaces may gIVe 
Origin to muWlumlnal channels, which constitute a classic 
hIstopathological landmark of previous thrombotic recanal-
Ization. 
cell outgrowth. Finally, there was no correlation be-
tween the number of ex plants used in each case and 
the outgrowth of smooth-muscle cells (4.5±1.6 and 
4.5±1.9 explants in cases with successful and failed 
culture, respectively; NS). 
Discussion 
Atherectomy has facilitated not only the study of the 
histological constitution of the atheromatous plaque 
[13,1S-20] but also the culture of smooth-muscle cells 
present in human atheroma [11,12,21-25}. Several 
groups [22,24], including ours [21], have reported 
improved cell outgrowth rates when an explant cell 
culture t€<.'hnique is used. TIle advantage of this 
method is that it minimizes the modifications of 
cell phenotype associated with enzymatic disper-
sion, prolonged culture, cell division, and succes-
sive cell passages f7-9J. and therefore allows a better 
appreciation of the in-vivo proliferative and migra-
tory potential of smooth-muscle cells. Since cell out-
growth occurs in the presence of the constituents of 
the atheromatous plaque present in the culture, the 
influence that the plaque milieu existing at the time 
of intervention has on the process of cell proliferation 
can be assessed. 
Histological findings in both de-novo and restenotic 
lesions ranged broadly from neointimal hyperplasia 
to typical atheroma containing dense fibrous tissue, 
calcium deposits, macrophages, and necrotic debris. 
In agreement with previous communications based 
on the study of atherectomy specimens, neointimal 
proliferation was seen not only in the classic sce-
nario of restenosis £1,26] but also in a substantial 
number of primary lesions [18,20,271. Although the 
prevalent view on the development of fibromuscu-
lar proliferation is that it constitutes a non-specific 
response to various types of vessel-wall injury [1]. 
the type of vascular insult responsible for its devel-
opment in de-novo lesions remains unclear. Its oc-
currence in younger patients {20,27,28] suggests that 
it may differ from the classic sequence of events ob-
served in the formation of atheroma [29]. leading to 
a more aggressive form of atherosclerotic disease. Fi-
nally, we have found that organization is common in 
thrombotic atherectomy samples from patients with 
unstable angina (20], in agreement with recent work 
by Isner et al. [30], who used atherectomy specimens, 
but not with post-mortem studies, emphasizing the 
distinct advantages derived from the use of atherec-
lomy samples in the in-vivo study of coronary syn-
dromes. 
Our explant culture success rale (44%) is low in 
comparison with other studies £12,24J, although this 
must be the result of the sole use of coronary ma-
terial. Cell culture from coronary alherectomy spec-
imens is difficult, however, because of the small 
amounts of tissue involved, and yields significantly 
lower outgrowth success rates than peripheral tissue. 
When culture of both coronary and peripheral tis-
sue has been attempted, a lower success rate and a 
longer time span until outgrowth has been observed 
in the coronary samples [12]. This observation was 
explained on the grounds that there were fewer coro-
nary specimens and that their wet weight was lower 
[12J. However, it must be remembered that there are 
major differences in the histopathological character-
istics of coronary and peripheral artery samples. The 
prevalence of thrombus in peripheral artery speci-
mens obtained during directional atherectomy is as 
high as 61% [13], significantly higher than that found 
in the present and previous studies in the coronary 
arteries [19,20]. Although the relevance of this fact 
for cell culture is highlighted by the conclusions of 
the present study, it is unfortunate that none of the 
previous studies reported on the histological charac-
teristics of the material used for culture, a limitation 
recently acknowledged in a report by Pickering et al. 
[24[. 
Our study is the first to consider the influence of a 
broad spectrum of histopathological features of re-
trieved tissue in addition to clinical features on cell 
outgrowth. Like Bauriedel and colleagues [12], we 
found that no clinical variables, including unstable 
angina and drug therapy, influence the outcome of 
plaque cultivation. nus is reflected in clinical expe-
rience, which has shown little evidence that clinical 
factors influence the restenosis rate, and in which all 
therapeutic strategies have been singularly unsuc-
cessful. Common sense dictates that clinical factors 
must operate through the histolOgical milieu of the 
atherosclerotic plaque. In spite of the fact that human 
smooth-muscle ceUs cultured from restenotic lesions 
appear to migrate more rapidly than those from pri-
mary atheroma [12] and show accelerated growth 
curves [25]. we did not find significant differences 
between the primary outgrowth of smooth-muscle 
cells from explants of restenotic and primary lesions. 
A possible reason for this discrepancy is that some 
of these studies used isolated smooth-muscle celis, 
obtained after several passages, and were free of the 
complex cell-cell and cell-extracellular-matrix inter-
actions which modulate smooth-muscle cell prolifer-
ation and migration in the atherosclerotic plaque ill 
vivo [10]. 
Evidence in the literature suggests an enhanced pro-
liferative potential of smooth-muscle cells present in 
restenotic lesions. An improved smooth-muscle cell 
outgrowth from the injured vascular wall has been 
demonstrated by Grunwald et al. (31) in a rat model. 
Smooth-muscle cell outgrowth has been found to oc· 
cur more rapidly in restenotic than in de-novo athe-
rectomy specimens obtained in peripheral vessels 
[12,24), although the initial outgrowth was similar. In 
our study, cell outgrowth was not significantly dif· 
ferent in expIants from de-novo or restenotic lesions. 
There are a nwnber of possible reasons for this. 
Our experiments were performed using only coro-
nary atherectomy specimens, which, as discussed 
before, may differ substantially in their histologi-
cal substrate from those obtained in peripheral ves-
sels. The time interval from the former percutaneous 
intervention may also be of importance because evi-
dence suggests that smooth-muscle cells experience a 
process of senescence during their migration to the 
neointima [32} and that their proliferation rate de-
creases after a period of time [331. 
We found that smooth-muscle cells present in coro-
nary atheroma where thrombotic organization is tak-
ing place had an enhanced proliferating potential. 
nus may be related to three major factors. First, 
mural thrombus is rich in circulating elements, such 
as platelets, monocytes, and lymphocytes, which can 
secrete a number of vascular growth factors [1], pro-
moting smooth-muscle cell proliferation. Thrombin 
and fibrin have both been shown to have chemo-
tactic and mitogenic activity on vascular smooth-
muscle cells [34]. an effect that may be prolonged 
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after the incorporation of thrombus into the plaque. 
lhrombin may also act as a competence factor, stim-
ulating the expression of growth factors, including 
platelet-derived growth factor, and their receptors 
[35..36}, and thus help to perpetuate the activation of 
smooth-musde cells. Any or all of these mechanisms 
may have been operating in our study, resulting 
in the increased migratory and proliferative activ-
ity of the smooth-muscle cells when surrounded by 
thrombus. 
Second, the process of thrombus organization may 
have played a key role in the observed outgrowth 
of cells; since organization was taking place in all 
of our thrombotic specimens, we believe that our 
conclusions should be restricted to the presence of 
organizing thrombus. Growing evidence suggests 
that thrombus organization plays a key role in the 
development of neointimal hyperplasia after vascu-
lar injury (37-39,15]. It has been suggested that the 
smooth-muscle cells involved in this process are de-
rived from circulating mononuclear cells rather than 
being of intimal or medial origin [15,16] (Fig. 3). 
Thrombus would serve as a biodegradabJe fibrin 
matrix colonized by circulating mononuclear cells 
that heal the injury site from the lumen side in-
wards, towards deeper vascular layers [15]. In this 
scenario the mononuclear cells that have colonized 
and started organizing the thrombus are self se-
lected for their migratory and proliferative ability, 
providing an unexpected explanation for a previous 
report showing that smooth-muscle cells in organiz-
ing thrombi have a monoclonal origin (40]. Although 
the smooth-muscle cells cultured from thrombotic 
and non-thrombotic origin were morphologically in-
distinguishable, the above tentative scenario remains 
plausible. 
Finally, a third explanation for our fmdings is that 
organizing thrombus may have facilitated cell out-
growth by optimizing cell transfer to the culture 
medium. 
In our study we tried to reach a compromise between 
obtaining information from histopathology and from 
cell culture. As discussed above, meticulous inspec-
tion of the samples under the dissecting microscope 
was performed to ensure that the tissue fragments 
dedicated to the histological examination and cell 
culture samples were equally representative of the 
whole specimen. However, the possibility that the 
two pieces were significantly different cannot be 
ruled out. Atherosclerosis is a segmental disease 
process; in this regard our study shares the limita-
tions of all histopathological studies using atherec-
tomy specimens, in which conclusions are reached 
using fragmented samples of the arterial wall [26]. 
A second limitation is that pretreatment of the cul-
ture wells with fibronectin may have facilitated the 
transformation of smooth-muscle cells from the con-
tractile to the synthetic phenotype (41], affecting 
explant outgrowth. We believe that this is unlikely 
to have occurred, however, because fibronectin is al-
ready present in serum and any additional effect that 
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the fibronectin coating of the wells may have had is 
likely to have been constant in all specimens. Fur-
thermore, poor adherence of atherosclerotic tissue 
to the culture meditml occurs in the absence of Ci-
bronedin, and results in decreased explant success. 
The final potential source of error is variability in the 
area of contact between the explant tissue and the 
fibronectin. However, this error will probably have 
been randomly distributed among all the specimens 
studied, making it unlikely to account for the ob-
served differences. We believe that the differences in 
cell outgrowth that we observed are a true reflection 
of the differing growth potentials of the cells present 
in the explants. 
Our study emphasizes the research utility of clini-
cally indicated directional coronary atherectomy and 
suggests that smooth-muscle cells present in athero-
matous plaque where thrombotic organization is 
taking place have an enhanced migratory and pro-
liferating potential. This supports the concept that 
plaque composition may influence the progression 
of atherosclerosis. II also suggests that monitoring in-
vitro cell outgrowth may provide a means of assess-
ing important biological features of the pathobiology 
of the atheromatous plaque. 
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Organ Culture of Human Coronary Artery 
Following Balloon Angioplasty 
A.G. Violaris, MRCP, S.E. Francis. Ph.D., C.M. Holt, 
Ph.D., C. Clelland, MRCPath, P. Gadsdon, FIMLS, 
G.D. Angelini, FRCS,' Sheffield alld Bristol, U.K. 
Abslracl 
lmimal smooth muscle cell proliferation is the primary cause of restenosis follow. 
ing balloon angiopiast)'. Its underlying basis and progression remain unclear. The 
authors developed an organ culture of human coronar), anery subjected to balloon 
angioplasty in order to investigate the cellular and molecular basis of intimal prolifer-
ation in a preparation that maintained the anatomic relationships of the vessel wall. 
Artery segments obtained from the explanted hearts of transplant recipients were 
maintained at 37°C in culture medium containing 30070 fetal bovine serum for four-
teen days. Balloon angioplasry produced partial endothelial denudation and medial 
smooth muscle cell damage, both of which tended to be reversed after fourteen days 
in cuhure. Transverse histologic sections of cuhured artery showed the development 
of a new intima containing smooth muscle cells identified by immunocytochemistry 
with anti-a-actin. Labeling of cultures with (H] thymidine showed proliferating cells 
in the neointima. 
The data demonstrate that intimal proliferation occurs in organ culture of human 
coronary artery subjected to balloon angioplasty. They also suggest the possibility that 
the smooth muscle cells in the neointimallayer are the result of both migration and 
proliferation. 
Introduction 
Coronary angioplasty is a technique widely used 
for the treatment of coronary artery disease. 14 The 
clinical benefits of the procedure are, however, tem-
pered by a 300/0 restenosis rate within six months. 15 
Clinical and experimental studies suggest that reste-
nosis is due to the development of a neointima 
secondary to vascular smooth muscle cell migration 
and proliferation. n.ll.!'; 
Our current understanding of the problem is limit-
ed by the difficulty in studying the process in man. 
Histopathologic specimens obtained at post 
mortem, although valuable, provide static informa-
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tion regarding a specific moment in the course of 
the disease. l Isolated cells cultures do not take into 
account the normal anatomic relationships of the 
different cellular components of the vessel wall or 
the cell;to.cell interactions that may modulate 
growth. 
\Ve sought, therefore, to establish whether intimal 
proliferation occurred in an organ culture of human 
coronary artery subjected to balloon angioplasty. 
Our strategy was first to assess the degree of injury 
produced by balloon angioplasty, determine whether 
tissue viability would be maintained in culture, and 
then detect, localize, and identify any proliferating 
cells, 
Malerials and Melhods 
Harvesting and [isslle cli/cure of coronary artery 
segments 
Hearts were obtained from 8 male patients (mean 
age 33.5, range fifteen to forty-seven years) under-
going cardiac transplantation. Six patients had 
ischemic and ~ congesti\·e cardiomyopathy. Romine 
premedication. anesthesia. and intraoperative 
heparinization were performed as previously 
described.: The heart. if possible, was explained 
with a cuff of ascending aorta to facilitate identifi-
cation of the ~oronary ostiae, which were then can-
nulated and perfused with 0.9(1:0 sodium chloride 
solution 10 clear any blood. The coronaries were dis-
sected free of surrounding tissue by use of nO-lOuch 
technique' and transported to the laboratory wi-
thin thirty minutes of explan-;ition in Hepes buffered 
RP!\lI 1640 culture medium supplemented with 
penicillin (100 flgimL) streptomycin (100 units/roL), 
gentamicin (2.5 /1g!mL), amphotericin (2.5 /1g/mL), 
glutamine (2mM), and sodium heparin (4 units/mL). 
Coronary artery segments were subjected to bal-
loon angioplasty twice by use of a 3mm balloon in-
flated to 10 atmospheres for sixty seconds. In one 
set of experiments the balloon was simply inflated 
and deflated while in the same position. In a separate 
set of experiments the baUoon was moved slightly 
backward and forward within the \'essel while in-
flated. Following angioplasty the vessel was cultured 
hy previously described standard techniques.~·l~ 
Briefly the vessel was opened and longitudinally, 
and, with minuten pins, the intimal surface was· 
pinned uppermost ontO a polyester gauze resting on 
set sylgard resin in the base of a Petri dish. Vessel 
segments were washed several times with medium 
and then maintained in culture medium containing 
sodium bicarbonate (2.0 giL) in place of Hepes, and 
30V'0 fetal calf serum at 37 "C in a humidified at-
mosphere with 5O'Jo ("Iv) CO: in air. The culture 
medium was replaced every tWO to three days. Cul+ 
tures were pulse labeled with I CilmL [,H}-
thymidine (concentration 25 Ci/mmol) for the last 
twenty-four hours of the fourteen-day culture 
p~riod. 
The measureinent of adenosine nucleotides, DNA 
and lotal (H]-thymidine incorp?ration were per-
formed as previously described:·!! 
Electron and light microscopy 
Artery segments were fixed in 100:0 buffered for-
malin, processed, and paraffin embedded. Trans· 
verse sections (4 m) were stained with 
hematoxylin.' eosin and Alcian blue/:-,.,tiller's elas+ 
tic·.'\·an Gieson for routine hislOlogic examination. 
Immunostaining of paraffin sections was per· 
formed with monoclonal anti-a-actin antibody to 
idemify smooth muscle cells. Oeparaffinized sections 
were incubated for thirty minutes with 1 :200 dilu-
tion of a-actin antisera following initial incubations 
with methanol/hydrogen peroxide to inhibit en-
dogenous peroxidase activity and with normal rab-
bit serum to inhibit nonspecific binding. Following 
twO washes in Tris-buffered saline, biotinylated 
secondary antisera was added for thirty minutes. 
Sections were washed twice more and strep-
tavidin/biotin complex was added for thirty 
minutes. Finally, diaminobenzidine was used to 
visualize the staining, and sections were counter-
stained with Mayer's hematoxylin. 
Autoradiography was performed to localize any 
cell proliferation occurring in culture. Unstained 3 
f1Il1 sections were deparaffinized, rehydrated through 
alcohol to water, dipped in K2 nuclear emulsion, 
and exposed for two weeks at 4°C. Sections were 
then developed, fixed, and post stained with orcein. 
Endothelial morphology was studied by means en 
face scanning .electron microscopy (SEM). Vessel 
segments were fixed in 3070 glutaraldehyde for 
twenty-four hours and then transferred to sodium 
cacodylate buffer. Dehydrated specimens were then 
critical point dried in liquid CO:, sputter coated with 
gold, and observed in a scanning electron 
microscope. 
Statistical methods 
Values are shown as mean ± standard error of 
the mean. Data were considered significant if P 
<0.05 using the Student's t test for u~paired data. 
Results 
Endothelial morphology 
SEf\·I of freshly isolated vessels showed a mor· 
phologically intact and almost continuous endothe-
lial monolayer in the central area with a more 
variable morphology, including areas of endothelial 
denudation at the cut edges. Segments of vessel in 
which the balloon was moved backward and for-
ward while inflated showed areas of substantial en-
dothelial denudation exposing subendothelial 
structures (Figure Ib), Segments of vessel where the 
balloon was simply inflated in position showed a 
confluent endothelial monolayer with only occasion-
al breaks (Figure Ic). After fourteen days in cul-
ture the endothelial monolayer was still intact but 
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TABLE I 
Purine- Me-laboIUe-s and 0:"\:\ Conce-ntrations In Freshl~' Isolated Coronary and 
Coronary SubJecte-d to 8alloon Angioplasty. Be-fore- and Arter Culture 
Freshly 
Vessel Isolated Angioplasty Angioplast}" 
Days in culture 0 0 14 
\:umber of observations 14 8 6 
:\ TP concentralion 240 (34) 103 (.25)* 210 (38)< 
(nmol·g we: WI) 
.-\ TP ADP ralio 2.1J (0.17) 1.39 (O.24)* 2.53 (0.'101' 
O:\"A concentration 0.'14 (0.03) 0.38 (0.041 0.45 (O.06) 
(}lg. mg we! \\t] 
·P<(r.(l5 \~ freshly isolated: 'p < 0.03 \ S day 0 ang-ioplaslY 
the cells appeared to be slightly swollen. Fine 
filamentous projections referred 10 as 
lamellipodia' were seen between cells (Figure Id). 
Tissue viabilifY 
~'leasurements of total adenosine triphosphate 
(A.TP) concentration and ATP/adenosine 
diphosphate (ADP) ratio (calculated from total 
.-\DP) were performed to Quantify the viability of 
the predominant cell type, the smooth muscle cells 
before and after culture.: Balloon angioplasty 
resulted in a 600io fall in A TP concentration and a 
35(170 fall in the ATP/ADP ratio as compared with 
freshly isolaled vessel, suggesting that the procedure 
causes subsiantial injury to the medial smooth mus· 
de cells (Table I). This damage was, however. ful-
ly reversed during the culture period as shown by 
the increase in A TP concentration and A TP I ADP 
ratio to values similar to those of freshly isolated 
(oronary (Table I). The DNA concentration, which 
gives a measure of total cell numbers, di<t not alter 
significantly during the fourteen day culture peri· 
od (Table I). 
Cell proliferalion 
Histologic examination of freshly isolated seg-
ments of coronary artery showed a convoluted in-
ternal elastic lamina with a thickened intimal layer. 
In patients with ischemic cardiomyopathy plaque 
formation was also seen. The medial layer , enclosed 
by the internal and external elastic laminae, was 
characterized by the presence of abundant elastic 
fibers and a\:ial and longitudinally arranged smooth 
muscle layers. 
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Balloon angioplasty resulted in disruption of the 
vessel wall with tears and fissures extending from 
the intima into the media (Figure 2a). In segments 
of vessels cultured for fourteen days, a neoinHmal 
layer was visible above the preexisting intima charac· 
terized by a layer of cells in a loose matrix (Figure 
2b. 2c). This neointimal layer. (mean thickness 
47 ± 12 /lm) did not develop over atherosclerotic 
plaque. Cell proliferation as assessed by (H]-
thymidine incorporation occurred during culture 
(841 ± 294 dpm/~g DNA). 
Immunocytochemistry with a monoclonal anti-
body to a-actin was performed to identify and local· 
ize vascular smooth muscle cells. In sections of 
uncultured coronaries most of the medial and in-
timal cells stained positively for a·actin. Following 
fourteen days in culture, posith'e staining was still 
observed in the media and intima but also through· 
out the neointimallayer (data not shown). Autoradi-
ography of trans\'erse sections showed cells that had 
incorporated [lHHhymidine predominantly in the 
neointimal layer, with a few dividing cells in the me-
dia (Figure 2d). 
Discussion 
The results from this study suggest that balloon 
angioplasty produces severe medial and endotheli· 
al damage that partly recovers after fourteen days 
in culture. A neointima develops during the culture 
period with proliferating cells identified as vascu-
lar smooth muscle cells by immunohistochemistry. 
Previous morphologic studies have documented 
that balloon angioplasty results in substantHl1 vessel 
wall damage with plaque fracture and medial as well 
fig. 1 TnnsHrse histologic ~t'cliom of human coronary artery before :lnd after culture. la) Angiopbstf \eswl da~' 0 stained "ilh Gadsdon's 
m'Jdlfied trichrome Slain. :-"011.' Ihe prenisliog intimalthicl;ening m abol 1.' the- internal elastic lamina II[U. Yessel damage- induced b~ an· 
glopia!l} lanO") e:\tends into the media (:-.11 (,25). tb) Angioplastf \es!eI daf 1.1 stained ~Ith Gadsdon's modified trichrome stain . .'\Ole-
(hr neointlmal furmation (.'\11 o\er the prenilling intimal thickeniog (Il and the relali\elr fe\\ cells surrounded b) a large- amounl of n-
Iranllular matrix (:\M). Id) AUioradiograph} of angioplasl}' HSSei at da) H . .'\ot1.' that I'HHh}mldine·Jaheled cells are pw,enl in Ihe neoln· 
limal la)ff larrO\\s) bUI 001 [0 the medial or adHnlilla1 b}ers {:\37J. 
as imimal tears.,·lf These findings were confirmed 
in our sludy with the use of quamitative biochemi· 
cal markers, Balloon angioplasty resulted in more 
than a 600:0 reduction in ATP concentration as com-
pared with comrol vessel, but this damage was ful-
ly reversed during the culture period as shown by 
the doubling in ATP concentration. The ATP I A DP 
ratio also increased after culture to values above 
those seen in fresh vessels. This may be a charac-
teristic of cultured vascular smooth muscle ceJls or 
may represent transformation of cells from the con-
(ractile into the synthetic phenotype as previously 
shown in organ culture of human saphenous 
\"ein~·'~ and internal mammary artery. j(. 
SEM demonstrated that balloon angioplasty 
produces a variable degree of endothelial disruption 
with exposure of the underlying basement mem-
brane. Following culture, endothelial regrowlh 
occurs in areas with limited damage with 
lamellipodia~likc filaments seen spanning the ex~ 
posed surface between endothelial cells, Endothellal 
regrO\\lh does not, however, take place in areas with 
extensive denudation. 
A ncw intimal layer developed after fourteen days 
in culture. This was clearly identifiable from the pre~ 
existing intima owing to its relatively low level of 
elastin staining. The neoimima was confined almost 
entirely to segments of nearly normal vessel wall. 
This finding is very similar to the clinical situa* 
tion after balloon angioplasty where the neointimal 
proliferation occurs over the normal segment of 
[he vessel wall and only later spreads to cover the 
atherosclerotic plaque. t The majority of the cells 
in the neointima were idelllified by immunocyto-
chemistry as \'ascular smooth muscle cells consistent 
with human postmortem studies of restenosis. H.B. 
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FIg. 2 Scanning electron mltroscop) of the intimal surface of human coronar, arturo before and after culture h12S01. (3) Angioplasl) 
>essel da) O. :'\ote tbe nlensiH endothelial denudation. e\posing subendothelial structure and the basal membrane. (bl Angioplasl) Hssel 
d~~ I·t Some regro\\lh of endothelium has lalien place. but there is slill fair!, e\lensiH denudation. lCI An~i(lpbSI) Hssel dar O. :'\ote 
the "ell·prestrled endothelium "i\h onl, occasional gaps het\\een Hils. (d) Angioplasl) 'essel da, 14. ;';ole the o~casional breaks In the 
~ndothdi31 monola)H spannu b, fine filamentous projections C\2~OOI. 
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These cells are likely to have originated from vas-
cular smooth muscle cells in either the preexisting 
intima or the vessel media. The smooth muscle cells 
may have been intimally directed as a result of a 
concentration gradient of exogenous growth factors 
in the culture medium. This is unlikely, however, 
for the vessel segments were completely immersed 
in culture medium. Previous organ culture studies 
ha\'e suggested that intimal proliferation. depends 
on the presence of endothelium, which suggests that 
an endothelium-derived chemoattractant may be 
released during culture. 2•1: Further e\'idence from 
cell cultures suggests that growing endothelial cells 
release factors able to stimulate smooth muscle cell 
proliferation in vitro.! The injury produced by bal-
loon angioplasty may therefore lead to increased 
synthesis of growth factors from damaged cells or 
from activated regenerating endothelial cells. 
Autoradiography at fourteen days showed most 
of the proliferating cells to be in the neointimallayer 
with few dividing cells in the media. The low rate 
of smooth muscle cell proliferation in the IUnica me-
dia is likely to be the result of constraints on prolifer-
ation by cell-cell interactions.~ Once cells have 
migrated into the intima they are free of any such 
interactions and are more likely to proliferate. The 
lack of cell interaction may also be responsible for 
the large amount of extracellular matrix produced 
by the neointimal cells. 
The organ culture system described here has cer-
tain limitations, in particular the variability in in-
timal thickening and plaque lesion both between and 
within vessels. This makes any direct quantitative 
comparison between angioplasty and freshly isolated 
vessel difficult. The high concentration of serum re-
quired to maintain the vessel in culture also prevents 
us from assessing the differential role of endogenous 
mitogens, which may play an important role in the 
development of intimal proliferation, 
Conclusions 
Nonetheless the model allows us to use segments 
of human coronary artery in which the cells main-
tain their normal anatomic relationships, in contact 
with the extracellular matrix. This interaction can 
therefore be studied in controlled conditions and 
both migration and proliferation can be monitored. 
The system may also be readily adapted [Q evalu-
ate the role of factors such as lipoprotein concen· 
tration and monocyte adhesion and migration into 
the tissue, which are known to influence restenosis. 
The recent development of serum-free or!!an cul-
ture techniques~ should also allow us to iO\~stigate 
the role of gro\\1h factors regulating intimal prolifer-
ation. Funhermore, since intimal smooth muscle cell 
proliferation occurs within a relatively short time 
span, the model may be useful in evaluating ther-
apeutic agents for the suppression of intimal 
proliferation. 
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Abstract 
The long term efficacy of coronaty angioplasty remains limited by restenosis 
secondary to intimal vascular smooth muscle cell (vsmc) proliferation. The relea-
se of growth factors from cells intrinsic to the vessel wall has been implicated in 
the development of restenosis despite the lack of direct evidence. 
To test tltis hypothesis, pig coronary arteries explanted 4 weeks after angioplasty 
(3nun balloon, 10 atmospheres, 60 seconds) were cultured for 24 hours in serum-
free media supplemented with [,H]-thyntidine. Growth factor activity was then 
evaluated in the conditioned media using a Swiss 3T3 fibroblast bioassay. 
Tissue viability assessed by adenosine triphosphate concentration (nmol/g wet wt) 
remained high during culture (267±21 [SEM], 0 hoUt' vs 265±32, 24 hours) and 
cell proliferation occurred as judged by total [,H]-thymidine incorporation 
(l326±226 dpm/mg wet wt). Transverse histological sections of angioplasty sites 
revealed the presence of a neointimallayer, with a mean thickness of 92.82±27 .95 
m (n=9, p<O.OO I vs freshly isolated coronary). Autoradiography showed prolif-
erating cells in the neointima identified as smooth muscle cells using a monoclon-
al antibody to a-actin. 
Conditioned media from the angioplasty vessel caused a 6 fold increase in the 
proliferation of Swiss 3T3 fibroblasts above that produced by basal culture media. 
Tltis mitogenic activity was inltibited by x% with a polyclonal neutralising antibo-
dy to platelet-derived growth factor (PDGF). Reverse transcription polymerase 
chain reaction analysis (RT-PCR) and Northern blot analysis demonstrated expres-
sion of PDGF B chain in angioplasty vessel but not in freshly isolated vessel. 
These data provide direct evidence for growth factor activity and PDGF-B gene 
expression by cells intrinsic to the allgioplasty site. They also suggest that a 
PDGF-like protein may playa role in regulating smooth muscle cell proliferation 
in vivo. 
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Introduction 
Percutaneous transluminal coronary angioplasty is an effective means of allevia-
ting ischaemia in coronary artery disease but is currently limited by restenosis in 
30-40% of cases (I, 2). Histopathologically restenosis is characterised by intimal 
thickening secondary to smooth muscle cell migration, proliferation and synthesis 
of extracellular matrix (3, 4, 5). The factors which control tlus process are incom-
pletely understood but preliminary work using isolated cell cultures has identified 
and characterised a number of growth factors, including platelet-derived growth 
factor (PDGF), basic fibroblast growth factor (bFGF), transforming growth factor 
(3 (TGF{3) and insulilllike growth factor I (IGF-I), all of which induce vascular 
smooth muscle cell migration and proliferation in vitro (6). There is however no 
direct evidence that any of these factors playa role in regulating vascular smooth 
muscle cell (vsmc) proliferation in vivo. 
To test the hypothesis that balloon angioplasty induces growth factor production 
by cells intrinsic to the vessel wall, pig coronary arteries previously subjected to 
balloon angioplasty were cultured for 24 hours in serum-fi'ee basal media. 
Release of growth factor activity was then assessed by the ability of the conditio-
ned media to stimulate the proliferation of quiescent 3T3 fibroblasts. Neutralising 
antibodies were employed to further characterise the nature of the growth promo-
ting activity. To confirm that cells intrinsic to the angioplasty vessel were respon-
sible for the growth promoting activity detected, growth factor messenger RNA 
expression was also investigated by reverse transcription polymerase chain reac-
tion (RT PCR) using primers derived from human gene sequences. 
Methods 
Coronary angioplasty 
Domestic pigs (Yorkshire white), intitially weighing 25-30 Kg were used in this 
study. The investigations were performed according to the national guide-lines for 
the care and use of laboratory animals and the study protocol was approved by the 
Home Office. After an overnight fast the animals were sedated with Ketamine 
12-15 mglkg, intubated with an endotracheal tube and ventilated with Halothane 
and Oxygen to maintain adequate anaesthesia. Their ECG and arterial blood pres-
sure were monitored continuously. Each animal was prepared and draped in a ste-
rile fashion. A right femoral cut down was performed and an SF introducer sheath 
(Cordis Inc) placed in the femoral artery. Each animal then received systemic 
heparin (200 units/kg iv) and Lignocaine (I mglkg) therapy. The left main or 
right coronary artery was engaged using standard teclmiques with an S F coron31Y 
guide catheter (Cordis Inc). 
37 
After coronary arteriography and under fluroscopic guidance a 3mm balloon 
angioplasty catheter (Mini-profile, Usci-Bard) was advanced and positioned in the 
mid-coronary artery. The balloon size (3mm) was substantially larger than the pig 
coronaries which were typically 1.5-2.0mm in diameter so as to induce maximum 
injury. Using random assignment each of the two branches of the left system 
(LAD and circumflex) underwent angioplasty or served as control. Balloon 
angioplasty was performed using two inflations at 10 atmospheres for 60 seconds. 
Following the procedures patency of the vessels was confirmed arteriographically, 
the catheters withdrawn and the cut down site repaired using 5.0 prolene sutures. 
The animals were allowed to recover and sacrificed at 4 weeks. Following seda-
tion and anaesthetic the chest was opened via a median sternotomy, a lethal dose 
of phenobarbitone administered and the inferior and superior venae cavae ligated. 
The aorta and pulmonary trunk were cross clamped and the heart explanted. The 
coronary vessels were washed by infusing normal saline at 100 mmHg into the 
aortic root until all effluent from the heart was clear. The vessels were then dis-
sected out using a no touch technique (7) and transported to the laboratOlY in ste-
rile transport medium ( RPM! 1640 tissue culture medium containing 20mM 
Hepes Buffer, 4 lU/ml of sodium heparin, Glutamine (200mm), Penicillin (100 
~lg/ml), Streptomycin (100 units/ml), Gentamycin (1 0 ~lg/ml), and Amphotericin 
(250 ~lg/11l1) 
Culture procedure 
Segments (1 cm long) of control vessel and vessel which underwent coronary 
angioplasty were cleaned of adventitial tissue and maintained in serum free organ 
culhlre by an adaptation of the method described by Pedersen and Bowyer (8). 
Briefly the vessel was opened out longitudinally and pinned intimal surface upper-
most onto a polyester mesh support resting on set sylgard resin in the base of a 
Petri dish. The vessel was washed several times and then maintained in culture 
medium (sterile RPM! 1640 tissue culture medium as above). The vessel was 
then rested for 30 minutes after which time the conditioned media was removed. 
Fresh basal culture media supplemented with [3H] thymidine (1 ~lcilml, Amersham 
International, Amersham, UK) was then added to the culhlres which were maintai-
ned at 37°C in a humidified atmosphere with 5% (v/v) CO, in air for 24 hours. At 
the end of this period the conditioned medium was collected, aliquoted into sterile 
tubes and stored at _80°C. The vessel was washed three times with non sterile 
phosphate buffered saline and then divided into two sections. One was placed in 
formalin for histology and the other in liquid nitrogen for assessment ofnucleoti-
des. Measurement of purine metabolites, DNA concentration and thymidine 
incorporation were performed as previously described (9). 
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Morphological studies 
Endothelial morphology was studied using en face scanning electron microscopy. 
Segments of vessel were fixed in 3% glutaraldehyde in cacodylate buffer. 
Dehydrated specimens were then critical point dried in liquid CO" splutter cOal'ed 
with gold particles and observed in a scanning electron microscope (Phillips SOO). 
For transmission electron microscopy specimens were treated similarly. After 
fixation in 3% glutaraldehyde followed by post fixation in I % aqueous osmium 
tetroxide the specimens were dehydrated in alcohol, transferred to polypropylene 
oxide and embedded in epoxy resin. Ultrathin (I OOmn) sections were stained with 
SO% alcoholic uranyl acetate and Reynold's lead citrate and observed using a 
Phillips 400 transmission electron microscope. 
For light microscopy vessel segments were fixed in 10% buffered formalin, pro-
cessed and paraffin embedded. 411111 transverse sections were stained with alcian 
bluelMiller's elastic Nan Gieson and the mean neointimal, intimal and medial 
thickness was determined from measurements taken at 20 equidistant points along 
the section length using an image analyser (Solitaire, Seescan, Cambridge, UK). 
The intima consisted of a monolayer of endothelial cells. The neointima was cle-
arly visible as a new layer above the internal elastic lamina and was distinguished 
by the presence of closely packed cells in an abundance of elastic fibres. 
Autoradiography was performed to localize and quantify cell proliferation. 
Unstained 3 11m sections were deparaffinised, rehydrated through alcohol to water, 
dipped in K2 nuclear emulsion and exposed for two weeks at 4T as previously 
described (9,10). The total number ofneointirnal and medial labelled cells were 
counted and related to the section length which was determined using a calibrated 
eye piece graticule. To identify the cells in the neointimallayer immunostaining 
of paraffin sections was performed using monoclonal anti-smooth muscle a-actin 
antibody as previously described (9, 10). 
Cell proliferation assay 
Swiss mouse 3T3 fibroblasts were used to assess the mitogenic activity of the 
coronary vessel conditioned media. Measurements were performed in triplicate 
and the mean value for each specimen calculated. Cells (Flow labs) were passa-
ged twice weekly and maintained in Dubecco's modified Eagles medium 
(DMEM) with bicarbonate (2g/l) and supplemented with 10% foetal calf serum 
(JBio chemicals, France), penicillin (IOOIIg/mi), Streptomycin (100 IUlml), 
Fungizone (2.Sllg/ml), Gentamycin (2.Sl1g/ml), and glutamine (2mM). Cells were 
plated at a density of 104 cells per well in a 96 well plate (Costar, UK) in DMEM 
supplemented with antibiotics and 10% foetal calf serum. After 24 hours the cells 
were made quiescent by incubation in medium containing 2% pig plasma derived 
senllll for a further 2 days before the addition of test samples and standards. 
[,HJ-Thymidine (1I1Cilml, specific activity 2S Cilmmol) was added to the cells 
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simultaneously with the test agents and its incorporation into DNA determined 
over a 20 hour interval. After exposure, the cell layers were washed three times 
with phosphate buffered saline (PBS) and fixed for 3 minutes with ice-cold 10% 
w/v Trichloroacetic acid (TCA). The TCA precipitable material was harvested by 
aspirating the media and solubilising the remaining TCA-insoluble material in 
100ft! of 1M sodium hydroxide overnight at 37°C. The solubilised material was 
added to 2ml of Scintillation fluid (Ultima Oold, Packard, UK) and radioactivity 
determined by liquid scintillation counting. The data are expressed as disintegra-
tions per minute (DPM/well) and as percentage stimulation over basal culture 
media and compared to 10% serum. 
In a separate series of experiments, a polyclonal antibody to platelet derived 
growth factor, neutralising all forms of POOF (British Biotechnology, Oxford, 
UK) was added, at an initial concentration of 50, and then a final concentration of 
100 llgiml to the conditioned media. The results were compared to those of the 
same sample of media incubated with non-immune IgO (Sigma chemicals, Poole, 
UK) at the same concentration. Media was pre incubated with antibody or non-
immune IgO for I hour at 37°C prior to the addition of the fibroblasts. 
Expression of mRNA for PDGF 
Reverse transcription polymerase chain reaction was used to assess mRNA levels 
for PDOF A and B chain in angioplasty vessels. Cellular RNA was isolated from 
snap-frozen segments of fi·eshly isolated coronary artery and angioplasty vessel 
using a one-step phenol chloroform method as previously described (II). For RT-
PCR, cellular RNA (I ftg) was reverse transcribed in a 20ft! reaction containing 
1.25 U.ml-I AMY reverse transcriptase and 2.5ftM MgCI" 10mM Tris-HCL, pH 
9.0, 50mM KCL, 0.1% Triton X-100 dNTPs (I mM each), and RNasin (lU.ml-'). 
RNA-cDNA hybrids were immediately used as a template for the polymerase 
chain reaction. Primers for the POOF A and POOF B chains were designed using 
a commercial software programme (OLIOO, National Biosciences) and screened 
for specificity using the EMBL database. Sequences used for POOF A were posi-
tioned on exon 3,5' CCC CTO CCC ATT COO AOO AAO A 3' (sense) and the 
exon 4-5 boundary, 5' TTO OCC, ACC TTO ACC CTO COO TO 3' (antisense) 
corresponding to nucleotides of the gene. Sequences used for POOF B were in 
the 3' untranslated region 5'CCO CAC CAA COC CAA CTT CC 3' (sense) and 
5'TTT OOC TCO CTO CTC CTO 00 3' (antisense) corresponding to nucleotides 
1318 to 1569. The predicted sizes for POOF A and POOF B cONA products were 
227 and 271 bp respectively. Oligonucleotides were synthesized using an automa-
ted DNA synthesiser (Applied Biosystems), purified by butanol extraction, divi-
ded into aliquots and stored in sterile water at -20Ge. For polymerase chain reac-
tion expansion each 50ftl reaction contained 10ft I cONA derived from I Ilg rNA, 
7.5pmol each primer, 1.25 U T aquaticus DNA polymerase, 10 mM Tris-HCL (PH 
9.0), 50mM KCl, 2.5mM MgCl, and 0.1 % Triton X-100 (all from Promega, 
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Southampton, UK). Samples were overlaid with light mineral oil to prevent eva-
poration. The cycling parameters were I min at 95°C, I min at 62°C (PDGF B) or 
55°C (PDGF A), and extension at nOc for 1 min for 40 cycles with a final exten-
sion period of 6 min at nOc. Chain reaction products were size fractionated and 
separated from unincorporated primers by electrophoresis through l.5% agarose 
gels. Amplified DNA was visualised by EtBr staining under ultraviolet light 
transill umina t ion. 
Statistical Methods 
Values are shown as mean ± SEM. Data were considered significant if p < 0.05 
using the Student's t-test for unpaired data. 
Results 
Measurements of ATP concentration and ATP:ADP ratio were performed to exa-
mine the viability of the predominant cell type, the smooth muscle cell before and 
after the 24 hour culture period (Table I). The ATP concentration for both control 
and angioplasty vessels remained unchanged indicating that tissue viability was 
maintained (296±28) and 270±19) before culture and 382±34) and 334±40) 
respectively after 24 hour culhlre). This was confirmed with the ATP:ADP ratio 
which again showed a similar pattern (2.15±0.05 and 2.26±0.06 before culture and 
2.56±O.lO and 2.41±0.09 respectively after culture) 
Total DNA was measured to assess total cell numbers and as an index of cell pro-
liferation (Table 1). Both fi-eshly isolated and balloon angioplasty vessels demon-
strated similar DNA levels before (0.52±0.08), 0.68±0.04) respectively) and after 
senllll free culture (0.74±0.09), 0.74±0.08) respectively) suggesting that the total 
cell number was maintained. 
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Vessel Control Ptca Control Ptca 
Hours in culture 0 0 24 24 
No of specimens 11 10 9 9 
ATP Conc. 296(28) 270(19) 382(31) 334(40) 
(nmollg wet wt) 
ADP Conc. 133(14) 128(15) 160(15) 125(17) 
(nmollg wet wt) 
ATP/ADP ratio 2.15 2.26(0.06) 2.56(0.10) 2.41(0.09) 
DNAConc. 0.52(0.08) 0.68(0.04) 0.74(0.09) 0.74(0.08) 
(f'g/mg wet wt) 
Table 1: Variation in purine metabolites and DNA concentrations at hour 0 and 
hour 24 for control and angioplasty vessel in serum free organ culture (RPM!) 
Morphological studies 
Histological examination of freshly isolated segments of coronary artery showed 
an intimal layer of endothelial cells separated from the muscular media by a con-
voluted internal elastic lamina (Figure la). Histological examination of angiopla-
sty vessels again demonstrated abundant elastic fibres and axial and longitudinally 
arranged smooth muscle layers in the media but now there was a clearly defined 
neointimallayer visible above the internal elastic lamina (Figure 1 b) 
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Figure I: Transverse sections of pig coronary artery stained with Miller's elastic 
van Gieson stain (x3?); 
(a) Control vessel demonstrating abundant elastic fibres and axially and longitu-
dinally arranged smooth muscle cell layers. Note the virtual absence of an intima. 
(b) Angioplasty vessel demonstrating the development of a neointima. Note the 
increased degree of intimal proliferation over the ruptured internal elastic lamina. 
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Morphometric analyses demonstrated a markedly thicker vessel wall in 
angioplasty vessels (n=9) compared to control vessels (n=lO) (291(26) vs 205(20), 
p < 0.001 vs control vessel). This was due to the presence of a neointima in 
angioplasty vessels (mean neointimal thickness, 92.8 ± 28.0 fun, n = 9) compared 
to the absence of a measurable intima in the control vessels. There was a marked 
difference in the intimal thickness over areas where the internal elastic lamina was 
ruptured compared to areas where the internal elastic lamina remained intact (206 
± 28 vs 39 ± 6fun, p<O.OOI). Measurement of the medial thickness demonstrated 
no difference between the angioplasty and control vessels (205 ± 20 vs 201 ± 16 
f1m) or between areas with intact or disrupted internal elastic lamina (206 ± 18 vs 
202 ± 26f1m respectively). 
Immunocytochemistry with a monoclonal antibody to <x-actin was performed to 
identify and localize vascular smooth muscle cells. In sections of control corona-
ry artery most of the medial cells stained positively for <x-actin. In the angioplasty 
vessels positive staining was observed in the media and also throughout the neoin-
timallayer (Figure 2) suggesting that the cells in the neointimallayer were predo-
minantly smooth muscle cells. 
This was confirmed by transmission electron microscopy which showed tltis layer 
comprised of extracellular matrix and smooth muscle-like cells containing an 
abundance of rough endoplasmic reticulum and few actin filaments suggesting 
them to be in a synthetic rather than a contractile phenotype. Scatming electron 
microscopy showed that the endothelial monolayer in both control and angioplasty 
vessels was largely undamaged during preparation and these appearances were 
maintained after serum free cui hIre. 
The basis of the neointimal accumulation of cells was investigated by pulse label-
ling the vessel segments with [,H)-thymidine during culhlre. Thymidine incorpo-
ration and autoradiography were then used to assess cell proliferation. Liquid 
scintillation counting reflecting overall cell proliferation (endothelial, smooth 
muscle and fibroblast) suggested that cell proliferation was occuring during cui hl-
re in both control and angioplasty vessel (mean count of 1200dpm/mg wet wt). 
Autoradiography of transverse vessel segments cui hIred and pulse labelled for 24 
hours with ['H)-thymidine was used to localise the proliferating cells. This demon-
strated the presence of cells with silver grains over their nuclear region in both the 
neointimallayer but also the medial layers of the angioplasty vessels (Figure 3). 
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Figure 2: Transverse sections of control and angioplasty pig coronary artery stai-
ned with anti smooth muscle a-actin (x37); 
(a) Control vessel demonstrating granular staining of the medial smooth muscle 
cells with no staining of the area of the internal elastic lamina or endothelium 
(Counterstained with Harris' haematoxylin) 
(b) Angioplasty vessel demonstrating granular staining of the medial smooth 
muscle cells but also granular staining of most of the cells in the neointima 
(Counterstained with Harris' haematoxylin). 
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(a) 
Figure 3: Transverse sections of pulse labelled control and angioplasty pig coro-
nary artery cultured for 24 hours. Sections were autoradiographed and then post 
stained with haematoxylin and eosin (x3?). 
(a) Control vessel demonstrating few labelled nuclei 
(b) Angioplasty vessel demonstrating proliferating cells both ill the neointimal 
but also ill the medial layers. 
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In the control vessels there were only a few proliferating cells in the medial layer. 
The number of ['H)-thymidine labelled cells /nun' in both intima and media of 
angioplasty and control vessels are given in Table 2. There were significantly 
more labelled intimal and medial cells in the angioplasty vessels than control ves-
sel suggesting that the neointimal cells were perhaps arising from both migrating 
cells from the media and also dividing cells in the neointima. 
Vessel 
No of specimens 
Thymidine incorporation 
(dpm/mg wet wt) 
Labelled nucleilmm 
Intimal 
Medial 
Intimal labelled nuclei 
Imm2 
Medial labelled nuclei 
inun2 
Control 
(+IEL) 
10 
1289(341) 
o 
2.12(0.45) 
o 
13.88(3.22) 
Ptca 
(-!EL) 
9 
1326(226) 
1.03(0.23) 
3.36(0.28)* 
26.39(8.82)* 
17.65(1.17) 
Ptca 
9 
1326(226) 
8.05(0.84) 
4.53(0.41)*+ 
48.74(2.57)*+ 
24.90(3.42)# 
Table 2: Quantification of intimal proliferation. Vessels were exposed to ['H) 
Thymidine for the last 24 hours. Labelled nuclei contained at least 20 silver 
grains. The number of nuclei is expressed per nun of intimal length. +IEL= Intact 
internal elastic lamina, -lEL= Ruptured internal elastic lamina. * p<O.OO I vs con-
trol, # p<0.05 vs control, + p<O.OO 1 vs +IEL. 
Cell proliferation assay 
A Swiss 3T3 fibroblast bioassay was used to assess mitogenic activity in the cul-
hIred media. Basal culhu'e medium produced proliferation of 3T3 fibroblasts as 
assessed by ['H)-thymidine incorporation of 1O,224±1,227 dpm/well (n=12). 
Conditioned media from control vessel caused a 5.8±0.45 fold stimulation over 
basal media whilst angioplasty vessels caused a 6.4±0.44 (n= 10) stimulation over 
basal media. By comparison 10% foetal calf senun resulted in a 5.6±0.49 stimu-
lation over basal media. 
A polyclonal neutralising antibody was used to assess the contribution of PDGF-
like activity to the growth promoting activity of the conditioned media. 
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Compared to non immune IgO, anti PDOF did not significantly affect the mitoge-
nic activity of the conditioned media at a concentration of either 50 or 100 f.lgiml 
(Table 3) suggesting that either the majority of the mitogenic activity of the condi-
tioned media must be due to other mitogenic peptides or the concentration of 
PDOF in the conditioned media was such as to abolish any effect from the antibo-
dy. 
Media Fold Stimuln Fold Stimuln 
PDGFAb Non iImnune 
IgG 
PDGF Ab [50l1g/ml) 
RPMI+ 10% FCS \.6(0.27) 
Conditioned Media from 
a) Control vessel 3.2(0.45) 2.3(0.36) 
Angioplasty vessel 2.5(0.34) 1.9(0.26) 
PDGF Ab [lOOllg/ml) 
RPMI+ 10% FCS 0.9(0.28) 
Conditioned Media from 
a) Control vessel 3.9(0.12) 3.3(0.88) 
Angioplasty vessel 3.2(0.46) 2.8(0.80) 
Table 3: Mitogenic activity of conditioned media and response to PDOF neutrali-
sing antibody or non limnune IgO at concentrations of 50 and 100f.lg/ml; The cell 
proliferation values are given as percent stimulation over basal culture media 
(mean (SEM)). FCS - Foetal Calf Serum. PDOF - Platelet Derived Orowth Factor 
Expression of mRNA for PDGF B 
RT-PCR analysis was used to assess levels for PDOF A and B chain in angioplasty 
vessel and controls. Using this technique similar levels of PDOF A and B chain 
were observed in both types of vessel (Figure 4). 
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MCACACA 
- PDGF A 
Figure 4: RT-PCR analysis of angioplasty and control vessels. Amplification of 
reverse transcribed DNA sequences for PDGF A and PDGF B were performed as 
described in the methods section. After electrophoresis of RT-PCR products from 
vessel segments intense bands were detected by ethidium bromide staining for the 
molecular weight marker(M). The upper panel illustrates amplification products 
for PDGF B whilst the lower panel illustrates amplification products for PDGF A. 
Lanes 2, 4 and 6 are control vessel and lanes 3,5 and 7 are angioplasty vessel. 
Similar levels of PDGF A (227 bp, lower panel) and B transcript (271 bp, upper 
panel) are seen in both control and angioplasty vessel. 
Discussion 
Tltis study has demonstrated that balloon angioplasty of normal porcine coronary 
arteries results in vsmc migration and proliferation with the subsequent formation 
of a clearly visible neointima. Furthermore, the degree of neointimal proliferation 
is sigttificantly increased if the internal elastic lamina is ruptured suggesting a criti-
cal role for the internal elastic lamina in restenosis. Explanted vessels can be main-
tained in short term serum free organ culhlre with no detectable loss of tissue via-
bility. Moreover conditioned media from these vessels induces proliferation of 
Swiss 3T3 fibroblasts equivalent to 10% calf serum. 
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The origin of this mitogenic activity is unclear but may relate to growth factor pro-
duction from the vessel wall itself. 
Efforts to reduce or eliminate restenosis have so far been hampered by the lack of 
knowledge regarding the pathophysiological mechanisms involved and the lack of 
an accurate animal model in which to study the phenomenon further. In the present 
model a reproducible neointima occurs within a reasonably short time following 
oversize balloon injmy to a normal coronary artety. The majority of the cells in tltis 
layer were identified as smooth muscle cells by immunocytochemical staining with 
smooth muscle cell a-actin antibodies. Furthet1110re autoradiography performed on 
ex-vivo cultured segments of artety suggests that these cells were actively prolifera-
ting. 
Why tltis intimally directed smooth muscle cell migration, proliferation and laying 
down of extracellular matrix occurs is unclear. It may relate however to the intimal 
and medial damage induced by balloon angioplasty. When the endothelial monolay-
er is denuded, it's barrier function is lost, resulting in the adherence of platelets 
which may then stimulate smooth muscle cell ntigration and proliferation by the 
release of different growth factors (12). Furthermore the discontinuity and dysfimc-
tion of the endothelium during endothelial regrowth may result in the loss of the 
physiological balance between the smooth muscle cell growth promoters and inhibi-
tors culminating in the smooth muscle cell migration and proliferation (13, 14). 
Adherent platelets, injured and dead smooth muscle cells and mechattical stretching 
of the smooth muscle cells may also result in the release of a number of mitogens 
resulting in the phenotypic change of smooth muscle cells to the synthetic type (15). 
The structural integrity of the internal elastic lamina appears to be crucial in mini-
mising neointimal thickening. The mean intimal tltickness increased fi'om 39(6) fun 
in regions where the internal elastic lamina was intact, to 205(2S)/lm where it was 
ruptured giving an overall mean intimal thickness of 92(2S)flm. Thus although rup-
ture of the internal elastic lamina is not a prerequisite for neointimal formation it 
appears to amplifY the phenomenon. This may be because it reflects greater vessel 
injury. Tltis is unlikely however as all portions of the vessel are equally stretched 
when the balloon is inflated. A more likely explanation is that rupture of the intern-
al elastic lamina exposes the medial tissues to flowing blood increasing local platelet 
deposition and local growth factor production. Furthermore associated medial tears 
result in the loss of contact inhibition, both between cells and between cells and 
their extracellular matrix, wltich mechanisms of which are known to constrain 
smooth muscle cell proliferation (16). Additionally, rupture of the IEL may result in 
the loss of any physical banier it may represent to the intimal ntigration of the 
medial smooth muscle cells. Any or all of these mechattisms could lead to the over 
exuberant vessel reaction seen in these areas. Similar observations regarding the 
importance of the internal elastic lantina have also been seen in pig coronaty arte-
ries injured by wire stents (17) and oversize balloon injury (IS). Moreover a recent 
report suggests that these observations may also be true in man (19). A comparable 
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phenomenon is also seen in atherosclerotic coronaty arteries in man where intimal 
smooth muscle cell proliferation is often associate with gaps in the internal elastic 
lamina (20). 
The angiographic facilities available did not allow quantitative measurements to be 
performed pre and post angioplasty to determine whether the degree of intimal pro-
liferation seen resulted in a significant stenosis, but based on the histological meas-
urements with a neointimal thickness of 92(28)l1m this is unlikely. Nevertheless the 
underlying pathophysiological process involved in restenosis, intimally directed 
smooth muscle cell migration and proliferation, occurred reproducibly within a 
short time span. 
The use of this pig model offers specific advantages over other animal models for 
the study of intimal hyperplasia. Pigs resemble man with respect to their coronaty 
circulation, platelet coagulation system and lipoprotein metabolism. Furthermore 
pigs are known to develop atherosclerotic plaques similar to those found in man and 
their intima contains smooth muscle cells that participate in the response to vascular 
injUly and in the development of spontaneous intimal thickening in older pigs (21). 
Additionally, the lesion produced by balloon angioplasty resemble those of human 
post angioplasty restenosis in being composed of smooth muscle cells. 
A number of pig models have previously been described. The pig carotid artery 
model (22), aIihough useful for studying the acute response of the vessel wall to 
angioplasty does not cause significant intimal proliferation and any significant pro-
liferative stenoses are due to organised thrombus. Furthermore the artery used (the 
carotid) is an elastic vessel with proportionally more smooth muscle than the mus-
cular coronaty artelY. The recently proposed coronary stent restenosis model (17, 
18) although resulting in gross and histopathologic lesions virtually identical to 
human restenosis tissue, is limited by the excessive tissue response perhaps as a 
result ofthe vessel wall being under constant tension by the stent, as well as the 
high cost of the stents themselves. 
The present model admittedly does not result in substantial vessel occlusion but 
nonetheless the underlying pathophysiological process involved occurs and can be 
monitored. Furthermore the use of standard catheterisation techniques means that 
the model may be useful for the assessment of new techniques for local drug deli-
velY such as the microporous balloon which offers the possibility of topical delivelY 
at concentrations which may be toxic at systemic level (23). 
There are however a number of limitations. The animals used are young with nor-
mal coronaries and no underlying atherosclerotic plaque. Tltis means that we are 
unable to comment on any effect the plaque/vessel wall interaction may have in the 
in-vivo human restenosis process. Furthermore the degree of intimal proliferation 
seen is unlikely to result in significant stenoses lintiting our ability to connnent on 
the influence of any local flow dynamics. These limitations can to some extent be 
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overcome by adaptation of the model. For example sequential balloon angioplasties 
at four weekly intervals may be a more realistic version of the in-vivo situation of 
stenosis dilatation. Furthermore the model may be adapted to produce occlusive dis-
ease by the addition of cholesterol feeding. Using cholesterol feeding and balloon 
denudation of the coron31Y arteries, for example, Lee and Lee produced significant 
coronalY stenoses with virtual occlusion ofthe vessels and resulting myocardial 
ischaemia, myocardial infarction and sudden death within 3-6 months whilst the ani-
mals were still relatively small (40-50 Kg) (24). 
We used our model to assess endogenous growth factor production using a serum 
free organ culture technique. Our first concern initially was to ensure that tissue via-
bility was maintained in the absence of serum. Once we confirmed that tissue viabi-
lity was maintained in short term senun-fi'ee organ culture we used the technique to, 
firstly, assess the presence of endogenous growth factors in the cultured media using 
a Swiss 3T3 fibroblast bioassay system and, secondly, to demonstrate proliferating 
cells in the neointimallayer. 
Conditioned media fi'OIn both control and angioplasty vessels resulted in a 6 fold 
increase in the proliferation offibroblasts compared to a 1.5 fold increase caused by 
10% serum, suggesting the presence of growth factor activity in the cultured media. 
The origin of this mitogenic activity is unclear. It may have originated fi'om a num-
ber of sources including adherent platelets, dying cells, tissue injUly or the cells of 
the vessel wall itself 
It is unlikely that the growth factor activity was fi'om adherent platelets as the vessel 
segments were thoroughly irrigated with saline prior to culture and scanning e1ec-
tronmicroscopy confirmed the absence of any adherent platelets on the intimal sur-
face of vessels prepared for culture. Similarly the maintenance of the ATP concen-
o'ation and ATP/ADP ratio in culolre also argue against the possibility of growth 
factor release from dying cells. The most likely explanation is that the growth factor 
activity detected was released fi'om the vessel wall. It is unclear why the cono'ol 
vessel demonso'ated as much growth factor activity as the angioplasty site. One 
possibility is that the, unavoidable, tissue damage during harvesting of the vessel 
may have resulted in induction of growth factor production fi'om sublethally dama-
ged cells. 
We o'ied to elucidate the nature of the mitogenic activity filrther by the addition of a 
commercially available antibody to PDGF and compared the results to those of 
sample media incubated with non inunune IgG at the same concentration. The ad-
dition of antibodies to PDGF did not result in any significant inhibition of mitogenic 
activity, in either the cono'ol, or the angioplasty vessel, suggesting that PDGF is not, 
perhaps, the major lnitogen involved. An alternative explanation however is that the 
concentration of released PDGF in the conditioned media was such that the neuo'ali-
sing antibody used was swamped. 
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We also tried to obtaio supplementary evidence that balloon angioplasty leads to the 
activation of growth factor gene expression in the vessel wall by pelforming RT-
peR analysis on segments of angioplasty and control vessel. This demonstrated the 
presence ofPDGF B mRNA in both vessels suggesting that the message for PDGF 
B is present in the vessel wall. Whether tlus was induced during harvestiog, or 
whether it is present in the normal vessel wall is not clear. Additionally the tecluu-
que is not quantitative enough to allow us to determine whether there is increased 
expression of PDGF B mRNA in the angioplasty vessel. 
Factors other than PDGF could also be involved. For example fibroblast growth 
factor is a particularly good candidate because it is synthesized by both endothelial 
and smooth muscle cells. Fmthermore although not secreted it is released from dis-
rupted cells (25, 26) and cell disruption during harvesting may account for the lack 
of difference between the control and angioplasty vessels. The nucleotide data 
would be against tIus but of course they only represent any additional cell degrada-
tion wluch has occurred in the 24 hour culture period and not the initial damage that 
the vessel may have sustained during harvesting. Whether the addition of commer-
cially available antibodies to bFGF will inhibit tllis nlitogenic activity is unknown. 
In addition to allowing us to assess the role of growth factor production, the senun 
free organ culhlre tec1uuque also allowed us to demonstrate proliferating cells in the 
neointimallayer ex-vivo. This avoided the dangers involved in giving radioactive 
isotopes in-vivo. Little is known of the accuracy of the ex-vivo labelling ofprolif-
erating cells however. In the only study to compare lll-vivo with ex-vivo labelliog of 
proliferating cells, ex vivo labelllllg resulted io a patchy dishlbution of labelled cells 
which did not correspond with the [,HJ-thymidine labelling pattern obtained in vivo 
(27). This was io colonic and vaginal mucosa however, rather than the vessel wall. 
Furthermore the lll-vivo S phase cells were labelled with (JHJ-thynlidioe injected 30 
minutes before sacrifice and evaluated by autoradiography whereas the ex-vivo 
labelling was with Bromodeoxyuridioe iocubation for 60 minutes and subsequent 
ioununohistochemishy We were unable to confirm in our Shldy whether the ex-vivo 
labelled cells corresponded to in-vivo proliferatiog cells. It is not however the state 
of proliferation that is important but the rate and celtainly in our case the proliferati-
ve activity III the angioplasty vessel was much higher than io the control vessel. 
Conclusion 
This study demonsh-ates that neointimal smooth muscle cell proliferation occurs 
reproducibly followiog balloon injmy to normal porcine coronary artelY. 
Furthermore it suggests a pivotal role for the internal elastic lamllra III tIus pheno-
menon. It also provides evidence for growth factor release by cells intrinsic to the 
vessel wall, thrther characterisation of which may help us understand the mecha-
nisms involved III restenosis and guide the development of new therapies allned at 
reducing its lllcidence. 
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Abstract 
Background: Local drug delivery by perfusion catheters has been proposed as a 
means of delivering high concentrations of active drug into the coronary arterial 
wall but pressure mediated trauma and duration of vessel occlusion are key limita-
tions of these devices. We investigated a new delivery catheter which promises to 
overcome both these restrictions. 
Methods: The Dispatch™ perfusion catheter has a triple lumen shaft with a dis-
tally located polyethylene coil balloon. The coils are connected by a membranous 
aerofoil which, when inflated, divides the vessel lumen into an external compart-
ment allowing local drug delivery to the vessel wall and an internal compartment 
which allows perfusion of the distal coronary bed. Using an over the wire techni-
que the device was positioned in 16 coronary arteries (luminal diameter (lmn) 
3.2±0.4(SD» of II non-atherosclerotic pigs (25-68kg) and inflated to 9 atmosphe-
res. Coronary flow was estimated during device inflation using a doppler flow 
wire. Infusion of a selection of 5 compounds with incremental molecular weight 
(Range 0.3-150 kDa) was then performed for 10 minutes using infusion rates of 
0.2 to 1.0 mllmin. Following device deflation the animals were sacrificed and 
macroscopic and histological examination of the vessels performed. 
Results: Inflation duration 19.9±9.7min (Range 3-60 min) did not result in any 
signs of ischaemia or haemodynamic compromise. Furthermore intracoron31Y 
infusion of adenosine with the catheter inflated demonstrated enhancement of 
coronary flow velocity similar to normal controls. Macroscopic examination 
demonstrated that compounds ranging from 0.3-70 kDa could be infused into the 
coronary wall. Microscopy showed that penetration of the compounds was limited 
to the subendothelium, which showed an oedematous appearance at higher flow 
rates. Most of the endothelial layer and the internal elastic lamina remained 
intact. Adventitial localization of the drugs was also observed, but this was proba-
bly due to side branches included in the target vessel segment and supplying the 
vasa vaSOl'Um. Compounds with sizes 150 kDa and larger did not reach the suben-
dothelium. 
Conclusion: This new drug delivelY device is capable of safe prolonged infusion 
of a wide range of compounds up to 70 kDa in the subendothelium of normal por-
cine arteries. The device thus has potential for ameliorating acute occlusion and 
late restenosis post coronary intervention. 
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Introduction 
Percutaneous coronary revascularisation has become increasingly complex with 
more advanced catheter teclUlologies (laser, atherectomy, stents) being used to 
treat increasing numbers of patients with more complex coronary lesions(l). Most 
teclUliques however remain limited by acute occlusion in 3-8%, and late restenosis 
in 30-50% of cases with only the implantation of stents having been shown to re-
duce angiographic restenosis, albeit in a selected patient population and at the ex-
pense of higher haemorrhagic complications (2, 3). Although progress in solving 
both early and late complications has been slow, recent evidence suggests that the 
systemic administration of new monoclonal antibodies directed against the platelet 
glycoprotein lIb/IlIa can reduce both acute occlusion and the late need for corona-
ry revascularisation procedures in high-risk angioplasty patients, again at the cost 
of higher bleeding complications (4, 5). Local delivery of these and other agents 
would, however, offer a means of ensuring high concentrations of the active drug 
at the intervention site whilst avoiding their systemic complications (6, 7). 
Moreover site specific drug therapy would also be invaluable for the catheter 
based treatment of intracoronary thrombus in the setting of unstable angina or 
acute myocardial infarction. 
Most methods of local drug delivery presently rely on catheters which isolate the 
target vessel by balloon occlusion (7). In the coronary circulation, this approach 
has the serious limitation of inducing myocardial ischaemia. In addition, the first 
generation of porous balloon catheters was also shown to induce substantial local 
vessel trauma due to the high pressure jets of the drug solution (8). Although the 
second generation of microporous and channelled balloon catheters have minimi-
zed the degree of vessel wall injury they are still limited by the need for coronaty 
artelY occlusion during drug delivery (7). In this study we assessed a new dmg 
infusion catheter designed to allow prolonged balloon inflation and local drug 
delivery with minimal vessel wall trauma. Our aims were to determine the safety 
of the procedure, assess coronary flow reserve during catheter inflation, assess the 
efficacy and depth of penetration of a range of compounds of incrementalmolecu-
lar weight and finally determine the amount of wall injury induced by the device. 
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Methods 
Coronary infusion catheter. 
The coronary infusion catheter shldied is a non-dilation, over the wire device 
designed for localized delivery of solutions (Dispatch™, Scimed Life Systems, 
Inc., Maple Grove, MN; Figures 1 and 2). The catheter has a triple lumen shaft, 
the first lumen to inflate a distally located 20 n1111 long coil encapsulated by a thin 
polyurethane sheath to isolate the selected vessel wall from the lumen. A second 
lumen permits the use of a 0.014 inch coronary guide wire. The third larger lumen 
of the shaft is used to infuse solution which can enter the sheath isolated vessel 
wall through slits in the shaft between the coils. A radiopaque marker runs the 
entire length of the inflation coil to assist precise placement. 
Figure I: Schematic representation of Dispatch infusion catheter. Note distally 
located polyethylene coil allowing local drug delivery whilst maintaining distal 
perfusion. 
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Figure 2: Lower panel shows deflated Dispatch infusion catheter whilst upper 
panel shows fully inflated device. Note distally located polyethylene coil allowing 
local drug delivery whilst maintaining distal perfusion. 
Animal preparation. 
Experiments were performed in II cross-bred Landrace Yorkshire pigs (25-68 kg 
in weight; HVC, Hedel, The Netherlands). The investigations were performed 
according to a protocol approved by the Committee on Experimental Animals of 
the Erasmus University. The anaesthetized animals were connected to a ventilator 
which administered a mixture of oxygen, nitrous oxide (I :2, viv) and 1-4 vol % 
enflurane. A 9F guiding catheter was advanced to the coronary ostium through an 
introduction sheath placed in the left carotid artery. Coronary angiography was 
performed using iopamidol (IopamiroR 370) as contrast agent. Using on-line quan-
titative measurement of the arteriograms a segment of the left or right coronary 
artelY was selected with a mean diameter of 2.5 - 3.8 nun for the placement of the 
infusion catheter (3.0, 3.5 or 4.0 null) which was inflated to 6 Atm. 
Three types of experiments were performed: I) To determine the safety of the pro-
cedure the infusion catheter was inflated for prolonged periods of time and the 
occurrence of myocardial wall motion abnormalities and serious arrhythmias 
recorded; 2) To determine the possibility of increasing distal coronary blood flow 
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during catheter inflation, coronary infusion of the vasodilator drug adenosine was 
performed ; 3) To assess the efficacy of acute delivery of compounds with incre-
mental molecular size into the coronary arterial wall macroscopic and microscopic 
evaluation was used to determine the depth of marker penetration and the degree 
of wall damage. 
Coronary flow velocity measurements. 
In three experiments a flexible coronary doppler angioplasty guidewire with a 12 
MHz piezoelectric transducer at the tip (Cardiometrics, Mountain View, CA) was 
positioned parallel to the infusion catheter shaft, across the inflated coil, in the 
distal coronary artery. After the animals had been haemodynamically stable for at 
least 30 min baseline recordings were made of coronary flow velocity with the 
infusion catheter coil inflated (9). Thereafter, a selective intracoronary dose of 
adenosine 20-60 ~lg/kg was administered and maximal flow velocity measure-
ments repeated until the hyperaemic response subsided. 
Drug infusion protocol. 
After inflation of the infusion catheter coil at the selected coronalY segment one 
of a selection of compounds or drug solutions was infused for 10 min. Target arte-
ries, drugs and infusion rates have been summarized in Table I. At the end of 10 
min infusion period, the coil was deflated and the infusion catheter removed. In 
cases of non-dye administration, the site of infusion was marked with a short infu-
sion of Evans Blue dye prior to removal of the catheter. After crossciamping the 
ascending aorta, the coronary arteries were perfusion fixed with 4% formaldehy-
de. The hearts were then excised and the coronary arteries dissected from the epi-
cardial surface. The infused segments and adjacent non-infused artery were placed 
in 4% formaldehyde in phosphate buffer (pH 7.3) for 48 hours in preparation for 
microscopy. 
Angiographic analysis. 
Coronary angiograms (at baseline, after placement and inflation of the catheter 
coil and finally after completion of the drug infusion protocol and removal of the 
catheter) were performed after i.c. injection of I mg isosorbide dinitrate and 
measured on-line by quantitative coronary arteriography (QCA) using the edge-
detection method (Cardiovascular Measurement System, Medis Inc, Nuenen, The 
Netherlands) (10). 
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Macroscopic examination 
The delivery of Evans blue or Evans blue-albumin complex in the vessel wall was 
assessed macroscopically and recorded using a dissection microscope 
Light- and fluorescence microscopy 
The coronalY vessels were fixed in 4% buffered formaldehyde, processed, sectio-
ned and paraffin embedded. Marker penetration was then assessed qualitatively. 
Evans blue-albumin non-stained sections were examined with fluorescence micro-
scopy and compared with non infused control sections. The 150 kDa anti-actin 
was assessed using a double antibody technique (secondary cross reaction with 
peroxidase labelled antibody). 
Infused 
Compound 
Fluorescent thiocyanate 
Evans Blue 
Evans Blue albumin complex 
Anti~actin antibody 
Activated Charcoal 
Activated charcoal 
Arteries 
(LADILCxlRCA) 
1I11-
-/2/-
I x 3.5 
4/-/-
1/-/1 
1I1/-
-/3/1 
Infusion Rate 
(mlfmin) 
0.2 
0.2 
0.2 
0.2 
0.2 
1.0 
D3 Size 
(mm) 
2 x 3.5 
I x 3.0 
I x 3.0 
3 x 3.5 
2 x 4.0 
I x 3.0 
I x 3.0 
2 x 3.5 
I x 4.0 
Mol weight (O)/Size 
3000 
1,0000 
70,0000 
150,0000 
10-25plll 
1O-25!'1ll 
Table I: Summary of target artelY, infused compound and infusion catheter size. 
FITC ~ fluorescent thiocyanate; EB ~ EVallS Blue; EBA ~ Evans Blue-albumin 
complex; 
Statistical analysis. 
All data are expressed as mean ± SD. Haemodynamic and angiographic parame-
ters were evaluated using paired t-test. A P-value <0.05 was considered statistical-
ly significant. 
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Results 
In all coronary arteries, the infusion catheter could be positioned at the site selected 
by QCA. After inflation of the coil, the distal coronary artelY received adequate 
baseline flow as assessed angiographically (TIM! Grade III flow in all cases, 
Figure 3). Continued coil inflation up to 60 min did not induce myocardial ischae-
mia as witnessed by direct observation of the heart after midline sternotomy, and 
the absence of ECG changes, while heart rate and blood pressure remained stable 
(Heart rate: pre 115±22, during 108±26, Mean aortic pressure: pre- 83±20, during 
67±20 lrull Hg (p=11S for both). 
Figure 3: Intracoronary doppler flow measurements at baseline after coil inflation 
(left panel) and after intra coronary adenosine (middle panel). D3 Infusion catheter 
in position and during angiogram (right panel). Note good distal perfusion even 
with catheter fully inflated. 
Coronary flow velocity measurements 
In the three experiments where coronary flow velocity was measured at baseline, 
administration of adenosine 20-60 fIg/kg i.c. induced reproducible increases in 
maximal velocity (Figure 3). 
Quantitative coronary angiography 
The average manufacturer specified infusion catheter coil size was 3.5 mm. 
Measurement of the baseline angiograms showed that the catheters were placed in 
coronary arteries 3.2 ± 0.4 nlln in diameter. It was not possible to measure the dia-
meter of the inflated coil during infusion because of interference by the strongly ra-
diopaque marker. After completion of the infusion protocol and removal of the ca-
theter the coronary diameter at the site of drug delivery had decreased to 2.7 ± 0.3 
lrull in the animals that had received infusion with a rate of 0.2 mJ/min, and to 2.3 
± 0.8 in the experiments where a rate of I mJ/min was used (p<0.05 vs baseline in 
both groups). 
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Acute drug delivery 
Macroscopic examination 
Macroscopic examination demonstratcd that compounds ranging from 0.3-70 kDa 
(Evans blue and Evans blue-albumin complex respectively) could be successfully 
infused into the coronary wall (Figure 4). 
Figure 4: Macroscopic appearances following infusion of Evans Blue. Note the 
'Zebra' effect secondary to the areas where the coil was in contact with the vessel 
wall 
Microscopic examination 
Fluorescence microscopy demonstrated Evans Blue penetration into the intima 
and adventitia but not into the media (Figure 5). 
Histological examination revealed localised endothelial damage with partial denu-
dation (Figure 6). The subendothelial space was oedematous with separation but 
no rupture of the internal elastic lamina. The media was intact as was the external 
elastic lamina and adventitia. Charcoal particles were seen in the adventitial vasa 
vasonnn and even in the adventitia and overlying muscle. 
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Figure 5: Histological section under fluorescence microscopy. Note the preserva-
tion of the endothelium and the presence of Evans blue in the subendothelial 
space and the surrounding adventitia. 
66 
Figure 6: Histological section stained with Haematoxylin and Eosin. Note locali-
sed endothelial damage with partial endothelial denudation. 
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Discussion 
The main findings of the present study are that prolonged infusion catheter infla-
tion (up to 60 minutes) is feasible with this device with no significant limitations 
to coronary flow or haemodynamic compromise. FlII'thermore compounds ran-
ging in molecular weight liOlll 0.3-70 kDa can be successfully infused into the 
coronary wall using tltis device. This is achieved with only minimal trauma to the 
vessel wall where there is only localised endothelial damage with preservation of 
the internal elastic. lamina and media. 
A number of drugs have been successful in altimal models of intimal proliferation 
but numerous large scale pharmacology trials in man have failed to demonstrate a 
significant reduction in clinical restenosis (11-14). These may have failed either 
because the drug used was ineffective in man or because the local concentration 
of active drug at the angioplasty site was inadequate. In animal models drugs can 
be given in ltigh doses which man Calmot tolerate without significant toxic side 
effects. Thus the systemic administration of an agent is lintited by significant side 
effects at high doses. Delivering agents directly into the angioplasty site has the 
theoretical advantage that a ltigh local dose of drug can be given without the 
worry of potentially toxic systentic side effects (6, 7, 15). 
A number of catheters have been proposed for such local drug delivery (6, 7). 
These include the double balloon catheter, the porous and nticroporous balloons, 
the stented porous balloon, the weeping balloon, the inflated externally strutted 
porous catheter and the porous sleeve. All have lintitations however. Some are 
limited by factors such as coupling of the perfusion presslll'e to the inflation pres-
slll'e resulting in substantial arterial wall injury including dissection (16, 17). 
Others are limited by a short infusion time in the coronary vessels due to the coro-
nary occlusive properties and expulsion of contents downstream or into side bran-
ches, either during delivery or on balloon deflation (18, 19). 
One of the major advantages of the present catheter is the independence ofbal-
loon inflation and hence artery-vessel wall fit from local drug delivery conditions. 
This is unlike a number of catheters, including the porous and microporous bal-
loon and weeping balloon, where both the balloon-artery fit and dl11g delivery 
conditions are deterntined by inflation presslll'e (19). This limits both the size and 
configuration of perforations within the balloon. Furthermore the coupling ofbal-
loon inflation and local drug delivery can also cause significant systentic adminis-
tration of the catheter contents during inflation and deflation of the balloon or as a 
result of a poor catheter-artery fit. In contrast the present catheter allows the cor-
rect pressure for the right balloon-artery fit and an independent infusion pressure. 
The lack of holes which may be plugged by blood also means that the present 
device can be used a number of times with no limitations to its efficacy. 
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The other important advantage of the present device however is the ability to 
bathe the vessel wall in drug for a prolonged period of time (up to 60 minutes) 
whilst maintaining distal perfusion. The intracoronary doppler studies would sug-
gest that even when fully inflated tltis catheter causes minimal obstruction to coro-
nary flow and preserves a normal hyperaemic response. This may be a substantial 
advantage if duration of drug infusion is important for the local concentration of 
drug. In addition prolonged coil inflation also suggests that the device may be 
useful in acute occlusion, allowing local infusion of, for example, thrombolytic 
therapy whllst ensuring the physical apposition of the vessel wall layers. 
The device allows prolonged local drug delivery wltilst causing mutimal trauma to 
the vessel wall. Although there is localised endothelial damage, the internal elas-
tic lamina remains intact at low infusion rates with no damage to the media. At 
the higher infusion rates although the internal elastic lamina appeared oedematous 
there was still no nticroscopic evidence of deep Uljury and medial damage. As the 
degree of deep injury may relate to the subsequent neointimal thickening (20) this 
suggests that use of the device is unlikely to cause additional damage to the vessel 
wall and increase neoultimal tltickening. 
We used 5 model compounds of incremental molecular weight to assess the range 
of compounds that tltis catheter could successfully transport into the vessel wall. 
The range ulcluded 0.3 kDa which is the lower limit of small synthetic drugs such 
as a calcium antagonist and beta blockers. Oligopeptides such as angiotensin and 
angiotensin II are Ul the range of 0.3-1 kDa wltilst the range of Evans Blue 
Albumul complex (up to 70kDa) is that of proteins such as Cytokines, growth fac-
tors and growth factor antagonists. The range 70- I 50kDa includes plasminogen 
(90kDa) and collagen type 4 (120kDa). Our study suggests that compounds in the 
range of 0.3-70 kDa can be successfully infused into the coronary wall. Thus 
compounds such as small synthetic drugs, growth factor antagonists and oli-
gopeptides may be successfully infused c1ulically using this device. 
As well as knowing whether an agent can be successfully unused it is also impor-
tant to know however whether the infused agent will be retained for a sufficient 
length of time. For example retention of heparin is less than 48hrs (2 I) whilst 
90% of deposited colclticule and methotrexate are cleared witltin a few hours (22, 
23). Tltis Iunitation may be addressed by the incorporation of biodegradable 
micro spheres into a matrix which can be deposited locally (24) or by using nticro-
particles such as charcoal as carriers, allowulg the controlled diffusion of unpreg-
nated drug over the course of time. A further advantage of using charcoal as the 
carrier particle is that the speed of release of the relevant agent from the charcoal 
can be substantially modulated. Although charcoal uptake into the vessel wall did 
not occur Ul our study it lllay do so Ul the c1utical situation where antecedent bal-
loon angioplasty is likely to have caused cracks, fissures and dissection planes 
(25) into which the charcoal may lodge. Certainly gold particles have been found 
in such dissection planes (26). The fUlding of charcoal particles in the adventitia, 
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carried there via the vasa vasorum also raises the possibility of local drug delivery 
by passive infusion inwards from the adventitia to the media. 
The penetration of marker dye into the adventitia in keeping with previous reports 
suggesting that a large proportion of radioactive microparticles and adenoviruses 
delivered endoluminally are deposited in the periadventitia and overlying muscle 
layers (27, 28). The most likely explanation for tltis is leakage of the dye into the 
side branches, the vasa vasonlln and from there into the adventitia. The effect of 
the delivered agent on this nontargeted tissue is unknown. Although it may detri-
mental if certain toxic substances are infused, if the appropriate agent is chosen 
this periadventitial deposition of a locally delivered agent with the resulting lumi-
nally directed diffusion, may be exploited as part of the local delivery strategy. 
Certainly periadventitial delivery of both heparin and dexamethasone have been 
shown to reduce neointimal formation (29, 30). In our experiments substantial 
infusion of drug into the local peri vascular environment may have occurred for 
the luminal diameter at the infused segment to have decreased so significantly at 
the time of the procedure. 
In our study the internal and to a lesser extent the external elastic lamina proved a 
sigltificant barrier to the penetration of the infused agent into the media. This, 
theoretically, may be a serious lintitatioll if, in clittical practice, it is itnportant that 
drug penetration into the media occurs for optimal treatment. It is not clear how 
relevant tltis barrier function of the TEL would be in the clinical situation however 
where the antecedent balloon angioplasty is likely to have already disrupted it. 
Even however ifthere is no medial drug delivery the device may still be useful for 
influencing surface events such as platelet adherence and thrombosis as well as 
for locally applied endothelial gene therapy (31, 32). 
Limitations of the study 
There are a number of potential limitations to the present study which must be 
acknowledged. As tltis was an acute study we only addressed the issues of feasi-
bility, safety and delivery efficacy of local ittfusion. We thus did not assess the 
retention properties of the infused agent or the selection of an appropriately effec-
tive agent. 
Secondly we only took itltO account the effect of molecular weight of the assessed 
compounds on their uptake. We do not therefore know what effect other molecu-
lar factors such as lipopholicity, ionic charge, tertiary and quartenary structure of 
the molecules may have on compound uptake. 
Third, the device was assessed itl normal coronaries with no preceditlg angiopla-
sty. Our findings may thus not be completely representative of the clinical sihl-
ation where the device would be used itl a diseased vessel. Ittitial experience sug-
gests however that the ability to maintain distal perfusion with no haemodynamic 
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compromise also applies to the clinical sihmtion (33). Additionally the infusion 
efficacy is likely to be increased rather than decreased in the clinical situation as 
the presence of atherosclerosis would help the transmural flux of fluid and macro-
molecules (34). Furthermore the greater vasa va sorum in the diseased vessel (35), 
would further increase the intramural surface area for drug movement by diffusion 
or convection. 
Conclusions 
Prolonged coil inflation (up to 60 minutes) is feasible with no significant limita-
tions to coronary flow or haemodynamic compromise. The device causes mini-
mal trauma to the vessel wall. Although there is localised endothelial damage the 
internal elastic lamina remains intact at low infusion rates with no damage to the 
media. Compounds ranging from 0.3-70 kDa can be successfully infused into the 
coronary wall. The device may thus have potential for ameliorating acute occlu-
sion and late restenosis post coronary intervention. 
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24. Intracoronary imaging with ultrasound 
ANDONIS G. VIOLARIS, CARLO DI MARIO, 
PATRICK W. SERRUYS, PIM J. DE FEYTER & 
JOS R.T.C. ROELANDT 
Summary 
Although intravascular ultrasound transducers were first developed and 
tested in the early seventies [1] it wasn't until the advent of catheter based 
coronary interventional techniques that a major impetus was given to their 
development. Because intracoronary ultrasound allows direct\ visualisation 
of the atherosclerotic plaque [2, 3], it may assist in the choice of intervention, 
guidance during the procedure and assessment of the results and any compli-
cations. Furthermore, direct real time visualisation of arterial wall morpho-
logy offers unique opportunities for the ill vivo assessment of arterial patho-
physiology and dynamics on a beat-to-beat basis. 
Instrumentation 
Two approaches are available for obtaining cross-sectional imaging of the 
vessel wall. Firstly by mechanical rotation, of either the ultrasound transducer 
itself, or an acoustic reflector in front of a fixed transducer. The advantage 
of these systems is high resolution imaging without the presence of a near-
field artefact. Realising a driving mechanism while keeping the catheter fully 
flexible and steerable are, however, challenging problems. Flexibility and 
steerability are not a major concern with the alternative, multi-element elec-
tronic approach, where sixty-four transducer elements are mounted circum-
ferentially in a 3600 radial array perpendicular to the long axis of the catheter, 
but this system is limited by near-field artifact and rcstricted resolution and 
dynamic range. The choice of equipment is important as there is evidence to 
suggest that image quality and interpretation varies between manufacturers. 
Image interpretation 
Comparisoll with allgiography 
A major limitation of contrast angiography is that it provides information 
predominantly about the vessel lumen. Consequently, morphological changes 
in the vessel wall are largely inferred from their effect on the lumen, but 
cannot be directly visualised. Furthermore, there is high inter- and intra-
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observer variability in the measurement of coronary stenosis and the com-
monly used percentage stenosis takes no account of the eccentricity, or 
otherwise of the stenosis or whether the 'normal' part of the vessel is truly 
normal. By contrast, ultrasound allows direct visualisation of the vessel 
wall and hence overcomes many of these inherent limitations of contrast 
angiography. Because intracoronary ultrasound almost invariably shows 
greater vessel involvement and lor more severe atherosclerosis, it is likely 
that new criteria for atherosclerotic severity, based on ultrasound findings 
will be required. 
Nevertheless intracoronary ultrasound cannot image the complete coron-
ary tree; therefore, contrast angiography will remain useful for road mapping, 
guiding the ultrasound probe to the area of interest. Ultrasound imaging will 
then provide more detailed information on the area of interest or target 
lesion. Greater integration of intracoronary ultrasound within angiographic 
equipment will be required to fully exploit the complimentary information 
provided, for improved real-time decision making during interventional pro-
cedures. 
Characteristics of the 1I0rmai wall 
III vitro and ill vivo studies have shown that muscular arteries can be distin-
guished from elastic arteries on the basis of their echographic characteristics 
[4]. Muscular arteries have a hypo echoic smooth muscle component in the 
media which results in a three-layered appearance, whereas elastic arteries 
and veins have a more homogeneous appearance to their vessel wall. Intimal 
atheroma and calcification may, however, induce diffuse attenuation or 
shadowing preventing the evaluation of the underlying media. Furthermore, 
in up to 20% of muscular arteries fibrous degeneration of the muscular 
component of the media results in a homogeneous appearance [5]. A homo-
geneous appearance is also seen in young people where the intimal layer is 
thin; some diffuse intimal thickening must be present before the (typical) 3-
layered appearance is visualised [6]. 
Study of the atherosclerotic plaque 
In vitro experience 
III vitro studies have shown that two types of atherosclerotic plaque can be 
distinguished [4, 5]. 'Hard' plaques, composed of dense fibrous tissue, are 
seen as bright echoreftective lesions with acoustic shadowing and perhaps 
duplicate echoes in the presence of calcific deposits. 'Soft' lipid rich plaques 
are weakly echoreftective (Figure 24.1). Thrombi, plaque rupture and dissec-
tion after intervention are also detected with great detail. 
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Figure 24.1. Intracoronary ultrasound images from diseased coronary arteries demonstrating: 
upper left panel. An eccentric, soft, weakly echo reflective plaque (arrow). Lower left panel. 
An eccentric, soft, weakly echo reflective, plaque with a 'lipid lake' (arrow). Upper right panel. 
A hard, strongly echogenic, fibrous plaque (arrow) extending from the 12 to the 5 o'clock 
positions. Lower right panel. A rim of superficial calcification (arrow), extending from the 1 to 
the 9 o'clock positions. Note the marked acoustic shadowing behind it. 
In vivo experience 
Peripheral vessels 
Intravascular imaging of the aorta, iliac and femoral arteries can be obtained 
easily and the severity of stenosis, type and extent of atherosclerotic plaque 
and involvement of the medial layer assessed [7, 8]. Quantitative analysis of 
lumen and plaque area shows a close correlation with digital angiography 
[9]. Various interventions such as transluminal angioplasty, atherectomy and 
endovascular stent delivery are accurately monitored [10]. In comparison 
with angiography, intravascular ultrasound demonstrates a higher sensitivity 
in depicting presence and extent of dissection, length of intimal tears and 
characteristics of flow in the true and false lumen. Direct insertion of the 
ultrasound catheter during surgery can be used to replace more complex 
angiographic procedures in the evaluation of the efficacy of arterial bypass 
operation or end-arterectomy in peripheral vessels [11]. 
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Corollary vessels 
The limitations of contrast angiography for guidance of coronary interven-
tional procedures has resulted in the development of smaller and more 
flexible catheters, amenable to coronary insertion. Intravascular ultrasound 
is able to detect and characterize atherosclerotic changes in what appear to 
be, angiographically, normal segments and in the presence of edge irregulari-
ties or luminal stenoses [12, 13]. 
Intracoronary imaging has provided direct evidence in support of previous 
pathology studies showing that coronary arteries undergo a progressive en-
largement in relation to increases in plaque area so that a reduction of lumen 
area is delayed until the atherosclerotic lesion occupies more than 40% of 
the area circumscribed by the internal elastic lamina [14]. These findings 
explain why angiographically normal arterial segments show extensive 
atherosclerotic involvement at surgery. Hermiller and colleagues [15], have 
demonstrated, in 44 consecutive patients, that when coronary segments with 
<30% area stenosis are examined, there is an excellent correlation between 
internal elastic lamina (IEL) area and plaque area. In these segments the 
IEL area increased by 2.7 mm2 for each 1 mm2 increase in plaque area 
suggesting that arterial enlargement may overcompensate for early atheros-
clerotic lesions. 
As well as being able to detect and characterize atherosclerotic changes in 
what appear to be, angiographically, normal segments, intracoronary imaging 
has also provided additional information in the presence of edge irregularities 
or luminal stenoses [12, 13]. Furthermore, directional atherectomy in con-
junction with intracoronary imaging has confirmed previous ill vitro studies 
suggesting that two types of atherosclerotic plaque can be distinguished [4, 
5] by demonstrating a higher collagen and calcium content in echogenic 
'hard' plaques and increased levels of fibrin, nuclei and lipids in 'soft' plaques 
[16]. 
As well as information on atherosclerosis, intracoronary imaging is also 
providing new insights into the pathogenesis of unstable coronary syndromes 
and accelerated atherosclerosis in transplant patients [17-23]. In the unstable 
coronary syndromes, ultrasound imaging has demonstrated more soft lesions 
and fewer mixed, calcified plaques with fewer intralesional calcium deposits 
than in stable angina, suggesting that ultrasound morphologic criteria are 
closely correlated to clinical anginal patterns [18-20]. Whether they correlate 
with clinical outcome, however, remains unknown. 
In cardiac transplant recipients, intracoronary imaging has demonstrated 
that even angiographically normal vessels show a range of coronary intimal 
thickening, which includes occasional evidence of focal, early atheromatous 
lesions [22]. Furthermore, it has also demonstrated a vasoconstrictor re-
sponse to acetylcholine at 1 year after transplantation suggesting endothelial 
dysfunction in the epicardial vessels [21] and that the vasodilatory response 
to nitroglycerin is attenuated during episodes of cardiac rejection, indepen-
dent of the degree of intimal thickening [23]. 
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Assessment of catheter based interventions 
Preliminary evidence suggests that imaging prior to interventions may be 
helpful for deciding which lesions may be most suitable for which specific 
treatment modality, and imaging post -intervention may be helpful in deline-
ating which patients are at increased risk of acute occlusion and long-term 
restenosis. 
Prior to intervention ultrasound allows the distinction of 'soft' plaques 
which are more likely to be dilated by compression, stretching and superficial 
intimal tears from 'hard' or clearly calcific plaques, which are at increased 
risk of extensive dissection after balloon angioplasty [24]. Furthermore, the 
presence of diffuse subendothelial calcification is associated with a lower 
success rate and higher risk of complications after directional atherectomy 
[25], indicating that alternative techniques such as rotational or laser atherec-
tomy should be used in this situation. Although echogcnic plaques are harder 
to resect by directional atherectomy than echolucent ones, they are also less 
likely to restenose [16]. These initial studies confirm previous clinical and 
pathological studies demonstrating that plaque morphology may affect out-
come, and suggest that increased stratification of patients for specific treat-
ment modalities, based on de 1I0VO plaque morphology, may help in reducing 
acute occlusion and long-term restenosis postwintervention. 
Following intervention, intracoronary ultrasound assessment may be useful 
in two ways, firstly in assessing and optimising the results and secondly in 
assessing the risk of acute occlusion and long term restenosis. Since angio-
graphy only provides an outline of the vessel lumen, an angiographically 
successful angioplasty may turn out to be a 'pseudo-success', perhaps because 
cracks and dissection planes in the vessel wall allow contrast flow, with, in 
reality, very little increase in the actual luminal area. Subsequent apposition 
of the split wall layers may result in an angiographic restenosis (a pseudo-
restenosis), a lesion being classified as restenosis whereas in fact it was never 
an actual success. Intracoronary ultrasound by visualising the vessel wall as 
well as the vessel lumen may have an important role to play in ensuring a 
good result, with a good luminal cross-sectional area after intervention 
(Figure 24.2). Furthermore, in the case of stent implantation, the clear 
imaging of the struts by intracoronary ultrasound ensures that the operator 
is aware of any incomplete stent expansion and can take appropriate action. 
A further important aspect of intracoronary imaging during intervention 
may be in providing prognostic information regarding the subsequent risk of 
acute occlusion or restenosis. Angiographic studies have shown that the 
presence of an intimal flap increases the risk of acute occlusion six-fold. 
Furthermore, post-mortem studies have shown that extensive medial tears 
also increase the risk of abrupt closure. As intracoronary ultrasound is very 
sensitive in detecting the development and characteristics of intimal flaps 
following interventional procedures [26, 27] it may be able to predict subse-
quent outcome. Preliminary evidence is supportive of this showing that in-
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Figure 24.2. Left panels. Quantitative angiographic assessment of an eccentric left anterior 
descending coronary artery stenosis prior (upper panel), and post (lower panel), successful 
rotablator therapy. Right panels. Angiograms prior (upper), during (middle) and post (lower) 
rotablator therapy with ultrasound images prior (upper) and after therapy (lower). Note the 
eccentric nature of the, mainly fibrous plaque, with deep seated calcification resulting in some 
acoustic shadowing, at the 5 o'clock position. Following rotablator therapy most of the plaque 
has been removed apart from the, previously, deep seated, calcification (arrow), 
timal tears are twice as common and also more severe in patients who 
subsequently went on to develop acute occlusion [28]. Preliminary evidence 
also suggests that intracoronary ultrasound may also be helpful in identifying 
a subset of patients who have a higher incidence of restenosis [26]. Both of 
these possibilities now need to be confirmed by the larger ongoing multicenter 
studies but the preliminary data sited above are already beginning to influ-
ence therapy with preliminary data from the ongoing GUIDE (Guidance by 
Ultrasound Imaging for Decision Endpoints) trial suggesting that the detailed 
information regarding plaque morphology provided by intracoronary ultra-
sound leads to a change in therapy in about 50% of cases. 
Pathophysiology of intervention and I'estenosis 
Intracoronary ultrasound has made a significant contribution to our under-
standing of the pathophysiology of coronary interventional procedures and 
restenosis. Intracoronary ultrasound studies have confirmed previous studies 
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in peripheral vessels showing that luminal enlargement following balloon 
angioplasty is achieved primarily by arterial wall stretching with lesion vol-
ume remaining essentially unchanged [29]. They have also suggested that 
both vessel stretch and dissection are uncommon after atherectomy [30] thus 
confirming that plaque removal rather than a 'dotter effect' as the major 
mechanism for improved lumen area after this procedure. 
Intracoronary ultrasound has also brought new understanding to the me-
chanisms involved in restenosis post-intervention. Our understanding of the 
mechanisms involved has previously been confined to serial angiographic 
assessment of the vessel lumen and post-mortem examination of limited 
histological tissue at specific time points in the disease process. Ultrasound 
has the potential to differentiate between the nature of the process (elastic 
recoil, mural thrombosis and intimal hyperplasia) and allow serial assessment 
of the if/-vivo vessel wall, hence increasing our understanding of the patho-
physiology of restenosis and allowing better targeting of therapeutic agents. 
These potential advantages have been recently confirmed by preliminary data 
from Kovach and colleagues, which suggest that chronic arterial recoil may 
have a far greater influence on late lumen loss and restenosis than previously 
thought [31]. 
Safety 
The safety of intravascular and in particular intracoronary ultrasound should 
be a major concern. So far no significant adverse events have been reported 
when intracoronary ultrasound studies were performed prior to and following 
interventional procedures, including patients with acute coronary syndromes. 
Transient coronary spasm has been observed and the catheter can occlude 
flow when advanced into stenoses or small distal arteries, in which cases 
prompt withdrawl is clearly necessary. Serial studies in patients have not 
shown an increase in stenosis of the instrumented vessels when compared to 
those which were not instrumented making endothelial damage and acceler-
ated atherosclerosis unlikely. These findings are of importance when one 
considers the use of intracorollary ultrasound in therapeutic trials for the 
study of regression/progression of atherosclerosis 
Potential clinical and research directions 
Angiography depicts only a silhouette of the vessel lumen; the extent of 
atherosclerotic disease and IUlninal narrowing, particularly in the early pre-
stenotic phase, may therefore be misinterpreted. Intravascular ultrasound 
has the potential for detecting atherosclerotic' changes in the pre-stenotic 
phase and allows accurate measuremen t of the plaque area as well as the 
vessel lumen. Furthermore it allows direct evaluation of plaque character-
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istics. These advantages have important implications for regression studies 
as dietary and pharmacological interventions are likely to induce regression 
of the vascular changes in the 'pre-stenotic' rather than the more advauced, 
phases of atherosclerotic disease. Intravascular ultrasound thus has the poten-
tial capability to directly visualise these vessel wall abnormalities and may 
differentiate lipid plaques, potentially amenable to regression from fibro-
calcific plaques which are less likely to respond to an intervention. Little 
progress has been made to date however because of financial costs and major 
problems in correctly locating the identical imaging position during long-
term follow-up. 
When a three-layered appearance is present in a muscular artery, the 
middle hypo echoic layer may be used as a landmark for the detection and 
quantitation of intimal and medial change [32]. Intravascular ultrasound 
could thus be useful in assessing changes in medial thickness induced by 
systemic arterial hypertension and evaluating the effects of long-term anti-
hypertensive treatment. Major limitations remain, however, as the plaque has 
a longitudinal architecture and is complex, requiring true 3-D reconstruction 
before these potential benefits may be realised. 
Work is also in progress in analysis of the backscatter signals to allow a 
more accurate and quantitative characterisation of plaque components. This 
may allow better discrimination between soft plaque and thrombus, which 
have roughly equivalent echogenicity, as well as characterising the lipid 
content of specific plaques and hence their propensity to rupture and acute 
occlusion. 
Three·dimellsiollal reconstruction 
The present imaging field is orthogonal to the catheter and is really only a 
two-dimensional representation of a complex three-dimensional process. 
Three-dimensional reconstruction of intracoronary ultrasound images is a 
major advance since tomographic views are now displayed longitudinally 
giving a more complete spatial picture of a coronary segment and any associ-
ated mural pathology (Figure 24.3). It thus offers an efficient gateway to 
the quantification of volumetric changes of atherosclerotic plaque, a better 
understanding of the complex longitudinal patho-anatomy and, when avail-
able on-line, would greatly help in guiding interventional techniques and 
assessing their results. Major problems remain, however, as present algo-
rithms do not take into account catheter shift during withdrawal and lumen 
curvature, resulting in a straight catheter line reconstruction and hence a 
three-dimensional image which is not correctly reconstructed spatially. 
Forward imaging 
All available imaging transducers to date are side facing, requiring advance-
ment of the transducer to the point of interest before images can be acquired. 
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Figllre 24.3. Intracoronary ultrasound cross-sectional image (left panel), taken at the level 
shown (middle panel), with the equivalent three· dimensional reconstruction (right panel). Note 
the detailed morphology visible on three-dimensional reconstruction. 
Forward imaging transducers would allow a more comprehensive assessment 
of severe stenoses/occlusions and may make the guidance of interventions, 
such as laser therapy, more feasible. 
Combination devices 
Therapeutic 
A combination device has inherent advantages over dedicated transducers 
by allowing real time ultrasound imaging during the procedure and obviating 
the need for repeat catheter exchanges. This would allow direct assessment 
of the immediate results and any associated elastic recoil. A number of 
combination devices incorporating balloons [33, 34], laser catheters [35J 
and atherectomy devices [36J have been developed and preliminary data is 
encouraging, suggesting that the on line qualitative and quantitative infor-
mation regarding the vessel wall obtained during the procedure influences 
operator strategy in over 40% of cases. 
Diagnostic 
The combination of intracoronary imaging with recording of blood velocity 
with a Doppler transducer mounted on the same catheter or on a separate 
guidewire would allow measurement of basal and post-intervention absolute 
regional coronary flow. In this way the effects of stcnoses can be adequately 
studied by integrating anatomic (stenosis cross-sectional area) and physiol-
ogic data (velocity increase at the site of the stenosis, regional flow reserve). 
The combination of intravascular imaging with simultaneous recording of 
high-fidelity blood pressure allows arterial compliance to be accurately calcu-
lated from the slope of the pressure-dimension relationship [37J. With this 
method the changes induced by disease or ageing on the arterial wall can be 
evaluated, and the effects of pharmacological agents monitored. 
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Problems and limitations 
There are important limitations of the present technology which are currently 
being addressed. Although a marvel of miniaturising technology, imaging 
transducers are still relatively large precluding the visualisation of clinically 
significant coronary stenoses prior to intervention or the more distal coronary 
arteries. Furthermore, the handling characteristics such as trackability, flexi-
bility and steerability of currently available systems are still not optimal. This 
has important implications, particularly for intracoronary applications, where 
all the elements of the catheter, including the distal end where the echo-
transducer is mounted, must be fully flexible in order to allow safe and 
successful negotiation of tortuous vessels. Furthermore, increased steerability 
of the catheters is required to correct for non-coaxial or eccentric intraluminal 
positions, as the perpendicularity of the ultrasound beam to the vascular wall 
influences the intensity with which a stmcture is visualised and partial drop-
out occurs above a critical angle [27]. In addition, the 'blooming effect' 
induced by off-axis positioning of the catheter, results in an overestimation 
of the vascular lumen and wall. 
The present images are not consistently enough adequate for a complete 
evaluation of vascular dimensions and morphologic changes. Furthermore, 
relatively long acquisition times limit the study of luminal changes during 
the cardiac cycle. Shorter acquisition times are desirable for a more precise 
study of systolic-diastolic changes in luminal dimensions. 
These technical problems are currently being addressed with the introduc-
tion of even smaller (2.9F), more flexible transducers and with industry talk 
of imaging guidewires, which would not only allow assessment of severe 
stenoses, but also serve as a platform for therapeutic devices allowing real 
time imaging, on-line during the procedure. 
Our knowledge of the appearance of normal and diseased vascular walls 
and the effects of intervention is still in its infancy, however, and the ad-
ditional diagnostic and prognostic information obtained in small studies to-
date must be confirmed in large on-going trials before the expected benefit 
outweighs the potential costs. 
Conclusions 
Direct visualisation of the vessel wall by intravascular ultrasound opens up 
a world of opportunities to us. It may provide prognostic information on 
atherosclerosis, and allow the assessment of the effects of dietary and phar-
macologic interventions in high risk patients. Furthermore, intracoronary 
ultrasound offers potentially unique information for the selection and guid-
ance of catheter based interventional techniques. 
89 
Acknowledgwments 
The authors wish to thank Mr J. Tuin for the preparation of the illustrative 
material. 
References 
1. Born N, ten HoffH, Lancee CT, Gussenhoven WJ, Bosch 10. Early and recent intraluminal 
ultrasound devices. Int J Card Imaging 1989; 4: 79-88, 
2. Roelandt J, Serruys PW. Intraluminal real-time ultrasonicjmaging: clinical perspectives. 
Int J Card Imaging 1989; 4: 89-97. 
3, Yock PG, Linker DT. Intravascular ultrasound. Looking below the surface of vascular 
disease. Circulation 1990; 81: 1715-8. 
4. Gussenhoven EJ, Essed CE, Lancee cr et af. Arterial wall characteristics determined by 
intravascular ultrasound imaging: an if! vitro study. J Am Coli Cardial 1989; 14: 947-52. 
5. Di Mario C, The SH, Madretsma S e( af, Detection and characterization of vascular 
lesions by intra\'ascular ultrasound: an in vitro study correlated with histology. J Am Soc 
Echocardiogr 1992; 5: 135-46. 
6. Fitzgerald PJ, St. Goar FG, Connolly AJ et al. Intravascular ultrasound imaging of coronary 
arteries. Is three layers the norm? Circulation 1992; 86: 154-8. 
7. Nishimura RA, Welch TJ, Stanson AW, Sheedy PF, Holmes DRJr. Intravascular ultrasound 
of the distal aorta and iliac vessels: initial feasibility studies. Radiology 1990; 176: 523-5. 
8. Gussenhoven EJ, Frietman PA, The SH et al. Assessment of medial thinning in atheroscler· 
osis by intravascular ultrasound. Am J Cardiol1991; 68: 1625-32. 
9. Da\'idson CJ, Sheikh KH, Harrison JK et al. Intravascular ultrasonography versus digital 
subtraction angiography: a human in vivo comparison of vessel size and morphology. J Am 
Coli Cardiol 1990; 16: 633-6. 
10. Isner JM, Rosenfield K, Losordo DW et af. Percutaneous intravascular US as adjunct to 
catheter-based interventions: preliminary experience in patients with peripheral vascular 
disease. Radiology 1990; 175: 61-70. 
11. van Urk H, Gussenhoven WJ, Gerritsen GP et al. Assessment of arterial disease and arterial 
reconstructions by intravascular ultrasound. Int J Card Imaging 1991; 6: 157-64. 
12. Tobis JM, Mallery J, Mahon D et al. Intravascular ultrasound imaging of human coronary 
arteries ill l'ivo. Analysis of tissue characterizations with comparison to ill vitro histological 
specimens. Circulation 1991; 83: 913-26. 
13. Nissen SE, Gurley lC, Grilles CL et al. Intravascular ultrasound assessment of lumen size 
and wall morphology in normal subjects and patients with coronary artery disease. Circu-
lation 1991; 84: 1087-99. 
14. Glagov S, Weisenberg E, Zarins CK, Stankunavicius R, Kolettis GJ. Compensatory enlarge· 
ment of human atherosclerotic coronary arteries. N Engl J Med 1987; 316: 1371-5. 
15. Hermiller lB, Tenaglia AN, Kisslo K et al. Compensatory enlargement of atherosclerotic 
coronary arteries: human in vivo validation [abstract]. Circulation 1992; 86 (4 Suppl): 1-
518. 
16. Suarez de Lezo J, Romero M, Medina A el al. Intracoronary ultrasound assessment of 
directional coronary atherectomy: immediate and follow·up findings. J Am Coli Cardiol 
1993; 21: 298-307. 
17. St Goar FO, Pinto FJ, Alderman EL, Fitzgerald PJ, Stadius ML, Popp RL. Intravascular 
ultrasound imaging of angiograpbically normal coronary arteries: an in vivo comparison 
with quantitative angiography. J Am Call Cardiol 1991; 18: 952-8. 
18. Hodgson 1M, Reddy KG, Suneja R, Nair RN, Lesnefsky EJ, Sheehan HM. Intracoronary 
ultrasoUlld imaging: correlation of plaque morphology with angiography, clinical syndrome 
90 
and procedural results in patients undergoing coronary angioplasty. J Am Coli Cardiol1993; 
n:~-«. . 
19. Torre SR, Sharma SK, Israel DR et al. Plaque morphology in acute coronary syndromes: 
new insights from intravascular ultrasound [abstract]. J Am ColI Cardiol 1993; 21(2 SuppIA): 
194A. 
20. de Feyter PJ, Escaned 1, Di Mario C et til. Combined intracoronary ultrasound and angios-
copie imaging in patients with unstable angina: target lesion characteristics [Abstract]. Eur 
Heart J 1993; 14(Suppl): 25. 
21. Mills RM Jr, Billett 1M, Nichols WW. Endothelial dysfunction early after heart trans-
plantation. Assessment with intravascular ultrasound and Doppler. Circulation 1992; 86: 
1171-4. 
22. SI. Goar FO, Pinto Fl, Alderman EL et al. Detection of coronary atherosclerosis in young 
adult hearts using intravascular ultrasound. Circulation 1992; 86: 756-63. 
23. Pinto Fl, St. Goar FG, FischeII TA et til. Nitroglycerin-induced coronary vasodilation in 
cardiac transplant recipients. Evaluation with ill vivo intracoronary ultrasound. Circulation 
1992; 85: 69-77. 
24. Fitzgerald PJ, Porls TA, Yock PG. Contribution of localized calcium deposits to dissection 
after angioplasty. An observational study using inlra\'ascular ultrasound. Circulation 1992; 
86: 64-70. 
25. Fitzgerald PJ, Muhlberger VA, Moes NY et al. Calcium location within plaque as a predictor 
of atherectomy tissue retrie\'al: an intravascular ultrasound study [Abstract]. Circulation 
1992; 86(4 Suppl): 1-516. 
26. Honye J, Mahon DJ, Jain A et al. Morphological effects of coronary balloon angioplasty 
ill vivo assessed by intravascular ultrasound imaging. Circulation 1992; 85: 1012-25. 
27. Di Mario C, Madretsma S, Linker D el al. The angle of incidence of the ultrasonic beam: 
a critical factor for the image quality in intravascular ultrasonography. Am Heart J 1993; 
125: 442-8. 
28. Tenaglia AN, Buller CE, KissJo KB, Phillips HR, Slack RS, Davidson CJ. Intracoronary 
ultrasound predictors of adversc outcomes after coronary artery interventions. J Am Coli 
Cardiol 1992; 20: 1385-90. 
29. The SH, Gussenhovcn EJ, Zhong Y el al. Effect of baI1o()J\ angioplasty on femoral artery 
evaluated with intravascular ultrasound imaging. Circulation 1992; 86: 483-93. 
30. Tenaglia AN, Buller CE, K1sslo KB, Stack RS, Davidson Cl. Mechanisms of balloon 
angioplasty and directional coronary atherectomy as assessed by intracoronary ultrasound. 
J Am Coil Cardiol1992; 20: 685-91. 
31. Kovach JA, Mintz GS, Kent KM et al. Serial intravascular ultrasound studies indicate that 
chronic recoil is an important mechanism of reslenosis following transcatheter therapy 
[abstract). J Am Call Cardiol1993; 21(Suppl A): 484A. 
32. Wenguang L, Gussenhoven WJ, Zhong Y et al. Validation of quantitative analysis of 
intravascular ultrasound images. Int J Card Imaging 1991; 6: 247-53. 
33. Isner JM, Rosenfield K, Losordo DW et al. Combination balloon-ultrasound imaging cath-
eter for percutaneous transluminal angioplasty. Validation of imaging, analysis of recoil, 
and identification of plaque fracture. Circulation 1991; 84: 739-54. 
34. Violaris AG, Linnemeier TJ, Campbell S, Rothbaum DA, Cumberland DC. Intravascular 
ultrasound imaging combined with coronary angioplasty. Lancet 1992; 339: 1571-2. 
35. Aretz HT, Gregory KW, Martinelli MA et al. Ultrasound guidance of laser atherectomy. 
Int J Card Imaging 1991; 6: 231-7. 
36. Yock PG. Fitzgerald PJ, Sudhir K. Linker DT, White W, Ports A. Intravascular ultrasound 
imaging for guidance of atherectomy and other plaque removal techniques. Int J Card 
Imaging 1991; 6: 179-89. 
37. Wilson R, Di Mario C, Krams R et al. Changes in large artery compliance measured with 
intravascular ultrasound [Abstract]. 1 Am Coli Cardiol 1992';·19 (Suppl A): 140A. 
91 
92 
Chapter 8 
Comparison of coronary luminal quantification obtained 
from intra coronary ultrasound and both geometric and 
video densitometric quantitative angiography, pre, and post, 
balloon angioplasty and directional atherectomy. 
Ozaki Y, Violaris AG, Keane D, Camenzind E, Di Mario C, de Feyter PJ, 
Roelandt JTRC, Serl'llYs PW. 
Circulatioll1997; 96 (2): 491-499 
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Comparison of Coronary Luminal 
Quantification Obtained From Intracoronary 
Ultrasound and Both Geometric and 
Videodensitometric Quantitative Angiography 
Before and After Balloon Angioplasty and 
Directional Atherectomy 
Yukio Ozaki, MD, PhD: Andonis G. Violaris, lvID, MD, MRCP; Tadashi Kobayashi, MD, PhD; 
David Keane, MB, PhD, MRCPI; Edoardo Camenzind, MD; Carlo Dj Mario, MD, PhD; 
rim de Feyter, i\.1D, PhD: Jos R.T.C. Roelandl, MD, PhD; Patrick W. Serruys, J'.ID, PhD 
Background Debate exists regarding the relationship be-
tween angiographic and inlracoronary ultrasound (IeUS) mea-
surements of minimal luminal cross-sectional afea after coro-
nary intervention. We investigated this and the factors that may 
influence it by using Jeus and quantita!i\'c angiography. 
Methods and Results Patients who underwent successful 
balloon angioplasty (n=loo) or directional athcrectomy 
(0=50) were examined by using Jeus and quantitative angiog-
raphy (edge-detection [EDJ and videodensitometry (VIOl) 
before and after intervention. Luminal damage postintelyen-
tion was qualitatively graded into three categories based on 
angiographic results (smooth lumen, haziness, or disse(:tion). 
Correlation of minimal luminal cross-sedional area measure-
ments by ICUS and ED was .59 before and .47 after balloon 
angioplasty. Correlation between ICUS and V1D was .50 
before and .63 after balloon angioplasty. Postintefvention, the 
difference between ICUS and VID was less than the difference 
Although QCA is the gold standard in interven-tional cardiology, pathology studies indicate that angiography may underestimate the extent 
and severity of atherosclerotic disease.J.2 While ICUS 
provides unique infonnation regarding vessel wall mor-
phology compared with angiography,J's precise quanti-
tative anal~is of luminal CSA by ICUS would offer a 
significant advantage in the guidance of coronary inter· 
vention procedures.9-11 A recent multicenter ICUS study 
in patients with coronary angioplasty indicated that 
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hetween ICUS and ED (P<.Ol). Additionally, the correlation 
was .74 between ICUS and ED measurements and .78 between 
JCUS and VID measurements in the smooth lumen group, .46 
and .63, respectively, in the presence of haziness, and .26 and 
.46, respec\i\'ely, in lesions with dissection. Similar results were 
obtained after directional atherectomy: the agreement bem'een 
ICUS and quantitative angiography deteriorated according to 
the degree of vessel damage, but less so with VID than ED. 
Conclusions Complex morphological changes induced by 
intervention may contribute to discordance between the m'o 
quantitative imaging techniques. In the absence of ICUS, VID 
may be a complementary technique to ED in lesions with 
complex morphology after balloon angiopJasty and directional 
atherectomy. (Cirel/folion_ 1997;96:491.499.) 
Kry Words _ angiography _ allgioplasty _ imaging _ 
coronary disease _ ultrasonics 
postinterventional luminal dimensions obtained by 
ICUS but not QCA may be a significant predictor of 
restenosis at follow-up.12 Additionally, another multi· 
center study suggests that a large residual plaque burden 
remains on ICUS imaging, despite optimal angiographic 
resuits.B Nakamura et al9 and Colombo et a110 also 
suggest that luminal measurements provided by ICUS 
may be helpful for optimal stent deployment. Previous 
studies, however, have provided conflicting evidence on 
the agreement between quantitative measurements de· 
rived from ICUS and those derived from QCA.J·4.1,14-l7 
The aim of our study was to clarify whether ICUS 
measurements agree with QCA measurements and to 
determine which factors, if any, may playa role in 
any discordance between the techniques. To do this, 
we compared MCSA obtained from ICUS and both 
ED and YID computer-based QCA before and after BA 
and DCA. 
Methods 
Patients 
Patients who had an ICUS examination before and after 
single-vessel BA (11=100) or DCA (n=50) with adequate 
Selffled Abbrenatlons and Acronyms 
BA '" balI(l(ln angiop!asty 
CSA = cross·sectioua! area 
DCA = directional coronary athereetomy 
ED = edge detection 
ED·QCA = edge-detection quantitative coronary 
angiography 
ICUS = intracoronary ultrasound 
MCSA = minima! luminal eross·sectional area 
MLD '" minimal luminal diameter 
QCA "" quantitative coronary angiography 
RD = reference diameter 
VID = videodensitometry 
VlD·QCA = videodensitometric quantitative coronary 
angiography 
quality of JCUS and angiographic images for quantitath'e 
analysis were enrolled in this study. Prcintelvention, the US 
catheter did not cross the target lesions in 20 lesions because of 
proximal yessel tortuosity, the severity of the target stenosis, or 
transient serious anh)1hmia during the Ieus examination. 
Additionally, the ultrasound catheter rompleteJy occluded the 
coronary lesion in 89 lesions. Thus, preinterYention MCSA of 
the stenotic segment was measured in the remaining 41 lesions. 
Postintervention Ieus measurements were obtained in .111150 
lesions in the 150 patients. 
DA or DCA Procedures 
All patients received full antiroagulant therapy including 
intra,·enous aspirin and heparin before leus examination and 
intervention. Coronary angiograms were rerorded on cinefilm 
after the intracoronal)' administration of isosorbide dinitrate (1 
to 2 mg). The size of the balloon or atherectomy de,ice was 
determined to match the yessel RD obtained from the online 
QCA measurement. Luminal damage postintervention was 
qualitatively graded into three categories by angiographie 
assessment as none (smooth lumen), generaliud haziness, or 
dissection. Dissection was defined acrording to the dissection 
classification types n, C, D, E, and F of the classification of thc 
National Heart, Lung, and Blood lnstitute.l~ 
ED·QCA 
The new veThion of the computer·based Coronal)' Angiog· 
raphy AnalYliis System (CAAS II)19.2tJ was used to perform the 
ED and VID quantitath'e analyses. In the CAAS analysis,I""'~ 
thc entire 18X24·mm cineframe j_~ digitized at a resolution of 
1329x 1772 pixels, and the boundaries of a selected coronary 
segment arc detected automaticaUy. The absolute diameters of 
the stenosis (MlD and RD) are detennined by using the 
rontrast-free guiding catheter as a scaling de,ice. To standard· 
ize the method of analysis before and after inter'o'Cntion, aU 
study frames selected for analysis were end·diastolic to mini· 
mize motion artifact, and arterial segments were measured 
between the same identifiable branch points in multiple ,iews 
after the administration of isosorbide dinitrate,ZO-H MCSA was 
calculated as rrX(MlOl)X(l\-fi..D2)-H from measurements 
obtained from the ED analysis in orthogonal views (MLDI and 
MLD2) before and after intervention. 
VID·QCA 
VIO measurement is based on the relationship between the 
attenuating power of tbe lumen filled "ith contrast medium 
and the x-ray image intensity,25 Using this relationship, a VID 
profile that was proportional to the CSA of the lumen was 
obtained. Subtraction of patient structure noise was applied 
after romputing the linear regre.ssion line through the back-
ground pixels located on both sides of the detected luminal 
contours. Consecutive densitometric profiles of the analyzed 
segment were acquired in all scan lines perpendicular to the 
vessel induding lesion, reference, and nondiseased areas, Con· 
\'ersion of the individual VIO profiles to absolute values was 
pcrfomled after a Iransfonnation of the VID profile found in a 
CSA of a nondiseased segment, assuming a CSA at any point is 
proportional to the dernitometric profiles at that point. MCSA 
was calculated from tbe average value obtained from the VID 
system in multiple ,·jews. The basic principles of the technique 
are illustrated in Fig 1. 
ICUS Image AC(juisition 
Following angiography, an ICUS ealheter (30 MHzj 2.9F, 
3.2F, or 4.3Fj Cardiovascular Imaging S)'stems) was introduced 
oyer a 0.014·in. guidc wire and positioned distal to the lesion. 
Lesion geometry was then imaged by using a slow, continuous 
c-atheter pull-back procedUre. Catheter position waS docu-
mented by simultaneous fluoroscopy superimposed on the 
Ieus display screen. JCUS inJages were stored on super VHS 
tape for ofIline anal}'liis. 
Quantitath'e and Qualitatiw Assessment of ICUS 
Luminal CSA was defined as the integrated area central to 
the mlinlal leading·edge echo. Images with MCSA were se-
lected from the pull·back sequence by reviewing the position of 
the ICUS catheter on the angiographic image that ·was reo 
corded on the same Ieus image and by reyiewing the time log 
and audio recording of the procedure to analyze the same 
coronary segment as the quantitative angiogram. Total yessel 
CSA was defined as the area inside the interface between the 
plaque-media complex and adventitia (ie, the area inside the 
cxtelllal elastic membrane). When the di.ssected lumen com-
municated constantly with the true lumen, the dissected lumen 
was included in the luminal area, as exemplified in Fig 2. Echo 
reflectivity was categorized as either low or high (plaque 
reflecti'lty lower or higher, respectively, than the bright adven-
tiliallayer}.26 Calcinm deposits were defined as highly echo-
reflective tissue with acoustic shadowing. A lesion was consid· 
ered homogeneous jf the plaque consisted of >75% of one type 
of echo reflecti\ity. A lesion was defined as mi'!:ed if it 
contained both high and low echo· reflective areas occupying 
>25% of the plaque area.u A lesion was considered predom· 
inantly calcific if calcium occupied > 180~ of the vessel 
circumferencc.26 
Luminal damage postintervention was qualitatively graded 
in to three categories: regular lumen, irregular lumen including 
a small tear not e.\tending to the media, and di.ssected IUlllcn 
\\ith circumferential tear behind the plaque or tear extending 
to the media.~·I;·17 The eccentricity ratio was c.llculated as the 
ratio between minimal and maximal wall thickncss (1 indicates 
concentric plaque, <1 indicates increasing eccentricity).21 To 
detennine the interobservervariabilityoflCUS measurements, 
3l) videotapes of the complete original recording were used by 
two independent observers to select and measure the minimal 
CSA. The mean signed difference and correlation of the 
measurements of minimal CSA were -0.12::':::0.79 mm l and 
0.9-l, respectively. 
Sinfistical Analysis 
In the absence of tbe known true values, Bland and Altman2'< 
recommend the use of the mean and SO of the signed 
difIerences between two measurement systems as an index of 
ag.-eement between the two systems. Thus, we took the mean 
and SD of the signed differences between ICUS and QCA 
measurements as an index of agreement between ICUS and 
QCA measurements instead of linear regre.ssion analysis. The 
individual measurements obtained from JeUS and QCA were 
compared by using the paired Student t test and correlation 
coefficient. A probability \'alue of <.05 was considered 
significant. 
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FIG 1. A, In the VlD technIque, a matrix Is placed over the area selected for analysis from the right coronary angiogram encompassing 
a complex coronary obstruction. B, Pseudo-three-dimenslonal representation of the brightness Information withIn the matrix and the 
coronruy artery can be recognized as a mountain ridge with a deep pass at the s1te of the obstruction; the brightness profile along one 
particular scan line Is plotted. C, Positions with maximal values of the sum of the first- and second-derivative functions left and right of 
the center posiUons of the artery correspond to the edge positions of the artery. D, Row chart of the analysIs Indicates the main 
procedures followed for the computation of the V1D area function. 
Results 
Baseline Clinical and Angiograpllic Characlerislics 
No difference was found in gender, age, anginal 
symptoms, or distribution of diseased vessels between 
the BA and DCA groups (Table 1). QCA measurements 
were obtained in 100 lesions before and after BA and in 
50 lesions before and after DCA. ED-QCA indicated 
that the RD before and after intervention and MLD 
postintcn'cntion were significantly larger in the DCA 
than the BA patients_ r-,'fCSA was measured by using 
ICUS in 26 lesions before BA and 15 lesions before 
DCA without wedge of the ICUS catheter. One hundred 
lesions after BA and 50 lesions after DCA were esti-
3.31mm 2 
FIG 2. Eo-QCA, V10-QCA, and ICUS analyses after BA In U.e middle segment of the left anterior descending coronary artery. left, 
Dissection is dearly seen In the reus image. Middle, EO algorithm partially traces bet-.."een the true and the dissected lumen. RighI, 
Complex morphological changes caused by BA may explain the discordance between MCSA measurements obtained from ICUS 
(4.9 mni) and Eo-OCA (2.96 mm2; Mlo, 1.43 mm) and VlD-QCA (3.31 mm~. The VID-OCA value Is nearer to the [CUS measurement 
than the ED-QCA value; see "Discussion!' 
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TABLE 1, Baseline Clinical and Anglographlc Characteristics of 150 Patients 
BA(II_1OO) DCA (II-50) P 
No. of patients (WF) 100 (81119) 50 (4JI7) 
Age, y 59~10 58±9 NS 
Stable/unstable angina, II 53/47 24126 NS 
RC.AAAOIlCX!SVG, n 31/47/18/4 8/34/610 NS 
luminal diameter by ED-OCA, mm 
MtD before 1.05±O.50 1.20±O.43 NS 
RD before 2.S5~O.64 3.51±O.61 <.001 
MlD after 2.04±0.5S 2.81:!:0.59 <.001 
RD after 2.98±0.70 3.69±O.59 <.001 
Plaque composit!oo estimated by IGUS, n 
Homogeneous plaque (echo refiectivity: 64 (54/812) 31 (26/5/0) NS 
PoorflJI9h with shadowflJ~h without shadow) 
Mixed plaque 36 19 NS 
None/<90'/290' calcium deposits 26/42/32 15/19/16 NS 
luminal measurement by lCUS 
Total vessel area before, mm~ 17.00±5.35 19.68±4.84 <.05 
Plaque and media area before, mm2 13.65±4.97 16.9n4.99 <.015 
Plaque and media area before, % 79±7% 86±5% <.05 
Eox:en!ricity Index O.43±O.24 O.38±O.22 NS 
RGA indicates right coronaI)' artery; lAD, left anterior descooding coronary artery; lCX. left circumflex 
coronaI)' arte!)'; and sva, sapheooos veln graft. NI 150 lesions were analyzed by OCA before and by OCA 
and IGUS after interventfoo. PreintefVention, 26 and 15 lesloos thai were to be treated by SA and DCA, 
respectiyety, were analyled by IGUS; lesions with wedge of IGUS catheter (BA=74 and DCA=35) were 
excluded from IGUS analysis. 
mated by using lCUS, wbich revealed that 64 lesions in 
BA and 31 lesions in DCA consisted of homogeneous 
plaque; aU remaining lesions were classified as mixed. 
Most of tbe homogeneous plaque was low echo reflec-
tive. Focal calcium deposits were observed in 42 lesions 
in BA and 19 lesions in DCA, while moderate-to-diffuse 
calcification was seen in 32 lesions in BA and 16 lesions 
in DCA (P=NS). Total vesscl CSA, plaque and medial 
CSA, and percent plaque and medial CSA preinterycn-
tion were larger in the DCA than the BA group. Lesion 
cccentricity was not significantly different between the 
two groups. 
MCSA Measured by lCUS, ED-QCA, and VID·QCA 
Before and Afler Intenentlons 
Table 2 shows thc MeSA measured by ICUS, ED-
QCA, and VID-QCA before and after BA and DCA. 
MCSA in Ilomvedged Icsions (DA=26 lesions and 
DCA= 15 lesions) as obtained by lCUS was significantly 
larger than MCSA measured by using ED- or VID-QCA 
pre-BA (both P<.OI) and pre-DCA (both P<.01). 
Post-BA MCSA in 100 lesioll5 as obtained by lCUS was 
significantly larger than the I\KSA measured by either 
ED- Qr VID-QCA (both P<.Ol). Post-DCA MeSA in 50 
lesions as obtained by ICUS ,vas significantly larger than 
MCSA as mcasured by ED-QCA (P<.01) but not 
VID·QCA. 
Agreement Between lCUS, ED, 'and VID Before and 
After BA and DCA 
Table 3 compares the agreement between the three 
measurement techniques, and Figs 3 and 4 display the 
postintervention agreement between measurements ob-
tained from ICUS and ED-OCA (Fig 3) and from ICUS 
and VID-OCA (Fig 4). Thc correlation coefficient be-
tween thc ICUS and ED measurements decreased from 
.59 pre-BA to.47 post-BA and from .57 pre-DCA to .44 
post-DCA. The absolute difference bet\veen ICUS and 
ED was significantly greater post-BA and post-DCA 
than pre-BA and pre-DCA (both P<.05). The agree-
ment between ICUS and ED deteriorated post-DA and 
DCA compared with the pre-BA and DCA agreement. 
The correlation coefficient bet\yeen ICUS and VID 
measurements increased from .50 pre-BA to .63 
post-BA and from .50 pre-DCA to .72 post-DCA (Table 
3). The difference bet\yeen ICUS and VID was not 
significantly different from pre~BA and DCA to post-BA 
and DCA. Postintervention, the difference bet\veen 
lCUS and VID was significantly less than the difference 
bet\veen lCUS and ED post~BA and post-DCA (both 
TABLE 2. Comparison of MCSA Measurements Between BA and DCA 
Pre-SA (nonwedged lesions) 
Pre-SA (all 1(>51oos) 
Post-SA 
Pre-DCA (nonwedged lesIons) 
Pre-DCA {aU lesions) 
Post-DCA 
·P<.05 vs ED-OCA 
tP<.(l5 vs VID·OCA 
lCUS 
3.36±O.99 (<1-26)"t 
5.19±1.90 (n=100)'t 
2.69±O.89 (n=15J't 
7.S7±I.S5 (n=50)' 
1.93±1.36{<1=26) 
1.12±O.96(<1=1oo)t 
3A6±1.76(n=IOO)t 
1.61 ± 1.08 (<1=15) 
1.2Q:!:O.79 (<1=50) 
6.58::t2.43 (n=50)t 
VID·QCA 
2.21 ~1.22 (<1-26) 
1.32±1.02 (n=IOO) 
3.92±1.82(n=100J 
1.64±1.02(n=15) 
1.26:!0.77 (<1=50) 
7.25:!2.20 (n=50) 
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TABLE 3. Comparison of Agreement Between 
Measurements of MCSA by ICUS, ED, and VID Before 
and After SA and DCA 
Correlation Mellfl:tSD, 
Coefficient mm' 
ICUS vs EO 
Pr~8A (oonwedged lesions) .59 1.43:tl.12 
Post·SA .47 1.71:tl.S7 
Pre·DCA (oonmdged lesIons) .57 1.08:tl.00 
Post·DCA .44 O.95:t2.30 
ICUS vs ViD 
Pr~BA (nonwedged lesioos) 
.'" 1.1S:t1.12 
Post·SA .63 1.2H1.6! 
Pr~DCA (oonwedged leslons) . ., 1.05:tO.96 
Post·DCA .72 O.2S:tl.54 
VID vs ED 
Pr~BA (a11Iesloos) .78 O.20:tO.65 
Post·SA. .82 O.43:tl.OS 
Pr~DCA (aillesJonsj .74 -O.OHO.56 
Post·DCA .73 0.67+1.71 
P<.OI), The discordance between rcus and YID was 
smaller than the discordance between lCUS and ED 
both post-DA and post-DCA. While in both prc-BA and 
DCA no significant difference was observed between ED 
and VID, in post-BA and DCA there was a significant 
difference between the two (BA, P<.OOI; DCA, P<.Ol). 
Luminal Damage PostinteITention as Assessed by 
Angiography and ICUS 
TIle degree of luminal damage postintervention as 
assessed by using angiography and ICUS is given ill 
Table 4. Concordance between the two qualitative im-
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FIG 3. Plots show agreement of measurements of MCSA be-
tween [CUS and ED·QCA after (A) BA and (B) DCA according to 
the statistical approach proposed by Bland and A1tman.28 Dill. 
Indicates difference. 
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aging techniques was found in 23 (70%) of the 33 
patients with angiographically detected di~ected lesions 
and 23 (66%) of the 35 patients with dissection as 
detected by ICUS post-BA and in 10 (83%) of the 12 
patients with angiographically detected dissected lesions 
and 10 (59%) of the 17 patients with dissection as 
detected by ICUS post~DCA. 
Influence of Vessel Damage Induced by BA and 
DCA in the Agreement Between JeUS and QCA 
The correlation coellkient of ICUS and ED quantita-
tive measurements ,vas .74 in lesions ,vith an angio-
graphically detennined smooth lumen, .46 in lesions 
wilh angiographic haziness, and .26 in lesions with 
ahgiographic evidence of dissection (Table 5). The cor-· 
relation of JCUS and ED quantitative measurements 
was .70 in lesions with a regular lumen as determined by 
ICUS, .52 in lesions with an irregular lumen, and .10 in 
TABLE 4. Luminal Damage As Assessed by UsIng IGUS 
and Angiography In 150 Patients After Coronary 
Intervention 
ICUS Luminal Assessment 
Anglographlc Luminal 
Assessment Regular Irre9ular DIssected 
SA 
Smooth [n=44) 26 13 
Hazlness [n=23) 2 14 
01ssectioo (1'\=33) 4 6 23 
DCA 
Smooth (n=24) 13 9 2 
Haziness (n=14) 8 5 
Dissection (n=12) 0 2 10 
TABLE 5. Comparison of Agreement Between 
Measurements of MCSA by ICUS, EO, and VID 
According to Degree of Vessel Damage Induced by BA 
Correlation Mean:!:SD, 
Coell1cient mm' 
ICUS vs EO 
Angiography 
Smooth lumen (n=44) .74 1.21±1.27 
Haziness (n=23) .46 2.01±1.69 
Dissection (n=33) .26 2.16±2.47 
ICUS 
Regular lumen (0=32) 
.70 1.36±1.66 
IJTegular lumen (n=33) 
.52 1.45±1.71 
Presence of dissection (n=35) .10 2.27±2.11 
IGUS vs VID 
Angioglaphy 
Smooth lumen (n=44) .78 1.02:!:1.29 
Hazioess (n=23) .63 1.46:!:1.34 
Dissection (n=33) .46 1.48:!:2.09 
ICUS 
Regular lumeo (0=32) .80 1.03±IA8 
IJTegular lumen (0=33) .54 1.02±1.70 
Presence of dissection (n=35} 
.37 1.73±1.57 
VlD vs EO 
Angiography 
Smooth lumen (0=44) .93 O.t9±O.7S 
Haziness (0=23) .86 O.55:!:O.89 
Dissection (0=33) .64 0.68±1.48 
ICUS 
Regular lumen (0=32) 
.93 O.32:!:0.92 
Irregular lumen (n=33) 
.79 O.43:!:1.09 
Presence of dissection (n=35) .60 0.54+1.22 
lesions with ICUS evidence of di:)section. Thus, the 
presence of vessel damage induced by BA was associated 
with a deterioration of agreement between ICUS and 
ED measurements. While agreement between ICUS and 
VID-QCA also deteriorated in the presence of morpho-
logical changes induced by BA, the difference of the 
measurements between ICUS and VID was significantly 
less than the difference belwcen ICUS and ED in the 
presence of both angiographic (P<,05) and ICUS 
(P<.05) evidence of dissection. While high agreement 
was obtained between ED-QCA and VID-QCA, agree-
ment between these two techniques also decreased 
post-BA according to the increase of vessel damage. 
A similar pattern was seen when lesions treated by 
DCA were categorized according to their morphological 
characteristics (Table 6). Poor agreement was obtained 
in lesions with angiographic or ICUS evidence of vessel 
damage compared ,vith lesions with an angiographically 
smooth lumen or ICUS appearance of a regular lumen. 
The absolute difference of the measurement between 
ICUS and VID was significantly Je.ss than the difference 
between ICUS and ED in the presence of both angio-
graphic (P<.OI) and ICUS (P<.Ol) evidence of 
dissection. 
Correlation Beh,·een QCA Analyses of the Same 
Lesion :From Multiple Views 
To ensure that the beller relationship between VID 
and ICUS was a tme phenomenon and not due to a 
greater variation in values obtained from different views, 
we looked at the correlation and differences between 
orthogonal measurements for both VID and ED before 
TABLE 6. Comparison of Agreement Between 
Measurements of MCSA by ICUS, ED, and VID 
According to Degree of Vessel Damage Induced 
by DCA 
Correlation Mean:!:SD, 
Coemclent . mm~ 
ICUS vs EO 
Angiography 
Smooth lumen (n=24) .70 O.58±1.72 
Haziness (n=14) .34 1.43±2.62 
Dissection (n= 12) 
.04 1.46±2.83 
ICUS 
Regular lumen (n=14) 
.72 O.30±I.S8 
IJTegular lumen (n=19) .49 O.77±2.39 
Presence of d;ssection (0=17) .2B 1.68±2.61 
IGUS vs VlD 
Angioglaphy 
Smooth lumen (0=24) .79 -O.D1±1.40 
Hazioess (n=14) .71 O.64±1.61 
Dissecllon (n=12) .55 O.46±1.84 
ICUS 
Regular lumeo (0=14) .83 -O.23±1.28 
Irregular lumen (0=19) .69 O.29:!:1.53 
Presence of dissectoo (n=l7) .70 O.69:!:1.71 
VIDvsEO 
Angiography 
Smooth lumen (0=24) .76 O.59±1.68 
Haziness (0=14) .74 O.80±I.68 
Dissection (0 = 12) .63 0.99±1.69 
!CUS 
Regular lumen (0=14) 
.87 O.53±t.15 
IJTegular lumen (n=19) .72 O.48±1.54 
Presence of dissection (0=17) .67 1.00±2.t9 
and after intervention.29-31 The correlation and differ-
ences between orthogonal measurements obtained by 
ED were 0.69 (0.21.:±:0.62 mml) preintervention and 0.49 
(0.39.:±:2.33 mm') postintervention. The values obtained 
for VlD were 0,69 (0.14±0.71 mm') preintervention and 
0.67 (-0.33.:±:1.79 mml) postintervention. 
Discussion 
The principle findings of our study were (1) that 
MCSA obtained by ICUS was significantly larger than 
MCSA as measured by either ED- or VlD-QCA both 
before and after BA and DCA, (2) that the agreement 
between ICUS and ED deteriorated considerably after 
both BA and DCA, (3) that the complex morphological 
changes induced by BA and DCA contributed to the 
discordance of the agreement between ICUS and ED, 
and (4) that VlD measurements were found to provide 
a belier agreement with rcus than ED measurements, 
particularly in lesions with complex morphological 
changes post-BA and DCA. 
Agreement Between ICUS and ED·QCA in 
PrcliollS Studies 
Previous studies have provided confiicting e\'idence 
on whether luminal measurements obtained from leUS 
agree with ED-QCA measurements in human coronary 
aTteries. In general, studies that examined leus and ED 
measurements in normal coronary segments report a 
favorable correlation between the two quantitative im-
aging modalities,3,7 while those thai examined lesions 
postangioplasty report a poor correlation.4,15,16 Naka-
99 
3.20mm' 
FIG 5. ED~QCA, V1D-QCA, and ICUS analysis after BA in the middle segment of the left circumflex coronary artery. left, ICUS Image 
shows an Irregular lumen with partial rupture of a soft eccentric plaque post-BA The elliptical and irregular shape of the lumen may 
explain the discordance between measurements of the MeSA obtained from ICUS (4.1 mm~ and ED-OCA (2.99 mm?; MLD, 1.92 mm) 
and VID-QCA (3.20 mm'). The VID-QCA value Is closer to the reus measurement than the ED-QCA value; see "Discussion." 
mura and collcagues17 report that dissection induced by 
BA plays a role in the discordance between ICoS and 
ED-QCA measurements, but there are several method-
ological differences between their study and ours. First, 
they did not examine VJD measurements. Second, they 
showed only the correlation coefficient in groups with 
and without dissection, and no statistical difference was 
found in the difference of the individual ICUS and 
angiographic measurements between two groups. Fi-
nally, they did not use a computer-based QCA system 
but rather caliper measurements, which have a poor 
reproducibility and result in frequent underestimation 
or overestimation of stenosis severity,32 Our study is the 
first to compare both ED- and VlD-QCA measurements 
with ICUS measurements. 
Factors Contributing to the Discordance of ICUS 
and QCA Measurements 
Agreement of luminal area measurements as obtained 
by using JCUS and ED deteriorated considerably after 
BA and DCA A progressive deterioration in the rela-
tionship between the ICUS and QCA measurements was 
seen in accordance with the presence of increasing vessel 
damage and increasing luminal complexity postinterven-
tion. Thus, the cross-sectional shape of the vessel lumen 
postintervention may be a significant factor in the dis-
crepancy between JCUS and ED-QCA measurements. 
MLD obtained from ED-QCA depends on the angio-
graphic projection. Although we calculated luminal area 
from two orthogonal views, the chances of obtaining the 
exact minimal and maximal diameters of the lesion CSA 
using ED-QCA would be small, particularly in the 
complex elliptical shape of the lumen postintervention 
(Fig 5). JCUS and YID are not projection dependent, 
and both would provide a measure of the "depth" as well 
as the "width" of the lumen cross section. ED, however, 
provides only a measure of one diameter (the "width") 
of the lumen. Consistent with this is the fact that 
VlD-QCA provided a better agreement and less relative 
100 
underestimation in relation to ICUS measurements than 
ED·QCA. 
The underestimation by ED relativc to ICUS mea-
surements may reflect the propensity of the contour-
detection algorithm to trace the change in the brightness 
profile in the contrast-weak channel bctween the true 
and false lumens33 (Fig 2), while ICUS measurements 
and VlD measurements in multiple vie,\'S may include 
the contribution of the false lumen. Such a phenome-
non, howevcr, would not account for the relative under-
estimation by ED in the preintervcntion phase. Another 
possibility is that the interventionai cardiologist tcnds to 
select angiographic projections that best demonstrate 
both the stenosis preintervention and the residual ste-
nosis postintervention, ie, "worst view" angiography. 
Even using multiple orthogonal views, as we did in our 
study, the assumed elliptical cross section may have been 
based on multiple "worst views," which although they 
were, per protocol, >450 apart, were not necessarily a 
combination or truly "worst view" and "best view," Such 
a limitation to ED-QCA has been an inherent problem 
in all coronal)' inlervenlional trials, and attempts to 
address this by three-dimensional imaging in tmly or-
thogonal views are currently under evaluation.3k'5. 
Two additional leUS-related factors may also have 
contributed to the observed discordancc between ICUS 
and quantitative angiographic measurements. Elliptical 
angulation of the ultrasound catheter within the longi-
tudinal axis of the vessel may have led to overestimation 
of luminal dimensions by ICUS. Additionally, introduc-
tion of the ultrasound catheter may have itself resulted 
in tacking back of dissection flaps, ,vith a resultant largcr 
lumen during ICUS examinations postinlervention com-
pared with the less invasive technique of contrast an-
giography. Our data also suggest that quantitative an-
giography may yield larger luminal measurements than 
ICUS in a significant number of patients (Figs 3 and 4). 
This increase in the apparent angiographic diameter 
may be caused by extraluminal contrast within fissures, 
cracks, and dissection as seen around the tme lumen. 
Study Limitations 
First, the coronary sites compared by ICUS and QCA 
may not have been exactly identical. Although we tried 
to ensure that this was the case by using simultaneous 
recording of fluoroscopy and ICUS imaging as well as 
landmarks such as side branches to guide us, there is no 
guarantee that \ye analyzed exactly the same point of the 
coronary artery in ICUS and QCA measurements. This 
is, however, a generic problem of any ICUS·QCA 
study3.4 that would be very difficult to overcome, as the 
presence of the ICUS catheter at the lesion site during 
coronary arteriography would interfere with the QCA 
measurements. Second, both ED- and VID·QCA anal-
ysis were performed using only the CAAS II system. 
Thus, further studies would be required to confirm if our 
findings can be generalized to other QCA hardware or 
software systems.21 It is conceivable that if ari ED 
algorithm were inaccurate in the nomml reference seg-
ment, then a systematic underestimation or overestima-
tion of ,'essel diameters could be translated to subse-
quent VlD measurements. 111ird, it is also possible that 
ultrasound image analysis fails to see the true leading 
intimal edge, espedaUy if the plaque has a low fibrous 
component and appears relatively hypoechoic, thus 
overestimating luminal dimensions. Additionally, a poor 
dynamic range can also induce technical intimal drop-
out, leading to lumen overestimation. 
Clinical Implications 
Although JCUS provides unique infonnation regard-
ing the vessel wall morphology, the clinical utility of this 
technique remains unprO\'en to date. ICUS luminal 
measurements, however, do provide important addi-
tional information to that obtained by visual assessment 
for optimal stent implantationY,1O Whether ICUS pro-
vides more accurate information than QCA, however, 
has not yet been determined. Additionally, whether 
luminal measurements obtained from ICUS are a supe-
rior index for the short~ and long·term success of 
interventional procedures awaits the results of recent 
multicenter trials. 12,\3;l6 While ICUS is not universally 
available and involves additional time and expense,ll 
QCA is more widely available and less time-consuming. 
Our data suggest that in the absence of the known true 
value and assuming that leus gives the most accurate 
estimate of luminal dimensions, QCA measurements, 
particularly ED, may be compromised, especially in 
assessing the complex luminal morphology following BA 
or DCA. Our study suggests that VID may offer a better 
correlation with the true luminal dimensions, as re-
flected by leUS, than ED·QCA. VJD may thus be the 
"poor man's" leUS, especially in lesions with complex 
morphology. 
Conclusions 
MCSA measurements obtained by leus arc signifi-
cantly larger than measurements provided by either 
geometric or VlD·QCA both before and after interven-
tion. Agreement between ICUS and geometric QCA 
measurements deteriorate considerably after inten'en-
tion. Complex morphological changes induced by inter-
,'ention may playa role in such a discordance between 
the two quantitative imaging techniques, In the absence 
of ICUS, VID, which is currently available in an online 
QCA system, may provide a better alternative than 
ED-QCA in lesions with complex morphology. 
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Intravascular ultrasound imaging combined with coronary 
angioplasty- Initial clinical experience. 
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Intravascular ultrasound imaging 
combined with coronary 
angioplasty 
A. G. VIOLARIS T. J. LINNEMEIER 
S. CAMPBELL D. A. ROTHBAUM 
D. C. CUMBERLAND 
A novel catheter combining ultrasound imaging 
and coronary balloon angioplasty was used in the 
treatment of 69 coronary*artery lesions in 51 
patients. The ultrasound transducer enables real-
time cross-sectional imaging and qualitative and 
Quantitative assessment of the vessel wall before and 
after angioplasty. The combination catheter 
successfully dilated 67 lesions. There was 
a characteristic three-layered appearance, 
representing intima, media, and adventitia, in 60 
cases. Intravascular imaging provided information 
on thevesse[ wall unobtainable by standard contrast 
angiogaphy in 28 cases and influenced our 
management in 6 cases. 
Lancet 1992; 339: 1571-72. 
Technological advances have enabled miniaturisation of 
ultrasound transducers to such an extent that they can now 
be mounted in catheters and introduced into the body 
percutaneously,' Intravascular ultrasonography allows 
direcr visualisation, in vivo, of vessel walls and assessment of 
the results of intcrventionaJ procedures.l We report here our 
experience with a catheter that combines coronary 
ultrasound imaging and balloon angioplasty; the vessel wall 
can be viewed before and after angioplasty. 
51 patienlS(691esions)ofmeanage 59·5 (range41-81)years, who 
.... -ere undergoing dinipilly indiC3ted coronary angiop1asty, gave 
Ultrasound iMagas frOM segMants of coronary arteries. 
8""'normal segment showing centrally located transducer (T), 
sUHounded by air bubble artefact (6), and characteristic three· layered 
appeafllnce of the normal vessel wall with a thin echogenic intima (Il, 
sono!UC(lnt media (M), and echagenic adventitia (A); b=segment 
showing intima! thickening (allow); c"'stenosis that appears as one 
thick echagenic layer encroachIng on transducer, with Me highly 
e<:hogenic area (arrow); d=segmenl of vessel wall immediately after 
angioplasty showing dissection (arlOw). 
informed consent for the use of the new catheter (Oracle; 
Endosonks, Pleasanton, CalifOrnia, USA). The device is inserted 
and used by standard tedmiques. Tbe catheter consists of a 
standard polyethylene angioplasty balloon; at the proximal end is 
mounted a 64 .... dement ultrasound tnmsducer, of diameter 1'83 mm, 
around the a'ltheter. Ultrasound signals are relayed from the 
transducer to a computer that generates.real-time, cross-sectional 
images of the vessel wall. 
67 of the 69 lesions were successfully crossed and dilated 
by the combination altheter. 2 lesions could not be crossed 
because of their severity and because the device was too 
wide. There were no complications from the procedure. 
Images were obtained for 60 lesions; in 28 cases these images 
provided infonnation not available by contrast angiography. 
Angiograpbically nonnal arterial wall gave a chamcteristic 
three-layered appearance (see figure, a). In 14 vessel 
segments apparently nonnal on angiography, the intima 
proximal to a stenosis seemed grossly thickened (figure, b). 
At the stenosis site the three-layered appearance was no 
longer present and the vessel waH appeared as one thick 
echogenic layer (figure, c); in 4 cases this layer included 
eccentrically located highly echogenic areas, with acoustic 
shadowing, which we thought might represent calcification. 
After angioplasty, imaging showed intimal disruption in 
almost every case. Dissections, not apparent in contrast 
angiography, were seen in 4 cases (figure, d). 
In 6 cases, ultrasonography gave additional infonnation 
that influenced our management. In I patient, an apparently 
significant stenosis on angiography was not confinned on 
ultrasound imaging and dilatation was not done. In 3 
patients, ultrasound imaging suggested substantial residual 
stenoses after dilatation despite an angiographically 
satisfactory result. The use of a larger balloon improved the 
ultrasound appearance. In the other 2 patients, 
ultrasonography repeatedly showed a substantial stenosis in 
an angiographica1ly normal segment distal to the target 
lesion. After dilatation there was substantial improvement 
on ultrasonography, although the angiographic appearance 
did not change. 
Ultrasound imaging gave morphological infonnation 
about the coronary arteries, before and after angioplasty, 
that added to infonnation available from contrast 
angiography in 28 cases. We were able to visualise 
morphological details within the vessel of interest, such as 
the degree of intimal thickening, calcification, and even 
plaque structure. This information may ultimately provide 
further insight into the pathogenesis of coronary artery 
disease and its progression. There have been attempts to 
characterise plaques in peripheral vessels in vitro according 
to their ultrasound characteristics.3.4 Plaques could not be as 
readily differentiated in our study as in the in-vitro studies, 
perhaps because of the much smaller diameter of the 
coronary stenoses, but they appeared as thick echogenic 
layers encroaching on the centrally located transducer. 
Nevertheless, some seemed to have highly echogenic areas 
with acoustic shadowing that suggested calcification, not 
apparent on fluoroscopy. 
We were able to assess dircct1y the result of balloon 
angioplasty on the coronary stenosis. Our experience is not 
yet sufficient to allow us to predict events from ultrasound 
appearance, but published evidence on coronary angiopJasty 
suggests that lesion morphology and wall disruption may be 
related to acute occlusion and long-tenn outcome.s In 
future, therefore, morphological features shown by 
intravascular ultrasonography may prove to be important 
predictors of outcome. Furthermore, ultrasound imaging 
provides a better perspective of the cross-sectional anatomy, 
and hence residual stenosis, than does angiography. 
The catheter we used had two limitations. The imaging 
transducer was large in relation to coronary artery stenosis 
size, so many stenoses were fully visualised only after 
balloon dilatation. Another problem was that air bubbles 
could become trapped around the transducer, reducing the 
image qUality. Modifications of the Oracle catheter have 
eliminated the latter difficulty and reduced the diameter to 
1·2mm. 
The clinical significance of morphological information 
obtained with this altheter is not yet certain; long~tenn 
follow-up in larger .studies is necessary to show whether 
morphological features visualised by intravascular 
ultrasonography are valuable in coronary angioplasty. 
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Chapter 10 
Impact of de novo vascular remodeling mode on the 
mechanisms of acute luminal gain and long term restenosis 
following coronary balloon angioplasty and directional 
coronary atherectomy: A serial intracoronary ultrasound 
study. 
Ozaki Y, Violaris AG, Camenzind E, Di Mario C, de Feyter PJ, 
Roelandt JTRC, Serruys PW. 
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Abstract: 
Background: Post mortem and intravascular ultrasound studies suggest that the 
coronary vessels respond to atherosclerosis by either compensatory enlargement 
or paradoxical shrinkage. The aim of our study was to determine the pathophysio-
logical role of this mode of de novo vascular remodeling on the subsequent 
mechanism of acute luminal gain and restenosis after coronary angioplasty and 
directional atherectomy. 
Method: Serial intracoronary ultrasound examinations (pre-, post intervention and 
6 month follow-up [flip]) and quantitative coronary angiography (QCA) were per-
formed in 36 patients who underwent successful balloon angioplasty (BA, n=18) 
or directional atherectomy (DCA, n=18). The minimal cross sectional area 
(MCSA) and proximal reference segment area (cross section with the least dise-
ased segment within 15mm proximal to the lesion) were determined during the 
pull-back sequence of the intracoronary ultrasound images. The vessel remodeling 
mode was expressed as the ratio of total vessel area (TVA) at MCSA to TVA at 
the reference site (TVA ratio) and classified into two categories; I) paradoxical 
slninkage (TVA ratio <1.00) (BA; 12 patients, DCA 12 patients) or 2) compensa-
tory enlargement (TVA ratio >1.00) (BA; 6 patients, DCA; 6 patients). Plaque 
area (PA) was defined as=TVA-MCSA. Acute plaque reduction was defined 
as=PA pre-PA post, and late intimal hyperplasia as=PA fup-PA post. Acute lumen 
gain was defined as=MCSA post-MCSA pre, and late lumen loss as=MCSA post-
MCSA fup. Acute vessel expansion was defined as=TVA post- TVA pre (at the 
segment of MCSA) and late vessel recoil was defined as=TVA post-TVA fup, at 
the segment ofMCSA. 
Results: Although the overall acute gain and late loss were similar between the 
compensatory enlargement group and paradoxical slninkage groups after both BA 
and DCA, there were significant differences in the mechanism of action involved 
in each. 
Balloon Angioplasty group (BA)- Both acute vessel stretch and late vessel recoil 
were significantly greater in the sluinkage group than in the compensatOly enlar-
gement group (2.4 ±1.3nllll' versus 0.9 ±0.6nll1l2 and 1.8 ±0.6nllll' versus 1.1 
±0.6mm', respectively, both p<0.05). There was also a significant positive correla-
tion (1=0.73, p=0.007) between the degree of acute vessel stretch and clll'onic ves-
sel recoil in the slll'inkage group. At follow-up chronic vessel recoil accounted for 
90% of late lumen loss in the slll'inkage group, and for only 55% of late lumen 
loss in the compensatory enlargement group (p=0.322). 
Directional Coronary Atherectomy group (DCA) - Both acute vessel stretch and 
cln'onic vessel recoil were significantly larger in the shrinkage group than the 
compensatory enlargement group (vessel stretch; 2.4±1.3 mm2 versus 0.3±0.6 
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mm', p<O.OI; chronic recoi12.4±1.3 mm' versus 0.7±0.9 mm', p<O.OI). Acute 
plaque reduction was, however, significantly greater in the compensatory enlarge-
ment group than shrinkage group (S.8±1.0 mm' versus 3.6±l.S mm', p<O.OI). At 
follow-up vessel recoil accounted for 89% of late loss in the shrinkage group and 
29% of late lumen loss in the compensatOlY enlargement group (p=0.340). 
Conclusions: Our study suggests that the underlying de novo vessel remodeling 
mode (vessel shrinkage/compensatory enlargement) may playa key role in the 
acute efficacy of a coronary revascularisation device (vessel expansion or debul-
king) and the subsequent mechanism ofrestenosis (remodeling or intimal hyper-
plasia). 
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Introduction 
Glagov originally proposed the hypothesis that compensatory enlargement of 
coronary vessels occurs as plaque volume increases until more than 40% of the 
vessel wall is composed of atherosclerotic plaque (compensatory enlargement) 
[I]. The mechanism can then no longer compensate and subsequent plaque 
growth results in lumen reduction [I]. The initial post mortem studies have been 
subsequently confirmed in vivo in man by both quantitative angiography and 
intravascular echocardiography [2-5]. Intravascular echocardiography has also 
confirmed that reverse glagovian modeling can also occur; that vessel shrinkage 
as well as vessel enlargement can occur in response to atherosclerosis (paradoxical 
shrinkage) [6,7]. We hypothesised that the mode of de novo vascular remodeling 
(compensatory enlargement or paradoxical shrinkage) prior to coronary interven-
tion may be important in influencing both the mechanism of acute gain and of late 
restenosis after percutaneous revascularisation. The aim of our study was thus to 
determine the pathophysiological role of the mode of de novo vascular remodeling 
on the mechanism of acute luminal gain and subsequent restenosis after coronary 
balloon angioplasty and directional coronary atherectomy using intracoronary 
ultrasound and quantitative angiography pre-, post- and at 6 months after inter-
vention. 
Methods 
Patient selection 
Fifty-four patients who underwent successful balloon angioplasty (BA) or direc-
tional coronary atherectomy (DCA) were candidates for this study. Successful 
angioplasty was defined as angiographic success «50% residual luminal diameter 
stenosis post intervention) with no major cardiac events (myocardial infarction, 
repeat intervention, coronary bypass surgery and death). For the purpose of this 
study patients in whom we could not obtain a complete set of high quality serial 
intracoronary ultrasound images either because of anatomical (total occlusion pre-
intervention or at follow-up (n=4), lesions located at the origin of major side bran-
ches thus making it impossible to measure the proximal reference segment area, 
n=4) or technical reasons (the presence of severe calcification preventing the 
measurement of total vessel area, n=5) were excluded from the study. Five patients 
whose vessels did not show either compensatory enlargement or vessel shrinkage 
were also excluded. Complete sets of serial ultrasound studies with sufficient 
image quality were obtained in the remaining 36 patients (BA; 18 patients, DCA; 
18 patients). 
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Balloon angioplasty (BA) or directional coronary atherecto-
my (DCA) procedures: 
All patients received full anticoagulant therapy including aspirin and heparin befo-
re intracoronary ultrasound examination and intervention. The size of balloon or 
atherectomy device was determined from on-line quantitative angiographic meas-
urement of the reference vessel diameter. 
Quantitative coronary angiography (QCA) 
The new version of the computer-based Coronary Angiography Analysis System 
(CAAS II) [8) was used to perform both the on-line quantitative analysis as well 
as the subsequent off-line cinefilm analysis. In the CAAS analysis which has been 
previously described and validated [8-10), the entire cineframe of 18 x 241111n in 
size is digitized at a resolution of 1329 x 1772 pixels. Correction for pincushion 
distortion is performed before analysis. Boundaries of a selected coronary seg-
ment are detected automatically. The absolute diameter of the stenosis (in mm) is 
determined using the guiding catheter as a scaling device. Using the diameter 
function, the luminal diameter at the site of lesion (minimal luminal diameter; 
MLD) and a computer-derived estimation of an interpolated reference vessel dia-
meter (RD) at the site of the lesion were determined. To standardize the method of 
analysis of the initial and follow-up angiograms, measures were taken as previous-
ly described; all study frames selected for analysis were end-diastolic to minimize 
motion artifact and arterial segments were measured between the same identifia-
ble branch points after the intracoronary administration of 2mg isosorbide dinitra-
te vasodilatory therapy [8-10). Coronary angiograms were read and analyzed by 
two independent blinded observers. 
Intracoronary Ultrasound (ICUS) examination 
Following selective coronary angiography, a mechanical intracoronary ultrasound 
imaging catheter (30-MHZ, 2.9Fr or 4.3Fr, CardioVascular Imaging Systems, 
Sunnyvale, CA) was introduced over a 0.014 inch guidewil'e. After the imaging 
catheter was passed beyond the lesion, a slow motorized pull-back (1.0 
Illllvsecond) was performed to obtain linages both proximal and distal to the target 
stenosis [11-13]. A simultaneous fluoroscopic image of the position of the ICUS 
catheter-tip was contlimously displayed on the same video screen [11-13]. ICUS 
linages were stored on super VHS videotape for off-line analysis. Cross sectional 
luminal area was defined as the integrated area central to the intimal leading edge 
echo [11-13]. Images with minimal cross sectional area (MCSA) were selected 
from the pull-back sequence by reviewing the position of the ICUS catheter on the 
angiographic image. Side branches and calcification pattern on ICUS images and 
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the position of th~ rcus catheter on the angiographic image recorded on the same 
rcus images were used as a landmark to obtain the same position, as far as possi-
ble, during serial ultrasound examinations. A reference segment was defined as 
the area with the least amount of plaque within 15mm proximal to the lesion but 
distal to a major side branch. To determine the interobserver variability of rcus 
measurements, 30 lesions were independently measured by two observers. The 
mean signed difference and correlation of the measurements of cross sectional 
area were 0.02±0.37 nUll' and 0.97, respectively. 
Qualitative Intracoronary IDtrasoulld (ICUS) Assessment 
Echo reflectivity was categorised into; I) poorly echo reflective plaque (reflectivi-
ty is lower than bright adventitia layer; 2) highly echo reflective plaque (reflectivi-
ty is higher than bright adventitia layer) [12]. Calcium deposit was defined as 
highly echo-reflective tissue with acoustic shadow. A lesion was considered homo-
geneous if the plaque consisted of >75% of one type of echo-reflectivity. A lesion 
was defined as mixed if it contained both highly and poorly echo-reflective area 
occupying >25% of the plaque area [12]. A lesion was considered predominantly 
calcific in calcium occupied >1800 of vessel circumference [12]. 
Quantitative Intracoronary IDtrasoUlld parameters 
The vessel remodeling mode was expressed as the ratio of the total vessel area 
(TVA) at the minimum cross sectional area divided by the TVA at the reference 
site (TVA ratio). Target lesions were classified into two categories based on tllis 
ratio; 1) compensatory enlargement (TVA Ratio> 1.00) and 2) paradoxical 
shrinkage (TVA Ratio <1.00)). 
Lumen eccentricity index was calculated as the ratio between the minimal and 
maximal wall thickness. Plaque area (PA) was defined as a TVA at thc point of 
MCSA minus MCSA. Acute lumen gain was defined as ~MCSA post-MCSA 
pre. Acute plaque reduction was defined as ~PA pre-PA post. Acute vessel 
expansion was defined as ~TVA post-TVA pre, at the segment of MCSA. Late 
lumen loss was defined as ~MCSA post-MCSA follow-up. Late intimal hyper-
plasia was defined as~ PA follow-up minus PA post. Late vessel recoil was defi-
ned as ~TVA post-TVA follow-up, at the segment ofMCSA. 
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Statistical analysis 
All values are expressed as mean values ± standard error of the mean. Paired 
Student's t-test was used to compare chronological changes at the same segment in 
the same patients. Unpaired Student's t-test were used for intergroup comparisons. 
Differences between categorical variables were analyzed by chi-square with cor-
rection. A p value <0.05 was considered significant. 
Results 
Clinical and angiographic characteristics 
The baseline clinical and angiographic characteristics of the 36 patients with bal-
loon angioplasty (BA) and directional coronary atherectomy (DCA) are provided 
in Table I. The two groups were comparable in terms of age, gender, coronary 'risk 
factors, anginal class [14] and distribution of diseased vessels. The two groups 
were also similar in both the type and location oflesions, but the reference diame-
ter was significantly higher in the directional atherectomy group. Although the 
minimal luminal diameter (MLD) pre intervention was similar in the two groups 
(1.15±0.42 nUll DCA versus 1.01±0.3Imm BA, p~0.288) MLD post DCA was 
significantly larger than post BA (2.85±0.55 111111 DCA versus 2. I 6±0.47 nUll BA, 
p<O.OOI). TIlls more favourable acute result after DCA was subsequently lost 
however with the MLD at follow-up being similar in the two groups (1.73±0.51 
mm DCA versus 1.57±0.50 lilill BA, p~0.369). 
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BA DCA p-value 
Patients 18 18 
Male/female 14/4 16/2 0.658 
Age (years) 58 ± 9 58 ± 8 0.846 
Ischemic syndrome 
Stable angina pectoris' 12 11 0.732 
Unstable angina pectoris' 6 7 0.732 
Prior myocardial infarction 2 4 0.658 
Prior balloon angioplasty 3 2 0.635 
Prior coronary bypass surgery 0 0 
Coronary risk factors; 
Hypercholesterolemia 2 6 0.228 
Systemic hypertension 5 6 0.721 
Cigarette smoking 6 4 0.710 
Diabetes 0 1 1.000 
Modified AHA/ACC classification 
type A 5 6 0.721 
type B1 7 7 0.732 
type B2 5 5 0.710 
type C 1 0 1.000 
Location of lesions 
RCA 6(33%) 2(11%) 0.229 
LAD 8(45%) 13(72%) 0.176 
LCX 4(22%) 3(17%) 0.678 
Quantitative analysis 
MLD pre 1.01±0.31 1.15±0.42 0.288 
RD pre 2.78 ±0.55 3.47±0.37 <0.001 
% OS pre 63 ± 11% 67 ± 13% 0.354 
MLD post 2.16 ± 0.47 2.85±0.55 <0.001 
RD post 2.85 ± 0.47 3.66 ± 0.54 <0.001 
% OS post 24 ± 12% 22 ± 10% 0.554 
MLD follow-up 1.57 ±0.50 1.73±0.51 0.369 
RD follow-up 2.73 ±0.58 3.20 ±0.46 <0.05 
% OS follow-up 42 ±15% 46 ±15% 0.471 
Balloon I vessel ratio 1.16+0.34 
Table 1: Clinical and angiographic characteristics of the study population. BA-
Balloon angioplasty, DCA- Directional coronmy atherectomy, * angina pectoris 
classification [14], LAD- Left anterior descending coronary artery, RCA- Right 
coronary artery, MLD- Minimal luminal diameter, RD- Reference diameter, %DS-
Percent diameter stenosis 
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Baseline ultrasonographic characteristics 
Baseline intracoronary ultrasonographic characteristics are shown in Table 2. No 
difference was found in plaque composition (soft or mixed plaque) and the presen-
ce and location of calcium deposits between the two groups. Minimal cross sec-
tional area (MCSA) pre and follow-up, and vessel cross sectional area (CSA) pre, 
post and at follow-up were also similar in the two groups. Acute luminal gain, and 
hence minimal cross sectional area (MCSA) post intervention were, however, sig-
nificantly greater after directional atherectomy than balloon angioplasty (acute 
gain; 6.0±1.5 mm' versus 3.8 ±1.6 mm', p=O.OOOI, and MCSA post; 7.6±1.5 mm' 
versus 5.3 ±1.7 mm', p=O.OOOI, respectively, Table 2). This difference was the 
result of greater plaque reduction in this group (plaque reduction; 4.3 ±1.7 mm' in 
DCA versus 1.8 ±1.8 nU112 in BA, p=O.OOOl). Late luminal loss was higher in the 
DCA group however resulting in a similar MCSA at follow-up in the two groups 
(4.9±2.8 11Ull' (DCA) versus 3.4 ±2.0 mm' (BA), p=O.051). 
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BA DCA p-value 
Lesion composition 
Homogenous plaque 
poorly echo reflective 8 10 0.739 
highly echo reflective 0 0 
Mixed plaque 10 8 0.739 
Calcium deposits 
Subendothelial 6 7 0.732 
Basal/Center 7 6 0.732 
Luminal measurement (mm2) 
TVA ratio 0.94±0.11 0.95±0.11 0.792 
Ref.TVA pre 16.6±4.1 18.5±3.9 0.162 
TVA pre 15.4±3.5 17.4±3.6 0.105 
MCSA pre 1.6±3.5 1.6±0.7 0.877 
Plaque area pre 13.9±3.8 15.8±3.7 0.125 
TVA post 17.4±3.3 19.2±3.9 0.149 
MCSA post 5.3±1.7 7.6±1.5 <0.001 
Plaque area post 12.0±3.5 11.5±3.2 0.653 
TVA follow-up 15.8±3.2 17.3±3.5 0.184 
MCSA follow-up 3.4±2.0 4.9±2.8 0.051 
Plaque area follow-up 12.5±3.7 12.3±4.8 0.935 
Eccentricity index 0.47±0.27 0.40±0.25 0.296 
Acute luminal gain 3.8±1.6 6.0±1.5 <0.001 
vessel stretch 2.0±1.3 1.7±1.5 0.677 
plaque reduction 1.8±1.8 4.3±1.7 <0.001 
Late luminal loss 2.0±1.4 2.5±2.4 0.382 
vessel late recoil 1.6±0.7 1.9±1.5 0.461 
intimal hyperplasia 0.4±1.7 0.6±2.5 0.618 
Table 2: Baseline uitrasonographic characteristics of the study population. BA-
Balloon angioplasty, DCA· Directional coronary atherectomy, TVA· Total vessel 
area in the segment with minimal cross sectional area. MCSA· Minimal cross 
sectional area. Ref TVA: Total vessel area in the reference segment. Eccentricity 
Index· see text 
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Comparison between the shrinkage and compensatory enlar-
gement groups in Balloon Angioplasty 
Whilst 12 patients showed paradoxical shrinkage (TVA ratio <1.00) (Figure I), the 
remaining 6 patients had compensatory enlargement (TVA ratio> 1.00). 
Figure I. Intracoronary ultrasound (IeUS) images obtained from a patient with 
paradoxical shrinkage and treated with balloon angioplasty (BA). Reference seg-
ment showed total vessel area (TVA) was 14.0 mm2 [extreme left panel]. Pre BA 
TVA was 10.9 mm2 and minimal cross sectional area (MeSA) was 1.6Iu11112 
[middle left panel]. The ratio of the total vessel area (TVA) at MeSA divided by 
TVA at the reference site pre intervention (TVA ratio) was 0.78, hence the de novo 
remodeling mode was one of paradoxical shrinkage. Post BA MeSA improved to 
6.5 mm2 associated with TVA enlargement 11-0111 10.9 mm2 to 13.8 n11112 [middle 
right panel]. At follow-up MeSA decreased from 6.5 mm2 to 1.61 mm2 associa-
ted with TVA shrinkage from 13.8 mm2 to 10.8 n11112. In tills case 39% ofluminal 
loss was derived from intimal hyperplasia and 61 % from late clU'OIllC recoil (ves-
sel remodeling) [extreme right panel]. 
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Minimal CSA, vessel CSA and plaque CSA pre-, post- balloon angioplasty and at 
follow-up as well as reference vessel CSA-pre were similar in both paradoxical 
slninkage and compensatory enlargement groups (Table 3). 
paradoxical compensatory p-value 
shrinkage enlargement 
Patients (n) 12 6 
Luminal measurement (mm') 
TVAralio 0.87±0.07 1.07±0.02 <0.001 
Ref.TVA pre 17.3±4.4 15.0±3.0 0.258 
TVA pre 15.1±3.8 16.0±3.1 0.635 
MeSA pre 1.5±0.7 1.8±0.7 0.367 
Plaque area pre 13.7±4.1 14.2±3.5 0.785 
TVA post 17.6±3.6 17.0±2.6 0.722 
MeSA post 5.3±1.6 5.3±1.9 0.977 
Plaque area post 12.2±3.7 11.6±3.1 0.746 
TV A follow-up 15.7±3.5 15.9±2.9 0.897 
MeSA follow-up 3.3±2.2 3.4±1.5 0.946 
Plaque area follow-up 12.4±3.9 12.6±3.5 0.939 
Acute luminal gain 3.9±1.4 3.5±2.1 0.670 
vessel stretch 2.4±1.3 0.9±0.6 <0.05 
plaque reduction 1.5±1.5 2.6±2.3 0.225 
Late luminal loss 2.0±1.3 2.0±1.7 0.897 
vessel late recoil 1.8±0.6 1.1±0.6 <0.05 
intimal hyperplasia 0.2±1.6 0.9±1.8 0.399 
Table 3: Comparison between paradoxical slninkage and compensatory enlarge-
ment groups in Balloon Angioplasty group. TVA- Total vessel area in the segment 
with minimal cross sectional area. MCSA- Minimal cross sectional area. Ref 
TVA: Total vessel area in the reference segment. 
Although overall acute gain and late loss were also similar in the two groups this 
masked significant differences in the mechanism of action involved in each. 
Acute vessel stretch was the predominant mechanism of acute luminal gain in the 
sln'inkage group (2.4±1.3 mm' versus 0.9±0.6 mm', p~O.O 163), and plaque reduc-
tion in the compensatory enlargement group (2.6±2.3 11U112 versus 1.5±1.5 lmll') 
although because of the small numbers involved this did not reach statistical signi-
ficance (p~0.2248). At follow-up the main mechanism for late loss was c111'onic 
vessel recoil in the slu'inkage group (1.8±0.6 nUll' versus 1.l±0.6 11Ull', p~0.0125), 
and intimal hyperplasia in the compensatory enlargement group (0.9±1.8 mm' 
versus 0.2±1.6 nUll'), although again, because of the small numbers involved, this 
did not reach statistical significance UF0.3991). The degree of acute vessel 
stretch and late vessel recoil correlated well (r ~ 0.73, p~0.0068) in the sll1'inkage 
group, but poorly in the compensatory enlargement group (r ~ 0.44, IFO.1496). 
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Thus vessel stretch was the predominant mechanism of acute luminal gain, and 
chronic vessel recoil the predominant mechanism of late loss in the shrinkage 
group compared to the compensatory enlargement group. 
Comparison between the shrinkage and compensatory enlar-
gement groups in DCA 
WIllIe 12 patients had paradoxical shrinkage, the remaining 6 patients showed 
compensatory enlargement (Figure 2). 
Figure 2. Intracoronary ultrasound (ICUS) u11ages obtained from a patient with 
compensatory enlargement and treated with dU'ectional coronary atherectomy 
(DCA). Reference segment showed total vessel area (TVA) was 18.91111112 [extre-
me left panel]. Pre DCA TVA was 21.6 1111112 and minimal cross sectional area 
(MCSA) was 1.61 mm2 [middle left panel]. The ratio of the total vessel area 
(TVA) at MCSA divided by TVA at the reference site pre ultervention (TVA ratio) 
was 1.14 hence the de novo remodeling mode was one of compensatory enlarge-
ment. Post DCA MCSA improved to 10.2 n11112 associated with TVA enlargement 
from 21.6 n11112 to 22.1 mm2 [middle right panel]. At follow-up MCSA decreased 
from 10.2 n11112 to 4.9 n11112 associated with TVA shrinkage from 22.1 mm2 to 
21.5 mm2. In this case 89% of luminal loss was derived fi'om intimal hyperplasia 
and 11% fi'omlate chronic recoil (vessel remodeling) [extreme right panel]. 
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Minimal CSA, vessel CSA and plaque CSA pre-, post- directional atherectomy 
and at follow-up as well as reference vessel CSA-pre were similar in both para-
doxical shrinkage and compensatOlY enlargement groups (Table 4). 
paradoxical compensatory p-value 
shrinkage enlargement 
Patients (n) 12 6 
Luminal measurement (mm2) 
TVA ratio 0.89±O.05 1.08±0.04 <0.001 
Ref.TVA pre 19.4±3.4 16.4±4.4 0.121 
TVA pre 17.2±3.1 17.8±4.9 0.756 
MCSA pre 1.5±0.8 1.8±0.5 0.356 
Plaque area pre 15.7±3.1 16.0±5.0 0.899 
TVA post 19.7±3.3 18.1±5.3 0.461 
MCSApost 7.5±1.6 7.9±1.4 0.567 
Plaque area post 12.2±2.5 10.2±4.3 0.231 
TVA follow-up 17.2±3.0 17.8±4.8 0.869 
MCSA follow-up 4.7±2.8 5.5±2.9 0.553 
Plaque area follow-up 12.5±4.2 12.0±6.3 0.825 
Acute luminal gain 6.0±1.7 6.1±1.3 0.900 
vessel stretch 2.4±1.3 0.3±0.6 <0.01 
plaque reduction 3.6±1.5 5.8±1.0 <0.01 
Late luminal loss 2.7±2.6 2.4±2.8 0.810 
vessel late recoil 2.4±1.3 0.7±0.9 <0.01 
intimal hyperplasia 0.3±2.9 1.7±2.4 0.249 
Table 4: Comparison between paradoxical shrinkage and compensatory enlarge-
ment groups in directional coronalY atherectomy. TVA- Total vessel area in the 
segment with minimal cross sectional area. MCSA- Minimal cross sectional 
area. Ref TVA: Total vessel area in the reference segment. 
Although overall acute gain and late loss were also similar in the two groups, tlus 
masked sigluficant differences in the mechanism of action involved in each. 
Acute vessel stretch was the predominant mechanism of acute luminal gain in the 
shrinkage group (2.4 ±1.3 mm' versus 0.3 ±0.6 mm', p=0.0014) wlulst plaque 
reduction was the predominant mechanism of acute luminal gain in the compensa-
tory enlargement group (5.8 ±I.O mm' versus 3.6 ±I.5 nun', p=0.0048). At fol-
low-up the main mecl)anism for' late ioss was chrOluc vessel recoil in the shrinka-
ge group (2.4 ±I.3 mm' versus 0.7 ±0.9 mm', p=0.0073), and intimal hyperplasia 
in the compensatory enlargement group (I.7±2.4 mm' versus 0.3 ±2.9 mm') 
although because of the small numbers involved tlus did not reach statistical signi-
ficance (p=0.2489). There was no significant correlation between acute vessel 
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stretch and late vessel recoil in either the shrinkage or compensatory enlargement 
group (r ~ 0.28, p~0.3673, and l' ~ 0.41, p~0.2823, respectively). 
Role of chronic vessel recoil (vessel remodeling) in the 
mechanism of restenosis between the shrinkage and compen-
satory enlargement groups in BA and DCA 
The mode of de novo vessel remodeling was found to playa significant role in the 
mechanisms involved in late restenosis. While in the shrinkage group of balloon 
angioplasty chronic vessel recoil (remodeling) accounted for 90% (1.8mm' / 
2.0nu11') of late lumen loss, in the compensatory enlargement group chronic ves-
sel recoil accounted for only 55% oflate lumen loss (l.lmm' /2.0mm'). While in 
the shrinkage group of directional atherectomy c1u'onic vessel recoil accounted for 
89% (2.41lll11' / 2.7nu11') of late lumen loss, in the compensatory enlargement 
group chronic vessel recoil accounted for only 29% (0.7mm' / 2.4 mm') oflate 
lumen loss. Thus the de novo mode of vessel remodeling, vessel sln'inkage versus 
compensatOlY enlargement, was seen to substantially influence the subsequent 
mechanism of restenosis following both balloon angioplasty and directional athe-
rectomy. 
Discussion 
The principle findings of our study were; I) Overall initial luminal gain and late 
loss were similar in the two different de novo vessel remodeling states for both 
BA and DCA; 2) at the time of intervention significantly larger vessel stretch was 
obtained in the shrinkage group for both BA and DCA, whilst significantly gre-
ater plaque removal was obtained by DCA in the compensatory enlargement 
group; 3) at follow-up late vessel recoil (vessel remodeling) was significantly gre-
ater in the sln"inkage group after either BA or DCA; 4) a high correlation (r ~ 
0.73) was observed between the degree of acute stretch and late vessel recoil in 
the sln'inkage group in BA; 5) wlule in the sln'lnkage group chrOluc vessel recoil 
(remodeling) accounted for 89% to 90% of late lumen loss after BA and DCA 
respectively, in the compensatory enlargement group remodeling accounted for 
only 55% to 30% of late lumen loss after BA and DCA respectively. 
Role of de novo vessel remodeling mode in acute luminal 
gain after coronary intervention 
Recent intracoronary ultrasound studies indicate that plaque reduction accounts 
for 52% to 67% and vessel stretch for the remaining 33% to 48% of acute luminal 
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gain after BA and DCA [13,15) This is in keeping with our Shldy where plaque 
reduction accounted for 47% of overall acute luminal gain after BA and 72% of 
overall acute gain after DCA in the total study population. However, our tomo-
graphical quantification based on the underlying de novo vessel remodeling mode 
indicates that in the shrinkage group ofBA vessel stretch accounted for 62% of 
acute gain, while in the compensatory enlargement group ofBA vessel stretch 
accounted for only 26% of acute gain. In the shrinkage group of DCA plaque 
reduction accounted for 60% of acute gain, while in the compensatory enlarge-
ment group of DCA plaque reduction accounted for 95% of acute gain. These fin-
dings indicate that the de novo vessel remodeling mode may have an important 
role in determining the mechanism of acute luminal gain (vessel stretch or plaque 
reduction) after coronary intervention. Pasterkamp and colleagues also recently 
examined the influence of the de novo vessel remodeling mode on the mechanism 
of balloon angioplasty in femoral arteries and again found that vessel stretch was 
significantly greater in the shrinkage group than in the compensatory enlargement 
group (7). Our findings expand on their initial observations and suggest that the 
same mechanisms may also be operative in the coronary vessels. Furthermore 
vessel stretch also appears to be a major mechanism of action in the paradoxical 
shrinkage group treated by directional atherectomy. The reasons for this are not 
clear. One possible explanation is that paradoxical shrinkage may be the result of 
stmchlral changes in the vessel wall, such as alterations in the relative proportions 
of elastin or collagen, resulting in alterations in the elastic properties of the vessel. 
Our findings also indicate that vessels which have undergone compensatory enlar-
gement are much more susceptible to plaque removal by directional atherectomy 
than vessels which have undergone paradoxical shrinkage, perhaps again reflec-
ting underlying differences in vessel wall characteristics. Against this however is 
the fact that we did not find any significant differences in ultrasound plaque char-
acteristics between the paradoxical shrinkage and compensatory enlargement 
groups. rcus visual plaque characteristic assessment however is still a fairly 
rough method of assessing plaque composition. Whether newer techniques such 
as angular dependent backscatter analysis by ultrasound may result in increased 
precision in cell wall characterisation and allow us to differentiate plaque compo-
sition further remains to be determined (16). 
Role of de novo vessel remodeling mode in restenosis 
The classical paradigm regarding the mechanisms of rest enos is after coronary 
angioplasty has been one of neointimal thickening from the migration, prolifera-
tion and extracellular matrix synthesis by vascular smooth muscle cells [17]. 
More recently this paradigm has been challenged by both experimental [18,19) 
and human intravascular ultrasound shldies which suggest that restenosis relates 
more to unfavourable late vascular remodeling thanneointimal hyperplasia [20-
23). The mechanisms involved in this however are unclear but are thought to 
122 
involve a combination of vessel wall fibrosis (particularly of the adventitia) in 
response to deep wall injury, apoptosis (programmed cell death), qualitative and 
quantitative changes in the extracellular matrix and changes in local flow dyna-
mics [22-26]. What factors may influence this process remains unknown. Our 
serial intra coronary ultrasound study clearly indicates a major role for the under-
lying de novo vascular remodeling mode on late restenosis after both balloon 
angioplasty and directional coronary atherectomy. Prcvious intracoronary ultra-
sound studies have reported that various degree of chronic vessel recoil ( "vascu-
lar remodeling" ; from 42% to 84%) account for late loss after BA and DCA 
[13,15]. Our study was consistent with these studies suggesting that cluonic recoil 
accounts for 71 % of late lumen loss after BA and for 69% of late lumen loss after 
DCA in the overall patient population. However, our study also suggests that wit-
hin the overall picture, the relative contributions of chronic vessel recoil and inti-
mal hyperplasia to restenosis can vary widely, depending on the de novo vessel 
remodeling mode. For example, in the shrinkage group subjected to balloon 
angioplasty chronic vessel recoil (remodeling) accounted for 90% of late lumen 
loss, whilst in the compensatory enlargement group of directional atherectomy 
remodeling accounted for only 29% of late lumen loss whilst intimal hyperplasia 
accounted for the remaining 71 % of late lumen loss. The reasons for these diffe-
rences are not clear but again are likely to be secondary to structural changes in 
the vessel wall as a result of whatever process underlies the initial de novo vascu-
lar remodeling mode. 
Relation of acute stretch and late recoil 
Glagov and colleagues suggested that in a coronary artery compensatory enlarge-
ment without luminal narrowing was frequently observed until plaque area incre-
ased up to 40% [I]. A recent intravascular ultrasound Shldy indicated that in a 
femoral artery compensatory enlargement was mainly observed in plaque area less 
than 25% and paradoxical shrinkage was frequently seen in plaque area more than 
25%, although no strong relation existed between the decrease of luminal area and 
the increase of the plaque area [6]. In our patients with significant fixed stenoses 
33% of the patients showed compensatory enlargement of the vessel and the 
remaining 67% of the patients had paradoxical shrinkage. Compensatory enlarge-
ment and paradoxical shrinkage may be natural stages in the atherosclerotic pro-
cess itself and may be associated with structural changes in the media and adven-
titia [I, 27]. In the paradoxical sln'inkage stage the elastin content of the vascular 
wall may be decreased and the rigidity of the wall hence increased [27], whilst in 
the compensatory enlargement stage vessel wall extensibility may be preserved. 
Our study would suggest that following balloon angioplasty of vessels which have 
undergone paradoxical shrinkage the dilated vessel wall may constrict gradtrally 
during the process of rest enos is and that the degree of this constriction relates 
directly to the original degree of vessel stretch at the time of the procedure. 
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Tlus relationship is however altered by directional atherectomy. Atherectomy spe-
cimen has been frequently reported to involve the adventitia [28], which may sub-
stantially weaken the vessel wall, and thus reduce and alter the degree of/ate ves-
sel recoil (remodeling) at follow-up. This phenomenon may be responsible for the 
poor correlation between the degree of vessel stretch and remodeling after direc-
tional atherectomy. An alternative mechanism may be that factors responsible for 
the initial paradoxical shrinkage vessel remodeling mode are still present and may 
therefore influence the subsequent vessel response to balloon angioplasty, whereas 
atherectomy, by removing vessel wall constituents, alters the local plaque burden, 
composition and characteristics thus altering the local vessel nulieu and hence the 
vessels response to the procedure. 
Study limitations 
Our study has a number of linutations. Firstly, the reference segment site used is 
critically important for our definition of vascular remodeling and hence our 
results. For our reference we used the least diseased segment witlun 15mm proxi-
mal to the narrowing but distal to a major side branch, as this is likely to be the 
site of least vessel wall remodeling and hence the most likely site to approximate 
the original vascular dimensions. We cannot discount the fact however, that a dif-
ferent, perhaps even more proximal, reference segment may provide a different 
value of TVA and hence affect the estimated remodeling mode. Secondly, perfor-
ming serial intracoronary ultrasound measurements of the same arterial segment at 
an interval of 6 months poses significant technical and logistic problems. We 
tried to overcome these however and ensure accurate localisation of the ICUS 
catheter by using permanent landmarks, such as side branches and areas of calcifi-
cation, for guidance and by careftllly observing the position of the ICUS catheter-
tip on the fluoroscopic image wluch was recorded simultaneously on a split 
screen. Thirdly, pre intervention several patients showed wedging of the rcus 
catheter and in these patients the site of muumalluminal cross sectional area may 
have already been slightly dilated by the ICUS catheter itself. However, the nuni-
mal cross sectional area pre intervention calculated from QCA was O.92nlln' 
whilst the cross sectional area of the most of ICUS catheter used is O.73nlln' so 
any "Dotter effect" would have been mUlimal. Finally, our patients were, to an 
extent, selected on the basis of a successftll interventional procedure with subse-
quent lugh quality serial ICUS images. We are unable to conllnent therefore on 
the role of de novo vascular remodeling on the acute success rate of the procedu-
re. As the number of patients reported in this early experience is also small our 
fUldings will need to be confirmed in larger multicenter studies. 
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Clinical implications 
Our study suggests that the underlying de novo vessel remodeling mode may sig-
nificantly contribute to the efficacy of a device (vessel expansion or debulking) 
and the subsequent mechanism of restenosis (remodeling or intimal hyperplasia). 
This has important clinical implications with regard to the optimal use of new 
devices. Our study suggests that in a vessel with paradoxical shrinkage stent 
implantation, to act as a scaffold for the vessel wall and prevent late vessel recoil, 
may be the optimal device to prevent restenosis. In vessel with compensatory 
enlargement plaque reduction (debulking) during the initial interventional proce-
dure and concomitant medical treatment to prevent the growth of intimal hyper-
plasia using local drug delivery (29) or endovascular radiation [30] may be the 
most useful way of reducing restenosis. Thus observation of de novo vessel remo-
deling mode provides novel information with which to determine the most suitable 
interventional device for each specific lesion. Our study also suggests that the de 
novo vessel remodeling mode may be substantially more important to both the 
mechanism of acute luminal gain and late restenosis than plaque characteristics. 
It may thus provide some insight into why intravascular ultrasound studies, to 
date, have not been wholly supportive of the role of plaque characteristics on the 
subsequent acute gain and late loss and may provide important lessons for the 
ongoing OARS and BOAT studies [15,31]. Finally our study once again high-
lights the limitations of quantitative coronary angiography which, although the 
gold standard for interventional work, is unable to differentiate between the diffe-
rent pathophysiological mechanisms involved in acute luminal gain and late reste-
nos is and hence guide optimal use of revascularisation devices. 
Conclusions 
Our study suggests that the underlying de novo vessel remodeling mode (vessel 
shrinkage/compensatory enlargement) may playa key role in the acute efficacy of 
a coronary revascularisation device (vessel expansion or de bulking) and the subse-
quent mechanism ofrestenosis (remodeling or intimal hyperplasia). 
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Chapter 11 
Influence of serum cholesterol and cholesterol subfractions 
on long term luminal renarrowing following coronary 
angioplasty. A quantitative angiographic analysis. 
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Influence of Serum Cholesterol and Cholesterol 
Subfractions on Restenosis After 
Successful Coronary Angioplasty 
A Quantitative Angiographic' Analysis of 3336 Lesions 
Andonis G. Violaris, MD, MRCP (UK); Rein Melkert, MD, MS; Patrick W. Scrruys, MD, PhD, 
Background Previous reports have suggested that hyperlip-
idemia may be associated with increased reslenosis after 
suttessfuI coronary angioplasty. These studies have been 
compromised, however, by their retrospective nature, the 
small numbers im'olvcd, differences in the definition of reste-
oosis, and inadequate quantitative angiographic follow-up at a 
prespecified time interval, The objective of the study was to 
examine the relation between serum cholesterol and long-Ienn 
restenosis after coronary 3l1giopiasty, using quantitati\'e angi. 
ography, at a predetermined time interval. 
Melhods and Resulls The study population comprised 2753 
patients (3336 lesions) prospectively enrolled and successfully 
completing four major restenosis trials. Cineangiographic films 
were processed and analyzed at a central angiographic core 
laboratory with the use of an automated interpolated edge-
detection technique. Serum total cholesterol was measured at 
trial entry and at 6 months. Hypercholesterolemia was defined 
as total cholesterol >7.8 mmol'L-1 at trial entry. 1\'>0 ap-
proaches were used to assess restenosis: first, a categorical 
approach using the cutoff point of >50% diameter stenosis at 
follow.up and seCQnd, a continuous approach examining 
changes in minimal luminal dimensions, the absolute loss 
(change in minimum luminal diameter after PTCA to follow-
up, in mm) and reiati\'e loss (abSOlute loss corrected for vessel 
size), which may give a better understanding of the underlying 
pathological process involved. One hundred sixty patients with 
191 lesions (5.73%) bad hypercholesterolemia (Iotal choles-
terol, >7.8 mmol· L -J; mean±SD, 8.46±0.75 mmol' L _I) and 
Restenosis after successful coronary angioplasty remains a major limitation of the technique. 1 Postmortem examination suggests that this is 
the result of intimal hyperplasia secondary to the inti-
malJy directed rrugration and proliferation of vascidar 
smooth muscle cells.2 Experimental in vitro cell studies 
have shown that vascular smooth muscle cell migration 
and proliferation may both be influenced by cholesterol 
and cholesterol subfractions.3 Furthermore, in vivo an-
imal work also suggests that serum cholesterol may be 
an important determinant of intimal hyperplasia after 
balloon angioplasty.4 Because of this body of experi-
Recel\'ed AprilS, 1994; rem/on received JUlie 27, 1994. 
From the Catheterization Laboratory, Thoralcenler, Erasmus 
UniYersity, and theDepanment of EpidemIology and Biostatistics 
(R.M.), Cardialysis, Rolterdam, the Netherlands. 
Correspondence toProfP.W. Serruys, MD, PhD, FACe, FESC, 
Catheterization Laboratory, Thor;ucenter, Erasmus Vni-,ersity 
Rotterdam, Postbus 1738,3000 DR, Rolterdam, the Netherlands. 
© 1994 American Hearl Association, Inc. 
132 
2593 patients with 3145 lesions (94.27%) nonnal cholesterol 
(5.67±1.06 mmol·L-I). The restenosis rate was similar in 
patients with and without hyperCholesterolemia (31.9% \'ersus 
33.7%, respectively; relative risk, 0.975; 95% CI, 0.882 to 
1.077; P=.68). Similarly, there was no difference in either the 
absolute or relative Joss between patients with and without 
hypercholesterolemia (0.31±0.53 versus 032±0.53 rom and 
O.12±O.20 \'ersus O.l3±O.21, respective/y, P=NS for both). 
Conversely, the total serum cholesterol in patients with reste-
nosis (using the categorical definition) was similar to those 
without restenosis (5.84±1.24 versus 5.81±1.22 mmollL, re-
spectively, P=NS). Dividing the population into deciJes ac-
cording 10 total cholesterol and examining the categorical 
restenosis rale (by Xl) as well as the absolute and relati\'e loss 
by ANOVA again re\'ealed no significant differences between 
deciles. Subgroup analysis of 579 patienls (667 lesions) with 
HOL and LDL cholesterol le\'els available again re\'ealed no 
differences in the categorical restenosis rate (by X 2) or the 
absolute or relative loss between deciles according to LDI.., 
HDI.., or LDl-!HDL ratio, suggesting no Influence of these 
cbolesterol subfractions on restenosis. 
Condflsions Our results indicate thai there is no associa-
tion between cholesterol and restenosis by either a categorical 
or continuous approach, suggesting that measures aimed at 
reducing total cholesterol are unlikely to significantly influence 
postangioplasty restenosis. (Cimt/alion. 1994;90~261-2279.) 
Key WQrds • angioplasty • cholesterol • stenosis • 
angiography 
mental evidence and also clinical evidence linking ele-
vated serum lipid fractions to atheroscierosis,s.6 a num-
ber of studies have sought to investigate the relation 
between serum lipids and restenosis. The results from 
these studies have been equivocal (Table 1), with some 
suggesting a positive correlation between the tw01- IO and 
others suggesting no association. ll•12 These differences 
arise for a number of reasons. First, most studies have 
been retrospective analyses using small numbers of 
patients. Second, angiographic follow-up was mostly 
incomplete and performed for the recurrence of symp-
toms rather than at a predetennined time interval, thus 
introducing selection bias. Finally, studies have almost 
invariably used visual aSsessment to estimate angio-
graphic severity. This is subject to wide interobserver 
and intraobserver variability, which further limits the 
reliability of the resuJts.13 This study attempted to 
overcome these limitations by using a validated auto-
mated edge-detection technique to evaluate the effect 
of serum cholesterol on restenosis prospectively in a 
TABLE 1. Summary of Studies In Which the Relation Between Lipid Levels and Subsequent 
Reslenosls Was Examined 
No. at Anglo Reatenosls 
Study Patients Follow·up, % Dellnlllon Rate,% Association 
Austin et all 443 100 loss >50% AG 41 TO. female 
Aspirin Ax gp 
Austin at alII 103 7' ? 36 Nona 
Arora et a1~5 723 100 loss >50% AG 41 Inverse relation to 
TO at fop 
Johansson at ala 157 100 >50% OS fop 33 lowHOl (M) 
High HOl (F) 
Rels at a19 166 37 >70% OS fop 32 TO:HOl cholesterol 
Folay at all~ 100 62 loss >50%AG 45 Nona 
InCt '%OS >30% 
Shah and Amlnl0 66 37 >70% OS fop 41 low HOl 
Present study 2753 60 >5<l% OS fop 33.6 None 
NRloss 
ANGINGI 
Anglo IndIcates anglographlc; AG, absolute galn; OS, diameter stenosis; fop, at fonow·up; NRloss, absolute! 
relative loss; ANG, absolute net gaIn; NGI, net gain Index; TO, lolal cholesterol; and Ax gp, treatment group. 
large series of patients undergoing successful balloon 
angioplasty and routine follow·up angiographic assess· 
ment at a predetermined time interval. 
Methods 
Patients 
The study population C{Jmprised 3582 patients with signifi· 
cant primary stenoses in nati\'e coronary arteries who were 
prospecth'ely enrolled into four major r<:stenosis trials.14-11 
These demonstrated that active therapy had no effect on 
restenosis or clinical outcome in the first 6 months after 
balloon angioplasty. so for the purposes of this study, the data 
for the active and pl<Icebo groups were pooled. Patients were 
eligible for study entry if they were symptomatic or asymptom' 
atic men, or women without child·bearing potential, with 
stable or unstable <Ingin<I pectoris and proyen angiographically 
significant narrowing in one or more major coronary arteries. 
InfOffiled consent was obt<Iined in <Ill cases before the coro· 
nary <Ingioplasty procedure. Patients with developing myocar· 
dial infarction and Significant left main coronary mtery disease 
were excluded from the study. 
Serum Cholesteroll\1easureruents 
Serum cholesterol measurements were taken before percu· 
taneous transluminal coronary angioplasty (PTCA) and at the 
time of 6·month follow·up angiography by each individual 
center. S<Imple analysis was carried out locaUy in <Ill partici· 
pating centers. HyperchoJesterolemi<I was defined as <I serum 
cholesterol level >7.8 mmol· L- l at trial entry.lg A cholesterol 
leyel of <7.8 mmol· L-l was, for the purposes of this study, 
defined as "nonnal" cholesterol. 
Angioplasty Procedure and Follow·up Angiography 
Coronary angioplasty was perfonned with a steerable, mov· 
able guide wire system by the femoral route. Standard balloon 
catheters were used. The choice of b<Illoon type and brand as 
well <IS inflation pressure <Ind dur<Ition were left to the 
discretion of the operator. Patients were followed up for 6 
months, at which time a follow.up study was performed. If 
symptoms recurred within 6 months, coronary <Ingiography 
was carried out earlier. If no definite restenosis was present 
<Ind the follow·up time was <4 months, the patient was asked 
to undergo further coronary arteriography at 6 months. 
QuantitatiYe Angiography 
Three coronary angiogrruns, in tolal, were obtained for each 
patient: before PTCA, after PTCA, and at anglographlc 
follow·up. The angiograms were recorded in such a manner 
that they were suitable for quantitative analYSis by the com· 
puter·assisted Coronary Angiography Analysis System 
(CAAS). To st<Indardize the method of data acquisition and to 
ensure exact reproducibility of the angfographic studies, me<I' 
sures wele taken as previously described, and <III angiograms 
were processed in a central <Ingiographic core laboratory.H.ll 
All cine<Ingiograms were an<Ilyzed ",itb the computer.assisted 
CAAS technique, which was described <Ind validated e<Irli· 
er.1J•19 Because the computer algorithm is unable to measure 
total occlusions, a v<Ilue of 0 mm W<IS substituted for the 
minimal lumen diameter and a Y<Ilue of 100% for the percent 
diameter stenosis before PTCA.ln these cases, the post<Ingio· 
plasty reference diameter W<IS substituted for vessel size. 
Angiographic Definitions Used 
Vessel size refers to the reference diameter of the releY<Int 
coron<Iry segment <Ind is represented by the interpol<Ited 
reference di<Imeter before PTCA, since this is the closest and 
most objective approximation of the disease·free \'essel wall. 
MinimUm luminal diameter (MLD) is the point of maxim<I1 
luminal narrowing in the analyzed segment. 
Many criteria have been proposed for the assessment of 
restenosis.w For the purposes of this study, two approaches 
were used: first, tbe categorical approach widely used by 
c1inid<Ins who favor the traditional cutoff point of >50% 
diameter stenosis at foliow·up; and second, a continuous 
approach using absolute and rela\i\'e losses, which reflect the 
behavior of the lesion during and after angloplasty and may be 
betler representations of the pathological process involved 
during foUOW.Up.Z1.2 l 
Absolute gain and absolute loss represent the improvement 
in minim<Illumin<Ii diameter achieved at inten'ention and the 
absolute change during follow·up, respectively, measured in 
mm. Absolute gain is defined as MLD after PTCA minus MLD 
before PTCA. Absolute loss is MLD after PTCA minus l\.fLD 
at follow· up. 
Relatr·re gain and relati-.'e loss depict the impro\'ement in 
minimal luminal diameter <Ichieyed at intervention and the 
change during follow.up, respectively, nonnalized for yessel 
size, Relati\'e gain is (MLD <Ifter PTCA minus MLD before 
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FIG 1. Flow chart of 3582 randomIzed pallents. In 102 pallents, 
angloplasty (anglo) procedure was unsuccessful; 10 28, percu· 
taneous translumlnal coronal)' angloplasty (PTCA) was 001 per-
formed; In 25, quantitative analysis was not possible; and In 199. 
no cholesterollevef was available. The study populatlon com· 
prlsed 2753 patients with an anglographlC follow·up rate of 80% 
of successful procedures. OCA Indicates quantitative coronary 
arteriography; Fup, follow·up; and cha!., chofesterol. 
PTCA) divided by vessel size. Relative loss is (MLD after 
PTCA minus Mill at follOW-Up) divided by "essel size. 
The absolute net gain is the MiD at follow-up minus MLD 
before PTCA. The net gain index is the net gain nonnalized 
fot the vessel size. Net gain index is (MLD at follow·up minus 
MLD before PTCA) divided by vessel size. 
Statistical Analysis 
Data were analyzed by the SAS statistical software package. 
All values are expressed as mean±SD. A Xl test was used to 
assess differences in categorical variables. Student's t test was 
used to assess differences in continuous variables bern-een tv>'O 
groups or one-way ANOVA for more than two groups. Serum 
total cholesterol, lIDL and LDL cholesterol, and LDL:HDL 
ratio were evaluated by linear regression analysis for their 
relation with absolute and relative loss during follow-up as well 
as absolute net gain and the net gain index. A lesion·based 
analysis was used, but since multiple lesions within a given 
patient are not independent \\lith respect to their cholesterol 
le\'el, repeat patient·based analysis using a single randomly 
selected lesion in patients with multi\'essel angioplasly was 
perfonned if the previous lesion·based analysis suggested 
statistical significance. Values of P<.05 were considered 
significant. 
Results 
Patient Characteristics and Procedural Results 
The study population comprised 2753 patients (3336 
lesions, 1.21 lesions per patient) who successfully com-
pleted the study (Fig 1). Of the 3582 patients initially 
randomized, the angioplasty procedure was unsuccess-
ful in 102 patients, PTCA was not performed in 28, 
quantitative analysis was not possible in 25, no choles-
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TABLE 2. Clinical Variables In Pallents WlIh and 
Without Hypercholeslerolemla* 
Cholaslerol Cholesterol 
Clinical Variable <7.8 mmol/L >7.8 mmol/L 
No. of patients 2593 160 
Men, % 82.0 73.8 
Age, y 57±9.3 55.3±9.3 
Ever smoked, % 45.3 57.5 
Current smoker, % 10.2 11.2 
History of hyperlipidemIa, % 31,4 4804t 
History of diabetes, % 10.2 9.4 
History of previous MI, % 41.7 36.9 
Previous PICA, % 2.7 0 
Previous CABO, % 2.9 3.2 
CCS cfass, % 
0 2.5 
13.9 14.9 
35,4 38.0 
III 33.2 36.4 
IV 16.0 10.7 
Drug therapy at trial entry, % 
Nitrates 18.9 17.9 
p.Blockers 26.3 26.2 
Calcfum antagonists 35.9 4004 
Upld·lowerlng agents 9.7 17.2 
Drug therapy at 6 months, % 
Nitrates 21.5 18.7 
p.Blockers 35.2 30.7 
Calclum anlagonlsts 40.8 30.7t 
Upld·lowerlng agents 13.9 26.7t 
Mllndicales myocardia! InfarctiOn; PICA, perCtJlaneouslranslu-
mlnal coronary angloplasly; CABQ, coronary artery bypass graft; 
and CCS, Canadian Cardklvascutar SocIety ang!na1 classificatlon. 
·Serum total cholesterol >7.8 mmol'l-', 
tP<.05. 
terollevel was available in 199, and 475 were excluded 
for other reasons, such as patient refusal for follow-up 
angiography, no quantitative coronary arteriography 
possible, or left main disease. Thus, the overall angio-
graphic restudy rate was 77% of all patients initially 
randomized and 80% of all patients undergoing success-
ful PTCA and no other interventional procedure. 
Within the study population, 160 patients with 191 
lesions (5.73%) had hypercholesterolemia (mean total 
cholesterol, 8,46±O.75 mmol· L -1) and 2593 patients 
with 3145 lesions (94.27%), normal cholesterol 
(5.67±1.06 rnmol' L -I) at trial entry. The clinical and 
angiographic characteristics of the patient population 
according to the presence or absence of hypercholester-
olemia are summarized in Tables 2 and 3. 
The incidence of known hyperlipidemia, as would be 
expected, was significantly higher in the high-choles-
terol group; otherwise, the two groups were comparable 
in terms of known risk factors for coronary artery 
disease. In particular, smoking, either past or current, 
TABU: 3. Lesion Location, Anglographlc 
Characteristics, and Quantitative Anglographlc Analysis 
of 160 Patients (191 Lesions) With and 2593 Patients 
(3145 Lesions) Without Hypercholesterolemlai. 
Cholesterol Cholesterol 
<7.6 mmolJL >7.8 mmolJL 
Anglographtc Parameter (0=3145) (n=191) p 
lesion location, % 
lAD 42.9 42.9 NS 
Circumflex 25.0 24.8 NS 
RCA 32.1 32.5 NS 
lesIon charactetistlcs, % 
Concentric 47.1 47.2 NS 
Tandem lesion 4.2 4.2 NS 
Branch point lesion 59.2 58.4 NS 
Calcification In lesion 12.33 9.0 NS 
Presence 01 thrombus 4.4 3.9 NS 
Tolal occlusion pre-PTCA 7.4 7 .• NS 
Dissection post-PlCA 34.6 27.5 NS 
Vessel size, rom 
Minimal luminal diameter, mm 2.60±0.53 2.59±0.62 NS 
Before angloplasty 1.00±0.39 0.98±0.39 NS 
After angloplasty 1.75±0.36 1.75±0.34 NS 
AtloUow·up 1.44±O.68 1.44±0.59 NS 
Differences In MLO 
Absolute gain, mm 0.75±0.41 0.76±0A3 NS 
Relative galn 0.30±0.16 O.30±0.16 NS 
Absolute loss, mm O.32±O.63 O.31±0.63 NS 
Relative loss 0.13±O.21 O.12±O.20 NS 
Absolute nel gain, mm O.17±O.23 O.18±O.24 NS 
Net gain Index 0.17±O.23 0.18±O.24 NS 
Percent slenosls, % 
Before angloplasty 6O.92±14.47 61.36±14.64 NS 
After angloplasty 33.39±8.40 33.64±7.88 NS 
AI follOW-Up 4S.86±19.16 45.47±19.46 NS 
OS al follow-up >50%, % 33.7 31.9 NS 
LAO Indicates left anterior descendIng coronary artery; RCA, 
righlCOronary artery; PTeA, percutaneous lfanslumlnal coronal)' 
angloplasty; MLO, minimal luminal diameter; and OS, diameter 
stenosis. 
*Serum lotal choleslerol >7.8 mmol. L -1. 
was present in about two thirds of the population and 
was similar in the two study groups. The anginal class of 
the two study groups also did not differ to any significant 
extent, most being in Canadian Cardiovascular Society 
anginal class II to III. Finally, there was no significant 
difference in drug therapy, although, perhaps not sur-
prisingly, more patients with high cholesterol were 
taking a lipid-lowering agent (Table 2). By the time of 
the follow-up angiography, this difference persisted, but 
in addition, a significantly lower percentage of patients 
with hyperlipidemia were taking calcium antagonists. 
The disease was predominantly mild to moderate, with 
63% of the total population having one-vessel disease, 
31% two-vessel disease, and only 6% three-vessel dis-
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FIG 2. (a), Cumulative disliibutlon culVe of minImal luminal 
dlameler (MLO) after percutaneous translumlnai coronary anglo-
plasty (PTCA) and at foUow·up for pallents with and without 
hypercholesterolemia. (b), Cumulative distribution curve o.f per· 
centage stenosis after PTCA and at fonow·up fOf palienls with and 
without hyperchOlesterolemia. TC Indicates lotal cholesterol. 
ease. Lesion characteristics were comparable in the two 
groups, with a similar incidence of concentric, tandem, 
and branch point lesions, thrombus present before- or 
after- PTCA, total occlusions before PTCA, and dissec-
tions after PTCA (Table 3). 
Quantitative Angiographic Analysis at Baseline and 
6 Months 
A mean of 212 matched angiographic projections per 
lesion had satisfactory quantitative analysis performed 
at the central angiographic core laboratory before 
PTCA, after PTCA, and at follow-up (Table 3). The 
distribution of lesions was similar in the two groups, 
with around 43% in the left anterior descending coro· 
nary artery, 32% in the right coronary artery, and 25% 
in the circumflex artery. There were no significant 
differences in the MLD and percent stenosis before 
PTCA between patients ,vith and patients without hy-
percholesterolemia, suggesting that the two groups were 
well matched angiographicaUy. After PTCA, the MLD, 
percent residual stenosis, and absolute and relative 
gains were similar for the two groups (Table 3, Fig 2), 
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FIG 3. (a), Cumulativa dIstribution curve of absolute loos for 
paUents with and without hypercholesterolemIa. (b), Cumulative 
dIstribution curve of absolute loss for paUenls In the top and 
boHom declles of lotal cholesterol (Te). 
again confirming the similarity in acute angiographic 
outcome between the two groups. Similar results were 
also obtained with patient rather than lesion analysis. 
Restenosis According to the Presence of 
Hypercholesterolemia at TrIal Entry 
At the 6-month angiographic follow-up, the overal 
restenosis rate for the study population was 33.6% b} 
the categorical (>50% stenosis at follow-up) approach. 
The MLD at follow-up was 1.44±O,59 mm for patients 
with and 1.44±0.58 mm for patients without hypercho-
lesterolemia (Fig 2). The percent stenosis at follow-up 
was again similar, 45.47±19.46% for patients with and 
45.86±19.16% for patients without hypercholesterol-
emia (Fig 2). The absolute loss was also similar for the 
two groups (Fig 3a), as were the relative loss, net gain, 
and net gain index (Table 3). By the criterion of >50% 
diameter stenosis at follow-up, there were no differ-
ences in restenosis rates between patients with and 
without hypercholesterolemia (31.9% versus 33.7%, re-
spectively: relative risk, 0.975; 95% el, 0,882 to 1.077; 
P=_68). Additionally, the total serum cholesterol in 
patients with restenosis (according to the criterion of 
>50% diameter stenosis at follow-up) was similar to 
those without restenosis (5.84±L24 verSus 5.81±1.22 
mmollL, respectively, P=NS) . 
Declles AccordIng to Total Cholesterol at 
Trial Entry 
Since definitions for hypercholesterolemia varylS,13 
and previous population studies suggest that even 
within the total cholesterol population there is a grada-
tion of atherosclerosis risk,s.6 the population was di-
vided into deciles according to total cholesterol at trial 
entry to further examine the role of serum cholesterol 
on restenosis and whether there is any evidence for a 
nonlinear relation between the r.vo. There ,,"'ere no 
significant differences between groups in either the 
categorical restenosis rate or the absolute or relative 
loss (Table 4). The net gain and net gain index were also 
similar in aU groups. Additionally, cumulative distribu-
tion cUr\'es of the top and bottom deciJes for cholesterol 
showed no differences in either MLD at follow-up, 
percent stenosis at follow-up (Fig 4), or absolute loss 
(Fig 3b). 
Linear Regression Analysis of Total Cholesterol 
Linear regression analysis was used to further evalu-
ate the relation between total cholesterol at trial entry 
TABLE 4. ReetenoBle Rates, Absolute Loes, Relative LoU, Net GaIn, and Net GaIn Index Per Decile AccordIng to 
Total Cholesterol Level 
Decile Rank n Te, mmol/l RR,% Absolute Loss, mm Relat/ve Loss Net GaIn, mm Net GaIn Index 
1 337 3.73±O,68 35.9 O.36±O.65 O,14±O,22 O.15±O.23 O.f6±O,29 
2 329 4.62±O.13 35.0 O.34±O.52 O,13±O.20 O.18±O.22 O.16±O.19 
3 330 5.02±O.11 33.3 O.34±O.SI O.14±O.21 O.f7±O.23 O.13±O.23 
, 338 5.37±O.09 36.7 O.32±O.S2 O,13±O,21 O.17±O,23 O,16±0.23 
5 332 5.67±O.09 30.1 0,31 ±0.50 O,13±O.20 O.17±O.23 O.18±O.19 
5 341 5,95±O.09 32.0 0.31±O.53 0,f2±0.22 0.17±0.23 O.17±0.24 
7 327 6.23±O,og 36.1 O.33±O.5-4 O,f4±0.22 O,16±O.24 O.20±0.23 
8 335 6.57±O,12 31.0 O.27±0.65 O.11±O.23 O.18±O,24 O.15±O.27 
9 33' 7_06±O.16 32.3 O.26±O,54 O.11±O.21 O.18±O.22 O.16±O.21 
10 333 8.08±O.72 32.3 O.33±O.51 O.13±O.21 O,17±O.23 O.20±O,19 
TC IndIcates tolal cholesterol; AR, restenosls rate. 
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FIG 4. (a), CumulatiVe distribution curva of minimal lumln<ll 
diameter (MLD) after percutaneous Irans!umlnal coronary anglo-
plasty (PTCA) and al follow·up lor patients In the top and bottom 
decUes of tolal cholesterol. (b), Cumulative dlslribuUon curve of 
percentage stenosis after PTCA and at follow-up for pallenls In 
the top and bottom declles of lolal cholesterol. 
and absolute loss (Fig 5). as well as relative loss, net 
gain, and net gain index (Table 5). There were no 
significant relations between any of the measured vari-
ables and total cholesterol (Table 5). 
The change in cholesterol level during follow-up was 
normally distributed around the zero mark. There was a 
high correlation between cholesterol level at trial entry 
and at the 6-tnonth angiographic follow·up (r=.61, 
P<.OOOOl). Linear regression analysis of the cholesterol 
level at 6 months, the mean cholesterol level. and the 
change in cholesterol level O\'er this period again failed 
to demonstrate any relation between these and any 
angiographic parameters of restenosis (Table 5). 
Exclusion of Covert Influence of Trial Medication 
To exclude any covert influence by the trial medica-
tion on lipid levels, subgroup analysis was perfonned, 
examining the change in cholesterol levels (romol' L -I) 
from trial entry to the 6-month follow-up in the sepa-
rate studies. There were no significant differences be-
tween the active drug groups (A) and the placebo 
groups (P) in any study [CARPORT, O.l3±l.19 (A) 
, , 
TOTAL Ct~ DECllES (rnrnot1j 
B 
4679111214 
TOTAl. CHOI.£STEROl (~11 
FIG 5. Plots Showing relation between absolute loss (y axis) 
and total cholesterol (K axis). A, Decl!es," mean with 95% confi· 
dence Intervals. B, Scattergram with regression line and 95% 
confidence Intervals. 
versus O.06±1.05 (P); MARCATOR. O.lO±1.02 versus 
O.11±1.05; MERCATOR, 0.13±1.07 versus O.03±1.05; 
PARK, O.05±O.97 versus O.07±l.07]. 
LDL and HDL Subgroup Analysis 
Subgroup analysis was perfom1ed on 667 lesions in 579 
patients in whom cholesterol subfractions were available 
to examine the influence of LDL cholesterol, HDL cho-
lesterol, and LDL:HDL cholesterol ratio on restenosis 
during follow· up. This patient population was divided into 
deciles acoording to these cholesterol parameters, and we 
examined for differences bem'een deciles for restenosis 
rates, absolute loss, relative loss, net gain, and net gain 
index (Table 6), There were no significant differences in 
any of the examined parameters bew:een deciles or be-
tween patients in the top and bottom deciles for HDL and 
LDL cholesterol or LDL:HDL ratio. 
Linear regression analysis was used to further evalu-
ate the relation between LDL (Fig 6), HDL (Fig 7). and 
LDL:HDL ratio (Fig 8) and absolute loss as well as 
relative loss. net gain, and net gain index (Tables 7, 8, 
and 9). There was a negative relation betvo'een increas-
ing LDL levels and absolute loss (Fig 6, Table 7). This 
negative relation between increasing LDL levels and 
absolute as well as relative loss (Fig 6, Table 7) persisted 
even when the data were analyzed on a population basis 
(P=.03 and P=.02, respectively). The negative relation 
between increasing LDL levels and absolute loss was 
due solely to 29 lesions that had occluded at follow-up 
angiography. When these were removed from the analy-
sis, there was no longer any significant relation between 
increasing LDL levels and absolute loss (P=.264). In-
terestingly, the mean LDL cholesterol level was signif-
137 
TABle 5. Linear Regression Analysis to Evaluate the Respective Contribution of Tolal Cholesterol 
Before PTCA, at 6 Months, Mean Total Cholesterol, and Change In Total Cholesterol to Absolute 
Loss, Relallve Loss, Net Gain, and Net Gain Index 
Regression Standard Error of 
Variable Intercept Coefficient Regression Coefficient P R' 
Total cholesterol before PlCA 
Absolute loss 0.38 -0.010 0.008 .'0 .0005 
Relative loss 0.15 -0.003 0.003 .30 .0003 
Net galn DAD +0.007 0.008 .43 .000' 
Net galn Index 0.15 +0.003 0.003 .38 .000' 
Tota! cholesterol at6 months 
Abso!ute loss 0.35 -0.007 0.008 .37 .0003 
Relalive loss 0.t4 -0.003 0.003 .3' .0003 
Net galn 0042 +0.005 0.009 .59 .0001 
Net galn Index 0.16 +0.002 0.004 .53 .0001 
Mean total cholesterol 
Absolute loss 0.39 -0.012 0.008 .14 .0007 
Relalive loss 0.15 -0.005 0.003 .18 .0005 
Net galn 0.38 +0.010 0.009 .'9 .0003 
Net galn Index 0.15 +0.004 0.004 .27 .000' 
Change In total cholesterol 
Absolute loss 0.31 -0.000 0.009 .99 .0000 
Relalive loss 0.12 -0.001 0.004 .72 .0000 
Net galn 0.45 +0.003 0.010 .74 .0000 
Net galn Index 0.17 +0.001 0.004 .8' .0000 
PTCA indicates percutaneous transtumlnal coronary anglopJasty. 
icantly lower in lesions that ocduded at follow-up 
(3.61±1.59 versus 4.13±1,26 mmol . L -I ,P=.03). logis-
tic regression analYSis was also suggestive of a relation 
between lower LDL levels and probability of occlusion 
at follow-up (P=.033). A1tbough there was a significant 
relation between HDL cholesterol at 6 months and 
absolute as \vell as relative loss and net gain index 
(Table 8), this relation became insignificant once the 
data were analyzed on a patient rather than a lesion 
basis (P=.07, .06, and .09, respectively). There was no 
relation between LDL:HDL cholesterol ratio and any of 
the angiographic parameters of restenosis (Table 9). 
Discussion 
Our study has demonstrated that there is no signifi-
cant association between restenosis, by either a categor-
ical or continuous approach, and serum cholesterol 
levels. This is in a large patient population with 80% 
quantitative angiographic follow-up at a predetermined 
time interval. Although the study has a number of 
limitations, it does suggest that measures aimed at 
reducing total cholesterol are unlikely to significantly 
influence postangioplasty restenosis. 
Epidemiological, pathological, and experimental 
studies have shown that serum total cholesterol is a 
causal factor in atherosclerosis and ischemic heart dis-
ease.v Furthermore, evidence from the MR-FIT study5 
suggests that there is a continuous curvilinear relation 
between serum total cholesterol and mortality from 
ischemic heart disease. It is not surprising, therefore, 
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that if restenosis after angioplasty is viewed as an 
accelerated form of atherosclerosis, risk factors for 
coronary artery disease should also be risk factors for 
this process. 
A number of studies have previously attempted to 
examine the relation between restenosis and serum lipid 
le\'els (Table 1). Shah and Amin lO found a strong 
correlation between a low HDL cholesterol level and 
the subsequent risk of restenosis. The study was limited, 
however, by the categorical definition of restenosis used 
(>70% diameter stenosis at follow-up) and the poor 
angiographic follow-up rate of 37%. Reis and col-
leagues9 found that in a group of 186 patients enrolled 
in a trial of fish oil for restenosis after angioplasty, 
serum lipid levels, in particular high triglyceride and a 
higher ratio of total cholesterol to HDL cholesterol 
were associated with an increased risk of clinical reste-
nosis after angioplasty. Contrary to this, Johansson and 
coworkers,8 in a group of 157 patients, did not find any 
significant relation bel\veen serum lipid levels and re-
stenosis except in subgroup analysis, in which they 
found that low HDL cholesterol in men and high HDL 
cholesterol in women were associated with increased 
risk of restenosis. A number of other studies have been 
negative. 1I•24 
Discrepancies bel\"'een studies have arisen for a number 
of reasons, First, most have been retrospective analyses 
using small numbers of patientsll and, as such, subject to 
a type B error. Second, they have almost invariably used 
visual assessment of the angiogram, which previous studies 
TABLE 6. Restenosls Rates, Absolute Loss, Relative Loss, Net Gain, and Net Gain Index Per DecHe According to (A) 
LOl. Level, (8) HOl. Level, and (C) LOl.:HDL Ratio 
Decile 
Rank n lOL·C, mmollL RR,% Absolute loss Relative loss Net Gain Nel Gain Index 
A 
50 1.70±O.70 30 O.35±O.68 O.14±O.29 O,45±O.64 O.17±O.25 
2 49 2.82±O.18 45 O,45±O.61 O.19±O.24 O.29±O.62 O.12±O.26 
3 50 3.32±O.12 30 O.32±O,44 O.13±O.t9 OAt±O.54 O.15±O.20 
4 4' 3.78±O.12 29 O.30±O.51 O.12±O.20 O,42±O.51 O.t6±O.19 
5 53 4.09±O.O7 40 O.34±O,48 O.13±O.20 O.40±O.63 O.15±O.26 
6 48 4.32±O.O5 3. O.28±O.57 O.lt±O.21 O,43±O.52 O.17±O.20 
7 46 4.51±O.09 24 O.24±0.58 0.09±0.24 O,48±O.61 O.20±0.24 
• 50 4.87±O.11 36 0.22±0,46 0.09±0.18 0,46±0.58 0.17±0.22 
• 4. 5.31±0.13 2. 0.24±0.51 O.10±0.23 O.53±0.55 O.20±0.26 
10 61 6.31±0.68 27 0.27±O,48 O.10±0.19 O,44±0.53 0.16±O.20 
B HDL·C 
57 O.65±0.07 47 0,43±0.54 0.18±0.22 0.39±0,49 O.16±O.20 
2 57 0.79±0.02 25 0.26±O.52 O.OO±0.19 0.54:t0.55 0.20±0.21 
3 61 O.87±0.03 33 0.29±0.60 0.lt±0.23 0.39±O.64 0.t5±0.24 
4 65 O.95±0.02 33 O.28±0.Bl O.12±O.27 0,44±O.55 O.17±O.23 
5 56 1.02±0.O2 36 0.30±O.52 0.13±0.24 0,41 ±O.56 0.14±0.22 
6 61 1.10±0.02 34 0.28±0.47 O.11±O.20 O.39±O.61 O.15±O.25 
7 61 1.20±O.O2 30 0.21 ±O,48 O.OO±O.19 0.54±OA4 0.21±O.t6 
8 54 1.28±O.03 26 O.23±O.52 O.09±O.20 O.56±0.69 O.2t±O.26 
• 64 1041 ±O.OS 38 O.33±O.SO O.13±0.21 0.37±OA8 O.14±0.2t 
10 53 2.11±1.09 32 OAO±O.65 0.15±0.26 0.36±0.64 0.14±0.26 
C LDL:HDL Ratio 
4. 1.OS±0.61 31 OA5±0.76 O.18±0.3t O.41±0.74 0.16±O.29 
2 4. 2.36±O.23 24 O.28±O.58 0.11 ±0.24 OA2±O.51 0.16±O.19 
3 4. 2.95±O.lt 3. O.35±0.S2 O.14±O.21 O.35±O.60 O.13±O.23 
4 51 3.35±0.11 35 O.31±O.50 O.12±O.21 0,41 ±O.56 0.16±0.23 
5 48 3.68±O.08 40 O.31±O.45 0.12±0.17 OA5±OA7 O.18±0.19 
6 50 4.03±O.12 20 O.21±O.51 O.O8±O.20 OA7±0.61 O.17±0.24 
7 47 4A3±O.12 34 0.25±0,43 O.tO±O.18 0,49±0.52 O.20±O.23 
8 52 4.95±O.15 40 O.27±O.57 O.12±O.25 OAO±O.64 O.t6±O.27 
• 4. 5.81±O.3t 29 O.37±0.56 O.14±O.21 OAt±0.54 O.16±0.21 
10 48 7.58±1.18 33 0.23±0.42 O.09±0.t6 0.53±O.52 O.20±O.19 
haYe shown 10 have wide interobserver and intraobserver be misleading. For example, if we have two lesions of 
variability,l3 Furthemlore, the angiographie follow-up rate identical reference diameter (3 mm), successfully dilated 
has been generally poor. I(l.13 Finally, and most impor- to a 40% (1.8-mm) and 25% (2.25-mm) residual stenosis, 
tantly, they haYe used varying but always categorical respectively, if both undergo the same reduction in lumi-
definitions of restenosis, such as >50% diameter stenosis nal diameter of 0.6 mm during follow-up, the first lesions 
at foll()l,v-up,s > 70% diameter stenosis at fo!low_up,9"o or would be classified as restenosis (1.2 mm, 60% stenosis) 
loss >50% acute gain.7.2S Although the >50% diameter and the second as no restcnosis (1.65 mm, 45% stenOSis) 
stenosis at follow-up criterion may give an indication of even though the absolute lumir!alloss is the same in both 
the functional significance of a stenosis at the time of lesions. 
follow·up angiography, it provides little infonnation aoout We thus believe that although the clinician is best 
the biological process involved, which hyperlipidemia sen'ed by the "present/not present" assessment ofreste-
would be expected to influence. Furthennore, the use of nos is, the biological process itself may be best analyzed 
percent measurements is inherently flawed, since it relies by measurement of absolute angiographic dimensions or 
on the nonnal vessel wall, which may itself undergo changes in absolute angiographic dimensions on a con-
restenosis.26 Finally, arbitrary categorical definitions may linuous scale.21 ,22 This is for two main reasons. First, as 
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FIG 6. Plots showing relation between absolute loss (y axis) 
and LOl choleslerol (x axiS). A, Deciles; mean with 95% confi-
dence Inlervals. B, Scaltergram with regressIon line and 95% 
confidence Intervals. 
we27 and othersUl have previollsly demonstrated, all le-
sions undergo restenosis to some extent during follow-up. 
in a gaussian distribution. Second, if we treat restenosis 
as a continuous variable, more information can be 
gleaned from the available dala regarding the underlying 
process itself.22 Furthermore, we have further expanded 
on experintenla129 and pathological evidencew suggesting 
that a greater acute gain after intervention is associated 
with a greater loss during follow-up by introducing the 
concept of relative gain to represent vessel injury and 
relative loss to represent "intimal hyperplasia."31 Thus, 
the application of quantitative angiography and the 
principles of absolute and relative loss provides a 
useful tool for the objective measurement of the 
degree of biological renarrowing during the weeks and 
months after intervention.21.n 
The application of this to our data allows us to comment 
on the biological processes occurring after intervention 
and examine the hypothesis that hyperlipidemia influ-
ences restenosis in detail. We have shown that hypercho-
lesterolemia is not a significant risk factor for restenosis. 
Furthermore, we have shovm that within the angioplasty 
population, there is no significant relation between serum 
cholesterol before PTCA and at 6·month follow-up, mean 
cholesterol le\'el or change in cholesterol level during 
follow·up. and restenosis. Subgroup analysis also demon-
strated that HDL and LDL:HDL ratios hare no signifi-
cant influence on subsequent restenosis. although there 
was a negative relation between LDL cholesterol level and 
absolute loss. Finally. we ha\'e shown that even if we take 
the two extreme deciles. again there is no difference in any 
angiographic measure of restenosis. Thus. the assumption 
that total cholesterol, a risk factor for atherosclerosis. may 
140 
'r-----------------------, 
A -,~~~~~~~~~~~~ 
0.6 0.7 011 O.{l 1.0 U 1-2 1.3 IA 1.5 1_6 1.7 1.6 
HOt.: DEClI.£S (~!) 
B 
, 
FlO 7. Plots showing relation between absolute loss (yaxls) 
and HDL !=holesterol (x axis). A, DecHes; mean with 95% confi· 
dence Intervals. B, Scatlergram with regression line and 95% 
confidence Intervals. 
also be a risk factor for restenosis after angioplasty has not 
been confirmed by this study. 
The negative relation bel\veen increasing LDL levels 
and absolute loss is interesting and was due solely to 29 
lesions that had occluded at follow·up angiography. 
When these wcre removed from the analysis, there was 
no longer any significant relation bel\veen increasing 
LDL levels and absolute loss. Intriguingly, the mean 
LDL cholesterol level was significantly lower in lesions 
with than \vithout occlusion at follow-up. This is a 
paradoxical finding, the reasons for which arc unclear. 
Although LDLcholesterol is known to promote platelet 
aggregationn and increases in plasma viscosity have 
been reported in hyperlipidemic patients,J3 it is unclear 
wby a low LDL cholesterol should increase the likeli-
hood of occlusion at follow-up angiography. Further-
more, this goes against recent hypotheses that LDL 
cholesterol reduction, by depleting lipid from fatty 
lesions prone to rupture, stabilizes the atherosclerotic 
plaque.3-t We arc unable to explain this finding, partic-
ularly since the occlusions at follow-up are likely to have 
been thrombotic events. There is evidence in the liter-
ature, however, to suggest that there may be a J·shaped 
LDL coronary heart disease risk function that puts a 
sizable subset of these patients with low WL choles-
terol at increased risk of cardiac death associated with 
lifestyle characteristics.35 Similar mechanisms may have 
been operating in our cohort of patients. 
There are a number of possible reasons why choles-
terol. a risk factor for atherosclerosis. is not a risk factor 
for restenosis after angioplasty. First. although choles-
tcrol has been shown to be a risk factor for atheroscle-
rosis, this is over the course ofyears,s·6 whereas careful 
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FIG 8. Plots shoWIng relatlon between absolute loss (y axis) 
and LDL:HDl cholesterol raUo (x axis). A, Deciles; mean with 
95% confidence Intervals. B, Scattergram with regression line 
and 95% confidence Intervals. 
serial quantitative angiographic studies have shown 
restenosis to occur in the first 3 to 6 months after 
inlcrvention.1,:J.6 11ms, total cholesterol may have little 
influence on the process over this short time frame. 
Second. the mechanisms of restenosis are still incom-
pletely understood and are likely to involve slow elastic 
recoil,37 thrombus incorporation/&,39 vessel remodel-
ing,40 and late myointimal hyperplasia.2,.30 Since the 
possible contribution of each of these factors may vary 
within individual patients as well as within the general 
population, it is perhaps not surprising that tolal cho-
lesterol, which is likely to influence only late myointimal 
hyperplasia, is not significantly related to restenosis. 
Furthermore, although quantitative coronary angiogra-
phy is the most objective and reproducible melhod 
currently available to describe the changes in stenosis 
geometry after intervention, it measures the process 
only indirectly without defining its actual nature (recoil, 
organized mural thrombus, neointimal hyperplasia). 
Finally, restenosis is likely to be a multifactorial process 
with different contributions from different factors, some 
of which are ill understood. For example, most multi-
variate models can explain only a low percentage of the 
available variance in the measurements, even when all 
available variables are incorporated.41 ,42 The most accu-
rate way to quantify restenosis would be with the direct 
measurement of neointimal thickening after coronary 
intervention. This, however, is not currently possible in 
humans, although the advent of new imaging modalities 
such as intravascular ultrasound,4J,4-I particularly with 
TABLE 7. linear Regression Analysis to Evaluate the Respective Contribution of LOL Cholesterol Before 
PTCA, at 6 Months, Mean LOL Cholesterol, and Change In LOl Cholesterol to Absolute Loss, Relative 
Loss, Net Gain, and Net Gain Index 
Regression Standard Error of 
Variable Intercept Coefficient Regression Coefficient P R' 
LOl cholesterol before PTCA 
Absolute 10$s 0.50 -0.046 0.019 .02 .0120 
Relative loss 0.21 -0.020 0.008 .01 .0135 
Net gain 0.35 +0.022 0.021 .29 .0024 
Net gain Index 0.13 +0.009 0.008 .30 .0023 
LDl ctioleslerol at 6 months 
Absolute loss 0.34 -0.010 0.022 .64 .0005 
Relative loss 0.14 -0.008 0.009 .52 .0009 
Net gain 0.38 +0.017 0.023 .47 .0012 
Net gain Index 0.14 +0.008 0.009 .39 .0017 
Mean LOl cholesterol 
Absolute loss 0.45 -0.004 0.021 .09 .0053 
Relative loss 0.18 -0.015 0.008 .07 .0063 
Net galn 0.41 +0.011 0.022 .63 .0004 
Net gain index 0.15 +0.004 0.009 .62 .0005 
Change In lOl cholesterol 
Absolute loss 0.30 +0.030 0.024 .21 .0041 
Relative loss 0.12 +0.012 0.010 .22 .0039 
Nel gain 0.42 -0.030 0.025 .25 .0035 
Net gain Index 0.16 -0.013 0.010 .19 .0045 
PTCA IndIcates percutaneous Iranslum!nal coronary angiop\asty. 
141 
TABLE 8. Linear Regression Analysis to Evaluate the Respective Contribution of HoL Cholesterol Before 
PlCA, at 6 Months, Mean HOL Cholesterol, and Change In HOL Cholesterol to Absolute Loss, Relative 
Loss, Net Gain, and Net Gain Index 
Regression Standard Error 01 
Variable Intercept Coefficient Regression Coefficient P R' 
HOt cholesterol before PTCA 
Absolute loss 0.32 -0.006 0.048 .• 0 .0000 
Relative loss 0.13 -0.002 0.019 .• 2 .0000 
Net galn 0.48 -0.018 0.048 .71 .0003 
Net galn Index 0.f8 -0.007 0.019 .71 .0003 
HDt cholesterol at 6 months 
Absolute loss 0.15 +0.151 0.072 .04 .0082 
Relative loss 0.06 +0.059 0.029 .04 .0081 
Net gaIn 0.59 -0.132 0.076 .08 .0057 
Net gain Index 0.24 ~0.062 0.029 .04 .0083 
Mean HOt cholesterol 
Absolute loss 0.26 +0.048 0.059 .42 .0011 
Relative loss 0.10 +0.020 0.024 .41 .0011 
Net gain 0.53 ~0.066 0.083 .30 .0018 
Net gaIn Index 0.21 -0.030 0.025 .24 .0023 
Change In HOt cholesterol 
Absolute loss 0.31 +0.040 0.047 .3. .0016 
Relative loss 0.12 +0.016 0.019 .3. .0016 
Net gain 0.43 -0.020 0.049 .• 8 .0004 
Nel galn Index 0.17 ~0.012 0.019 .55 .0008 
PTCA Indicates percutaneous IranslumlnaJ coronary angloplasty. 
three·dimensional reconstruction and quantitative anal-
ysis of plaque volume,45 may one day make this possible. 
Our findmg that cholesterol level has no significant 
bearing on long-term restenosis has several important 
clinical implications. First, it explains why trials designed 
to reduce overall cholesterol level have failed to influ-
ence restenosis.v5 and why studies still pendmg are nega· 
tive.47 AJthough one study has been positive,48 this was in 
a small patient population with a poor follow-up rate; 
thus, the reswts were biased. Second, it suggests that 
although lipid lowering is generally desirable, lowering 
cholesterol and its subfractions per se will not reduce 
_ restenosis. Whether newer compounds such as lovastatin, 
which also act on the vessel wall, reducing smooth muscle 
cell migration and proliferation as well as affecting lipid 
subfractions, may be more effective remains to be an· 
swered. Finally, it suggests that, ideally perhaps, future 
studies should include intravascular wtrasound assess-
ment of the acute results of intervention and the mech-
anism of subsequent restenosis, differentiating between 
slow recoil, thrombus formation/incorporation, and inti· 
mal hyperplasia, to have a a better likelihood of demon· 
strating benefit from lipid lowering. 
limitations of the Study 
A number of limitations of the present study are to be 
acknowledged. First, the study was a retrospective anal· 
ysis of prospectively gathered data and is hence subject 
to the limitations inherent in any retrospective analysis. 
Additionally, because of the nature of the data, we are 
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also unable to comment on the importance or otherwise 
of any lipid subfractions, such as Lp(a), on long-term 
restcnosis.49 Second, all cholesterol measurements were 
performed locally at the participating center and not by 
a central laboratory, so we are unable to comment on 
the variability of these measurements. Since all partic-
ipating centers were large, internationally recognized 
institutions previously vetoed for trial participation, we 
have assumed that the variability in cholesterol mea· 
surements was small. Furthermore, in view of the large 
numbers involved, this is unlikely to have been a signif-
ieant limitation. Third, certain patients with nonnal 
cholesterol levels at study entry were on treatment for 
hypercholesterolemia either with diet or with cholester-
ol·lowering drug therapy. It is not clear what effect Ihis 
may have had on our results, but the absence of any 
trend even when cholesterol levels were analyzed in 
tenns of deciles makes it unlikely thatlhis would ha"e a 
significant influence on our results. Finally, data were 
amalgamated from the four previously described stud· 
ies1H7 to fonn our patient study population. We believe 
that this amalgamation of data is justified because the 
number of patients in each individual study was limited, 
the data amalgamated were those common to all studies, 
and the angiographic criteria were standardized, with 
one central angiographic core laboratory performing the 
quantitative angiographic analysis in all studies. Further-
more, it provides a unique opportunity to obtain accurate 
quantitative angiographic data at a predetermined time 
interval in a field where few such data exist to date. 
lABlE 9. Linear Regression Analysis to Evaluate the Respective Contribullon of LDL:HDL Cholesterol Ratio Before 
PlCA, at 6 Months, Mean LOL:HDL Cholesterol Ratio. and Change In LDL:HDL Cholesterol Ratio to Absolute Loss. 
Relative Loss, Net Gain, and Net Gain Index 
Variable Intercept 
lDL: HDl cholesterol ratio before PTCA 
Absolute loss 0.37 
Relative loss 0.15 
Net gain 0.40 
Net galn Index 0.15 
LDl:HDL cholesterol rallo at6 months 
Absolute loss 0.41 
Relative loss 0.16 
Net galn 0.36 
Net galn Index 0.13 
Mean lDL:HDL cholesterol ralio 
Absolute loss 0.41 
Relative loss 0.17 
Net galn 0.40 
Net gain Index 0.15 
Change In lOL:HOl cholesterol raUo 
Absolute loss 0.30 
Relative loss 0.12 
Net gain 0.43 
Net gain Index 0.16 
Conclusions 
Our results indicate that there is no association, by 
either a categorical or continuous approach, between 
restenosis and serum cholesterol levels, suggesting that 
measures aimed at reducing total cholesterol are unlikely 
to signiftcantly influence poslangioplasly restenosis. 
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Abstract 
Background: Although smoking is a well known risk factor for atherosclerosis 
it's influence on post angioplasty restenosis, is unclear. 
Methods: We investigated the incidence of smoking on restenosis in 2,948 
patients prospectively enroled and successfully completing 4 major restenosis 
trials utilising quantitative angiography prior, illlmediately post successful angio-
plasty and at six months 
Results: Within the study population there were 530 current smokers, 1690 ex 
smokers and 728 patients non smokers. Smokers were more likely to be male 
(85.9% vs 87.5% vs 65.3%, current vs ex vs never, p<O.OOI), to be younger 
(54.0±9.0 vs 57.0±9.1 vs 59.9±9.4 years, p<O.OOI), to have peripheral vascular 
disease (7.2% vs 5.5% vs 2.3%, p<O.OOI), have sustained a previous myocardial 
infarction (42.9% vs 43.9% vs 37.9%, p=0.022) and be in a worse anginal class 
(p=0.017), but less likely to be diabetic (9.1% vs 9.5% vs 12.6%, p=0.043) or 
hypertensive (24.9% vs 29.3% vs 37.2, p<O.OOI). They were more likely to have 
the dilated lesion in the RCA (36.2% vs 34.1% vs 25.9%, p=0.002) and their 
lesions required a longer duration of inflation (344±288secs vs 323±264 vs 
301±267, p=0.021) at higher pressures (S.7±2.5 vs 8.6±2.5 vs 8.2±2.5 atm, 
p<O.OOI). There was no significant difference in the categorical (>50%DS) reste-
nosis rate at 6 months (35.28% vs 35.33% vs 37.09%, current vs ex vs never, or 
the absolutelrelative loss (Absolute loss 0.29±0.54 vs 0.33±0.52 vs 0.35±0.55m!l1, 
p=O.l72, relative loss O.l2±0.22 vs O.13±0.2I vs O.l4±0.22 respectively, 
p=0.085). 
Conclusion: Thus smokers, despite having a lower incidence of known predispo-
sing risk factors for atherosclerosis, require coronary intervention almost 6 years 
earlier than non smokers and 3 years earlier than ex smokers. Once they undergo 
successful coronary angioplasty however their short term (six month) outcome is 
similar to non smokers. 
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Introduction 
Restenosis after successful coronary angioplasty remains a major limitation of the 
technique (1,2). Post mortem and recent intra coronary ultrasound studies suggest 
that it involves a combination of slow elastic recoil, vessel remodelling, thrombus 
incorporation and late myointimal hyperplasia (3-7). Cigarette smoking call theo-
retically be involved in any of these mechanisms. Studies have shown that ciga-
rette smoke can inhibit prostacyclin production by the vascular endothelial cells 
(8), impair endothelial function (9,10), activate platelets (II) and lower the base-
line fibrinolytic activity in blood (12) thus enhancing platelet aggregation and 
thrombosis (9, 13), all of which may be involved in the restenosis process (14,15). 
Cigarette smoke and its constituents can also cause acute coronary vasoconstric-
tion (16), substantially altering local flow dynamics at the angioplasty site resul-
ting in increased platelet deposition and local thrombus formation (17), further 
increasing the possibilities of acute occlusion and long tenn restenosis (18). 
Because of these theoretical consideration and also the large body of experimental 
and clinical evidence linking smoking habits with atherosclerosis, resulting in an 
increased risk of myocardial infarction, unstable angina and sudden death (19-21), 
a number of studies have investigated the role of smoking on restenosis after suc-
cessful coronary angioplasty (22-26). The results have been conflicting however 
with two studies suggesting a positive relatjonship (22,23) and others suggesting 
no relationship (24-26) between the two. Discrepancies between studies have ari-
sen for a number of reasons. Firstly most have been retrospective analyses using 
small patient numbers and as such subject to a type BerroI' (23). Second they 
have ahnost invariably used visual assessment of the angiogram which previous 
studies have shown to have wide inter- and intra- observer variability (27). 
Furthermore the angiographic follow up rate has been generally poor and perfor-
med for recurrence of symptoms (22, 24), thus introducing important selection 
bias. We attempted to overcome these limitations by using a validated automated 
edge detection technique to evaluate the effect of smoking habits on restenosis in 
a large series of patients undergoing successful balloon angioplasty and routine 
follow up angiographic assessment at a pre determined time interval. 
Methods 
Patients 
The study population comprised 3,582 patients with significant prinlalY stenoses 
in native coronary arteries who were prospectively enrolled into four major reste-
nosis trials (28-31). These demonstrated that active therapy had no effect on res-
tenosis or clinical outcome in the first 6 months after balloon angiopJasty so for 
the purposes of this study the data for the active and placebo groups were pooled. 
Patients were eligible for study entry if they were symptomatic or asymptomatic 
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men, or women without child bearing potential, with stable or unstable angina 
pectoris and proved angiographically significant narrowing in one or more major 
coronary arteries. Informed consent was obtained in all cases before the coronary 
angioplasty procedure. Patients with developing myocardial infarction and signi-
ficant left main disease were excluded fi'om the study. 
Smoking history 
A history of smoking was requested as part of the routine work up. Patients were 
asked if they had ever smoked and whether they were continuing to smoke and 
their answers recorded on the data sheet. In a subgroup of 1048 patients (those 
taking part in the Park and Carport studies) smoking status was also ascertained at 
both the I and 6 month follow up visits. 
Angioplasty procedure and follow up angiography 
Coronary angioplasty was performed with a steerable, moveable guide wire sys-
tem by the femoral route. Standard balloon catheters were used. The choice of 
balloon type and brand as well as inflation pressure and duration were left to the 
discretion of the operator. Patients were followed up for 6 months at which time a 
follow up study was performed. If symptoms recurred within 6 months coronary 
angiography was carried out earlier. If no definite restenosis was present and the 
follow-up time was below 4 months, the patient was asked to undergo further 
coronary arteriography at 6 months. 
Quantitative angiography 
Tln'ee coronary angiograms, in total, were obtained for each patient, pre-, post-
PTCA and at angiographic follow up. The angiograms were recorded in such a 
manner that they were suitable for quantitative analysis by the computer assisted 
Coronary Angiography Analysis System (CAAS) which has been described and 
validated earlier (32). To standardise the method of data acquisition and to ensure 
exact reproducibility of the angiographic studies, measures were taken as pre-
viously described and all angiograms were processed in a central angiographic 
core laboratory (28-31). Because the computer algorithm is unable to measure 
total occlusions, a value of Omm was substituted for the minimal lumen diameter 
and a value of 100% for the percent diameter stenosis pre PTCA. In these cases 
the post angioplasty reference diameter was substituted for vessel size. 
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Angiograpbic Definitions used 
Vessel size refers to the reference diameter of the relevant coronaty segment and 
is represented by the interpolated reference diameter pre-PTCA. 
Minimum luminal diameter (MLD) is the point of maximal luminal narrowing in 
the analysed segment. 
Restenosis was assessed using both a categorical and a continuous approach (33, 
34). For the categorical approach we used a cut-off point of >50% diameter ste-
nosis at follow up. For the continuous approach we examined the absolute and 
relative loss which may reflect the behaviour of the lesion during and after angio-
plasty better, and may therefore be better representations of the pathological pro-
cess involved during follow up (33). 
Absolute Gain and Absolute loss represent the improvement in minimal luminal 
diameter achieved at intervention and the absolute change during follow up 
respectively, measured in mm. Absolute Gain ~ MLD post PTCA - MLD pre 
PTCA. Absolute loss ~ MLD post PTCA - MLD at follow up. 
Relative gain and relative loss depict the improvement in minimal luminal diame-
ter achieved at intervention and the change during follow up respectively, nonnali-
zed for vessel size. Relative gain ~ [MLD post PTCA - MLD pre PTCA jNessel 
size. Relative loss ~ [MLD post PTCA - MLD at follow up jNessel size. 
The absolute net gain is the MLD at follow up - MLD pre-PTCA. 
The net gain index is the net gain normalised for the vesel size. Net gain index~ 
[MLD at follow up-MLD pre-PTCAjNessel size. 
The loss index is the late loss expressed as a fi'action of the acute gain (loss/gain). 
Statistical analysis 
Data was analysed using the SAS statistical software package. All values are 
expressed as mean value ± I standard deviation. Differences in categorical varia-
bles were assessed using the Chi-square test. Analysis of variance was used to 
assess differences in continuous variables between the 3 groups. Whenever the 
difference between 2 of the 3 subgroups were tested, Bonferroni correction was 
applied. Comparisons of ranked variables (clinical end points) were tested using 
the Kruskal-Wallis test. The difference in event fi'ee survival time between the 
three groups was evaluated using the Kaplan-Meier method with the log rank and 
Wilcoxon test. As mUltiple lesions within a given patient are not independent 
with respect to smoking, a patient based analysis, using a single, randomly selec-
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ted lesion in patients with multivessel angioplasty, was performed. To study the 
relationship between a binary outcome parameter (the occurence of a clinical 
event) and multiple categorical and continuous determinants multiple logistic 
regression analysis was used. To study the relationship between continuous outco-
me parameters and multiple categorical and continuous determinants multiple 
linear regression analysis was used. p values <0.05 were considered significant. 
Results 
Baseline patient clinical characteristics 
The study population comprised 2,948 patients (3,581 lesions, 1.22 lesions per 
patient) who successfully completed the study and had follow up quantitative 
angiography. The overall angiographic restudy rate was 86% of all patients under-
going successful PTCA. Within the study population there were 728 patients (889 
lesions) who had never smoked 1690 patients who were ex smokers (2,057 
lesions) and 530 patients who were still smoking (635 lesions) at the time of the 
index procedure. Within the subgroup of 1048 patients (those taking part in the 
Park and Carport studies) where smoking status was also ascertained at the I and 
6 month follow up visits, 2 (0.72%) of279 patients who never smoked previously, 
took up smoking by I month and continued to six months. Fifty two (8.79%) of 
603 ex smokers restarted smoking by six months (26 (4.31 %) by I month) whilst 
64 (38.55%) of 166 current smokers had given up by the six month follow up visit 
(43 (25.90%) by I month). 
The clinical and angiographic characteristics of the three groups are summarised 
in Tables I and 2. 
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Lesion type Never smoked Ex Smoker Current smoker Significance 
Level 
Number of patients 728 
Men 65.3% 
Age (years). 59.9±9.4 
Previous Myocardial Infarction 37.9% 
Previous CABG 3.6% 
Previous PTCA 4.1 % 
Diabetes mellitus 12.6% 
Insulin dependent diabetes mellitus 1.8% 
History of hypertension 37.2% 
History of hypercholestcl"olaemia 32.0% 
History of Peripheral vascular disease 2.3% 
Anginal class 
None 
CCS Class I 
CCS Class II 
CCS Class III 
CCS Class IV 
Duration of angina (wceks) 
Days since deterioration of angina 
Medication at screcning 
Beta blockers 
Calcium antagonists 
Nitrates 
Anticoagulants 
Thrombocyte aggregation inhibitor 
Aspirin 
Persantin 
Laboratory Investigations 
Haemoglobin 
Haematocrit 
\Vhite cell count 
Platelet count 
Total cholesterol (mmolll) 
HDL cholesterol (mmolll) 
LDL cholesterol (mmoVI) 
6.3% 
9.8% 
34.6% 
31.5% 
17.9% 
120±208 
80±198 
52.3% 
65.4% 
62.1% 
0.8% 
64.3% 
77.9% 
10.6% 
8.72±0.86 
004l±0.04 
7.05±2.94 
260±80 
5.88±1.31 
1.20±0.34 
4.15±1.18 
1690 
87.5% 
57.0±9.1 
43.9% 
4.6% 
5.1% 
9.5% 
0.7% 
29.3% 
31.5% 
5.5% 
5.8% 
11.7% 
32.6% 
29.9% 
20.2% 
llI±209 
79±181 
49.2% 
70.4% 
66.7% 
1.5% 
63.5% 
83.4% 
11.6% 
8.89±0.80 
0.42±0.04 
7.34±2.09 
255±66 
5.80±1.21 
1.13±0.56 
4.16±1.33 
530 
85.9% 
54.0±9.0 
42.9% 
4.0% 
5.5% 
9.1% 
0.4% 
24.9% 
31.9% 
7.2% 
4.3 
11.3% 
29.4% 
29.1% 
25.9% 
94±202 
65±127 
51.5% 
72.3% 
66.2% 
2.5% 
67.7% 
83.1% 
15.2% 
8.99±0.86 
0043±0.04 
8.26±2.24 
258±70 
5.88±1.20 
1.11±0.69 
3.94±1.20 
0.000 
0.000 
0.022 
00470 
0.486 
0.043 
0.009 
0.000 
0.965 
0.000 
0.032 
0.205 
0.524 
0.321 
0.016 
0.659 
0.067 
0.203 
0.032 
0.121 
0.000 
0.000 
0.000 
0.276 
0.249 
0.477 
0.519 
Table I. Baseline clinical characteristics of current smokers, ex-smokers and non 
smokers. CCS- Canadian classification system. CABG- Coronary artery bypass 
graft. PTCA- Percutaneous transluminal coronaty angioplasty. * p <0.05 vs 
never, + p <0.05 vs ex smoker, " p<0.05 vs current 
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Lesion type Never smoked Ex Smoker Current smoker Significance 
Level 
No of diseased vessels 0.347 
1-VD 65.0% 62.9% 66.0% 
2-VD 26.4% 29.5% 25.7% 
3-VD 7.8% 7.2% 7.6% 
Lesion Location 0.002 
LAD 50.6% 42.0% 41.1% 
LCx 22.8% 24.7% 23.8% 
RCA 26.5% 33.3% 34.9% 
Lesion characteristics 
Total occlusion pre PICA 7.8% 7.5% 7.0% 0.852 
Concentric 46.2% 43.8% 44.6 0.606 
Tandem lesion 3.8% 4.2% 3.9% 0.871 
Multiple Irregularities 8.3% 7.5% 8.4% 0.742 
Branch point in stenosis 37.3% 32.2% 26.8% 0.054 
Branch point in dilatation site 65.4% 65.5% 61.8% 0.635 
Coronary artery bend 19.9% 19.7% 18.3% 0.772 
Calcified lesion 12.5% 12.8% 10.2% 0.275 
Thrombus visible (pre or post PTCA) 5.4% 4.5% 6.0% 0.316 
Degree of collateral supply 0.005 
No collaterals 78.5% 85.1% 87.7% 
Slight (minimal perfusion) 5.9% 4.2% 3.1% 
Medium (partial perfusion) 6.8% 4.4% 4.6% 
Major (complete perfusion) 4.0% 3.7% 1.6% 
Not assessed 4.8% 2.7% 2.9% 
PTCA procedure 
Nominal size oflargest balloon (nun) 2.87±0.42 2.89±0,43 2.87±0.42 0.342 
BaUoon to artery ratio 1.13±0.18 1.12±0.18 1.12±0.19 0,402 
Total number of inflations 3.6±2.6 3.6±2.2 3.8±2,4 0.412 
Total duration of inflation (sees) 301±267 323±264 344±288* 0.021 
Maximum Inflation pressure Catm) 8.2±2.5 8.6±2.5* 8.7±2.5* 0.001 
Post PTCA .. esult 
Dissection at the dilated site 37.5% 34.2% 31.3% 0.069 
Dissection Type 0.255 
Type A 16.0% 14.9% 15.7% 
TypeD 16.7% 15.1% 11.1% 
TypeC 4.1% 3.7% 4.0% 
TypeD 0.2% 0.0% 0.0% 
TypeE 0.2% 0.2% 0.0% 
TypeF 0.2% 0.0% 0.0% 
Days to follow up 161±45 162±44 163±44 0.553 
Table 2. Baseline angiographic and procedural data of current smokers, ex-smo-
kers and non smokers. 2-VD Two vessel disease, 3-VD, three vessel disease. 
LAD, left anterior descending, LCx, left circumflex artelY, PTCA, percutaneous 
transluminal coronary angioplasty, RCA, right coronary artery, SVD, Single vessel 
disease. *=p<0.05 vs never, + p <0.05 vs ex smoker, A p<0.05 vs current 
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There were marked differences in the baseline demographic characteristics of the 
three groups. There was a significantly higher proportion of men in the two smo-
king categories and they were also younger. In addition they were more likely to 
have had a previous myocardial infarction and a history of peripheral vascular dis-
ease. Smokers were also less likely to be diabetic or have a history of hyperten-
sion. There were also marked differences in anginal class with smokers more 
likely to have angina in CCS class III and IV and in medication with smokers and 
ex smokers more likely to be taking calcium antagonists and aspirin. 
Haematologically smokers were distinguished by having higher haemoglobin 
levels, haematocrit and white cell counts. 
Clinical follow up. 
One hundred and eight (20.3%) of the current smokers, three hundred and seventy 
five (22.2%) of the previous smokers and one hundred and eighty five (25.41%) 
of the non smokers had a clinical end points (Redo PTCA, CABG, Acute 
Myocardial Infarction or death) during follow up (p=0.085) When we compared 
the event fi'ee survival by way of the Log rank test the p value was 0.088 whilst 
the Wilcoxon test, which places more emphasis on early events rendered a p value 
of 0.095 which is comparable. The individual components for current, ex and non 
smokers were: death, 0% vs 0.12% vS 0.55%, myocardial infarction, 2.64% vs 
2.66% vs 3.57%, Coronaty artery bypass grafting, 1.89% vs 2.66% vs 2.75% and 
and re-PTCA, 15.85% vs 16.75% vs 18.54% respectively (p=0.057). The time 
course of clinical end points are sUlllmarised in Figure I. 
G 
z 
UJ 
::::> 
o 
UJ 
a:: 
LL 
30 
20 
10 
smoking status 
never 
ex 
current -- - --
O~--'---'---'---'---'---'---T 
o 30 60 90 120 150 180 210 
days to first event 
153 
The mean time to clinical follow up was similar in the three groups (Current smo-
kers 163±44, ex smokers I 62±44, non smokers 161±45). 
Figure I. Cumulative distribution curve of clinical end points over time for cur-
rent smokers, ex-smokers and non smokers. 
In order to exclude the possibility of selection bias influencing our results we also 
examined the clinical end points in the 14% of the population in whom no QCA 
measurements were available, either pre, post or at follow up, and who were there-
fore excluded liOl11 the study population. Of these patients 22.5% of current smo-
kers, 22.6% of previous smokers and 23.2% of the non smokers had a clinical end 
points (Redo PTCA, CABO, Acute Myocardial Infarction or death) during follow 
up. The difference was not statistically significant (p~0.99). The individual com-
ponents of worse clinical end point such as death, myocardial infarction, Coronary 
artery bypass grafting and re-PTCA were 7.14%. 2.04%, 6.12% and 7.14% 
respectively for current smokers 3.17%, 4.37%, 4.76% and 10.32% for ex smo-
kers and 0.89%. 3.57%, 7.14% and 11.61% for non smokers. The differences in 
the individual clinical end points between the tlu'ee groups were not significant 
(p~0.340). 
In order to exclude the possibility of cross over from the current smokers to ex 
smokers influencing our results we also examined the clinical end points in the 
sub group of the study population who stopped smoking after the index procedure 
and theoretically would have crossed over from the current smokers to the ex smo-
kers group. Of these 27.7%, had a clinical end point compared to 23.8% of 
patients who continued to smoke (p~0.60) 
Quantitative angiographic analysis and coronary angioplasty 
procedure. 
A mean of2.12 matched angiographic projections per lesion had satisfactory 
quantitative analysis performed, at the central angiographic core laboratory, pre-, 
post- PTCA, and at follow up (Table 2 & Table 3). The distribution of lesions was 
significantly different in the three groups with non smokers having more lesions 
in the LAD and less in the right coronary than smokers and ex smokers. 
Non smokers were also more likely to have visible collaterals on baseline angio-
graphy. (Table 2) 
There were no significant differences in the baseline quantitative angiographic 
measurements between the three groups apart from a borderline significant higher 
mId pre PTCA in current smokers (Table 3). 
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Never smoked Ex Smoker Current smoker Significance 
Level 
Reference Diamctcr (mIll) 
Before angioplasty 2.60±0.54 2.65±0.53 2.64±0.54 0.116 
After angioplasty 2.65±0.52 2.69±0.50 2.67±0.51 0.129 
At follow up 2.67±0.56 2.71±0.56 2.7l±0.54 0.200 
lHinimalluminal diameter (mm) 
Before angioplasty 0.96±OAO 1.00±OAO 1.02±0.38 0.046 
After angioplasty 1.75±0.37 1.78±0.36 1.76±0.34 0.144 
At follow up 1.40±0.62 1.44±0.57 1.46±0.59* 0.096 
Differcnces ill lHLD 
Absolute Gain 0.78±OA3 0.78±OAI 0.74±OAO 0.128 
Relative Gain 0.31±0.16 0.30±0.16 0.29±0.15 0.074 
Absolute Loss 0.35±0.55 0.33±0.52 0.29±0.54 0.172 
Relative Loss 0.14±0.22 0.13±0.21 0.12±0.22 0.085 
Absolute Net Gain OA3±0.61 OA5±0.56 OA5±0.61 0.870 
Net Gain Index 0.16±0.25 0.17±0.22 0.16±0.24 0.282 
Loss Index OA1±2.37 0.60±5.01 OA9±1.34 0.545 
Pcrcentage stenosis 
Before al1gioplasty 62.35±14.38 61.75±14.32 60.74±14.02 0.142 
After angioplasty 33.57±8.43 33.55±8.33 33.70±7.81 0.929 
At follow up 47.32±20.34 46.19±18.91 45.69±19.11 0.278 
DS at follow up >50% 37.09% 35.33% 35.28% 0.687 
Table 3. Quantitative angiographic analyses of current smokers, ex-smokers and 
non smokers. DS, diameter stenosis. MLD, Millimalluminal diameter. *=p<O.05 
vs never. 
Smokers however required a higher duration of inflation (current) and inflation 
pressure (both current and ex) for a successful angioplasty procedure. Post-PTCA 
all quantitative angiographic measurements and derived parameters were similar 
for the three groups (Table 3, Figure 2) again confirming the similarity in acute 
angiographic outcome. 
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Figure 2. Upper panel: Cumulative distribution curve of MLD post PTCA and at 
follow up for current smokers, ex-smokers and non smokers. Lower panel: 
Cumulative distribution curve of percentage stenosis post PTCA and at follow up 
for current smokers, ex-smokers and non smokers. 
At the 6 month angiographic follow up there was no significant difference in 
angiographic outcome between the three groups (Table 3, Figure 2). The overall 
restenosis rate for the study population was 35.8% using the categorical (>50% 
stenosis at follow up) approach (Current smokers 35.28%, Ex smokers 35.33%, 
non smokers 37.09%, p~0.687). Additionally the absolute and relative loss were 
also similar between current, ex smokers and non smokers (Absolute loss 
0.29±0.54 vs 0.33±0.52 vs 0.35±0.55mm, p~O.I72, relative loss O.l2±0.22 vs 
O.l3±0.21 vs O.l4±0.22 respectively, p~0.085) (Table 3, Figure 3). 
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Figure 3. Upper panel: Cumulative distribution curve of absolute loss for current 
smokers, ex-smokers and non smokers. Lower panel: Cumulative distribution 
curve of relative loss for current smokers, ex-smokers and non smokers. 
Multiple lineal' regression analysis 
We have previously demonstrated that Vessel size, mid pre-PTCA, absolute gain 
and Lad location make a significant contribution to late angiographic outcome 
(35). Adding smoking to this model did not significantly improve it's predictive 
value. Least Squares means for absolute loss were 0.348, 0.311, 0.307 for non 
smokers, ex smokers and current smokers respectively. The p value of adding the 
variable smoking to the model was 0.15, which is not significant. 
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In order to ascertain whether the tendency towards improved clinical outcome in 
patients who smoke was related to differences in the underlying baseline characte-
ristics we corrected for these variables to see whether smoking had any signifi-
cant, independent, predictive value. We performed logistic regression with the 
above mentioned baseline characteristics as covariates resulting in a p value for 
the variable smoking of 0.122 suggesting that differences in clinical Olltome were 
related to differences in baseline characteristics. 
Discussion 
Our results indicate that there are marked differences in baseline clinical, angio-
graphic and procedural characteristics between smokers and non smokers under-
going coronary allgioplasty. Smokers, despite having a lower incidence of known 
predisposing risk factors for atherosclerosis, require coronary intervention much 
earlier than non smokers but once they undergo successful coronary angioplasty 
their short term (six month) outcome is similar to non smokers. 
Two previous studies have suggested that smoking may be associated with an 
increased risk of restenosis (22, 23). Both studies however were in small patient 
populations, with a low angiographic follow up rate, performed for recurrence of 
symptoms, and without quantitative angiographic analysis. Using a large patient 
population with a high quantitative angiographic follow up rate at a predetermi-
ned, six month, time interval our study has shown that smoking, a risk factor for 
atherosclerosis in general, is not a significant risk factor for restenosis. 
There are a number of possible reasons for this. First, although cigarette smoking 
has been shown to be a risk factor for atherosclerosis tltis is over the course of 
years (19-21), whereas careful serial quantitative angiographic studies have shown 
restenosis to occur in the first 3 to 6 months after intervention (1,2). Thus cigaret-
te smoking may have little influence on the process over this short time frame. 
Second, the mechanism(s) of rest enos is are still incompletely understood and like-
ly to involve differing contributions of slow elastic recoil (4), thrombus incorpora-
tion (5,36), vessel remodelling (6,7) and myointimal hyperplasia (3,4) in each 
individual patient. Cigarette smoking is unlikely to influence all of these mecha-
nisms. Third, it is possible that the sudden withdrawl of cigarettes during and 
immediately after the procedure in the smokers may have had some favorable 
effect on vascular or haematological systems (37, 38) that discouraged local plate-
let deposition, mural thrombus formation and consequent restenosis. Fourth, there 
may be substantive differences in plaque characteristics between smokers and non 
smokers which may ameliorate any tlu'ombogenicity associated with smoking. In 
support of tltis are the higher inflation pressures and duration of inflation required 
for successful dilatation of the atherosclerotic plaque in the smoking group and 
evidence in the literature suggesting that lesions in smokers have a higher content 
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of collagen (39) and that the type of lesion which precipitates myocardial infarc-
tion in smokers is less severe and possibly generated by a different mechanism in 
smokers (38). 
Differences in baseline characteristics 
There were significant differences in the baseline clinical, angiographic and pro-
cedural characteristics between the smoking classes which could have been 
responsible for, or associated with, the outcome of the procedure. Smokers were 
younger, more likely to be male, to have peripheral vascular disease and to have 
sustained a previous myocardial infarction. Conversely, they were were less likely 
to have diabetes mellitus or a history of hypertension. These differences in base-
line characteristic may be related to age. For example as smokers tend to develop 
atherosclerosis at a younger age they would be less likely to develop diseases of 
the older age group such as hypertension and diabetes. Many epidemiological 
studies have however also reported that smokers have significantly lower blood 
pressures than ex smokers or non smokers (40), but the mechanism for tlus negati-
ve relationship is unknown. These differences in baseline clinical characteristics 
may have influenced clinical and angiographic outcome in a number of ways. For 
example, diabetics are more likely to have restenosis than non diabetics (24), 
whilst dilatation of a vessel supplying previously infarcted territory is more likely 
to result in occlusion at the time of follow up angiography. 
There were also sigluficant differences in baseline haematological characteristics 
with smokers having a significantly higher haemoglobin, haematocrit and white 
cell count than non smokers, with ex smokers somewhere in between. Evidence 
in the literature suggests that smokers are also more likely to have a lugher fibrin-
ogen level and blood viscocity (41). What influence these variables may have on 
clinical and angiographic outcome after intervention is unclear. Although elevated 
fibrinogen levels have not been associated with a higher restenosis rate in a small 
series (42) elevated white cell counts (43) are known to be strong predictors of 
myocardial infarction (44, 45) and to be a marker of important cellular injury. 
There were also differences in the distribution of lesions with smokers having 
more lesions in the RCA and less in the LAD than non smokers, and ex smokers 
somewhere in between. This is in keeping with other evidence in the literature 
suggesting a more proxhnal location of coronary lesions in hypercholesterolae-
mic non smokers with more distally situated lesions in normocholesterolaemic 
smokers (46). The lower incidence of LAD lesions with their known lugher inci-
dence of restenosis (35) may be responsible for the trend towards less absolute 
and relative loss in smokers with concordance.from current smokers, through ex 
smokers to non smokers. 
There were also significant differences in procedural characteristics with lesions 
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in smokers requiring a longer inflation time at a higher pressure. This would sug-
gest that there may be differences in plaque characteristics between the two 
groups which may have affected clinical and angiographic outcome in both a posi-
tive and a negative way. This is supported by evidence in the literature suggesing 
that smokers have a significantly higher content of collagen in coronary endarte-
rectomy specimens (39), whilst smoking has also been shown to increase arterial 
wall stiffness- a change which may be associated with reduction of medial porosi-
ty and reduces flow pulsatility (47). 
Clinical implications 
Smokers should be strongly discouraged from smoking. In our study population, 
smokers, despite having a lower incidence of known predisposing risk factors for 
atherosclerosis, such as hypertension, diabetes and hypercholesterolaemia, requi-
red coronary intervention ahnost 6 years earlier than non smokers and 3 years ear-
lier than ex smokers. This was on a background of increased risk of previous 
myocardial infarction and peripheral vascular disease. If the patient is completely 
unable to stop smoking however, continued smoking per se should not be a con-
traindication for coronaty angioplasty. 
Limitations of the study 
Our study has a number of limitations. Firstly, it was a retrospective analysis of 
prospectively gathered data and is hence subject to the limitations inherent in any 
retrospective analysis. For example it is possible that unknown variables not exa-
mined in our logistic regression model may account for the lack of a worse clini-
cal and angiographic outcome in smokers. Second, our data only apply to succes-
sful angioplasty procedures and to a 6 month follow up period. Thus we do not 
know if smoking reduces the chances of acute success or increases the ilmnediate 
acute complications of the procedure. Additionally, although restenosis is usually 
manifest in the first 6 months, we do not know whether a longer follow up period 
may in fact demonstrate progression of the angioplasty lesion in smokers. Third, 
we do not have objective verification of the patient's self reported smoking status 
as we did not specifically assess, perhaps by periodic measurement of urinary pro-
ducts, whether supposed ex-smokers had truly stopped or whether they were con-
tinuing to smoke. This is especially pertinent as patients may give misleading 
answers in order to ensure the doctor's approval. It is also possible that, given the 
large effects of secondhand smoke on arterial function, passive smoking could 
have affected the data in the ex smokers and to a lesser extent the non smokers 
and thus lead to an underestimate of the effects of smoking. Conversely we also 
do not have information on how many current smokers stopped smoking after 
angioplasty, and on the contribution of this to their improved outcome. In the 
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small subgroup in which this information is available however, a large proportion 
(38%) of smokers, stopped smoking by the time of the six month follow up visit. 
A further possibility is that our study may have been underpowered to detect a 
small enough difference between the groups. Given the number of patients and 
the restenosis rate (both categorical and continuous (absolute loss)) in the never 
smoked group, our study has a power of 90% to detect a difference of 20% in the 
smoking group for the categorical restenosis rate and 0.10 111111 for the absolute 
loss. We would consider both of these to be clinically significant but the fact 
remains that if the effect of smoking is below these levels we would have been 
unable to detect it. Ideally, future studies should include intravascular ultrasound 
assessment of the acute results of intervention (48) and the mechanism of subse-
quent restenosis, differentiating between slow recoil, tln'ombus formation/incorpo-
ration and intimal hyperplasia (6, 49), to have a better likelihood of demonstrating 
benefit from cessation of smoking. 
Conclusions 
Our results indicate that smokers, despite having a lower incidence of known pre-
disposing risk factors for atherosclerosis, require coronary intervention almost 6 
years earlier than non smokers and 3 years earlier than ex smokers. This is on a 
background of increased risk from previous myocardial infarction and peripheral 
vascular disease. Once they undergo successful coronary angioplasty however 
their short term (six month) outcome is similar to non smokers. Our findings thus 
warrant continuing strong efforts to discourage smoking in our patients. 
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Chapter 13 
Role of angiographically identifiable thrombus on long term 
luminal renarrowing following coronary angioplasty: A 
quantitative angiographic analysis. 
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Role of Angiographically Identifiable Thrombus 
on Long-term Luminal Renarrowing 
After Coronary Angioplasty 
A Quantitative Allgiographic Analysis 
Andonis G, Violaris, MO, ~1RCP; Rein Melkcrt, ~lD, MS; 
Jean-Paul R. Hernnan, 1\1D; Patrick W. Serruys, MD, PhD 
Backgrollnd Experimental studies suggest that mural 
thrombus may be involved in postangioplasty reslcnosis. The 
aim of our study was to examine the role of angiographicall)' 
identifiable thrombus in the clinical situation. 
Me/hods and ReslIlIs The study population comprised 2950 
patients (3583 lesions). The presence of angiographicalJy iden-
tifiable thrombus either before or after the procedure was 
defined as the presence of a generalized haziness or filling defect 
\\ithin the arterial lumen. Restenosis was assessed by both a 
categorical (>50% diameter stenosis at fo!low-up) and a contin-
uous approach (absolute and relative losses). The study popula~ 
tion induded 160 le.sions \\ith and 3423 lesions \\ithout angio-
graphically identifiable thrombus. The categorical restenosis rate 
wns significantly higher in lesions containing angiogwphically 
identifiable thrombus: 43.1 % versus 34.4%. P<.Ol; relam·c risk, 
1.449; CI, 1.051 to 1.997. The absolute and relative 105&s were 
also higher in le.sions containing angiographicaHy identifiable 
thrombus (absolute loss. OAJ±O.66 versus 0.32::'::0.52; relatp,·c loss., 
0.16::'::0.26 versus 0.13::'::0.21; both P<.05). The higher restenosis 
Since the introduction of coronary angioplaSlY by Gruentzig et aJi and the subsequent refinements in equipment, the indications for the technique 
have been expanded to include patients with unstable 
angina2-4 and acute myocardial infarction.5 In these 
situations, however, angioplasty carries increased risks 
thought to relate, in part, to the presence of thrombus. A 
number of studies have demonstrated that the presence 
of angiographically identifiable thrombus either before 
or after dilatation of a coronary stenosis carries an 
increased risk of acute oeclusion.6.7 TIle influence of 
thrombus on long-term restenosis, however, is less clear. 
Experimental work suggests that local platelet deposi-
tion with the subsequent release of a number of chemo-
tactic and mitogenic factors, such as platelet-derived 
gro\\1h factor and thrombin,S may mediate the fibropro-
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in these lesions was due primarily to an increased incidence of 
occlusion at follow-up angiogrophy in this group: 13.8% versus 
5.7%, P<.OOI. When Ie.sions that went on to occlude by the timc 
of follow-up angiography were excluded from the analysis, the 
restenosis rate between the t\'oo groups was similar by both the 
categorical (34.1% versus 30.4%, P=NS; relative risk, 1.183; CI, 
0.824 to 1.6%) and continuous (absolute loss, 0.23::'::0.46 versus 
0.24::'::0.42, P=NS; relative loss, 0.09::'::0.17 versus O.09.±0.16, 
P=NS) approaches. 
Conclusions Our results indicate that the presence of an-
giographically identifiable thrombus at the time of the angio-
plasty procedUre is associated \\ith higher restenosis. Thc 
mechanism by which this ocrurs is through vessel occlusion at 
follow-up angiography. Measures aimed at improving outcome 
in this group of patients should bc focused in this direction. 
(Circfllation. 1996;93:889-897.) 
Key lIords , angioplasty , thrombus , angiography , 
trials , meta-analysis 
Jiferative response. Recurrent platelet aggregation at the 
site of injul)' with associated vasoconstriction and the 
consequent increased frequency and severity of cyclic 
coronal)' blood flow variations may also play an impor-
tant role in the subsequent development of neointimal 
proliferationY Although one study suggested that throm-
bus formation and incorporation into the vessel wall may 
play a pivotal role in restenosis,lo this has not been 
confirmed by other"invcstigators. 1I Fcw clinical studies 
have actualJy assessed the role of angiographically iden-
tifiable thrombus on subsequent restenosis. The aim of 
this study was to examine the role of angiographically 
identifiable thrombus on long-term restenosis in a large 
series of patients undergOing successful balloon angio-
plasty and routine follow-up QCA a&sessment. 
Methods 
Patients 
The study population was taken from the 3582 patients with 
significant primary stenoses in native coronal)' arteries who 
were prospectively enrolled into four major restenosis tri-
alsP-IS These demonstrated that acti~·e therapy had no effect 
on restenosis or clinical outcome in the first 6 months after 
balloon angioplasty, so for the purposes of this study, the data 
for the active and placebo groups wcre pooled. Patients, men 
or women, were eligible for study entry if they were s)mptom-
atie or asymptomatic, had stable or unstable angina pectoris, 
and showed angiographically significant narrowing in one or 
more major coronary arteries. Patients with recent «1 week) 
Selected Abbrc\iallons and Acronyms 
LAD = left anterior descending COIOnary artery 
Mill = minimum luminal diameter 
PTCA = percutaneous tral15luminal coronary angioplasty 
QCA = quantitative coronal)' angiography 
RCA = right coronal)' artery 
or evolving myocardial infarction and those with significant left 
main coronary artery disease were excluded from the study. 
Angioplasty Procedure and Follow-up Angiography 
Coronary angioplasty was perfonned with a steerable, rna\'-
able guide-\\ire system by the femoral route. Standard balloon 
catheters were uscd. The choice of balloon type and brand as 
well as inflation duration and inflation pressure were left to the 
discretion of the operator. Patients were followed up for 6 
months, at which time a follow-up study was performed. If 
symptoms recurred within 6 months, coronary angiography was 
carried out earlier. If no definite restenosis was present and the 
follow-up time was <4 months, the patient was asked to 
undergo further coronary arteriography at 6 months. 
Quantitative Coronary Angiography 
Thee 1;oronary angiograms, in total, were obtained for cach 
patient: before and after PTCA and at angiograpilic fol[ow-up. 
To standardize the method of data acquisition and to ensure 
exact reproducibility of the angiographic studies, measures 
were taken as previously desnibed and all angiograms were 
processed in a central angiographic 1;ore laboratory.H-1S The 
angiograms were recorded in such a manner that they were 
suitable for QCA by the 1;omputer-assistcd Coronal)' Angiog-
raphy Analysis System (CMS), which was described and 
validated earlier.16 Because the computer algorithm is unable 
to measure total occlusions, a value of 0 mm was substituted for 
the MLD and a value of 100% for the percent diameter 
stenosis before PTCA In these cases, the postangioplasty 
reference diameter was substituted for vessel size. 
DefinHions 
Angiographica11y identifiable thrombus was defined as the 
presence of a filling defect within the coronary lumen, sur-
rounded by contrast material, seen in multiple projections and 
in tbe absence of calcium "itmn the filling defcct. 17•IB Alterna-
tively, the persistence of contrast material within the lumen or 
visible emboliUltion of intraluminal material downstream was 
also taken to represent intracoronal)' thrombus. 
Total occlusion was present if no anterograde filling beyond 
the lesion was visible or if faint, late anterograde opacification 
of the distal segment was present in the absence of a discernible 
luminal continuityP Occlusion at fo11ow-up angiography was 
similarly defined. 
Vessel size refers to the reference diameter of the relevant 
coronary segment and is represented by the interpolated 
reference diameter before PTCAMID is the point of ma:cimal 
luminal narrO\'1ug in the analyzed segment. 
Restenosis: Many criteria ha"e been proposed for the assess-
ment of restenosis.2<),21 For the purposes of this study, we used, 
first, the categorical approach with the traditional cutoff point 
of >50% diameter stenosis at follow·up and second, a contin-
uous approach using absolute and relative losses.21 
Absolute gain and absolute loss represent the inlproYement 
in MLD achievcd at intervention and the absolute change 
during follow-up, respectively, measured in millinleters. Abso-
lute gain is the MLD after PTCA minus MLD before PTCA 
Absolute loss is the MID after PTCA minus MLD at follow·up. 
Relative gain and relative loss depict the imprm'ement in 
MLD achieved at intervention and the change during follow-
up, respectively, normalized for vessel size. Relative gain is 
[MLD afler PTCA minus ~n.D before PTCA] divided by 
'-essel size. Relative loss is JMLD after PTCA minus MLD at 
fo11ow-up] divided by yessel size. 
Absolute net gain is the MLD at follow-up minus MLD 
before PTeA 
Net gain index is the net gain normalized for the vessel size. 
Net gain index is JMLD at follow-up minus MLD before 
PTCA] divided by vessel size. 
Statistical Analysis 
Data were analyzed \\lth the SAS statistkal software pack-
age. A ;e test was used to assess differences in categorical 
variables. Student's r test was used to assess differences in 
continuous variables. To test the assumption that the variances 
were equal, the folded-form F statistic was used. Whenever this 
assumption was violated, the Cochran and Cox approximation 
of the r tcst was used. Differences in variables with an ordinal 
scale (severity of clinical outcome) were assessed "ilh the 
Wilcoxon rank-sum test. The difference in event-free sunlval 
time between the two groups was evaluated by the Kaplan-
Meier method with the log rank and Wilcoxon tests. To study 
the relation between a binary outcome parameter (occlusion at 
follow-up, the occurrence of a dinical event) and multiple 
categorical and continuous detenninants, multiple logistic re-
gression analysis was used. To study the relation between 
continuous outcome parameters and multiple categorical and 
continuous determinants, multiple linear regression analysis 
was used. Lesion characteristics were investigated with a lesion-
based analysis and patient characteristics with a per-patient 
analysis in which a single lesion was randomly selected in 
patients with multivessel angioplasty. Values of P<.05 were 
considered significant. 
Results 
Baseline Patient Cbaracteristics, Procedural 
Results, and Clinical Follow-up 
The study population comprised the 2950 patients 
(3583 lesions, 1.21 lesions per patient) who successfully 
completed the study and had follow-up QCA The 
overall QCA restudy rate was 86% of all patients 
undergoing succcssful PTCA with a residual QCA ste-
nosis of <50%. Of 3583 lesions in 2950 patients, 160 
lesions in 158 patients complied with the angiographic 
definition of thrombus present either before or after 
PTCA. 
The two groups were comparable in terms of age and 
sex, but patients with angiographicalJy identifiable 
thrombus at PTCA were more likely to have sustained a 
previous myocardial infarction and less likely to have 
had a previous PTCA (Table 1). There were, hmvever, 
subslantial differcnces in lesion and procedural charac-
teristics between the two groups (Table 2). Thrombotic 
lesions were more likely to be located in the RCA than 
in the LAD and had a much higher proportion of total 
occlusions and multiple irregularities. They were also 
morc likely to require a larger balloon and a greater 
number and duration of inflations. After the procedure, 
this group of lesions was also more likely to have a 
dissection (Table 2). 
Forty-fOur (28%) of the patients with angiographically 
identifiable thrombus present and 625 (22.4%) of the 
patients without thrombus had a clinical end point 
during follow-up (P:=.1l6). The individual components 
of dcath, myocardial infarction, coronary artery bypass 
graft surgcry, and repeat PTCA were 0%, 8.3%, 2.6%, 
and 17.2%, respectivcly, for lesions containing angio-
graphically identifiable thrombus and 0.2%, 2.6%, 2.5%, 
and 17.0% for lesions without thrombus (P=.053). The 
mean time to clinical end point was significantly less in 
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TABLE 1. Demographic Data of Patients With 
and Without Thrombus Preangloplasty or 
Postangioplasty Included in Analysis 
Thrombus Thrombus 
ClinIcal VarIable Presenl Absenl 
Patients. n 158 2792 
Les!ons,o 160 3423 
Men, % 83 82 
Age, Y 57.!.9.3 55.3±9.3 
Ever smoked, % 74 75 
CufTenl smol<er. % 22 18 
HypertensIon, % 36 31 
Diabetes, % 8 11 
HyperlipIdemIa, % 35 32 
History of previous PTeA, % 1 4' 
History of previous MI, % 61 421 
Previous CABG, % 
" 
4.5 
Pain al rest, % 28 34 
No. of vessels diseased, % 
1 VD 61 59 
2VD 33 32 
3VD 9 
MI irxEcates myocardial infarction; CABG, coronary aIle!)' bypass glaft 
surgery; and VD, vessels diseased. 
'P<.05, tP<.OOl. 
the angiographically identifiable thrombus group 
(63::t63 versus 92::t56 days, P<.05, Fig la), and when 
we compared the pattern of occurrence of clinical end 
points by way of the log rank test, the probability value 
was .051, whereas the Wilcoxon test, which places more 
emphasis on early survival times, rendered a value of 
P=.026, indicating the diverging survival curves in the 
begitming. When lesions that went on to occlude at the 
time of follow-up angiography were excluded from the 
analysis, there was no significant difference in the mean 
time to clinical end poinl (Fig Ib), and the log rank test 
gave a value of P=.209, whereas the Wilcoxon test 
rendered a value of p= .159, suggesting that the excess 
early events were related to the occlusions at follow-up 
angiography. 
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FIG 1. a, Cumulative dislribution curve of clinical end points 
over time for patients with and without the presence of thrombus 
at the time of angioplasty. b, Cumulative distribution cwve of 
clinical end poInts over time for patients with and without the 
presence of thrombus at the time of angioplasty (excluding 
lesions that went on to occlude at the time of follow·up angiog-
raphy). Numbers given are mean±SD. ·P<.05. 
To exclude the possibility of a selection bias influenc-
ing our results, we also examined the incidence of 
thrombus-laden lesions and clinical end points in the 
14% of the population in whom full QCA measurements 
TABLE 2. Baseline Anglographlc and Procedural Data of Lesions 
Les!on Type 
Number of lesions 
LeSion location, % 
LAD 
LC, 
RCA 
Type of lesion, % 
Multiple irregulaJ'ities 
Total occlusion 
Tandem lesion 
Branch polnt in lesion 
Lesion ca\cif.catlon 
PTCA procedure 
Nominal size of laJ'gest balloon, mm 
Balloon·lo-artery ratio 
Tolalnumber of innatfons 
Tolal duration of innatfon, S 
Maximum Innatlon pressure, aim 
Post·PTCA resu:t 
Dissectfon althe d;lated site, % 
LCx indicates left circum Hex arte!)'. 
·P<.05. 
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Thrombus 
160 
33.8 
20.6 
45.6 
13.0 
20.0 
1.3 
28.0 
16.9 
3.oo±0.43 
1.12±0.18 
4.2±2.9 
380±325 
8.35±2.53 
54.4 
No 
Thrombus 
3423 
43.2 
25.0 
31.8 
7.6 
6.8 
4.2 
32.8 
12.1 
2.SS±0.43 
1.13±0.19 
3.53±2.3 
308±266 
8,48±2.50 
33.1 
Significance 
Level 
.0040 
.0400 
.0000 
.1120 
,4660 
.0990 
.0001 
,4345 
.0013 
.0016 
.5423 
.0000 
TABLE 3. Quantitative Analysis of 160 Lesions With and 
3423 Lesions Without Thrombus Before or After 
Angioplasly Included in Analysis 
No Significance 
Thrombus Present Thrombus Thrombus level 
No. 
Reference diameter, mm 
Before angloplasty 
After angioplasty 
AI follow~up 
MlD, mm 
Before angfopJasty 
After angioplasty 
At fOllow-up 
Differences In MlD 
Absoil.l!e gain, mm 
Relative gain 
Absoll.l!e loss, mm 
Relatr.·e loss 
Absolute net gain, mm 
Net gain Index 
loss index 
Percentage stenosis 
Before angioplasty 
After ang;oplasty 
AI follow~up 
OS at follow-up >50%, % 
160 
2.77::!;O.54 
2.80::!;O.53 
2.87::!;O.64 
0.88::!;O.52 
1.6O:!:0.35 
1.37::!;OJl 
O.92::!;O.53 
0.34::!;O.19 
0.43::!;O,66 
0.t6::!;O.26 
0.49::!;O.72 
0.18::!;O.27 
1.57±.13.59 
67.78:!:18.27 
35.15:!:7.4S 
51.71::!;23.70 
43.13 
DS Indicates diameter stenosIs. 
·P<.05. + P<.Ol, ~P<.ooI. 
3423 
2.60::!;O.54 
2.65::!;O.51 
2.67::!;O.56 
1.01::!;O.39 
1.75.:t0.36 
1.44::!;O.58 
OJ5±0.4t 
0.29::!;O.16 
0.32.:t0.52 
0.13±0.21 
0.43::!;O.57 
0.17.:t0.23 
0.46:!:2,44 
6O.63.:t14.30 
3-3.38:!:8.37 
4S.71:!:19.00 
34.36 
.0006 
.0007 
.0000 
.0001 
.0S68 
.1552 
.0000 
.0002 
.0070 
.0339 
.1970 
""" .0002 
.0000 
.0039 
.0001 
.0260 
were not available and who were therefore excluded 
from the study papulation. The incidence of thrombus in 
these patients (6.7%) was comparable to that in our 
study population (5.4%, P=NS). Of these patients with 
thrombus, 22.6% and of patients without thrombus, 
22.6% had a clinical end point during follow-up 
(P= 1.000), The individual worst clinical end-point com-
ponents of death, myocardial infarction, coronary artery 
bypass graft surgery, and repeat PTCA were 3.2%, 9.7%, 
3.2%, and 6.5%, respectively. for lesions with and 3.5%. 
3.2%, 5,8%, and 10,2% for lesions without thrombus 
(P~.403). 
QCA Analysis 
Satisfactol)' QCA was performed in a mean of 2.12 
matched angiographic projections per Icsion (Table 3). 
The reference diameter did not change from beforc to 
after the procedure but was significantly larger in lesions 
containing angiographieally identifiable thrombus. and 
this difference remained at follmv-up (Table 3), Al-
though the MLD before angioplasiy was significantly 
smaller in lesions containing angiographicalJy identifi-
able thrombus, the MLD after angioplasty was similar. 
The residual percent stenosis after PTCA was higher in 
the angiographieally identifiable thrombus group, as 
were the absolute and relative gains (Table 3, Fig 2), At 
follOW-Up, although the MLDwas similar in both groups, 
the percent stenosis was significantly higher in lesions 
containing thrombus (Fig 2, Table 3), as were the 
categorical restenosis rate (43.1% versus 34.4%, P<.OI; 
relative risk, 1.449; CI. 1.051 to 1.997) and the absolute 
and relative losscs (Table 3, Fig 3). 
The higher restenosis rate in the angiographically 
identifiable thrombus group was predominantly due to 
an increased number of occlusions at follow-up angiog-
raphy (13,8% versus 5.7%, P<.OO1; relative risk, 2.639; 
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FIG 2, a, Cumulative distribution cUlVe of MLD after PTCA and 
at follow-up for patients with and without the presence of 
thrombus at the lime of angioplasty. b, Cumulative distribution 
culVe of percent stenosis arter PTCA and at follow-up (or 
pallents with and without the presence of thrombus at the time 
of angioplasty. Numbers given are mean±SD, 'P<.OS. 
95% CI, 1.645 to 4.233). When lesions that went on to 
occlude at follow-up angiography were excluded from 
the analysis, there remained a tendency for a higher 
catcgorical rcstenosis rate in the thrombus group (34.1 % 
\'ersus 30.4%; relative risk. l.183; CI, 0.824 to 1.696), but 
this was no longer statistically significant (P=.41 1). The 
absolute and relative losses were now also similar 
(0.23±OA6 versus 0.24±OA2 and 0.09±0.17 versus 
0.09±0,16. respectiYely, both P=NS). 
~IuUiplc Linear Regression AnalysIs 
We have previously demonstrated that vessel size, 
MLD before PTCA, absolute gain, and LAD location 
make a significant contribution to late angiographic 
outcomc.21 Adding thrombus to this model significantly 
impro\'cd its predictive value. Least-squares means for 
absolute loss were 0.404 for lesions with thrombus and 
0.318 for lesions without thrombus. TIle probability 
value of adding the variable thrombus to the model was 
.037. Adding thrombus to the model when lesions that 
went on to occlude at follow-up angiography were 
excluded did not improve its predictive value. Least-
squares nleans for absolute loss were 0,222 for lesions 
with thrombus and 0,243 for lesions without thrombus, 
The probability value of adding the variable thrombus to 
the model was ,549. 
To ascertain whether the trend toward a worse clinical 
outcome in patients with thrombus was related to dif-
ferences in the underlying baseline characteristics, we 
corrected for these variables to see whcther thrombus 
had an independent predictive valuc. We perfonned 
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FIG 3. a, Cumulative distribution curve of absolute (Abs) loss 
(change In MLD from before PICA to follow-up) for lesions with 
and without thrombus, b, CumulaUve distribution curve of rela~ 
tive (Re~ loss (change In MLD from before PICA to follow-up 
corrected for vessel size) for lesIons with and without thrombus. 
Numbers given are mean±SD. ·P<.OO1. 
logistic regression with the above-mentioned baseline 
characteristics as cOV<lriates resulting in a value for the 
\'ariable thrombus of P"".038, implying that thrombus 
has a positive relation with the probability of a clinical 
end point. Perfonning the analysis when lesions that 
went on to occlude at follow-up angiography were 
excluded gave a value of P=.183, suggesting that the 
positive relation with the probability of a clinical end 
point was related to occlusion at follow-up angiogmphy. 
Unh'arlate and Multh'ariate Analyses of Occlusions 
at Follow-up Angiography 
The finding that the higher restenosis in lesions con-
taining angiographically identifiable thrombus was pre-
dominantly due to an increased number of occlusions at 
follow-up angiography prompted us to examine the time 
to c,linical and angiographic follow-up and a number of 
varia.bIes predictive of late occlusion in this group (Table 
4). The time to clinical and angiographic follow-up was 
significantly shorter in lesions that occluded at the time 
of angiographic follow-up. These lesions had a higher 
incidence of total occlusion, a tighter stenosis before 
PTCA, a longer duration of inflation with the use of a 
smaller balloon in a smaller vessel with a tighter residual 
MLD, and a greater likelihood of a dissection after 
PTCA. Logistic regression analysis confinned the pres-
ence of a total occlusion before PTCA and total inflation 
time (seconds) to be positively related and the reference 
diameter after PTCA (millimeters) to be negatively 
related to occlusion at follow-up angiography (Table 5). 
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Discussion 
Our study has specifically addressed the role of angio-
graphically identifiable tbrombus in long-term restenosis 
in a large patient population with a control group, a high 
angiographic follow-up rate, and QCA at a predeter-
mined time interval. We have demonstrated. using both 
a categorical and a continuous approach, that restenosis 
is significantly increased by the presence of angiographi-
cally identifiable thrombus during coronal)' angioplasty. 
Furthermore, we have also shown that the mechanism 
for this is an increased rate of occlusion at follow-up 
angiography and that this is positively related to the 
presence of a total occlusion before PTCA and the tolal 
duration of balloon inflation and negatively related to 
the residual stenosis after intervention. If lesions that 
subsequently occlude at follow-up angiography are ex-
cluded from the analysis, then rcstenosis is similar in 
both groups. TIlese findings support and expand our 
current understanding regarding the role of thrombus in 
long-teml luminal renarrowing and occlusion after suc-
cessful PTCA. 
Our findings support a role for thrombus in restenosis 
after successful PTCA in terms of both clinical and 
angiographic outcomes. They suggest that the contribu-
tion thrombus makes to restenosis relates to vessel 
occlusion by the time of follow-up angiography. The 
timing of this occlusion is unclear. If it occurred early, it 
is likely to have been the end result of an acute 
thrombotic process, whereas if it occurred late, it would 
be the final end result of the process of restenosis itself. 
We do not know when the occlusion at follow-up 
angiography occurred in our patients, so our results must 
be speculative. We suspect, however, that it occurred 
carly. In support of this is the higher incidence of 
previolls myocardial infarction in the thrombus group 
(successful dilatation of the infarct-related vessel is 
associated with a higher rate of early silent occ1usionD) 
and the Wilcoxon test indicating early divergence in the 
survival curvcs when occlusions at follow-up angiogra-
phy are included. Additional evidence comes from the 
much earlier occurrence of clinical and angiographic end 
points in the thrombus-laden lesions that had occluded 
by the time of follow-up angiography and the fact that 
the excess in clinical end points is driven by a much 
higher incidence of acute myocardial infarction. Our 
hypothesis thai the occlusions occurred carly is also 
supported by evidence in the literature suggcsting that 
2% to 8% of elective PTCA lesionsz-t occlude during the 
first 24 hours, silently in many cases. Thus, although our 
data support a role for thrombus in vessel occlusion by 
the time of follow-up angiography and hence resteno-
sis, they do not provide any strong evidence to support 
a role for angiographically identifiable thrombus in 
late myointimal hyperplasia. Further prospective stud-
ies are thus required to evaluate this important matter 
further. 
Unimriate regression analysis was suggestive of a 
number of procedural and angiographic variables re-
lated to occlusion at follow-up angiography. These in-
cluded the presence of a total occlusion and a tighter 
stenosis before PTCA, a longer duration of inflation 
with the use of a smaller balloon diameter in a smaller 
vessel with a tighter residual MLD, and a greater 
likelihood of a dissection after PTCA at the dilated site. 
Thus, the more difficult dilatation of a more complex 
TASlE 4. Univariate Analysis of Patlent-, Lesion-, and Procedure-Related 
Characteristics Relevant to Occlusion at Fe-liow-up Angiography 
In 160 Lesions Containing Thrombus 
Occlusion No Occlusion 
at FoUow·up at Follow·up Significance 
lesion Type (n-22) (n-l38) level 
Anginal class. % 
.365 
None 4.6 11.6 
CCS class I 9.1 13.8 
CCS class 11 40.9 26.8 
CCS class HI 31.8 22.S 
CCS class IV 13.6 25.4 
Duration of angina. wI( 106±219 63:':;132 .326 
Medication at screening, % 
AnilC039u1ants 0 0.7 1.000 
Thrombocyte aggregaHon Inhibitor 68.2 65.2 .976 
Aspirin 80.0 742 .872 
Oipyridamole 20.0 7.' .317 
Laboratory Investigations 
Hemoglobin 8.70:!:I.OO 8.81:t0.86 .593 
Hematocrit 0.42:<:'0.04 0.42:t.0.04 .863 
Platelet count 2740':55 2670':80 .691 
lesion location, % .085 
LAO 13.7 37.0 
LC' 22.7 20.3 
RCA 63.7 42.8 
Lesion characteristics, % 
Concentric 26.3 36.6 .542 
Multiple irregularities 10.5 13.4 1.000 
Branch point in stenosis 16.7 16.4 1.000 
Coronary artery bend 15.6 24.1 .615 
Calcified lesion 31.8 14.5 .088 
Tolal occlusion 45.5 15.6 .003' 
Degree of collateral supply, % .138 
No collaterals 66.7 61.3 
Slight (minimal perlus!on) 0 7.3 
Medium (partial perfusIon) 26.7 
" Major (complete perfusion) 1.0 
Not assessed 6.7 3.1 
PTCA procedure 
Nominal size of largest balloon, mm 2.81±0.40 3.03:t.0.43 .0264 
8alloon to artel)' ratio 1.10:t.0.19 1.12±0.18 .7172 
Total number of Inflations 4.5:t.3.2 4.2±2.9 .6687 
Total duration of inflation, s 530±484 356±289 .0248' 
Maxlmum Inflation pressure, aim 9.10±2.93 824:<:'2.45 .2159 
Post-PTCA result 
DiSSection at the dilated site, % 77.3 50.7 .036 
Quantitative angi09raphlc measurements 
Rel&f8flCe diameter, mm 
8elore angloplasty 2.62±O.53 2.79±0.54 .3101 
After angioplasty 2.54±O.39 2.84::':0.54 .0036' 
MLO, mm 
Before anglop!3Sty O.55:t.O.56 0.93:<:'0.49 .0052 
After angloptasty 1.66±0.3Q 1.82:!:0.35 .0277 
Oiff&f8flCes in MLD, mm 
Absolute galn 1.11::':0.60 0.89±0.51 .1161 
Relative gain 0.44::':023 0.33::':0.18 .0360 
PefC€-l1tage stenosis 
Before angloptasty 79.00::':20.40 65.99±17.33 .-After angioplasty 34.35::':8.38 35.28±7.35 .6276 
lesion length post·PTCA, mm 6.14:<:.1.99 6.26::t2.35 
.0" 
Days to follow·up 127::t79 160::':46 .007 
CCS Indicates Canadian CaralOvascular Society angina ctassiflcatfoo; lCx, left circumflex artery. Values 
are mean±SD. 
'Retained In multivariate model. 
lesion in a smaller vessel with a less satisfactory result 
would be more likely to occlude by the time offolJO\y-uP 
angiography. Multivariate regression analysis confirmed 
the presence of total occlusion before fleA and a 
longer total inflation time to be positively related to the 
risk of subsequent occlusion and the reference diameter 
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TABLE 5. Result of Multiple LogIstic Regression Analysis to Evaluate 
the Respective Contributions of Clinical, Anglographlc. and 
Procedural Variables to Occlusion at Follow-up 
Angiography in lesions Containing Thrombus 
Variable 
Pleseoce of total occlusion ple-PTCA 
Total Infiation ttme, $ 
Refefence diametef post-PlCA. mm 
after PTCA to be negatively related. The relation be-
hveen total occlusion and subsequent risk of occlusion 
may be secondary to the highly thrombogenic surface 
generated by the successful dilatation of a total occlu-
sion, without a preexisting endotheliallining.'--' Success-
ful dilatation of a total occlusion may also expose flowing 
blood to activated thrombin bound to fibrin in the 
internal layers of a previously fomled thrombus. The 
prothrombotic processes stimulated by the activated 
thrombin would be even more severe than those associ-
ated with the deeply injured artery and would further 
accelerate thrombosis after PTCA in these lesions,l6.17 
thus contnbuting to both enhanced local thrombus 
formation after sllccessful dilatation of these lesions and 
an increased likelihood of thrombotic occlusion. TIle 
total inflation lime may represent the more complex 
dilatation of a total occlusion, multiple irregularities, or 
a more complicated angioplasty. TIlis is further sup-
ported by the higher incidence of dissections requiring 
prolonged inflation in lesions that occlude by the time of 
follow-up angiography. TIle negative relation behveen 
increasing vessel size and subsequent occlusion is prob-
ably representative of the locaillow dynamics.2S 
Our study has a number of limitations. First, it was a 
retrospective analysis of prospectively gathered data and 
is hence subject to the limitations inherent in any 
retrospective analysis. For example, there are significant 
differences in the baseline clinical, angiographic, and 
procedural characteristics between the two groups that 
could have been responsible for, or associated with, the 
outcome of the procedure, including the presence of 
thrombus. Patients with angiographie evidence of 
thrombus before or after angioplasty had a significantly 
greater history of previous myocardial infarction and a 
significantly lower proportion of previous coronary an~ 
gioplasty, both of which may have had an impact on the 
clinical and angiographic outcomes. There is evidence 
for a silent early occlusion after successful acute dilata~ 
tion of infarct-related vesseIs~.13 and evidence that after 
stent implantation in coronary vessels supplying an 
infarcted segment, the low flow makes the vessel more 
prone to tluombotic ocdusion.29 Similar mechanisms 
may be operating in our study, but we do not know 
whether the vessel dilated was the infarct-related vessel, 
and we do not know the length of time since myocardial 
infarction, except that it was longer than 1 week. Similar 
arguments also apply to the history of previous PTCA. 
Again, we do not know whether the present procedure 
was performed at the same site, and it is not possible to 
draw conclusions about what effect it may have had on 
subsequent clinical and angiographic outcomes. 
There were also significant differences in lesion loca-
tion and lesion characteristics. There was a higher 
proportion of lesions containing thrombus in the RCA 
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Standard Error 
RegressIon of Regress!on 
CoefficIent Coeffic!ent P 
.379 .163 .021 
.002 .0006 .002 
-1.634 .6311 .009 
and less in the LAD. This may have had an impact on 
angiographic outcome in two ways. First, the RCA is 
significantly larger than the LAD, and this may explain 
why the reference diameter in lesions containing throm-
bus was significantly larger. Second, there arc significant 
differences between the two vessels in terlllS of local How 
dynamics, vessel geometry, and external compressive 
forces}{) that may have a substantial inHuence on the 
subsequent risk of occiusion.JI Although lesion location 
Was not a major risk factor in our multivariate analysis of 
occlusions at follow-up angiography, it is nonetheless 
interesting to note that the trend was for lesions that 
occluded to be in the RCA (P=.085). Thus, similar 
mechanisms may be operating in our study. 
The type of lesion was also significantly different, with 
a greater proportion of total occlusions ill the thrombus 
group. Successful dilatation of these may have enhanced 
local thrombus formation and may have contributed to 
the increased incidence of occlusion at follow-up angiog-
raphyP.32 It may also partly explain the smaller r>..fLD 
before PTCA and greater absolute and relative gains in 
this group of lesions. Differences in lesion location and 
characteristics could also have been responsible for the 
significant differences in the PTCA procedure. For 
example, the prevalence of RCA lesions could explain 
the larger nominal size of the largest balloon, whereas 
the greater number of inflations and total duration of 
inHation may reHect the more complex dilatation of a 
total occlusion, multiple irregularities, or a more com-
plicated angioplasty. 
Although we tried to compensate for these differences 
in baseline characteristics by using multivariate analysis 
and demonstrated that thrombus has a predictive value 
on restenosis and clinical outcome independent of the 
underlying clinical and angiographic characteristics, 
nonetheless, we cannot exclude the possibility of covert 
factors not available in the study influencing outcome. 
For example, we do not know what proportion of the 
angiographically identifiable thrombus group had a suc-
cessfully treated occlusive dissection, a recognized risk 
factor for restenosis,33 and tolal occlusion as a late 
outcome.J4 
Second, although the angiographic definition of 
thrombus we used is the standard definition found in the 
Iiterature,17·IB the individual sensitivity and specificity of 
the three criteria have, to the best of our knowledge, 
never been addressed. In addition, contrast angiography, 
although the gold standard for randomized studies, has 
a poor sensitivity for intra coronary thrombus. UI When 
we used the above angiographic definition and coronal}' 
angioscopy as the gold standard, we found the specificity 
of contrast angiography to be good (100%) but the 
sensitivity to be poor (19.4%). This is in keeping with 
other evidence in the literature. Coronary angioscopy, 
for example, suggests a very high incidence of macro-
scopic mural thrombus, not identifiable by contrast angiog-
raphy, aftcr balloon angioplasty,>S.36 whereas directional 
atherectomy suggests that thrombus may contribute to 
arterial narrowing in 8% to 25% of restenosis cases.37 
Thus, although our results apply to angiographically iden-
tifiable thrombus, they may not apply to patients with 
mural thrombus not visualized by contrast angiography. 
Finally, the study relies on data pooled from four 
separate restenosis trialsy-ts We believe that the pool-
ing of data was justified, however, since the number of 
patients with angiographically identifiable thrombus pres-
ent in each individual study was limited, Furthermore, 
the entry criteria for the studies were broadly similar, the 
data pooled were those common to all studies, and the 
angiographie criteria were standardized, ,vith one cen-
tral angiographic core laboratory performing the QCA 
analysis in all studies, In addition, the resulting large 
study popUlation provides a unique opportunity 10 ob-
tain accurate QCA data at a predetermined lime interval 
in a field in which few such data exist to date. 
Clinical Implications 
Our data support previous work suggesting Ihat local 
thrombus formation may result in acute occlusion7,3S,39 
and expand it to include late subacute occlusion and 
hence restenosis, This may have important clinical im-
plications with regard to recent studies using monoclo-
nal antibodies and synthetic peptides directed against 
the platelet glycoprotein IIbJIIJa receptor,4!} .. .u Although 
preliminary data suggest that they reduce the need for 
coronary revascularization procedures in high-risk an-
gioplasty patients,42 most of the reduction occurred in 
the first 30 days after intervention, and the effects were 
not verified at the angiographic level. Our data would 
suggest that perhaps some of their improved clinical 
outcome may relate to eliminating subacute occlusion in 
a subset of the population without necessarily affecting 
the restenosis process, 
Conclusions 
Our results indicate that the presence of angiographi-
cally identifiable thrombus at the time of the angioplasty 
procedure is associated with a higher rate of angio-
graphic restenosis. The mechanism by which this occurs 
is through increased vessel occlusion at follow-up an-
giography. Measures aimed at improving outcome in this 
group of lesions should be focused in this direction, 
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Long-term Luminal Renarrowing Mter 
Successful Elective Coronary Angioplasty 
of Total Occlusions 
A Quantitative Angiographic Analysis 
Andams G, Violaris, MD, MRCP (UK); Rein Melkert, MD, MSj Patrick W. Serruys, MD, PhD 
Background The long-tenn angiographic outcome after 
successful dilatation of coronary ocdusions remains unclear, 
The objective of this study was to examine long.term reslenosis 
after succes.sful balloon dilatation of corollary ocdusions at a 
predetermined lime interval ",ilh quantitative angiography and 
compare this "llh a control population of stenoses. 
i'.fflhods and Results The study population comprised 2950 
patients (3583 lesions) prospectr,ely enrolled in and succ5Sfully 
completing four major restenosis trials (86% quantitative angio-
graphic follO\v+up). Qneangiographic films were processed and 
analyzed at a central core laboratoryv.ith the use of an automated 
interpolated edge detection technique. The study population 
comprised 266 occlusions (7%) defined as total when there was 
absent anterograde filling beyond the lesion (109 lesions) and 
functional (157lesions) when faint, late anterograde opacification 
of the distal segment was seen in the absence of a discerruble 
luminal continuity; 33171e.sions were defined as stenoses (93%). 
Restenosis was significantly higher after su~ dilatation of 
occlusions than of stenoses. With the categorical (>50% diameter 
stenosis at follow·up) approach, the restenosis rate was 44.7% in 
occlusions compared .... ith 34.0% in stenoses (P<.OOlj relative 
risk, 1.575; 0, 1.224 to 2.027). Similarly, the absolute loss (defined 
as the change in minimal lumen diameter between post coronary 
A fter the introduction of coronary angioplasty by Griintzig et al in 1979,1 the indication for its use were at first tentatively and subsequently 
more strikingly expanded to include patients with total 
occlusions.2-6 Although a number of factors are known to 
influence the acute success rate,4,7-9 relatively little is 
known regarding long·term luminal renarrowing after 
successful dilatation of total occlusions. A number of 
studies have investigated this, but uncertainty continues 
with restenosis rates in the literature varying from 20% 
to 65%.2,3.5.6.10.-17 This variation has three primary 
sources. First, most studies have been retrospective 
analyses that use small patient numbers and no control 
group.2,3.11,ll,15.16 Second, the angiographic follow-up 
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angioplasty and follow·up; in millimeters, mean::':::SD) (0.43±0.68) 
in occlusions was significantly higher than in stenoses (031±051, 
P<.OOI), as was the relative loss, defined as the change in minimal 
lumen diameter between postangioplasty and follow·up, adjusted 
for the yessel size (0.17±0.28 \'ersus 0.12±0.20, P<.OOl). The 
higher restenosis rate in the occlusions group was due predomi· 
nantly to an increased number of occlusions at follow·up angiog· 
raphy in this group (19.2% compared with 5.0% for stenoses, 
P<.OOl). Within the occlusions group, there were no significant 
differences in long·term outcome hem'een total and functional 
occlusions (restenosis rate, 45.0% versus 44.6%: reocclusion rate, 
23.9% yersus 15.9%; absolute loss, 0.53±0.69 versus 0.36::':::0.67; 
relative loss, 0.21±0.28 yCrsus 0.15::':::0.28; P=NS). 
Conclusions These results indicate that successfully dilated 
coronal)' occlusions, both total and functional, have a higher 
rate of angiographic restenosis at 6 months than stenoses. This 
is due chiefly to a higher rate of occlusion at follow.up 
angiography in this group of lesions. Measures aimed at 
reducing restenosis after successful dilatation of coronary 
occlusion should be focused in this direction. (CircuiatiOll. 
1995;91:2140.2150.) 
Key Words • angioplasty • occlusions • angiography 
rates have been low and performed for the recurrence of 
symptoms rather than at a predetermined time interval, 
thus introducing important selection bias.s.6.17 Finally, 
some have used visual assessment to estimate angio-
graphic severity, which is subject to wide interobserver 
and intraobserver variability.ls This study attempted to 
overcome these limitations by using a validated auto-
mated edge detection technique to evaluate restenosis 
prospectively in a large series of patients undergoing 
successful balloon angioplasty and routine follow-up 
angiographic assessment at a predetermined time inter-
val. Furthennore, a control cohort of patients ,vith 
stenoses \Va'> used to directly compare the long-term 
results. 
See p 2113 
Methods 
Patients 
The study population comprised 3582 patients with signifi· 
cant primal)' stenoses In native coronal)' arteries who were 
prospectively enrolled in four major restenosis trialsl~22 and 
who underwent successful coronary angioplasty (postproce-
dural stenosis <50%). These trials demonstrated that active 
therapy had no effect on restenosis or clinical outcome in the 
first 6 months after balloon angioplasty, so for the purposes of 
this study, the data for the active and placebo groups were 
pooled. Men or women were eligible for study entry if they 
were symptomatic or asymptomatic with stable or unstable 
angina pectoris and proven angiographicaJly significant narrow-
ing in one or more major coronary arteries. Informed consent 
was obtained in aU cases before the coronary angioplasty 
procedure. Patients with evolving myocardial infarction and 
significant left main disease were excluded from the study. 
AnglopJasty Procedure and Follow-up Angiography 
Coronary angioplasty was perfonned with a steerable, move-
able guide \\ire system by the femoral route. Standard banoon 
catheters were used. The choice of balloon type and brand, 
inflation duration, and inflation pressure was left to the discre-
tion of the operator. Patients were followed up for 6 months; 
then a follow.up study was perfonned. If S)mptoms recurred 
within 6 months, coronary angiography was perfonned earlier. 
If no definite restenosis was present and the follow-up time was 
less than 4 months, the patient was asked to undergo further 
coronary arteriography at 6 months. 
Quantitath'e Angiography 
In total, three coronary angiograms were obtained for each 
patient-before and after percutaneous transluminal coronary 
angioplasty (PTCA) and at angiographic follow-up. To stan· 
dardize the method of data acquisition and to ensure exact 
reproducibility of the angiographic studies, measures were 
taken as previously described, and aU angiograms were pro-
cessed in a central angiographic core laboratory.19,20,22 The 
angiograms were recorded in such a manner that they were 
suitable for quantitative analysis by the computer-assisted 
CORO~ARY ANGIOGRAPHY ANALYSIS SYSTEM, which was de-
scribed and validated earlier.2-l,2~ Because the computer algo· 
rithm cannot measure total occlusions, a value of 0 mm was 
substituted for the minimal lumen diameter and a value of 
100% for the pre-PTCA percent diameter stenosis. In these 
cases, the post-PICA reference diameter was substituted for 
ve~el size. 
Definitions 
Totaf Occlusioll 
As in previous studies, total occlusions were divided into 
absolute occlusions (Thrombolysis in Myocardial Infarction 
(TIMI) flow grade 0) where no anterograde filling beyond the 
lesion was visible and functional occlusions (TIl-.U grade 1) 
where faint, late anterograde opacification of the distal seg-
ment was present in the absence of a discernible luminal 
continuity.I7,1.5 
Occlusion at Foffow-up Allgiography 
Occlusion at follow-up angiography was defined as the 
presence of an absolute or functional occlusion at the previ-
ously dilated angioplasty site on angiographic follow-up. 
Allgiographic Parameters Assessed 
Vessel size refers to the reference diameter of the relevant 
roronary segment and is represented by the interpolated 
reference diameter pre-PTCA because this is the closest and 
most objectiye approximation of the disease-free vessel wall. 
Minimum luminal diameter (MLD) is the point of maximal 
luminal narrowing in the analyzed segment. 
Many criteria have been proposed for the assessment of 
restenosis.u-u For the purposes of this study, two approaches 
were used: the categorical approach with the traditional cutoff 
point of >50% diameter stenosis at follow-up and a continuous 
approach that used absolute and relative loss, which reflect the 
beha\ior of the lesion during and after angioplasty and may be 
more representatr,e of the pathological proce~ involved dur-
ing follow-up.u.19 
Absolute gain and absolute lo~ represent the improvement 
in MLD achieved at intervention and the absolute change 
during follow.up respectively, measured in millimeters. Abso· 
lute gain is post-PTCA MLD minus pre-PTCA MLD. Absolute 
loss is post-PTCA MLD minus MLD at follow-up. 
Relative gain and relative loss depict the improyement in 
MLO achieved at intervention and the change during follow-up 
respectively, normalized for vessel size. Relative gain is (post-
PTCA MLD minus pre-PTCA MLO) divided by vessel size. 
Relative loss is (post·PTCA l\fLO minus l\fLD at follow.up) 
di.vided by vessel size. 
The absolute net gain is the MLD at follow-up minus 
pre-PICA MLD. The net gain index is the net gain nonnalized 
for the vessel size. The net gain index is (MLD at follow-up 
minus pre-PTCA MLO) divided by vessel size. 
The loss index is the relation of late loss to acute gain: loss 
index is (l\fLD at follow-up minus pos!-PTCA MLO) divided 
by (post-PTCA MLO minus pre-PTCA l-.fLD). 
Statistical Analysis 
Data were analyzed ",ith the SAS statistical softv.'are package. 
Categorical variables are presented as absolute numbers (%). 
Continuous variables are expressed as mean value±SO. Dif· 
ferences betv.-een groups were evaluated ",ith adjusted X 2 tests 
for categorical variables and Student's t tests for continuous 
variables. The contributions of clinical, angiographic, and 
procedural variables to the categorical outcome parameters 
were evaluated .... ith logistic regression analysis. For the con-
tinuous outcome parameter (absolute loss), multiple linear 
regression analysis was used. Categorical variables were dichot-
omized and entered into the analysis as indicator variables \\ith 
values of 0 and 1. Selection of variables was achieved in a 
stepwise fashion. The adjusted R2 was used as the criterion for 
model selection. Probability values <.05 were considered 
significant. 
Results 
Patient Characteristics and Clinical Follow-up 
The study population comprised 2950 patients (3583 
lesions, 1.211esions per patient) who successfully com· 
pleted the study and had follow-up quantitative angiog· 
raphy. The overall angiographic restudy rate was 86% of 
all patients undergoing successful PTCA. We found that 
266 lesions in 249 patients out of 3583 lesions in 2950 
patients complied with the angiographic definition of 
total occlusion. Of these, 109 were absolute and 157 
were functional total occlusions. 
Tables 1 and 2 summarize the clinical and angio-
graphic characteristics of the 249 patients with occlu· 
sions compared with the 2701 with stenoses. Patients 
with total o<:c1usions were younger and had a signifi-
cantly higher rate of previous myocardial infarction than 
patients with stenoses. Furthermore, the duration of 
angina in this group was significantly shorter than in 
stenoses. Additionally, the presence of thrombus either 
before or after PTCA was significantly higher in o<:c1u-
sions. Of the procedural characteristics, the nominal size 
of the largest balloon was significantly higher in stenoses, 
while the total number of balloon inflations required, 
total duration, and maximum innation pressure were 
higher in occlusions. Within the occlusions group, there 
were no significant differences behveen lesions ,vith total 
and functional occlusions. 
Seventy-one (28.5%) of the patients with successfully 
dilated total occlusions and 598 (22.1%) of the patients 
with stenoses had clinical end points (additional PTCA, 
coronary artery bypass graft [CABG] surgery, acute 
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TABLE 1. Baseline Clinical Characteristics of Patfents 
With Occlusions and Stenoses Before 
Coronary Angloplasty 
Lesion Type 
Ocduslon Stenoses 
Patients, n 24' 2701 
Men, % 85.1 81.4 
Age,y 54.4.:t9.6 51.4.:t9.3' 
Smoking status, % 
Ever smoked 73.1 15.5 
Current smoker 17.2 18.3 
PreYlous myocardial Infarction, % 54.2 41.1' 
Prevloos CABG, % 1.6 4.5 
Prevloos PlCA, % 3.6 5.0 
Diabetes mellftus, % 10.8 10.2 
History of hypertensIon, % 30.1 30.5 
History of hypercholesteroiemla, % 33.3 31.5 
History of peripheral vascular disease, % 3.5 5.1 
CCS anginal class, % 
"""' 
5.0 5.5 
I 10.0 11.2 
33.1 32.4 
III 28.9 302 
IV 21.3 20.6 
Duration of angina, wk 69±126 114±207" 
Medication at screenIng, % 
Nrtrates 51.6 55.2 
Calcium antagonists 69.1 69.5 
J3·blockero 51.4 49.8 
Anticoagulants 1.5 1.5 
Aspirin 60.2 82.0 
laboratory Investigations 
Total cholesterol 5,58±1.30 5.85.:!:1.23 
Hemoglobin 8.89.:!:0.80 8.86otO.83 
HematOClit 0.42±0.04 0.42±0.04 
Platelet count 259ot58 251.:!:71 
CABG indicates corooary artery bypass grafts; PlCA, percutaneous 
translumlnaJ coronary angloplasly; and CCS, canadian Card"lQvascular 
Society. 
'P<.05. 
myocardial infarction, or death) during follow-up. The 
difference was statistically significant (P=.026). The 
individual components of death, myocardial infarction, 
CABG, and re-PTCA were 0%, 3.6%, 3.6%, and 21.3%, 
respectively, for occlusions and 0.2%, 2.8%, 2.4%, and 
16.7%, respectively, for stenoses. The dilferences in the 
individual clinical end points between the two groups 
were also statistically significant (P=.022). Fig 1 summa-
rizes the time course of clinical end points. Although the 
mean time to clinical follow-up was similar in the two 
groups, when we compared the pattern of occurrence of 
clinical end points by way of the log-rank test, clinical 
end points in the occlusions group were found to occur 
earlier than in stenoses (P= ,022). 
Interestingly, when lesions that went on to occlude at 
follow-up angiography were excluded from the analysis, 
50 patients (25.1%) \vith occlusions and 541 patients 
(21.1%) with stenoses rcached a clinical end point, and 
the difference was no longer statistically significant 
(P=.217). The individual clinical end points and the time 
to a clinical end point were also no longer significantly 
different (P=.238 and .214, respectively). 
Quantllalh'c Anglographlc Analysis 
A mean of2.12 matched angiographic projections per 
lesion had satisfactory quantitative analysis performed at 
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TABLE 2. Baseline Anglographlc and Procedural Data 
of Patients With Occlusions and Stenoses Before 
Coronary Angloplasty 
lesion Type 
OCClusions Stenoses 
lesloos, n 256 3317 
Lesloos per patlefll, n 1.07 1.23 
Number of diseased vessels, % 
SVD 61.0 64.2 
2·VD 34.5 27.5 
3·VD 3.6 7.6 
Lesion location, % 
lAD 39.4 44.2 
LC, 26.9 24.0 
RCA 33.7 31,7 
Type of lesloo, % 
Multiple IrregulariUes 6.' 6.0 
Side brancflln lesion 21.1 20.2 
LesIon calcification 12.0 12.4 
PlCA procedure 
Nominal size of largest ballooo, mm 2.74.:!:0.43 2.69±0.43' 
Ballooo to artery ratio 1.14:':0.18 1.13:';0.19 
Total number of Inflatioos 4.6±3.2 3.47±2.2' 
Total duration of Inflation, s 404:';341 303±261' 
Maximum Inflation pressure, atm 6.60:':2.59 8.45:':2.50' 
Posl-PlCA result, % 
Dissection at the dilated site "'.6 34.' 
Thrombus visible (befOfe Of after 
PlCA) 12.9 4.2' 
SVO Indicates single-vessel disease; 2ND, two-vessel disease; 3-VD, 
three-vassel disease; lAD, left anterior descending; Lex, left circumflex 
artery; RCA, right C(lrOflary artery; and PlCA, percutaneous transtuminal 
corooary ang!oplasty. 
'P<.05. 
the central Angiographic Core Laboratory before and 
after PTCA and at follow-up (Table 3). TIle reference 
diameter was significantly lower in occlusions than in 
stenoses, and this difference remained at follO\y-up. As 
expected, the MLD increased substantially more after 
dilatation of occlusions than of stenoses, which was 
reflected in the substantially greater relative gain. Nev-
ertheless, the post-PTCA MLD was significantly lower in 
occlusions, perhaps reflecting the smaller vessel diame-
ter in this group (Fig 2a). When this was taken into 
account, the percent stenosis after PTCA was similar in 
both groups (Fig 2b). At follow-up, previously occluded 
",-------------------------------, 
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*Stenoses 
Days to clinical end poInt 
FIG 1. Graph showing cumulative distribution CUNSS of clinical 
end points over time for total occlusions and stenoses. Numbers 
given are mean±SD (days). 'P<.OS. 
TABLE 3. Quantitative Analyses of 266 Lesions in 249 
Patients With Occlusions and 3317 Stenoses in 2701 
Patients Included In the Analysis 
Lesion Type 
Occlusions, Slenoses, Significance 
noo266 "003317 level 
Reference diameter. mm 
Befwe angioplasty 2.61±0.54 
Mer ang\opl.asty 2.46±0.49 2.67:!:0.51 <0.001 
At follow-up 2.60±0.55 2.69±0.56 0.026 
MlD. mm 
Befwe angioplasty 0 1.08±0.29 
After angioplasty 1.61±0.34 1.77±0.36 <0.001 
At follow·up 1.1B±0.69 1.46±0.57 <0.001 
Differences in MlD. mm 
Absolute gaTn 1.61±0.34 0.69:!:0.34 <0.001 
Relatf..·e gain 0.66±0.09 027±0.13 <0.001 
Absolute loss 0.43±0.68 0.31:!:0.51 <0.001 
Relative loss 0.17±0.28 0.12±0.20 <0.001 
Absolute net gain 1.18±0.69 0.38±0.53 <0.001 
Net ga:n Index 0.48±0.28 0.14±0.21 <0.001 
Loss index 0.26±0.43 0.53±3.88 0.255 
Percentage stenosTs 
Before angioplasty 100 57.83±9.86 
After angloplasty 34.16±8.46 33.40±8.33 0.15$ 
At foTiow-up 54.08±25.67 45.33±18.52 <0.001 
OS at follow·up >50%. % 44.74 33.95 <0.001 
MLD Indicates minimal luminal diameter; OS. diameter stenosIs. 
lesions deteriorated significantly more in terms of both 
absolute and relativc loss (Fig 3, Table 3), resulting in a 
smaller follow-up MLD and higher percent stenosis (Fig 
2a and 2b, Table 3). Thus, in addition to restenosis being 
higher when the continuous, absolute, and relative loss 
approach was used, the restenosis rate when thc cate-
gorical approach was used was also significantly highcr 
(44.74% in occlusions compared with 33.95% in sleno-
ses; P<.OOl; relative risk, 1.575; CI, 1.224 to 2.027). 
Although angiographic restenosis was higher in occlu-
sions than stenoses, there were no significant differences 
in the presentation of restenosis between the two 
groups. Of recanalized total occlusions with angio-
graphic restenosis, 40% were symptom-free, while 
18.5% complained of angina and 41.5% had a clinical 
end point. This compares wilh 39.9%, 18.7%, and 
41.4%, respectively, for stenoses with angiographic 
restenosis. 
The higher restenosis rate in the occlusions was due 
predominantly to an increased number of occlusions at 
follow-up angiography in this group (19.2% versus 5.0% 
for stenoses, P<.OOI). TItUS, recanalized occlusions ac-
counted for 23.5% of all occlusions at follow-up angiog-
raphy even though they formed only 7% of the total 
study population. The relative risk for occlusion at 
follow-up angiography was 4.503 (95% cr, 3.196 to 
6.344). 
Subgroup Analysis of Occlusions Group 
Subgroup analysis of the occlusions group revealed 
109 absolute and 157 functional occlusions (Table 4). 
The reference diameter after angioplasty was signifi-
cantly higher in absolute than in functional occlusions, 
but this difference did not persist to follow-up angiogra-
phy. There were no significant differcnces in the MLD or 
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FlO 2. Graphs showIng (a) cumulative distribution curves of 
mean luminal diameter (MlD) after percutaneous transluminal 
coronruy angloplasty (PlCA) and at follow-up for total occlu-
sions and stenoses and (b) cumulative distribution curves of 
percentage stenosIs after PlCA and at follow-up for total 
occlus!ons and stenoses. Numbers given are mean±SO. 
·P<.OO1. 
percent stenosis after PTCA or at follow-up (Tablc 4) 
between the two groups. The categorical restenosis rate 
(>50% diameter stcnosis at follow-up) was almost iden-
tical (44.95% versus 44.59%) in the two groups. Al-
though the reocclusion rate in absolute occlusions 
tended to be higher than in functional occlusions (23.9% 
versus 15.9%), this did not reach statistical significance 
(P=.06). By use of the continuous measurements of 
rc.stenosis, the absolute and relative loss tended to be 
lower in functional occlusions (Table 4), resulting in a 
significantly higher net gain index and a significantly 
lower loss index. 
Unh'ariate and Multlyariate Analyses of Restcnosis 
in Total Occlusions 
Univariate analysis of the available c1inical-, procedural-, 
and lesion-related characteristics was perfomlcd to asscss 
whether any of these variables were associated with an 
increased categorical restenosis rate (fable 5). The only 
significant associations were with a shorter duration of 
angina, a longer balloon total inflation time, higher residual 
stenosis after PTCA, and a lower relative gain. Step\\1Se 
logistic regrcssion analysis wa" used to further evaluate the 
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FlO 3. Graphs showing (a) cumulative distribUtion curves of 
absolute loss (Abs) (change in mean luminal diameter [MLDJ from 
before percutaneous angloplasty to follow-up) for lotal occlu-
sions and stenoses and (b) cumulative distribution curves of 
relative (reQ loss (change In MLO from before percutaneous 
ang!oplasty to follow-up corrected for vessel size) for total 
occlusions and stenoses. Numbers given are mean±SD. 
·P<.OO1. 
relation between this dichotomous definition of restenosis 
and the above variables, as well as ali other clinical, lesion, 
and procedural characteristics. The number of diseased 
vessels and the percent stenosis after PTCA were positively 
related; duration of angina (in days) was negatively related 
to the probability of restenosis at follow-up (Table 6). 
Univariate analysis of clinical, procedural, and lesion 
characteristics related to absolute loss showed the only 
significant associations to be with total inflation time 
(P=.OO04), presence of thrombus (P=.0039), post-
PTCA MLD (P=.0144), duration of angina (P=.0262), 
left anterior descending coronary artery location 
(P=.0418), and lesion calcification (P=.0443). Multiple 
linear regression analysis was used to further evaluate 
absolute loss. Of the variables assessed, total inflation 
time (in seconds) and the presence of thrombus were 
both positively related to absolute loss (Table 6). 
Dnh'ariale and Multivariate Analysis of Occlusions 
at Follow-up Angiography 
The finding that the higher restenosis rate after dila-
tation of occlusions was due predominantly to an in-
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TABLE 4. Quantitative Anglographlc Analysis of 109 
Total and 167 Functional Occlusions Included in 
the Analysis 
lesion Type 
TIMIO, l1M11, Slgnfficancf) 
0=109 n=157 level 
Reference diameter, mm 
Before af'l9iop!asty 
After angiop!asty 2.5S±Q.S2 2.40±o.56 0.015 
AI follow-up 2.66±O.SS 2.56-':0.54 0.200 
MLD, mm 
Before anglop!asty 
After ang'oplasty 1.65±O.35 1.58:':0.34 0.096 
At follow-up 1.12±0.74 1.21±O.65 0.285 
Diiferences In MLD, mm 
Absolute gajn 1.65±O.3S 1.58±O.34 0.096 
Relative gain O.65±o.09 Q.66±o.08 0.440 
Abso'ute loss Q,53±O.69 O.36±O.67 0.051 
Relat",s loss 0.21±0.28 0.15±0.28 0.003 
Absolute net gain 1.12±O.74 1.21±O.65 0.285 
Net gain Index O.44±O.29 0.51±0.28 0.037 
LoSS index O.32±OA4 O.22±OA2 0.042 
Percentage stenosis 
Before ang1op!asty 0.285 
After angioplasty 34.61±8.69 33.86~8.32 0.481 
At follow·up 57.52.!:26.38 51.70.!:24.96 0.072 
DS at follow-up >50%, % 44.95 44.59 1.000 
llMlll1dicales Thrombosis 111 Myocardial lnfarcti<>o classmcatioo; MlD, 
minimallumll1al diameter. 
creased number of reocclusions at follow-up angiogra-
phy in this group prompted us to examine a number of 
variables predictive of reocclusion (Table 7). The clinical 
characteristics of the two groups were similar, although 
lesions that went on to reocclude had a shorter duration 
of angina (27±52 versus 74±132 weeks). Procedural 
characteristics were also similar, although lesions that 
went on to reocdude required a longer balloon inflation 
(537±478 versus 373±294 seconds). Logistic regression 
analysis was performcd for the above and for all other 
clinical, angiographic, and procedural parameters 
thought to be associated with the occlusion at follow-up. 
Of these variables, the total inflation time (in seconds) 
was positively related and the post-PTCA reference 
diameter (in millimeters) was negatively related to reoc-
clusion at follow-up angiography (Table 6). 
Discussion 
Our study specifically addressed the problem of long-
term luminal renarrowing after dilatation of total coro-
nary occlusions in a large patient population with a 
control group, a hlgb angiographic follow-up rate, and 
quantitative angiography at a predetermined time inter-
val. We demonstrated using both a categorical and a 
continuous approach that restenosis is significantly 
greater after balloon dilatation of occlusions than of 
stenoses. Furthermore, we also showed that tIlis is 
mainly the result of an increased rate of occlusion at 
follow-up angiography, which is specifically related to 
total inflation time and reference diameter after inter-
vention. We also demonstrated that restenosis and re-
occlusion occur to an equal extent in both absolute and 
functional occlusions. These findings support and ex-
pand our current understanding of the long-term angio-
TASLE 5. Univariate Analysis of Patient-. leslon-. and 
Procedure-Related Characteristics Relevant to long-term Restenosls· 
In 266 Occlusions 
No 
Reslenosls al Restenosls al 
Follow·up, Follow-up, Slgnfficance 
n",119 n",147 Level 
ecs angInal class, % 0.700 
N~ 6.7 4.' 
I .,4 11.6 
" 
31.1 34.7 
'" 
31.1 29.3 
IV 22.7 19.7 
Duratfor! of angina, wk 40,,76 85±146 0.018t 
Medlcatfor! at screenIng, n 
Antfcoagulan!s 1.7 1,4 1.000 
Thrombocyte aggregation Inhibitor 70.6 70.8 1.000 
Aspirin 79.8 81.6 0.896 
Persantin 14.3 9.2 0.400 
Labofatory InvestfgatJons 
Hemoglobin 8.83±0.77 8.95:':0,80 0.235 
Hematocrit 0.42:!:0.04 0.42±0.04 0.398 
Plate',&! count 261:!:63 257±56 0.564 
LesIon Iocatkm, % 0.554 
lAD 37.0 43.5 
lCx 27.7 24.5 
RCA 35.3 32.0 
LesIon characteriStics, % 
Concentric 19.3 15.6 0.645 
Multiple Irregularities 5.7 8.0 0.861 
Branch point In stenosis 30.2 20.8 0.430 
Coronary artery bend 9.4 7.2 0.707 
Calcified lesion 14.3 10.2 0.408 
Degree of ool1ateral supply, % 0.704 
No coIlaterals 52.3 47.1 
Slight (minimal periuslon) 7.0 10.1 
Medium (partial perfUSfor!) 25.6 21.9 
Major (completa perfusion) 12.8 18.8 
Not assMSlld 2.3 4.2 
PTCA procedure 
Nominal size of largest balloon, mm 2.74±0.43 2.75:!:O.43 0.846 
Balloon to artery ratio 1.13±0.18 1.15±0.19 0.293 
Total number of InHations 4.6±3.4 4.6±3.0 0.925 
Total duratfor! of Inflation, s 452±390 365±293 0.043 
Maximum InflatTon pressure, atm 8.92±2.63 8.69±2.44 0.464 
post·PTCA resul1, % 
Dissection altha dilated site 42.0 38.1 0,601 
Thrombus 'Ilsible (before or after PTCA) 15.1 9.5 0.227 
Quantitative angklgraph!c measuremenls 
Reference diameter after PTCA 2.48±O.48 2.44:,:0.50 0.590 
Minimal lumInal diameter after PTCA 1.59:':0.35 1.62±0.34 0.474 
Stenosis after PTCA, % 35,50:':7.99 33.08±8.70 0.019t 
Absolute galn 1.59±0.35 1.62:,:0.34 0.474 
Relative gain 0.64:':0.08 0.67±0.09 0.024 
Lesfon length after PlCA, mm 6.29±2.35 6.44±2.71 0.631 
nme to folloW-Up, d 147+55 167+41 <0.001 
CCS IfJdicates Canadian Cardjo~ascu!ar SoCiety angina c!assif>ealion; lAD, left anterior 
descending; LCx, left c!rcumfiex; RCA, right OOfonaJy artmy; and PleA, percutaneous 
trans!umtnal coronary angloplasty. Values ara mean±SD. 
'>50% diameter stenosts at follow-up angIography. 
tRetalned In multivariate model. 
graphic outcome after successful angioplasty of coronary 
occlusions. 
Our overall restenosis rate of 44.7% with the categor-
ical (>50% diameter stenosis) approach compares with 
the previously reported recurrence rate of 65% from our 
centecJ and is within the 20% to 65% range described 
previously_2,3,5.6.10- 16 Our restenosis rale, however, is sig-
nificantly lower than those of the two largest studies 
published to date/·6 perhaps as a result of our high 
angiographic follow-up rate. With univariate analysis, a 
number of risk factors have been postulated for the 
higher restenosis rate after dilatation of chronic occlu-
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TABLE 6. Regression Analyses to Evaluate the Respective 
Contributions of Clinical, Anglographic, and Procedural Variables on 
the Categorical Restenosis Rate, * Absolute Loss, and Reoccluslon 
During Follow·up 
Standard Error of 
Regression Regression 
Varfab!e Coefficient Coefficient P 
Categorical restefl()sls rate 
Duration of ang;na, d ~O,OOO7 0.0003 .032 
Diseased ~'essels, n 0.649 0.307 .034 
StenosIs efter PlCA. % 0.043 0.023 .049 
Absolute loss 
Total inflation time, $ O.OOOS 0.0001 .0004 
Presence of thrombus 0.379 0.163 .021 
Reoccluslon at fo!low·up ar)Qiography 
Total Inflation lime. s 0.002 0.0006 .002 
Reference diameter after PTCA. nun -1.634 0.630 .009 
PTCA indi<;ates percutaneous transluminaJ coronal)' angioplas!y. logistic regression 
analysTs was used fO( the categorical restenosiS rata and reocclusion at fotlow·up. Multiple 
Hn-ear regresskm analysIs was used for absolute loss. 
">50% diameter stenosis at follow·up. 
sions. These include anatomic factors such as lesion 
location (left anterior descending and circumflex)6.14 and 
absence of functional occlusion,6 procedural factors such 
as multiyessel dilatations6 and increased balloon infla-
tions at higher pressures,iO and residual stenosis after 
intervention.6.12,14.15 A final risk factor is thought to be 
the presence of collateral vessels, which may exert 
competitive pressure even after they are no longer 
visibly functionaP() and thus lead to an increased reste-
!losis rate. 
Univariate analysis in our study confirmed significant 
associations between the categorical definition of reste-
nosis (>50% diameter stenosis at follow-up) and a 
shorter duration of angina, a longer balloon total infla-
tion time, higher residual stenosis after PTCA, and a 
greater relative gain. Multh'ariale analysis, however, 
suggested that the only significant positive relations were 
with the number of diseased vessels and the percent 
stenosis after PTCA, while duration of angina was 
negatively related to the probability of restenosis .at 
follow-up. The positive relation between the number of 
diseased vessels and the percent stenosis after PTCA 
with a categorical definition of restenosis is in keeping 
with previous studies in both occlusions6 and stenoses.31 
The negative relation with duration of angina is also in 
keeping with previous studies suggesting a positive rela-
tion bctween recent onset of symptoms and a higher risk 
of restenosis.32.J.i 
Interestingl)" when 'we looked at the absolute loss as a 
marker of restenosis, an outcome measure that may 
better indicate the underlying pathological process in-
volved, the above variables were no longer significant. 
The only significant relations were found to be with total 
inflation time and the presence of tluombus. Both of 
these were positively related to the subsequent absolute 
loss. The duration of balloon inflation as a positive risk 
factor may represent the sum total of the lesion charac-
teristics and a more dimcult, more complex procedure 
with a consequently higher risk of occlusion, thereby 
markedly influencing the absolute loss. In keeping with 
this is the fact that we also demonstrated lotal inflation 
time to be positively related to the subsequent risk of 
occlusion at follow-up angiography. The positive rcla-
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tion between the presence of thrombus and the subse-
quent absolute loss may also reflect a greater likelihood 
of subsequent occlusion, although we were unable to 
demonstrate this in our study. Previous studies, however, 
showed thrombus to be a risk factor for subsequent 
occlusion,35.}6 perhaps acting as a nidus for further 
platelet deposition. 
The main reason for the significantly higher rale of 
angiographic restenosis in rccanalized occlusions in our 
study was the high rate of occlusion at follow-up angiog-
raphy in this group (19.2% versus 5.0% after dilatation 
of stenoses). A number of reasons may account for this. 
First, this group may represent a subset of the total 
population tbal has an intrinsic hematological propen-
sity to thrombosis. Although our laboratory data did not 
confirm this, there are other hematologic factors such as 
fibrinogen levels that we did not measure that may 
influence reocc1usion covertly.:J.5 
Second, there are substantial morphological differ-
ences between lesions,37 which may have considerable 
influence on the subsequent risk of occlusion. Angiog-
raphy provides little information on this or on the 
pathway of subsequent recanalization, which lllay vary 
from subintimal to periatlieromatolls and transathero-
matous.:J.S What effect these variables may have on the 
subsequent reocclusion and indeed restenosis rates is 
unknO\\11. Differences in these lesion characteristics may 
be reflccted in the total inflation time, which was signif-
icantly higher in lesions more likely to reocclude. 
Third, the coronary vasomotor responses after bal-
loon angioplast)' of chronic total occlusions may be 
abnormal. Distal vasoconstriction occurs frequently 
after angioplasty and correlates well with coronary 
perfusion pressure, suggesting that chronic hypoper-
fusion resets epicardial coronary autoregUlation and 
that restoration of normal perfusion pressure after 
PTCA may provoke reflex vasoconstriction,39 thus 
precipitating early reocclusion, 
Finally, the increased reocclusion rate may relate to 
local flow dynamics. The reference diameters before and 
after PTCA and at follow-up ,vere significantly lower in 
occlusions than in stenoses. Furthermore, within the 
occlusions group multivariate analysis suggested that 
TABLE 7. Univariate Analysis of Patien1, lesion, and Procedural 
Characteristics Relev~nt to Reocclusion During Follow·up in 
266 Occlusions 
No Significance 
Reoceluslon at OC(;luslon at Level, 
Follow·up, Follow-up, Unlvatiate 
n=51 n=215 Analysis 
CCS anginal class, % 0.125 
NM' 9.8 4.7 
r 3.9 11.6 
25.5 34.9 
'" 
39.2 27.9 
N 21.6 20.9 
Duration 01 angina, Vi\'( 27±52 74±132 0.044 
Medicatlon at screening, % 
Anticoagulants 0 1.8 0.733 
Thrombocyte aggregatk>n Inhibitor 64.7 72.1 0.384 
Aspirin 73.5 82.4 0.344 
Persantin 11.8 11.5 1.000 
laboratO!)' Investigations 
HemoglobIn 8.82±0.81 8.91±0.78 0.505 
Hematocrit OA2±0.03 0,42±0.04 0.960 
Platelet COIlnt 256±55 259±60 0.706 
lesIon location, % 0.400 
lAD 37.3 41.4 
lCx 23.5 26.5 
RCA 39.2 32.1 
lesIon characteristics, % 
Concentric 16.3 20.7 0653 
Multiple Irregularities 2.3 8.0 0.325 
Branch poInt in stenosIs 13.3 22.8 0.355 
Coronary artery bend 9.3 8.0 1.000 
Calcified lesion 15.7 11.2 0.514 
Degree 01 collateral supply, % 0.779 
No collaterals 44.7 5O.3 
Slight (mlnlmal perlllSlon) 7.9 90 
Medium (partial perfusion) 31.6 21.6 
Major (complete perfusion) 13.2 15.6 
Not assessed 26 3.6 
PTCA procedure 
Nominal sIze 01 largest baHOOf!, rom 2.67±OA7 2.76±0,42 0.214 
Balloon to artery (alk! 1.15±0.18 1.14±0.18 0.665 
Tolal number ollnfiatlons 4.S±3.1 4.6±3.2 0.777 
Total duration ollnflation. s 537±478 373±294 0.003' 
Maximum lnflation pressure, atm 9.10±2.80 8.72±2,46 0.370 
Post·PTCA result, % 
Dissection at the dilated Site 43.1 39.1 0.708 
Thrombus visible (!>ewe or after PTCA) 19.6 10.2 0.107 
Quantitative anglographTc measurements 
Reference diameter after PTCA 2.36±0,47 2A8±0.49 0.105' 
Minimal lumlnal diameter after PTCA 1.S4±0.36 1.62±0.34 0.123 
Stenosis after PTCA, % 34.52±8.33 34.08±8.51 0.735 
Absolute gain 1.S4±0.36 1.62±0.34 0.123 
Relative galn 0.66±0.08 0.66±0.09 0.693 
lesion length after PlCA, mm 6.17±2.47 6.42±2.58 0.519 
CCS indicates Canadian Cardiovascular Soc!ety; lAD, left anterior descellding; lCx. left 
circumflex; RCA, right coronary artery;alld PTCA, percutaneoos uansl.um1nal coronary artel)'. 
Values are mean±SD. 
'Retained!n multivariate analysTs. 
there is a negative relation between vessel size and 
subsequent risk of rcocclusion. 'nlUS, successfully dilated 
occlusions in larger vcssels were less likcly to rcocclude 
tban those in smaller vessels. T1lis is in keeping with 
experimental work tbat suggested that smaller vessel 
diameters and hence higher shear rates favor local 
platelet activation and deposition,40,41 resulting in a 
grcater Iikclihood of occlusion. 
In add ilion to being responsible for the higher rate of 
angiographic restcnosis, the high reocclusion rate in 
rccanaIizcd occlusions also secms to have been respon· 
sible for the higher rate of clinical events in this group of 
patients, Patients with recanalized occlusions had a 
significantly higher proportion of clinical events, mainly 
in terms of myocardial infarction, CABO, and repcated 
PTCA. Furthermore, these occurred earlier in OCcili' 
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sions than in stenoses. When patients with occlusions 
that went on to occlude at the time of follO\y-up angiog-
raphy were removed from the analysis, the differences 
betwecn the t\yO groups were no longer significant, 
suggesting that the excess risk relates to the highcr rate 
of occlusion at follow-up angiography_ Interestingly, 
despite the higher rate of rem:clusion in rccanalized 
occlusions, there were no significant differences in the 
presentation of restenosis bet\veen the two groups, with 
approximately 40% of patients with angiographie reste-
nosis in both groups being symptom-frec_ 
Although studies of total occlusions suggest that there 
are inlportanl differences in the acute success rates 
bct\veen tolal and functional occlusions/.s our data 
suggest that in terms of restenosis and reocclusion, there 
is little difference between the two groups. Although 
reocclusion after successful dilatation of total occlusions 
was higher than in functional occlusions (23.9% versus 
15.9%), this did not reach statistical significance. HO\v-
ever, there was a tendency for functional occlusions to 
mount less of a fibroproiiferative response, which was 
reflected in the significantly greatcr net gain index and 
lower loss index. The cause for this is unclear but is likely 
to reflect differences in the underlying pathological 
substrate_ 
Clinical ImpUcations 
Up to 20% of patients undergoing diagnostic catheter-
ization have one or mOre total m:clusions; thus, they make 
up 10% to 20% of the tolal angioplasty population.42 
FurthemlOre, in muItivcssel disease, they may make the 
difference in referring the patient for angiopJasty or for 
CABO surgery. Although great attention has been paid to 
increasing the acute success rate with the use of sophisti-
cated new devices such as the low-speed rotational angio-
plastytJ and the Excimer laser;" relatively little attention 
ha~ been paid to long-tenn restenosis and its amclioration. 
Our results suggest that the higher restenosis in these 
lesions is likely to relate in part to the very high rate of 
occlusion at follow-up angiography in this group. Thus, it 
SUggests that if we can identify these lesions and stop 
reocclusion, then the angiographic and clinical courses of 
recanalized total occlusions are likely to be similar to those 
of stenoses. The question of how we do this, however, is a 
vexing one. The clinical course in our patient population 
and previous studies would suggest that reocdusions tend 
to occur early.45 A number of pharmacological and me-
chanical approaches have been tried. Ellis and colleagues17 
demonstrated that drug therapy with aspirin, dipyridamole, 
or warfarin did not influence the overail restenosis rate. In 
a prospective study, Di Sciascio and colleagues46 demon-
strated that restenosis is not modified by a longer balloon 
inflation time. A more recent study assessed the value of 
coronary stenting for dissection with threatened closure 
following recanalization of total occlusionsY The resteno-
sis rate at follow-up was high at 57%, as was the recurrent 
occlusion rate (20%). When stenting "'as used routinely 
after recanalization of chronic total occlusions and hence 
when vigorous anticoagulation was used, the restenosis rate 
was low at 24% in a small patient population (65 patients) 
,vith an 80% angiographic follow-up rale.43 llms, whether 
the reocclusion rate can be ameliorated by additional (eg, 
stenting) or alternative percutaneous revascularization 
techniques (high-speed rotational athereetomy or laser 
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angioplasty) \\ith or ,vithout concomitant phannacological 
therapy remains to be established. 
Study limitations 
A number of limitations of the present study are to be 
acknowledged. First, the study was a retrospective analy-
sis of prospectively gathered data and hence is subject to 
the limitations inherent in any retrospective study. 
Second, there were minor variations in the entry 
criteria of the studies. In CARPORT and PARK, for 
example, patients were randomized before PTCA, 
whereas in MERCATOR and MARCATOR, patients 
were entered into the trial only after a successful angio-
plasty procedure.19.:U Thus, we are unable to comment 
on clinical, angiographic, or procedural factors influenc-
ing the acute success rate of the procedure. Further-
more, patients taking part in large multicenter studies 
like these are selected in certain ways; therefore, care 
needs to be taken in extrapolating our results to the 
broader angiopiasty population. 
Third, for obvious reasons, the reference diameter in 
the occlusions group before PTCA could not be reliably 
measured, so we took the reference diameter after 
dilatation as the rcference diameter before dilatation. 
The statistical analyses remain valid, however, because 
even if we substitute the post-PTCA reference diameter 
for the pre-PTCA reference diameter in the stenoses 
group, the significant differences bet\veen the two groups 
remain. 
Fourth, because of the nature of the data, we unfor-
tunately are unable to comment on whether certain 
previously documented risk factors for restenosis such as 
the degree of collateral supplyll or the measured coro-
nary wedge pressure49,5{1 may relate to reocclusion rather 
than to long-term restenosis. 
Finally, data from the active therapy group and the 
placebo group were amalgamated. Although the drugs 
did not seem to influence the overall restenosis rate, the 
Kelanserin in the PARK study and the thromboxane 
A2-receptor blocker in the CARPORT studies may have 
had a covert influence on the reocclusion rate after 
dilatation of occlusions that we were unable to detect. 
Nonetheless, we believe that the merging of the data is 
justified because the data amalgamated were common to 
all studies and the angiographic criteria were standard-
ized, with one central laboratory perfonning the quan-
titative angiographic analysis in all studies. Furthermore, 
the resulting large study population provides a unique 
opportunity to obtain accurate quantitative angiographic 
data at a predetennined time interval in a field where 
sllch few data currently exist. 
Conclusions 
These results indicate that successfully dilated coro-
nary occlusions, both total and functional, have a higher 
rate of angiographic restenosis at 6 months than steno-
ses. This is due chiefly to a higher rate of occlusion at 
follow-up angiography in this group of lesions. Measures 
aimed at reducing restenosis after successful dilatation 
of coronary occlusions should therefore be focused in 
this direction. 
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Abstract 
Background. Experimental and human intravascular ultrasound studies suggest 
that unfavourable vascular remodelling may contribute to restenosis after coronary 
angioplasty. We evaluated whether favourable remodeling and hence luminal 
enlargement, defined as a negative absolute loss, may also occur following succes-
sful balloon angioplasty and which factors may influence this. 
Methods and Results. Our study population consisted of 3,583 lesions in 2,950 
patients taking part and successfully completing four major restenosis studies. 
Within the study population there were 980 lesions (27.3%) which underwent 
luminal enlargement during follow up and 2,603 lesions (72.7%) which did not. 
As expected the categorical restenosis rate was significantly lower in lesions 
which underwent favourable remodeling (1.53% vs 47.25%, p<O.OOOI) as was the 
rate of clinical events during follow up (8.23% vs 26.91 %, p<O.OOO I). 
Multivariate analysis suggested that diuretic therapy (p=0.024), MLD pre PTCA 
(p=0.0003), diameter stenosis pre PTCA (p=4.E·1S), balloon artery ratio (p=6.E"12) 
and dissection post PTCA (p=0.0084) increased the probability of luminal enlar-
gement whilst age (p=0.036), heparin therapy (p=I.E"07), number of vessels dise-
ased (p=0.037), lesion length (p=O.OOOI), LAD location (p=O.OOI), total inflation 
time (p=0.0 139) and relative gain (p=O.E''') decreased the probability of luminal 
enlargement during follow up. 
Conclusions. Luminal enlargement may occur after successful coronary angio-
plasty and can be substantially influenced by clinical, angiographic and procedural 
variables. 
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Introduction 
The classical paradigm regarding the mechanism of restenosis after successful 
coronary angioplasty has been one of neointimal thickening fi'om the migration, 
proliferation and extracellular matrix production by smooth muscle cells(l-3). 
More recently this paradigm has been challenged by both experimental (4,5) and 
human (6-8) intravascular ultrasound studies which suggest that restenosis relates 
more to unfavourable vascular remodeling than neointimal hyperplasia (9-11). 
The data regarding this however are still controversial with some studies confir-
ming this whilst others refute it (12). We hypothesized that favourable arterial 
remodeling and hence luminal enlargement may also occur, increasing luminal 
dimensions during follow up. The aim of our study was to assess whether such 
luminal enlargement occurs in man and define which, if any, factors may influen-
ce it. 
Methods 
Patients 
Our Shldy population was taken fi'om the 3,582 patients with significant primary 
stenoses in native coronmy arteries who were prospectively euroled into four 
major restenosis trials (13-16) and consisted of the 2,950 patients with coronary 
angioplasty and quantitative angiographic follow up. Patients were eligible for 
Shldy entry if they were symptomatic or asymptomatic men, or women, with sta-
ble or unstable angina pectoris and proved angiographically significant narrowing 
in one or more major coronary m·teries. Informed consent was obtained in all 
cases before the coronary angioplasty procedure. Patients with evolving myocar-
dial infarction and significant left main disease were excluded from the Shldy. 
Angioplasty procedure and follow up angiography 
Coronary angioplasty was performed with a steerable, moveable guide wire sys-
tem by the femoral route. Standard balloon catheters were used. The choice of 
balloon type and brand as well as inflation duration and inflation pressure were 
left to the discretion of the operator. Patients were followed up for 6 months at 
which time a follow up Shldy was performed. If symptoms recurred within 6 
months coronary angiography was carried out earlier. If no definite restenosis 
was present and the follow-up time was below 4 months, the patient was asked to 
undergo further coronmy arteriography at 6 months. 
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Quantitative angiography 
Three coronary angiograms, in total, were obtained for each patient, pre-, post-
PTCA and at angiographic follow up. The angiograms were recorded in such a 
manner that they were suitable for quantitative analysis by the computer assisted 
Coronary Angiography Analysis System (CAAS) which has been described and 
validated earlier (17,18). To standardise the method of data acquisition and to 
ensure exact reproducibility of the angiographic studies, measures were taken as 
previously described and all angiograll1s were processed in a central angiographic 
core laboratory (13-16). Because the computer algorithm is unable to measure 
total occlusions, a value of Onlln was substituted for the minill1allumen diameter 
and a value of 100% for the percent diameter stenosis pre PTCA. In these cases 
the post angioplasty reference diameter was substituted for vessel size. 
Definitions 
Luminal enlargement 
Lurninal enlargement was defined as an increase in minimal luminal diameter 
during angiographic follow up (ie a negative absolute loss). 
Clinical end point 
A clinical end point was defined as the occurrence of death, myocardial infarc-
tion, Coronary artery bypass grafting and repeat PTCA during follow up (13-16). 
Angiographic definitions 
Reference diameter refers to the reference diameter of the relevant coronary seg-
ment and is represented by the interpolated reference diameter pre-PTCA. 
Minimum luminal diameter (MLD) is the point of ll1aximalluminal narrowing in 
the analysed segment. 
Many criteria have been proposed for the assessment of restenosis (20,21). For 
the purposes of this study a categorical approach with the traditional cut-off point 
of >50% diameter stenosis at follow up was used. 
Absolute Gain and Absolute loss represent the improvement in minimal luminal 
diameter achieved at intervention and the absolute change during follow up 
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respectively, measured in mm. Absolute Gain ~ MLD post PTCA - MLD pre 
PTCA. Absolute loss ~ MLD post PTCA - MLD at follow up. 
Relative gain and relative loss depict the improvement in minimal luminal diame-
ter achieved at intervention and the change during follow up respectively, normali-
zed for vessel size. Relative gain ~ [MLD post PTCA - MLD pre PTCA ]Nessel 
size. Relative loss ~ [MLD post PTCA - MLD at follow up]Nessel size. 
The absolute net gain is the MLD at follow up - MLD pre-PTCA. The net gain 
index is the net gain normalised for the vessel size. Net gain index~ [MLD at fol-
low up-MLD pre-PTCA]Nessel size. 
Statistical analysis 
Data was analysed using the SAS statistical software package. A chi square test 
was used to assess the difference in categorical variables. A Student t-test was 
used to assess differences in continuous variables. To test the assumption that the 
variances were equal, the Folded form F statistic was used. Whenever this 
assumption was violated the Cochran and Cox approximation of the t test was 
used. Differences in variables with an ordinal scale (severity of clinical outcome) 
were assessed with the Wilcoxon rank-sum test. The difference in event free sur-
vival time between the two groups was evaluated using the Kaplan-Meier method 
with the log rank and Wilcoxon test. To study the relationship between a binary 
outcome parameter (the occurrence of a clinical event) and multiple categorical 
and continuous determinants multiple logistic regression analysis was used. To 
study the relationship between continuous outcome parameters and multiple cate-
gorical and continuous determinants multiple linear regression analysis was used. 
P values <0.05 were considered significant. 
Results 
Baseline patient characteristics, procedural results and clini-
cal follow up 
The study population comprised 2,950 patients who underwent successful corona-
ry angioplasty and quantitative angiographic follow up. 980 lesions (27%) in 668 
patients out of 3583 lesions in 2,950 patients underwent luminal enlargement 
uring angiographic follow up (Figure I). 
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Figure 1. Cumulative distribution curve of absolute loss (change in MLD from 
before percutaneous angioplasty to follow up) for all lesions in study. Note that 
28% have luminal enlargement (a negative absolute loss). 
The clinical and angiographic characteristics of the 980 lesions which underwent 
luminal enlargement compared with the 2,603 which did not are sUlmnarised in 
Tables I and 2. The two groups were broadly comparable in terms of baseline 
demographic characteristics although patients who underwent luminal enlarge-
ment were less likely to have grade 3-4 angina. They were also less likely to be 
on heparin and a thrombocyte aggregation inhibitor and more likely to be on oral 
diuretics (Table I). The lesion characteristics were also broadly similar although 
lesions which underwent luminal enlargement were less likely to have a branch 
point in the middle of the stenosis (Table 2). 
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Remodeling Yes No Significance 
Level 
Patient No 668 2282 
Lesion No 980 2,603 
Men 
82% 81% 0.672 
Age (years). 57±9.4 57.4±9.3 0.247 
Ever smoked 75% 75% 0.913 
Current smoker 20% 18% 0.173 
Hypertension 30% 31% 0.679 
Diabetes 8,6% 10.7% 0.101 
Hypcrlipidaemia 32% 32% 0.906 
History of previous PTCA 5,1% 4,9% 0.806 
History of previolls MI 42% 43% 0.493 
Previous CABG 3.8% 4.4 0.472 
Pain at rest 40% 42% 0.461 
Vessels diseased 0.058 
IVD 68% 63% 
2VD 24% 29% 
3VD 7% 8% 
Anginal class 0.047 
None 5.3% 5,8% 
CCS Class I 11.5% 10.9% 
CCS Class II 35.8% 31.5% 
CCS Class III 30.6% 30.0% 
CCS Class IV 16.8% 21.8% 
DUI'atioJl of angina (weel{s) 114±189 110±205 0.627 
IHedication at screening 
Anticoagulants 1.8% 1.5% 0.516 
Thrombocyte aggregation inhibitor 59.7% 65.8% 0.004 
Aspirin 79.1% 82.6% 0.125 
Persantin 12.5% 11.9% 0.763 
Heparin 36.5% 48.3% <0.0001 
Beta blocker 47.9% 51.2% 0.136 
Calcium antagonist 67.4% 70.0% 0.189 
Nitrates 65.1% 65.8% 0.866 
Diuretic 9.28% 6.53% 0.015 
Cholesterol lowering agent 9,9% 9,8% 0.934 
Laboratory Investigations 
Haemoglobin 8.87±0.82 8.86±0.83 0.8779 
Haematocrit 0.42±0.04 0.42±0.04 0.8729 
White cell count 7.36±2.08 7.46±2.47 0.2971 
Platelet count 255±69 257±71 0.4866 
Total cholesterol (mlllol/l) 5.91±1.23 5.81±1.23 0.0641 
HDL cholesterol (mmol/I) 1.I2±0.51 1.15±0.55 0.5561 
LDL cholesterol (mmol/l) 4.32±1.l8 4.06±1.31 0.0753 
Table I. Demographic data of patients with and without luminal enlargement 
included in analysis. CABO indicates coronary artery bypass grafts, PTCA, per-
cutaneous transluminal coronary angioplasty and CCS, Canadian Cardiovascular 
Society angina classification. 
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Remodeling Yes No Significance 
No. 980 2,603 Level 
Lesion location 0.120 
LAD 39.6% 43.9% 
LCx 25.5% 24.5% 
RCA 34.8% 31.5% 
Type of lesion 
Concentric 44.4% 44.8% 0.884 
Multiple Irregularities 8.4% 7.7% 0.599 
Tandem lesion 3.6% 4.3% 0.400 
Branch point in stenosis 26.9% 35.0% 0.005 
Branch point in dilatation site 61.4% 65.2% 0.209 
Coronary artery bend 21.7% 19.6% 0.222 
Lesion calcification 12.2% 12.4% 0.940 
Thrombus (pre/post PTCA) 4.2% 4.6% 0.681 
Total occlusion pre PTCA 8.5% 7.0% 0.164 
Lesiolliength pre 6.l36±2.165 6.337±2.331 0.020 
Degree of collateral supply 0.224 
No collaterals 85.7% 84.1% 
Slight (minimal perfusion) 4.0% 4.2% 
Medium (partial perfusion) 4.4% 5.0% 
Major (complete perfusion) 3.9% 3.1% 
Not assessed 2.1% 3.7% 
PTCA procedure 
Nominal size of largest banoon (mm) 2.SS±0.45 2.85±0.43 0.1915 
Balloon to artery ratio 1. 13±0. 19 1.13±0.19 0.4183 
Total number of inflations 3.3±2.2 3.7±2.4 0.0002 
Total duration of inflation (sees) 275±262 325±271 <0.0001 
Maximum Inflation pressure (atm) 8.32±2.63 8.53±2.45 0.0258 
Post PTCA result 
Dissection at the dilated site 35.3% 33.5% 0.339 
Table 2 (continued) 
Dissection Type 0.055 
Type A 13.7% 15.3% 
TypeB IS.2% 13.5% 
TypcC 3.9% 3.5% 
TypeD 0.0% 0.1% 
TypeE 0.1% 0.1% 
TypeF 0.0% 0.1% 
Table 2. Angiographic baseline data of patients. SVD, Single vessel disease, 2-
VD Two vessel disease, 3-VD, tln'ee vessel disease. LAD, left anterior descen-
ding, LCx, left circumflex artery, RCA, right coronary artery. PTCA, percutane-
ous transluminal coronary angioplasty. CCS, Canadian Cardiovascular Society 
angina classification. Mean values ± SD. 
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As our data set was composed of four negative restenosis trials we also assessed 
whether active drug therapy had any effect on luminal enlargement in each indivi-
dual data set. There was no difference in the Carport Mercator or Marcator Shl-
dies (31.89 vs 28.16, 31.23 vs 26.58, 22.65 vs 26.95, respectively, active therapy 
vS placebo, p=ns) but a tendency in the Park Shldy for less patients on the active 
drug therapy (Ketanserin) having luminal enlargement during follow up (26.35% 
vs 36.09%, p=0.08). 
Fifty five (8.2%) of the patients with lesions which underwent luminal enlarge-
ment compared to 614 (26.6%) of the patients without luminal enlargement had a 
clinical end points (Redo PTCA, CABG, acute myocardial infarction or death) 
during follow up (p<O.OOO I). The individual components of death, myocardial 
infarction, Coronary artery bypass grafting and re-PTCA were 0.15% vs 0.22%, 
2.40% vs 3.02%, 1.05% vs 2.98% and 4.64% vs 20.68% respectively for lesions 
which underwent luminal enlargement vs lesions which did not. The differences 
in the individual clinical end points between the two groups were also statistically 
significant (p<O.OOOI). The time course of clinical end points are summarised in 
2, which also demonstrate that the two curves only begin to diverge after the first 
40 days of follow up. The mean time to clinical end point was significantly lon-
ger in the luminal enlargement group (l72±38 vs 159±46 days, p=O.OOOI). 
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Figure 2. Cumulative distribution curve of clinical end points over time for 
patients with and without luminal enlargement during angiographic follow up. 
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Quantitative angiographic analysis and angioplasty procedure 
A mean of 2.12 matched angiographic projections per lesion had satisfactory 
quantitative analysis performed, pre-, post- PTCA, and at follow up. Lesions 
which subsequently underwent luminal enlargement had a shorter length and nee-
ded fewer inflations for a shorter duration at a lower pressure (Table 2). Both the 
absolute and relative gain were significantly lower in lesions which underwent 
remodeling. Post-PTCA the MLO was significantly lower and the % residual ste-
nosis significantly higher in the group which underwent luminal enlargement. 
Remodeling Yes No Significance 
No. 980 2,603 Level 
Reference Diameter (mm) 
Before angioplasty 2.62±0.56 2.60±0.53 0.2626 
After angioplasty 2.62±0.53 2.67±0.51 0.0243 
At follow up 2.80±0.56 2.63±0.56 <0.0001 
Minimal luminal diameter (mm) 
Before angioplasty 1.02±OA3 0.99±0.38 0.1602 
After angioplasty 1.68±0.35 1.78±0.36 <0.0001 
At follow up 1.92±OAO 1.25±0.53 0.0001 
Differences in MLD 
Absolute Gain (mm) 0.67±OA1 0.79±OAI <0.0001 
Relative Gain 0.26±0.16 0.31±0.16 <0.0001 
Absolute Loss (tmn) -0.24±0.20 0.53±OA5 0.0001 
Relative Loss -0.10±0.08 0.21±0.19 0.0001 
Absolute Net Gain (nnn) 0.91±OA4 0.26±0.53 0.0001 
Net Gain Index 0.36±0.18 0.1O±0.21 0.0001 
Loss Index -0.61±2.22 0.93±4.09 0.0001 
Percentage stenosis 
Before angioplasty 60.71±15.23 61.05±14.30 0.5573 
After angioplasty 35.39±8.09 32.73±8.32 <0.0001 
At follow up 30.76±8.75 51.71±19.04 0.0001 
OS at follow up >50% 1.53% 47.25% <0.0001 
Table 3. Quantitative angiographic analysis 0[980 lesions which underwent lumi-
nal enlargement compared with 2,603 which did not. MLO, Minimal luminal dia-
meter. OS, diameter stenosis. 
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Figure 3. Upper panel: Cumulative distribution curve ofMLD pre, post PTCA 
and at follow up for patients with and without luminal enlargement during folh;l\v 
up. Lower panel: Cumulative distribution curve of percentage stenosis pre, post' " 
PTCA and at follow up for patients with and without luminal enlargement during 
follow up. 
At follow up the reference diameter was significantly higher in the luminal enlar-
gement group suggesting that the whole vessel size had been reset (Table 3). As 
would be expected the categorical restenosis rate was significantly lower at 1.53% 
in lesions with luminal enlargement compared to 47.25 in lesions without. 
Multiple linear regression analysis 
Univariate analysis suggested that anginal class as well as drug therapy and pro-
cedural characteristics such as balloon pressure, number and duration of inflation 
may influence subsequent luminal enlargement (Table I and 2) so logistic regres-
sion analysis was performed for the above as well as all other clinical, angiograp-
hie and procedural parameters listed in tables 1-3. Of these variables diuretic the-
rapy (regression co-efficient 0.41), MLD and diameter stenosis pre PTCA (1.11, 
0.08 respectively), balloon artery ratio (2.70) and dissection post PTCA (0.27) 
199 
Variable Regression Standard Error of p value Odds ratio 
Co-efficient Regression co-efficient 
Remodeling at follow up angiography 
Intercept -0.704 1.182 3.E.w 0.001 
Diuretic therapy 0.407 0.180 0.0240 1.502 
MID pre PTCA 1.109 0.303 0.0003 3.032 
Diameter stenosis pre PTCA 0.084 0.010 4.E"IS 1.088 
Balloon artery ratio 2.700 0.392 6.E'11 14.88 
Dissection post PTCA 0.265 0.101 0.0084 1.303 
Age -0.011 0.005 0.036 0.989 
Heparin therapy -0.549 0.103 1.E-07 0.578 
No of vessels diseased -0.168 0.081 0.037 0.845 
Lesion length -0.078 0.024 0.0001 0.925 
LAD location -0.336 0.102 0.001 0.715 
Total inflation time -0.001 0.000 0.0139 0.999 
Relative gain -6.001 0.590 O.E+{o) 0.002 
Table 4. Regression analyses to evaluate the respective contributions of clinical, 
angiographic and procedural variables to remodeling at follow up angiography in 
these lesions. Logistic regression analysis was used for this_ Incl, Including. 
Excl, Excluding. Fup, follow up. PTCA, Percutaneous Transluminal Coronary 
Angioplasty. MLD. Minimal Luminal Diameter. 
increased the probability of luminal enlargement whilst age (regression co-effi-
cient -0.01), heparin therapy (-0.55), number of vessels diseased (-0.17), lesion 
length (-0.08), LAD location (-0.34), total inflation time (-0.001) and relative gain 
(-6.00) decreased the probability ofluminal enlargement (Table 4). 
Discussion: 
Our results indicate that luminal enlargement may occur after successful coronary 
angioplasty, resulting in improved clinical outcome, and that a number of factors 
can substantially influence tillS. Future prospective studies are required to investi-
gate this phenomenon further. 
The reasons for the luminal enlargement in the angiographic follow up period are 
unclear. It may however reflect improvements in local flow dynamics and reset-
ting of the vessel wall during follow up_ The increase in blood flow velocity fol-
lowing successful dilatation of a stenosis results in an increase in wall shear stress 
which may stimulate endothelial dependent vasodilatation and resetting of the ves-
sel wall (22-25). The higher residual stenosis and lower MLD post intervention in 
the luminal enlargement group however auger against tillS. It may still be a plau-
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sible explanation however if there were covert differences in endothelial vasodila-
tor function between the two groups (24). An alternative explanation is that the 
process reflects differences in wall and plaque composition and hence susceptibili-
ty to regression or favourable "Glagovian" arterial remodeling. In support of this 
are the differences in lesion length and procedural characteristics between the two 
groups, with fewer inflations at a lower pressure for a shorter time in the group 
which underwent luminal enlargement, perhaps reflecting a softer lesion, more 
likely to undergo regression and remodeling during follow up. 
Multivariate analysis was suggestive of a number of clinical procedural and angio-
graphic variables related to luminal enlargement. Those which increased the pro-
bability of luminal enlargement included diuretic therapy, mid and % stenosis pre 
PTCA, balloon artery ratio and dissection post PTCA, whilst those which decre-
ased the probability ofluminal enlargement included age, heparin therapy, no of 
vessels diseased, LAD location, lesion length, total inflation time and relative 
gain. 
Both sets of variables revolve around lesion characteristics. The increased likeli-
hood of luminal enlargement with balloon artery ratio and dissection may reflect 
enough damage to the vessel wall to allow freeing of the atherosclerotic plaque. 
The characteristics which decrease the probability of luminal enlargement again 
revolve around lesion characteristics and may reflect less likelihood of luminal 
enlargement in more advanced, more calcified, atherosclerotic disease. This is 
reflected in increased age, increased involvement of other vessels, increased lesion 
length and the requirement for increased total inflation time. 
The relationship with drug therapy was also interesting and warrants further inves-
tigation. The positive relationship with diuretic therapy may reflect the influence 
of a third factor, such as hypertension, on vascular remodeling. Additionally both 
hypomagnasaemia and spironolactone can inhibit growth of vascular cells and 
decrease collagen synthesis, both of which may weaken the reparative processes in 
the vessel wall and allow luminal enlargement. The negative relationship with 
heparin therapy may provide one possible explanation as to why heparin which 
has been shown to suppress smooth muscle proliferation in vitro (26) and reduce 
neointimal hyperplasia in animal models of vascular ittiury (27,28) has failed to 
influence restenosis in the clinical situation (29). Ifrestenosis is a result of both 
neointimal hyperplasia and vascular remodeling the negative effect of heparin on 
luminal enlargement may obviate any differential effect on neointimal hyperplasia. 
It is not clear why heparin should exert a negative influence on luminal enlarge-
ment. One possible explanation may be through strengthening of the vessel wall. 
Heparin is known to stimulate endothelial cell migration and angiogenesis which 
may result in faster healing, increased strengthening of the vessel wall and hence 
minimisation of any luminal enlargement. In addition heparin is also known to 
activate Transforming growth factor beta, an enhancer of matrix secretion and 
matrix contraction, which again may minimise any luminal enlargement. 
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Clinical implications: Our finding that luminal enlargement may occur after 
coronary angioplasty has important clinical implications for coronary interven-
tion. If we can differentiate lesions which undergo favourable luminal enlarge-
ment we may be able to target newer percutaneous revascularisation techniques 
such as coronary stenting more effectively. Furthermore, by identifying clinical 
and procedural factors favourably influencing luminal enlargement and applying 
them to the other group we may be able to reduce restenosis. Additionally our 
data also suggest that luminal enlargement can be influenced by dmg therapy in 
both a positive and a negative manner. This may open a second therapeutic win-
dow in tackling the problem of restenosis after coronary angioplasty and may also 
explain why agents such as heparin, which has been shown to suppress smooth 
muscle proliferation neointimal hyperplasia in animal models of vascular injury 
have failed to influence restenosis in the clinical situation. Future prospective stu-
dies, ideally utilising intracoronary ultrasound imaging to directly visualise the 
atherosclerotic plaque, are required to investigate this phenomenon further. 
Limitations of the study: Our study could have been confounded by a number of 
methodological problems including measurement variability. We feel tltis is unli-
kely however for 2 reasons. Firstly previous work from our group (30) has shown 
that the re-measurement of the same lesion renders a difference between the meas-
urements of 0.007nnn with a standard deviation of 0.2nnn. So we assume that 
0.2mm is the standard deviation of the measurement error. In a worst case scena-
rio where we assume all lesions to have a loss of Onnn we would expect 95% of 
the observations to be within 1.96 times the standard deviation, so even in this 
hypothetical situation, we would expect only 2.5% of the lesions to have a negati-
ve loss of 0.4 nnn or more. In our database, we find, in fact 6.0% of lesions 41 
this category. Testing for the difference between these proportions, we find a p-
value of <0.00001. More importantly however as the mean loss in fact is much 
grater than zero at 0.30mm, measurement variability is extremely unlikely to be 
responsible for the negative loss which we see. Thus our results are unlikely to be 
due to measurement variability but are more likely to reflect real luminal increases 
over time. Our results may also relate to local dissection and inappropriate con-
tour detection by the CAAS system. Again, this is unlikely as there was no signi-
ficant difference in the overall incidence or type of dissection between the two 
groups. Another possible explanation is variability in vasomotor tone at the diffe-
rent time points. We controlled for this however with intracoronary nitrates admi-
nistered innnediately before each angiogram, again making this an unlikely expla-
nation. Furthermore, as can be seen from Figure 2 the two curves do not begin to 
diverge until after 40 days, again suggesting that the cause of this is unlikely to be 
coronary spasm at the time of the procedure. We thus believe that we are seeing a 
true phenomenon, wltich is reflected in the low rate of clinical events in the lumi-
nal enlargement group. The fact that the process also affects the reference vessel 
segment, wltich has, in the past been shown to undergo the same restenosis pro-
cess as the lesion itself (31) adds addi tional strength to tltis argument. 
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Our study was also a retrospective analysis of prospectively gathered data and is 
hence subject to the limitations inherent in any retrospective analysis. 
Additionally, contrast angiography can only provide an image of the vessel lumen 
and not the vessel wall. It is thus unclear whether the mechanism for luminal 
enlargement is plaque regression or vessel expansion over time or any combina-
tion of these factors. 
Conclusion: Our results indicate that luminal enlargement may occur after suc-
cessful coronary angioplasty, resulting in improved clinical outcome. They also 
suggest that lesion related characteristics, reflected by procedural variables, and 
dl11g therapy may substantially influence this process. 
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Chapter 16 
Randomised trials, registries or experience-based common 
sense? 
Violaris AG, Serruys PW. 
Ellis SG, Hohnes DR (Editors) Strategies for coronary intervention: a practical 
approach. 1995 (Williams and Wilkins Publishers), pp190-204 
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Percutaneous transluminal coronary angio-
plasty (PI'CA), introduced by Gliintzig in 
the late 19708, has been a major break-
through in the treatment of obstmctivc coro-
nary artery disease. Increasing operator expe-
rience and improvements in balloon catheter 
technology have resulted in a high immediate 
success rate and a low incidence of complica-
tions, which in tum has resulted in an 
increasing number of patients with morc 
advanced coronary miery disease now being 
considered candidates for balloon angio-
plasly. Substantial limitations still remain, 
however, which include technical factors 
relating to the coronary anatomy that limit the 
intervention to particular subgroups of 
patients with coronary artery disease, acute 
occlusion resulting in increased morbidity 
and mortality, and longer-term restenosis in 
30 to 40% of patients. Because of these limi-
tations inherent in balloon angioplasty, phar-
macologic agents to reduce restenosis and a 
plethora of new devices designed to improve 
the sh0l1- and long-term results of catheter-
based revascularization have been intro-
duced. 
Considerable difficulties exist, however, in 
assessing long-term. restenosis and making 
valid compmisons between the different 
treatment modalities available. We therefore 
need a means of rapidly and effectively as-
sessing not only the acute efficacy and safety 
of new devices but also of comparing their 
long-term results with those of balloon angio-
plasty. Randomized trials, registries, and 
personal expelience all go some way toward 
answeling these questions. In this mono-
graph we review the use of these three meth-
ods and propose a compromise approach, 
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based on matching patient and lesion charac-
teristics, that may result in the more rapid 
and efficient assessment of new devices and 
phannacologic agents. 
RANDOMIZED STUDIES 
The best way to compare the short- and long-
term clinical and angiographic results of dif-
ferent coronary interventions or pharmaco-
logic agents is with a randomized study. The 
proper design of a randomized study to com-
pare different interventional techniques re-
quires the selection of the appropriate angio-
graphic vatiables reflecting the restenosis 
process. In a recent study we examined which 
angiographic parameter best described func-
tional status 6 months after successful single-
vessel coronary angioplasty (1). Sensitivity 
and specificity curves for the prediction of 
anginal status and exercise electrocardiogra-
phy of four quantitative angiographic vari-
ables were constructed, and the point of high-
est diagnostic accuracy for the variables was 
determined at the intersection of the sensi-
tivity and specificity curves. The points of 
highest diagnostic accuracy using minimal 
luminal diameter were similar for both angi-
nal status and exercise electrocardiography at 
1.45 and 1.46 mm, respectively. This sug-
gests that the minimal luminal diameter at 
follow-up may be useful for predicting clini-
cal events such as recurrence of angina. In 
addition, the use of a central angiographic 
core lab, using a well-validated system of 
quantitative coronary angiography, with the 
expertise required to ensure the accuracy of 
all collated data and to minimize the possibil-
ity of introducing methodologic errors and 
bias is required. Also required are a sufficient 
number of patients undergoing repeat angiog-
raphy at a predetermined time. This number 
depends on the variability in outcome among 
the patients, the magnitude of the difference 
in outcome, and the alpha and beta errors. 
Changing the power of the study in one way or 
another will affect the number of patients 
needed. Accepting a larger chance of missing 
an effective treatment (large beta eITor and 
thus a reduction in power) means substan-
tially less patients are needed. 
A randomized study has several theoreti-
cal advantages. It guarantees population 
homogeneity in terms of clinical and angio-
graphic variables and thus allows the direct 
comparison of different therapeutic treatment 
modalities with no bias regarding selection of 
treatment. Furthermore a well-designed ran-
domized study may ensure that if a device is 
used, the device has a fair trial by requiring 
adequate expertise of all participating inves-
tigators. For example, with most devices there 
is often a steep learning curve, and therefore 
to ensure the fair evaluation of a device a min-
imum requirement would be that participat-
ing personnel have perfol111ed a set number of 
procedures using the device, with acceptable 
success and complication rates. 
Problems Related to All Studies 
Despite the above advantages randomized 
studies also have some inherent, logistic limi-
tations. These include patient exclusions 
by viIiue of the inclusion/exclusion criteria 
and inconsistencies in the timing of random-
ization, follow-up duration, and definitions of 
clinical and angiographic plimary endpoints. 
"\,\Te would like to expand on these using as an 
example four, recently completed, multicen-
ter, restenosis trials: MERCATOR (ran-
domized, double-blind, placebo-controlled, 
restenosis prevention hial of cilazapril 5 
mg) (2), MARCATOR (randomized, double-
blind, placebo-controlled, restenosis preven-
tion trial of cilazaprill, 5, or 10 mg) (3), CAR-
PORT (randomized, double-blind, placebo-
controlled, restenosis prevention trial of a 
thromboxane A2 receptor antagonist) (4), and 
PARK (randomized, double-blind, placebo-
controlled trial ofketanserin40 mg) (5). 
Patient Selectioll Bias-IllcltlsiolllE>,'clllsioll 
C,'itel'ia 
The inclusion/exclusion Cliteria for a study 
may have a substantial influence on both the 
power of a study and the applicability of the 
results to the general angioplasty population. 
The main inclusion/exclusion Cliteria in most 
studies relate to the coronary anatomy (sin-
gle-vessel versus multivessel disease)/lesion 
morphology, the pattern of angina (stable ver-
sus unstable), a previous histOlY of myocar-
dial infarction, and concomitant dmg therapy 
or device use. 
SINGLE-VESSEL VERSUS MULTIVESSEL DISEASE 
Large centers likely to pa11icipate in ran-
domized studies often repmi that a large pro-
portion of their patients have multi vessel 
disease requiring multilesion angioplasty. If 
you therefore confine your study to single-
vessel disease, you will limit the number of 
eligible patients. If you decide to include 
multi vessel angioplasty, however, the prob-
lem then alises of how to handle restenosis. 
Do you peliorm a lesion- or a patient-related 
analysis. If you choose a patient-related anal-
ysis, how do you handle three dilated lesions 
in the same patient? It is much easier in 
statistics to work with single numbers than 
a collection of numbers. Because restenosis 
is likely to be a lesion-related rather than a 
patient-related problem (even the so-called 
patient-related factors such as unstable an-
gina or recent angina actually I"eRect lesion 
instability) (6), we tend to reconcile lesion 
with patient analysis by using the average 
MLD (minimal luminal diameter) of multiple 
lesions obtained from multiple views so 
that statistically you deal with one MLD 
per patient. It is interesting, however, that 
despite the onus in the planning stage to 
include llluitivessel dilation, over 80% of 
patients randomized in the large multicentre 
trials have single-vessel disease ·with 16% 
two-vessel disease and 4% three-vessel dis-
ease. 
STABLE VERSUS UNSTABLEANGINA PECTORIS 
One reason for including unstable patients 
is that in multivariate analysis the greatest 
loss in MLD occurs in the unstable patients. 
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For example, in the CARPORT study the 
change in MLD at follow-up was -0.37 ± 
0.59 mm in patients with duration of angina 
<2.3 months (n = 210), while it was only 
-0.26 ± 0.53 mm in patients with duration 
of angina >8.5 months (n = 229). A similar 
pattem was seen in the MERCATOR study 
where the change in MLD at follow-up was 
-0.33 ± 0.55 mlll in patients with duration 
of angina <86 days (n = 252), while it was 
only -0.19 ± 0.48 mm in patients with du-
ration of angina >305 days (n = 256). Tile 
importance of this is in the power calcula-
tion. If unstable patients are excluded, then 
the calculation of the power of the trial be-
comes extremely difficult and large numbers 
of patients are required. In the ongoing 
FLARE study looking at fluvastatin for 
1'esten08is, the dmg has to be st81ied 3 weeks 
prior to PTCA which mealls unstable pa-
tients are excluded from the study, increas-
ing the number of patients required. 
If you do decide to include patients with 
unstable angina, the problem then arises that 
there is no accepted definition of this telID. A 
practical definition, used in the CARPORT 
study, was pain at rest controlled by intra-
Table 12C.1. 
venous nitrates. Even within this group, how-
ever, there is a marked heterogeneity of 
patients, and a better definition and subdivi-
sion of unstable angina is needed. In the 
ongoing HELVETICA study (randomized, 
double-blind, placebo-controlled, restenosis 
prevention trial of recombinant hiIudin) 
patients are entered using the Braullwald 
classification, which will hopefully provide 
better information on the long-tenll restenosis 
rate in the various subgroups of unstable 
angina. 
PREVIOUS MYOCARDIAL INFARC710N 
Most studies have systematically excluded 
patients with recent myocardial infarction 
from trial entry. In the MERCATOR study, for 
example, patients with a myocardial infarct 
within 3 weeks were excluded (Table 12C.1). 
In the MARCATOR study an amendment was 
passed 3 months into the hial allowing 
patients within 5 days of myocardial iIuarc-
tion to be entered into the study. This high rate 
of recent myocardial infarction lllay be 
responsible for the increased loss in MLD in 
the MARCATOR compared with the MER-
CATOR study (0.37 versus 0.28 mm). 
Screening Results of 17 Log-Keeping Clinics Participating In the MERCATOR Multicenter Randomized 
Study of Cllazaprll-
Reason for ExclusIon 
History of susla!ned essential hypertension 
Previous and/or failed PTCAatihe same sile 
Q-wave MI less than 4 weeks prior to study entry 
Follow-up coronary angIography unlikely 
logIstic reasons 
Significant concomitant disease 
Older than 75 years 
Dilatation of bypass graft 
Primary perfusion therapy 
No Informed consent given 
Current evidence 01 prior hIstory of heart faiture 
Participation In other trial 
Atherectomy/stent 
Other reasonsc (tess than 1% each) 
'From MERCATOR study group. Circulation 1992; 86-100-101 Wllh permIssion. 
'ScreenIng results of 17 dinlcs wh1ct1 recruited 65% of the patients. 
NUml>erb 
271 
268 
174 
109 
67 
50 
43 
40 
39 
39 
28 
14 
13 
122 
% 
21.2 
21.0 
13.6 
8.5 
5.2 
3.9 
3.4 
3.1 
3.1 
3.1 
2.2 
1.1 
1.0 
9.6 
'teft malo disease. hIstory of type 11 hypercholesterolemIa. previous e>erebr()-vascular accident, previous participation 10 MERCATOR, hypotensIon. con· 
tralodlcation to ACE Inhiblti<>Nasplrln. women of chHdbearlng potential. Insulin-dependent diabetes, miscellaneous. 
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EXCLUSION CRITERIA BASED ONTRIAL 
MEDICATION 
The trial medication may also play a sig-
nificant role in selection bias by exclud-
ing patients with contraindications to the 
medication or those on concomitant therapy 
that may interact with the trial medica-
tion. For example, in the MERCATOR and 
MARCATOR studies hypmtension was a 
major exclusion Cliterion because of the 
associated hypotensive effect of cilazaprll 
(Table 12C.1). In the MERCATOR study 
15% of all patients screened were excluded 
because of sustained essential hYPcl1ension. 
In the CARPORT and PARK studies the use 
of platelet-inhibiting or nonsteroidal antiin-
flammatory mugs within 7 days preceding 
the study was responsible for the exclusion 
of 28% of patients. The use of oral anticoag-
ulants at the time of the procedure excluded 
a fmiher 9% of patients. 
EXCLUSION CRITERIA BASED ONTECHNOLOGY 
Most randomized pharmacologic studies on 
restenosis have specifically excluded the use 
of new devices. This means that when the 
results are published, a possible cliticislll 
will be that they do not reflect and therefore do 
not apply to the real world. Statistically, as 
long as the use of new devices occurs in less 
than 10% of randomized patients, dealing 
with them·is not a problem. Once they reach 
50%, however, stratification of patients 
according to treatment modality would be 
required. Future trials are thus likely to 
include all new technologies, apalt from 
stents. It is of interest, however, that in the 
ongoing HELVETICA study, where the use of 
new technology is allowed, these only occur in 
4% of the patients entered, so there is no need 
for posthoc stratification. 
Stringent enhy critelia designed to mini-
mize the randomization of high-risk patients 
Illean that only a minority of eligible patients 
may be reclUited for a particular study. In the 
MERCATOR study, for example, 1755 pa-
tients were screened but only 478 (27.2%) 
were actually reclUited into the study. The 
reasons for exclusion included a history of 
sustained essential hypeltension (271 pa-
tients, 15.4%) and previous and/or failed 
PTCA at the same site (268 patients, 15.3%), 
as well as a variety of other less frequent fac-
tors (Table 12C.1). In the PARK study even 
fewer screened patients were enrolled into 
the study (704/5636, 12.5%). 
The exclusion of high-lisk patients may 
have a significant influence, however, on the 
power of a ttiaI. HistOlically, the loss in MLD 
during follow-up has been around 0.4 mm 
(7). For the trial power calculations, for a 
30% reduction in the treatment group the 
expected loss would be 0.25 mm. For all the 
recent trials, however, the MLD loss has 
been much lower (CARPORT 0.31 mm, 
MERCATOR 0.30 mm, PARK 0.26 mm), re-
suiting in a reduction in the power of the hi-
als and making it more difficult to demon-
strate significant benefit. This is because 
they have taken the minimalist approach to-
ward patient reclUitment-only enrolling 
patients with single-vessel disease and sta-
ble angina pectoris and specifically exclud-
ing high-risk patients such as those with re-
cent myocardial infarction and unstable 
angina. 
Inclusion of such patients should increase 
the loss in MLD during follow-up and hence 
increase the power of a hial. Thus future tri-
als are likely to take a "maximalist" approach 
by including patients with muItivessel dis-
ease, unstable angina, recent myocardial 
infarction, and previous PTCA and resteno-
sis. In the ongoing HELVETICA trial, for 
example, only difficult unstable patients are 
included, which will hopefully increase the 
power of the study. 
In addition, oftelllittle indication is given 
of the prop0l1ion of eligible patients entered 
into the study and the likely outcome of 
patients excluded from the study. Therefore 
tlie i'esults of a study may not apply to the 
large propOltion of patients seen in clinical 
practice. 
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Timing of Randomizatio1l 
The optimal timing of randomization is also 
unclear. Do you randomize the patients before 
the procedure as in the PARK, HELVETICA, 
and CARPORT studies, or do you only ran-
domize them once the procedure has been 
successfully performed as in the MERCA-
TOR and MARCATOR studies? In the PARK 
and CARPORT studies, since the mechanism 
of drug action implied that it would prevent 
both acute occlusion caused by platelet 
aggregation-induced thrombus formation 
and late restenosis caused by platelet aggre-
gation-induced hyperplasia, trial medication 
was started before the procedure, that is, 
before wall injury occurred. This had major 
consequences for the definition of the clinical 
endpoint. On the one hand, all failure 
between first balloon inflation and the end of 
the procedure could have been influenced by 
the tlial medication and were therefOl'e 
counted as clinical endpoints. On the other 
hand, as the aim of this trial was to study the 
effect ofketanserin on the inhibition of neoin-
timal hyperplasia following balloon wall 
injury, it seemed reasonable to exclude from 
the analysis of the main clinical endpoints 
those patients in whom no balloon inflation 
had occulTed. 
In the MERCATOR and MARCATOR 
studies, concem was voiced over the possible 
hypotensive effect of the medication if it was 
given plioI' to the procedure. The debate cen-
tei'ed around whether the medication should 
be given prior to the procedure and any peri-
operative hypotension treated with volume 
expansion or whether it would be safer to 
administer the study medication after the pro-
cedure. Since preliminary animal experi-
ments had shown no major difference in inhi-
bition of neointimal proliferation whether the 
dlUg was given 1 hour before or within 2 days 
after wall injUl)', we were able to screen 
patients before the procedure but only enroll 
those who had undergone a successful coro-
nal)' angioplasty into the study. This approach 
eliminated problems relating to the influence 
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of the dlUg on the success of the procedure but 
may also have introduced selection bias. For 
example, if the investigator noted the pres-
ence of thrombus postangioplasty, this may 
have influenced the likelihood of a patient 
being subsequently entered into the study. 
This may explain why in a multivariate analy-
sis of the CARPORT study the presence of 
thrombus was associated with the relative 
loss, whereas this was not the case in the 
MERCATOR study. 
Timing of Follow-Up DU1'IItion 
One of the consequences of having sys-
tematic, follow-up angiography at 6 months is 
that it dist0l1s the natural occurrence of clin-
ical endpoints (reinterventions). As a conse-
quence, all indications for a revascularization 
procedure that have been triggered by the 
6-month repeat angiogram are counted as 
endpoints, provided that the indication is also 
substantiated by anginal symptoms or posi-
tive findings at exercise testing. In the CAR-
PORT study clinical events were counted up 
to the 6-month angiogram minus 2 weeks. 
This meant that the therapeutic implications 
of the diagnostic angiogram were circum-
vented, resulting in a lower rate of events 
compared "nth similar studies. This led to two 
problems. Firstly, it reduced the power of the 
study to detect a difference in restenosis, and 
secondly, it may have tempted investigators to 
await recatheterisation before further ther-
apy. To overcome these problems, in the 
MERCATOR study we increased the cutoff 
point to 7 months. This, however, tended 
to overestimate the clinical event rate by 
including cosmetic dilatations following the 
6-month angiograms and thus introduced a 
different problem into the analysis. For the 
PARK study we again extended the study to 7 
months, but excluded cosmetic dilatation by 
insisting that for a repeat PfCA to be a clini-
cal event the clinician had to justify his deci-
sion on the basis of objective evidence of 
ischemia. Fm1henuore, the decision to redo 
the PTCA was counted as a clinical event 
PARK 
CUMULATIVE DISTRIBUTION of 
CLINICAL ENDPOINTS 
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Figure 12C.1. Cumulative distribution 
CUNe of clinIcal endpoints for the Post An-
gloplasty Restenosls Kelanserin (PARK) 
lrial. Note the distribuUon of endpoints and 
how the timIng of recalhelerizalion may in-
fluence the results, (Reprinled by permls-
s!on from Serruys PW et a!. Circulallon 
1993;88: 1586-1601.) 
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o 2 3 4 5 
months after PTCA 
intontlon to tr ... t M"'Y.I! 
even if it did not physically occur during the 
follow-up period. This did not completely 
solve the problem, however, as certain 
patients were marked down for repeat inter-
ventions that never occUlTed for a variety of 
reasons. Thus the optimal time for restudy 
may playa role in the clinical endpoints as 
shown graphically in Figure 12C.1. 
It may be best in the future therefore to 
have a plim81Y endpoint at 7 months and a 
secondary endpoint at 12 months. 
Defitlitiotl ofPrimaty Etldpo;,zts 
The primary goal in restenosis trials is an 
improvement in the short- and long-tenl1 clin-
ical outcome in patients undergoing PTCA. It 
is assumed that the improvement in clinical 
outcome relates directly to the prevention of 
the stenosis recurrence. This may not be com-
pletely hue, however. 
CLINICAL ENDPOINTS 
For the MERCATOR study as our primary 
clInical endpoints we chose a combination of 
the major untoward clinical events, namely, 
death, myocardial infarction, referral for 
coronmy aliefY bypass surgery, or an indica-
tion for repeat angioplasty. The advantages 
are obvious in that if the endpoint is based on 
these so-called "hard" critmia, the endpoint 
6 7 
is evaluable in all randomized patients and 
leads to simple effect estimates with corre-
sponding 95% confidence intervals. Because 
hard endpoints only occur, however, in ap-
proximately 20% of cases, our ability to de-
tect even a 500/0 difference in restenosis rate 
between intervention and control requires a 
very large sample size with all the associated 
logistic problems. Surrogate, soft endpoints 
such as recurrence of angina or noninvasive 
evidence of myocardial ischemia may also he 
introduced to increase the event rate to 50% 
and hence to reduce the sample size-required 
(Table 12C.2). Because of the subjective na-
ture of these, however, bias is introduced into 
the study. 
For example, in hials testing pharmaco-
logic compounds with possible antiischemic 
or antianginal effects unrelated to postinjury 
hyperplasia, subjective, soft endpoints may 
be misleading and obscure the reasons for 
observed improvement. In the MERCATOR 
study fewer patients in the cilazapril-treated 
group experienced anginal pain during exer-
cise testing compared with the control group, 
despite similar workloads, double product, 
and ST-segment changes (Table 12C.3). This 
was regardless of angiographically similar 
restenosis rates suggesting that cilazapril had 
no effect on intimal hyperplasia but perhaps 
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Tabl.'2C.2. 
Total Number of Events and Ranking Scale In the CARPORT Study8 
Total No. of Events During 6·Month Follow-Up Ranking of Clinical Status 6 MonthsAfler PTCA 
Control GR321918 Control 
N'" 346 N =351 N=346 
Death 
·late 6 4 
·AIl 6 (2%) 4 (1%) 6 (2%) 
Myocardial Infarction 
·Procedural 5 5 
-Early 11 7 
·late 6 6 
·All 22 (6%) 18 (5%) 22 (6%) 
CASG 
-Procedural 3 7 
-Early 5 2 
-lale 18 18 
·All 26 (8%) 27 (8%) 19 (6%) 
Repeal angloplasty 
-Early 9 6 
-lale 59 54 
·All 68 (20%) 60 (17%) 52 (15%) 
'@CCSIV 5 (2%) 1 (0.3%) 5 (2%) 
'@CCSIII 19 (6%) 18 (5%) 11 (3%) 
'@CCSII 36 (11%) 47 (14%) 23 (7%) 
'@ccsr 26 (8%) 32 (9%) 14 (4%) 
None 254 (75%) 249 (72%) 194 (56%) 
'Flom Serruys PW etal. Circulation 1991; 84;l568--f560wilh permlsskl!l. 
" For687 patientsaUve at 6-rnonth follow-up; @,seoondruyendpolnt; CCS, Canadian Cardiovascular SOCIety anginaclasslflcation. 
Tabl. 12C.3. 
Exercise Tesl Results of 564 Pallents Randomized In the MERCATOR Study· 
Maximum workload (Walls) 
Exerclse time (sec) 
SystOlic blood pressure at peak exerclse (mm Hg) 
Heart rate at peak exerclse (bpm) 
Double product (mm Hg 1001bpm) 
ST devIation >1 mm 
Anginal symploms dun"ng lest 
Combination of ST > 1 rom and symptoms 
Conlrol 
N=291pts 
146 ± 39 
446 ± 124 
196 ± 27 
142 ± 22 
279 ±65 
102 (38%) 
74 (25%) 
39 (13%) 
'From MERCATOR study group" Circulation 1992; 86:100-101 with perm!sslon. 
PIs, Patients. 
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Cilazapril 
N = 273 pts 
151 ± 44 
454 ± 127 
192 ± 28 
142 ± 21 
275 ± 68 
99 (37%) 
42 (15%) 
25 (9%) 
GR32191B 
4 
18 
22 
49 
1 
11 
30 
19 
197 
N=351 
(1%) 
(5%) 
(6%) 
(14%) 
(0.3%) 
(3%) 
(9%) 
(5%) 
(56%) 
PValue 
NS 
NS 
NS 
NS 
NS 
NS 
0.03 
NS 
may have affected endothelial function. A 
similar effect was seen in the PARK study 
where patients receiving ketanserin demon-
strated a trend toward a lower incidence of 
revasculaIization procedures (77 versus 95 in 
the control group). This may have been sec-
ondary to the arteIiolar dilating effect of 
ketanserin, resulting in left ventricular 
unloading, or perhaps to its effect on rheo-
logic parameters, resulting in increased coro-
nalY blood flow. 
A further confounding variable is the fact 
that not all v8liables are of equal impOliance. 
For example, death is of a different order of 
magnitude from myocardial infarction, which 
in tum is of a different order of magnitude 
from repeat angioplasty. Furthermore, the 
total count of events only gives a general 
impression of complications as events are not 
mutually exclusive and may overlap. A 
patient may, for example, sustain an acute 
occlusion resulting in myocardial infarction 
and subsequent death despite emergency 
coronary artery bypass grafting; in terms of 
total count of events this patient might be 
counted foul' times. 
Ranking endpoints in terms of relative 
descending importance (Table 12C.2) may 
overcome some of these problems, but the 
problem of quantifying each complication 
and its relative importance then arises. For 
example, how many myocardial infarctions 
are equivalent to death? Such methods are 
standard in the field of decision analysis, 
however, and a similar composite endpoint 
has been recently proposed for late follow-up 
after coronaIY angioplasty (8, 9). Although 
such an approach requires prospective valua-
tion, it clearly provides the ability to combine 
both clinical and angiographic endpoints and 
may thus be useful in early, phase 2 clinical 
trials to improve statistical power. 
In attempting to address these questions 
other models have also been proposed. 
Friedrich and colleagues showed that the 
constant-hazard model cannot be applied to 
coronal)' interventional techniques as the risk 
is not constant but varies over time (10). Fur-
thenllore, this rate combines two underlying 
hazards: an early time-dependent hazard 
caused by restenosis of the target vessel and a 
more constant hazard caused by the progres-
sion of coronary atherosclerosis or comorbid 
disease. This temporal sequence of events is 
highest at the time of the initial procedure and 
at the follow-up cathetelization, where there 
is an artificial increase in the rate of events 
(Fig. 12C.l). 
An altemative llleans of overcoming some 
of these problems is also with the use of event-
free survival curves. These provide in a 
graphic fomI information on the time course, 
as well as on the incidence of endpoints. 
NONINVASIVE ElffiUATJON OF RESTENOSIS 
As far as detection of restenosis by noninva-
sive diagnostic tests is concerned, it can 
generally he said that an abnormal exercise 
ECG response or myocardial perfusion de-
fect on a thaHium-201 scintigram is usually 
associated with either an angiographically 
demonstrable restenosis of the dilated seg-
ment, a functionally inadequate original di-
lation, or the presence of additional disease. 
The sensitivity and specificity of the test may 
therefore be increased by performing the test 
plior to the procedure to document a bas'e-
line result, immediately after angioplasty to 
filter out the presence of additional disease 
or inadequate functional dilation, and sub-
sequently at 6 months to document reste-
nosis. 
Logistic problems arise, however, in trying 
to pClionn the exercise test. Firstly, most of 
the centers paliicipating in large multicenter 
studies are regional referral centers draining 
large areas, whose first contact with the 
refelTed patient is at the time. of the proce-
dure. It is logistically difficult [or them there-
fore to ensure that all patients have an exer-
cise test plioI' to the procedure. Secondly, 
problems arise in performing the exercise test 
immediately after the procedure with doubts 
raised as to the safety of this policy. Thus 
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insurn10untabie difficulties arise in trying to 
anange the exercise test prior to and immedi-
ately after angioplasty. The concept is ad-
vanced, however, that perhaps we do not need 
to do this and, since all we are doing is COIll-
paling two groups-an active and a placebo 
group, perhaps we should just exercise test all 
patients at 6 months. For the reasons outlined 
above, however, the positive predictive value 
oflate treadmill testing varies from 39 to 64% 
(Table 12C.4), making it difficult to make 
valid intergroup observations. The only use-
ful role we have found for the exercise test is 
to substantiate the need for a repeat thera-
peutic PTCA at follow-up. 
Similar arguments can also be used against 
the role radioisotopes. The need for pre-, 
immediate, post-, and follow-up scans also 
raises two additional issues. Firstly, objec-
tions are raised regarding the repeated use of 
radioisotopes and the long-ternt result of 
doing so. Secondly, problems arise in the 
objective assessment of the results as there is 
still no agreed standardized procedure for 
image acquisition and interpretation. 
For all the above reasons exercise testing 
or thallium scintigraphy are of little value in 
the assessment of long-tenll restenosis. Their 
only role may be to substantiate the therapeu-
tic' procedure if repeat angiography is sugges-
tive of a significant restenosis. 
Tabte 12C.4. 
Detection of Restenosls by Exercise Treadmill Testing-
Ang!ograph!c Restenosls 
Author FoHow-Up% % 
O'Keefe 100 13 
Schon 83 12 
WiJnsb 74 35 
Wijnsb 89 40 
Bengston 96 51 
RosIng 100 34 
Ernst 100 4 
Honan 88 58 
Scholl 83 12 
ANGIOGRAPHIC ENDPOINTS 
The most accurate way to quantify the pro-
liferative response as part of restenosis 
would be with the direct measurement of 
neointimal thickening follmving coronary in-
tervention. This is not, however, cunently 
possible in man, although the advent of new 
imaging modalities such as angioscopy and, 
more especially, intravascular ultrasound 
may one day make it possible. For debulk-
ing devices that may alter both acute di-
mensional gain and the later proliferative 
response, cunently quantitative coronary an-
giography is the most objective and repro-
ducible method available to desclibe the 
changes in stenosis geometry following in-
tervention. Although it only measures the 
process indirectly without defining its nature 
(recoil, organized mural thrombus, neointi-
mal hypetplasia), it has nonetheless become 
the accepted gold standard in documenting 
restenosis. 
There is still, however, no agreed on an-
giographic definition of restenosis (11, 12). 
To date there have been a total of 13 differ-
ent definitions used in the literature, but 
none have become widely accepted. Al-
though the clinician is best served by the 
"present/not present" assessment of resteno-
sis, the biologic process of restenosis itself 
may be best analyzed by measuring the ab-
PPV NPV 
% % TimIng orresl 
29 73 <1 month 
40 27 1 month 
50 65 3-7 weeks 
60 52 3-8 weeks 
39 84 6 months 
47 76 8months 
50 95 4-8 months 
57 84 6 months 
84 50 6 months 
'Modified from Califf elal. Reslenosls: the clinical Issues. In: Topol EJ. ed. Textbookof inlerventional cardiology. Philadelphia: WB Saunders, 1990. 
~Thoraxcenler 
ppv, Positive preolCtive value; NPV, negative preofctivavalue. 
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solute angiographic dimensions on a contin-
uous scale. This is for two main reasons. 
Firstly, as we have previously demonstrated, 
all lesions undergo restenosis to some extent 
during follow-up in a Gaussian distlibution. 
Secondly, if we treat restenosis as a continu-
ous variable, more infOiTIlation can be 
gleaned from the available data regarding 
the underlying process. Fm1hermore, the use 
of a continuous variable in statistical analy-
sis allows us to reduce the number of pa-
tients required to demonstrate benefit in a 
specific study by two-thirds. For example, if 
treatment reduces the loss of luminal diame-
ter from 0.40 mm under placebo to 0.25 nun 
under active medication (SD = 0.5 mm), 
233 patients per group would be required to 
have a power of 90%. The above reduction 
conesponds to restenosis rates (defined as a 
loss of minimal luminal diameter of 0.72 
Illm) of 25% and 17.5%, respectively. This 
difference, however, can be statistically de-
tected with a power of 90% with 620 patients 
per treatment group. Thus the quantitative 
outcome determined from direct measure-
ments of continuous v31iables can be evalu-
ated statistically with only one-third the 
number of patients required for the categori-
cal outcome. 
The minimal luminal diameter provides 
more reliable and meaningful infolTIlation 
than percentage diameter stenosis with 
regard to the hemodynamic significance of a 
coronal), artery lesion and has been shown 
to correlate at foHow-up with the reCUlTence 
of angina or exercise-induced myocardial 
ischemia (1). The minimal luminal diameter 
at follow-up thus best describes the lesion 
severity at this point in time, while the 
process of restenosis can best be addressed 
by measming the changes in luminal diame-
ter from postintervention to follow-up in phar-
macologic studies looking at restenosis. In 
studies examining devices, however, because 
of differences in the initial gainl1oss, it is 
impossible to use the change in luminal diam-
eter at follow-up and is best to look at a static 
parameter such as the MLD at follow-up to 
assess restenosis. 
Are QtlflIltitativeAtlgiographic Parameters a 
Good Surrogate for Clillical Evmtsf 
One of our convictions is that the difference in 
minimal luminal diameter at follow-up 
between two populations will be translated 
into clinical temlS. This has been generally 
hue, as illustrated recently by the results of 
the BENESTENT and STRESS trials. A dis-
cordance, however, was noted in the CAVEAT 
I hial wherein a modest improvement in lumi-
nal dimensions at follow-up after directional 
atherectomy compared with PTCA did not 
"translate" into clinical benefit. 
A more detailed analysis is available for 
the CARPORT study. In that study the mean 
difference in coronal)' diameter between 
postangioplasty and follow-up angiogram was 
similar in the control and GR32191B groups 
(-0.31 ± 0.54 mm and -0.31 ± 0.55 mm, 
respectively), and this was reHected in similar 
rates of clinical events. If you separate the 
population into two, however, on the basis of 
symptoms or positive ergometry, the cumula-
tive distribution curves for change in minimal 
luminal diameter clearly separate (Fig. 
12C.2), suggesting that the change in MLD 
may indeed reflect clinical events .. FUl1her-
Illore, in the MERCATOR study when the 
patient population was stratified according to 
the minimal lumen diameter at follow-up 
(Table 12C.5), the percentage of patients 
reaching one of the predefined clinical end-
points was as high as 65% in the worst cate-
gory (MLD at follow-up <1.15), whereas the 
percentage of event-free patients ranged from 
63 to 78% in the other categories. Addition-
ally, 41% of the patients in the worst versus 
only 6% in the best anatomic categOl), had 
reintervention irrespective of the initial 
dilatation site. Besides the prognostic value, 
the anatomic results also had a clear fUllc-
tional impact because only 2% of the patients 
in the best anatomic categOl), had a positive 
exercise test versus 26% in the worst. 
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Figure 12C.2. Top panel. Cumulative distribution 
(CUM %) curve lor change In minimal luminal diameter 
(MLD) for symptomatic and asymptomatic patients at 
foHow-up angiography. Bottom panel. Cumulative dis-
tribuUon (CUM %) curve for change In minimal lumlnat 
diameter (MLO) for patients with positive and negative 
ergometry at foHow-up angiography. (Reprinted by per-
mission from Serruys PW et al. Circulation 1991; 
84:1568-1580.) 
Table 12C.5. 
Limitations o/Differences in MLD Behueen 
varlOtlS 1",'als 
Over the last few years it has become ap-
parent that the loss in MLD in different trials 
could vary considerably, and in the placebo 
groups Ihe loss in MLD ranged from 0.24 10 
0.36 mm. The reasons for this are unclear, 
although one possibilily is Ihal Ihese differ-
ences in mean luminal diameter at follow-up 
reflect differences in baseline demographic 
data. Factors such as the percentage of 
recmited patients in angina class 4, pa-
tients "rith recent onset of angina, unstable 
patients, and diabetic patients and the fre-
quency of total occlusion have a major im-
pacl on Ihe loss in MLD al follow-up. Popma 
and colleagues suggest that in future trials 
high-lisk patients not be excluded to there-
fore avoid a misrepresentation of the pop-
ulation of typical patients undergoing an-
gioplaslY (9). FurlhemlOre, Ihey suggesl that 
by selecting elective patients the expected 
late loss in MLD may be reduced, resulting 
in a requirement for a larger study popu-
lation. 
Lilli itatlo", of Quolltita ti ve Angiogl'aphy 
Quantitalive coronalY angiography (QCA) 
provides an outline of the vessel lumen and 
not the vessel wall, which is where the un-
Prognostic Value of Minimal Luminal Diameter at Follow-Up In the Preprotocol MERCATOR Population 
Divided Into Five Equal Segments' 
Exerclse Test Clinical Outcome 
MLO <tmm 2:1mm 
FollOW-Up STT Changes STTChanges 
(mm) and No Chest Pain and Chest Paln MI Aelnlervention Angina None 
<1.10 70 (75%) 24 (26%) 5 (4%) 49 (41%) 24 (20%) 41 (35%) 
1.10101.39 88 (88"10) 12 (12%) 1 (1%) 18 (15%) 25 (21%) 74 (63%) 
1.39101.63 103 (90%) 11 (10%) 2 (2%) 10 (8%) 31 (26%) 77 (64%) 
1.63101.91 99 (93%) 8 (7%) 1 (1%) 7 (6%) 21 (15%) 89 (75%) 
1.91 or more 111 (98%) 2 (2%) 1 (1%) 7 (6%) 18 (15%) 94 (78%) 
471 PIs 57 Pis 10 Pis 91 Pis 119PIs 375 Pis 
'From MERCATOR sludygloup. Circo!alioo 1992; 86:100-101 with permission. 
MLD, Minimal luminal diameter, mm, mHflmeter, MI, myocardia! Infarction: Pts., patients. 
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Figure 12C.3. Ultrasound ImagIng prior 10 ba!1oon anglo-
plasty and following angiographica11y successful balloon 
dilalalion. It can be clearly seen post-PTCA that the anglo-
graphIc success is as a result of eccentric tears In the ves-
sel wall with only a small Increase in the residual luminal 
area (pseudosuccess). Following successful slent implan-
tation there Is a good residual luminal area. (Images cour-
tesy of Or. C. diMario, Thoraxcenter, Erasmus University, 
RoHerdam, The Netherlands.) 
derlying pathologic process is occurring. 
Thus much of what may be an angiographic 
success may turn out to be a pseuclosuccess, 
perhaps because of cracks and dissection 
planes in the vessel wall giving the impres-
sion of a successful result whereas in reality 
there may be little increase in the actual 
luminal area (Fig. 12C.3). Thus a split in the 
vessel wall may provide an angiographical-
ly successful result (a pseudosuccess), hut 
subsequent apposition of the split-wall lay-
ers may result in an angiographic restenosis 
(a pseudorestenosis), a lesion being classi-
fied as restenosis whereas in fact it was 
never an actual success. 
Thus we may have to separate the clinical 
outcome, which may be measured by QCA, 
from the pathologic process OCCUlTing in the 
vessel wall. V;rhether new concepts in the 
visualisation of the vessel wall such as 
angioscopy or, perhaps more imp0l1antly, 
intravascular ultrasound can refine our 
understanding of the underlying pathologic 
process is still unclear but holds a great deal 
of promise. 
IdealTNal 
As outlined above, although randomized 
studies are the best means we have of COlll-
paring the acute and long-ternl results of dif-
ferent interventional devices and the impact 
of pharmacologic therapies, they remain lim-
ited by inherent logistic problems. Our ideal 
Tandomized hial would be based purely on 
clinical follow-up of hard endpoints at 1 year. 
This would assess the effect of the interven-
tion, whether it is drug therapy or a device 
compared with stand-alone angioplasty with-
out the inteIference from the recatheteliza-
tion procedure. 
MATCHING STUDIES 
In view of the large number of pharmacologic 
and mechanical interventions available to us 
and the time, energy, and financial burdens 
involved in conducting a large randomized 
hial, we have developed the concept of 
matching to use as a sun-ogate for a random-
ized study. Matching Illay offer insight into the 
effects of different interventional techniques, 
screen devices, and yield statistically helpful 
infOInlation such as a required sample size for 
the proper design of a randomized 'triaL" , 
The principles of matching by quantita-
tive angiography are threefold. Firstly, the 
angiographic dimensions of matched lesions 
are assumed to be identical. Secondly, the 
observed differences between the two identi-
cal lesions must be within the range of sys-
tem-analysis reproducibility (0.1 mm; lSD). 
Finally, the reference diameter of the lesions 
to be matched must be selected to be within 
a range of ±O.3 mm (3 SDj confidence limits 
99%). Matching can also be extended to in-
clude lesion location and clinical parameters 
such as male sex, stable/unstable angina; di-
abetes, total occlusions, and other risk fac-
tors that lllay confound the incidence of 
restenosis. 
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Figure 12C.4. Cumulative distribution curves of MlD at 
follow·up for matched populations. A. Athereclomy ver-
sus PTCA. B. Stent implantation versus PTCA. C. Ex-
elmer laser versus PTCA. 
Matcbing inAction 
v;re have used the principles outlined above to 
assess late luminal renarrowing in atherec-
tomy, stent implantation, and excimer laser 
versus balloon angioplasly (Fig. 12C.4). 
In atherectomy versus baBoon angioplasty 
we demonstrated that matching for clinical 
and angiographic v8liables resulted in h\'o 
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comparable groups with identical baseline 
stenosis charactelistics (13). Atherectomy 
resulted in a more pronounced increase in 
minimal luminal diameter than did balloon 
angioplasty (1.l7 ± 0.2910 2.44 ± 0.42 mm 
versus 1.21 ± 0.38 to 2.00 ± 0.36 mm), 
but this favorable immediate result was sub-
sequently losl during lale angiographic fol-
low-up, as the minimal luminal diameter at 
follow-up did nol differ belween Ihe Iwo 
groups (1.76 ± 0.62 versus 1.77 ± 0.59mm, 
athereclomy versus balloon angioplasty) (Fig. 
12C.4A). This suggesls Ihat in malched popu-
lations, atherectomy induces a greater initial 
gain in minimal luminal diameter than bal-
loon angioplasty bUI thallh" greater vascular 
wall injury induced by this device is associ-
ated with a more pronounced late loss. The 
results of this study were subsequently 
reHecled in Ihe CCAT and CAVEAT sludies. 
Using coronary stenting we demonstrated 
that V;rallstent implantation results in a supe-
rior immediate increase in millimalluminal 
diameler (from 1.22 ± 0.34 10 2.49 ± 0.40 
mm) compared with balloon angioplasty 
(from 1.21 ± 0.29 10 1.92 ± 0.35 mm) (14). 
Despite a greater decrease in minimallumi-
nal diameter after WaHstent implantation 
compared wilh balloon angioplaslY (0.48 ± 
0.74 versus 0.20 ± 0.46 mill), the minimal 
luminal diameter at follow-up was signifi-
cantly greater after stent implantation 
(2.01 ± 0.75 versus 1.72 ±0.54 mm) (Fig. 
12C.4B). Although different stenls were eval-
uated, our results paralleled those of the re-
cently reported BENESTENT and STRESS 
trials. 
Using excimer laser we demonstrated that 
despite similar acute increases in minimal 
luminal diameter (from 0.73 ± 0.47 to 
1.77 ± 0.41 mill, excimer laser, versus 
0.74 ± 0.46 to 1.78 ± 0.34 mm, coronary 
angioplasty), the minimal luminal diameter 
after excimer laser was significantly lower at 
follow-up (1.17 ± 0.63 versus 1.46 ± 0.63 
mm) (Fig. 12C.4C), suggesling Ihal in suc-
cessfully treated matched coronary lesions 
there is reduced long-term efficacy after 
excimer laser compared with balloon angio-
pJasty. 'Whether these preliminary results will 
be reflected in clinical outcome wiII be 
answered in the ongoing AMRO randomized 
study of excimer laser versus balloon angio-
plasty. 
Limt'tatt'olls of Matching 
The major limitation of a matching study is its 
retrospective design and the inevitable pres-
ence of selection bias. It controls for bias only 
in those variables taken into account. It is not 
possible to match for all variables because of 
practical difficulties in finding patients who 
meet all the matching ctiteria. Moreover, if 
categories of matching are relatively clUde, 
there may be room for substantial differences 
between matched groups. For example, if 
clinical variables such as unstable angina or 
perhaps diabetes, which are known to predis-
pose to a higher restenosis rate, are not 
included in the matching, substantial differ-
ences will occur between the two groups that 
may influence the validity of statistical com-
parisons. 
Role ill Clillical Decision Making 
The use of matching studies as a sUlTogate for 
randomized studies offers the potential to 
rapidly screen a number of devices and to 
assess which are most likely to represent 
advances in balloon angioplasty. These can 
then be examined in larger randomized stud-
ies. Furthermore, matching yields statisti-
cally helpful information regarding the proper 
design of subsequent randomized trials such 
as required sample size. 
REGISTRIES 
The advantage of a registry is that data are 
collated in a coordinating center that aHows 
infonuation to be gleaned regarding the suc-
cess and acute complications in a self-
selected group of patients from a variety of 
('enters with vatTing expeliise. It therefore 
gives an impression of the acute results at the 
ground level and may, if adequate follow-up is 
encouraged, give an indication of the long-
term restenosis rate. Information is obtained 
at little expense in tenns of time or money as 
it is nonnally freely available at each institu-
tion. 
There are a number of major limitations to 
extrapolating the results from registries to the 
general population, however. Firstly, the 
patients are entered on an ad hoc basis by the 
operator and may not be representative of the 
totality of patients on whom the device was 
used. This may explain, for example, why the 
reported complication ratesfrom registries are 
consistently lower than the complication rates 
observed in clinical practice. Secondly, there 
are usually no central angiographic core lab 
and no independent verification or audit of 
the data supplied by the investigator to ensure 
accuracy and reproducibility. FUlihennore, 
the angiographic analysis is nOlTIlally per-
formed by the operator with visual assessment 
of the coronat)' angiogram, a technique intro-
ducing bias and inaccuracies. Finally, the 
analysis is usually perfonned on a post hoc 
basis with multiple statistical comparisons 
being made on a small number of selected 
patient subgroups. 
Because of the inherent limitations out-
lined above it is difficult to interpret the data 
from the various registries and to draw mean-
ingful conclusions (15). The only useful infor-
mation that may be gleaned from registries 
may be some idea about trends in various 
patient subgroups; for example, that calcifica-
tion may not be good for atherectomy. 
EXPERIENCE-BASED COMMON SENSE 
Whatever the results of large randomized 
studies, it is ultimately the skill and judgment 
of the individual doctor in assessing and 
treating a paliiculal' lesion in an individual 
patient that will detenlline the safety and effi-
cacy of the procedure. The main advantage of 
experience-based common sense is that it will 
limit cardiologists to the use of specific 
devices that are safe in their hands on specific 
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lesions in their pa11icular circumstances. 
Experience-based common sense, howevel', 
will tell them little regarding long-term 
restenosis. 
Furthermore, there are a large number of 
other potential limitations to expelience-
based common sense, Vil1ually all new 
devices have a steep learning curVe so that an 
individual doctor may never do enough cases 
to get past this leaming curve. Thus an oper-
ator who has never attained a sufficient level 
of skill in using the device will be prejudiced 
against it and perhaps only use it in specific 
patient subgroups. This combination of indi-
vidual expel1ise and selection bias means 
that the safety and efficacy of particular 
devices can never be adequately quantified 
and that any differences between devices 
would be extremely difficult to prove, 
SUMMARY 
Adverse coronary anatomy, acute occlusion, and 
long-ternl restenosis remain major limitations of 
coronary angioplasty. Over the last 5 years ath-
erectomy, stenting, and laser techniques have 
been introduced as potentially safer alternatives 
to balloon angioplasty with improved short- and 
long-term results. Considerable difficulty exists, 
however, in making valid comparisons between 
the different modalities with regard to the above 
outcome measures, Device registries may be use-
ful for the initial assessment of the initial safety 
and success of the device, Matching studies may 
help to screen devices for subsequent randomized 
studies to delineate the precise role of each ne"w 
device. We must never forget, however, that irre-
spective of the results of registries and matching 
and randomized studies, the final arbiter of the 
success or failure of the procedure will be the caT-
dialogist and the team treating the individual 
patient. 
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Abstract 
Coronary slents were developed to overcome the two main limitations of balloon angiopiasty, acute occlusion and 
long term rcstenosis. Coronary stenls can tack back intimal flaps and seal the dissected vessel wall and thereby trcat 
acute or threatened vessel closure after unsuccessful balloon angiopiasly. Following successful balloon angiopiasly 
stents can prevent late vessel remodeling (chronic vessel recoil) by mechanically enforcing the vessel wall and 
resetting the vessel size resulting in a low incidence of restenosis. All currently available stents are composed of 
metal and the long-term effects of their implantation in the coronary arteries are still not clear. Because of the 
metallic surface they are also thrombogenic, therefore rigorous antiplatelet or anticoagulant therapy is theoretically 
required. Furthermore, they have an imperfect compromise between scaffolding properties and flexibility, resulting 
in an unfavourable interaction between stenls and unstable or thrombus laded plaque. Finally, they still induce 
substantial intimal hyperplasia which may result in reslenosis. Future stenl can be made less thrombogenic by 
modifying the metallic surface, or coating it with an antithromboticagent or a membrane eluting an antithrombotic 
drug. The unfavourable interaction with the unstable plaque and the thrombus burden can be overcome by covering 
the stent with a biological conduit such as a vein, or a biodegradable material which can be endogenous such as 
fibrin or exogenous such as a polymer. Finally the problem of persisting induction of intimal hyperplasia may be 
overcome with the use of either a radioactive stent or a stent eluting an anliproiiferative drug. 
Introduction 
Coronary stents were developed to overcome the two 
main limitations of balloon angioplasty, acute occlu-
sion and long term restenosis. Coronary stents can tack 
back intimal flaps and seal the dissected vessel wall 
and thereby treat acute or threatened vessel closure 
after unsuccessful balloon angioplasly. Following suc-
cessful balloon angioplasty stent can prevent late ves-
sel remodeling (chronic vessel recoil) by mechanically 
enforcing the vessel wall and resetting the vessel size 
resulting in a low incidence of restenosis. These theo-
retical advantages of coronary stenting have been tested 
in two major randomised trials [l, 2]. Both BENES-
TENT and STRESS confirmed the theoretical advan-
tages of coronary stenting by demonstrating a reduc-
tion in angiographic restenosis and clinical events dur-
• Andonis G. Violaris was the recipient of a Wellcome Tru'lt 
International Research fellowship 1992-1995. 
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ing follow-up [1, 2]. This reduction in restenosis was 
achieved by a greater luminal gain despite the accom-
modation of a greater absolute loss in lumen diame-
ter in the sten! group, suggesting greater neointimal 
hyperplasia in this group. The reduction in long-term 
restenosis was counterbalanced by bleeding complica-
tions related to the anticoagulant therapy. Therefore, 
a number of limitations have to be overcome before 
coronary stenling achieve its full potential. 
Currently ami/able stems 
The currently available stents, a description of their 
design, and the year of their clinical introduction are 
listed in Table 1 and illustrated in Figure 1. In the 
absence of prospective randomized interstent compar-
ative trials, it is difficult to draw conclusions on the 
relative merits and demerits of each stent design. Indi-
vidual experience and registry data from each stent, 
Figure 1. Coronary stents which ha\'c undergone clinical evaluation_ Thesc are going clocko.vise from the left. Wal\stent (Schneider), Palmaz-
Schatl (Johnson & Johnson), Wiktor (Medtronic), Gianturco-Roubin (Cook), Cordis, Micro (A.\ZE.), MuHilink (A.C.S.) 
Table 1. Currently availabele ~tents undergoing clinical evaluation 
Coronary Stenl De~ign Deployment Premounted De\i\-ery Diameter l.ength First Oinical 
(mm) (mm) Implantation 
Wallstcnt Wire mesh Self-expanding balloon not over-the-wire 3.5--6.0 12-42 1986 
required 1991 (Less ~hortening) 
Palmaz-Schatl Slotted tube Balioon-expandab!e pre-mounted over-the-\virc 3.0-4.0 8-18 1988 
& unmounted & both 1994 (Heparin coated) 
Gianturco-Roubin Incomplete coil B311oon-expandable premounted over-the-wire 2.5-4.0 20-40 1989 (GR-I) 
clam shell loop 1995 (GR-II) 
Wiktor Sinusoidal BalJoon-expmdabJc premounted over-the-wire 3.0-4.5 16 1991 
helical coil or monorail 1995 (Shorl wave) 
Multilink Multiple rings with Balloon-expandable premountw oycr-the-wire 3.0-3.5 15 1993 
multiple links 
Cordis Sinusoidal Balloon-expandable premounle.d over-the-wire 3.0-4.0 15 1994 
helical coil 
AVE Micro Zig-Zag axial struts Balloon·expandable premounted monorail 2.5-4.0 6-36 1994 (Micro-I) 
1995 (l\ficro-II) 
NIR E.xpandable uniform Balloon-expandable unmounted both 2.0-5.0 9-32 1995 
cellular mesh 
Wallstent - Schneider Bulach, Switzerland; Palmaz-Schatl-Johnson &. Johnson, Warren, New Jef5cy, USA; Gianturco-Roubin -Cook, 
Bloomington, Indima, USA; Wiktor - Medlronic, Minne.apolis, Minnesola, USA; ACS - Advanced Cardiovascular Sys!ems, London, 
V.K.; Cordis, Cordis, Miami, Florida, USA; AVE Micro, Advanced Vascular Engineering, Santa Rosa, California, USA; NIR, Medina, 
Tel Aviv, Israel. 
however, allow preliminary impressions to be made on 
the advantages and limitations of each stent. 
Wails/ell! 
The Wallstent was the pioneer of slcnts [3, 4] through 
which we learnt thc risk profile and indications for 
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Figure 2. Coronary angiography of the right coronary artery in a patient with total occlusion pre-balloon angioplasty. Post balloon angioplasty 
diffuse narrowing associated with a proximal dissection was observed [left panel). The radiopaque stent struts c-.an be seen post Wallstent 
deployment [middle panel). An excellent angiographic result [right panel]. 
coronary stenting and the necessity and adverse effects 
of antithrombotic measures. The new Less Shortening 
Wallstent has been developed recently with a change 
in the braiding angle and results of the first clinical 
implantation of this second generation stent in coro· 
nary vein grafts have been promising [5, 6J. The 
unique ad\'antages of the Wallslent include the exten-
sive range of diameters and lengths available, thercby 
allowing the Wallstent to be used for the management 
of long spiral dissections [71. and for vessel reconstruc-
tion [8]. The sheathed 'balloon-less' delivery system 
'ill combination with the free unconnected wire mesh 
design. render the Wallstent one of the most track-
able, pushable and flexible stents for negotiating tor-
tuous vessel and passing through proxinlally deployed 
stenls (Figure 2). Furthermore recent modification of 
the delivery system allows recapture of the stent pri-
or to final deployment and also improved positioning, 
raising the possibility of shorter Wallstcnts in clinical 
practise. Its fine cross-hatched mesh design provides 
excellent scaffolding properties; particularly well suit-
ed to entrap friable material in diffusely diseased vein 
grafts. Additionally enforced mechanical remodeling 
produced by oversizing Wallstent implantation con-
veys a favourable 6 month clinical and angiographic 
outcome in both stenosis and total occlusions in nath'e 
coronary arteries both [7, 8]. Its primary limitations 
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arc the longitudinal shortening of the stent upon radial 
expansion and motion of the stent during retraction of 
the rolling membrane rendering the stentless suitable 
for ostial lesions. 
l'almaz-Schatz stelll 
The Palmaz-Schatz stent has been extensively investi· 
gated in a broad range of coronary lesions [9-18]. It 
is the only stent to date to have completed prospective 
randomized trials comparing the clinical and angio-
graphic outcome with that of balloon angioplasty 
[1, 2}. The angiographic results following Palmaz-
Schatz stent implantation are predictable and the slot-
ted tube design allows the performance of high pres-
sure intrastent balloon inflations without risk of struc-
tural deformation. The low radiopacity of the Palmaz-
Schatz stenl, however, can render the positioning of 
a non- compliant balloon for post deployment high 
pressure intrastent inflations difficult. Additionally, a 
higher incidence of restenosis has been reported at the 
site of the central articulation [19J. To overcome this 
limitation a recent model has been developed with-
out the central articulation (spiral articulation design). 
This model has a higher radiopacity compared to the 
standard single articulation design. The availability of 
a free unmounted Palmaz-Schatz stent which can be 
crimped by the operator on any balloon provides more 
procedural versatility and results in a lower profile dur-
ing stent delivery. It docs, however, increase the risk 
of losing the stent during deployment. 
Giallturco-Roubill stellt 
Prior to obtaining FDA approval for non-inves-
tigational clinical usc, most of the clinical data on 
the Gianturco-Roubin slen! was gathered in single and 
multicenter registries in the U.S.A. [20-25]. The indi-
cation for the Gianturco-Roubin stent for which most 
data has been gathered is for the bailout of subocclusive 
and occlusive dissections following balloon angioplas-
ty in native coronary arteries. The data gathered com-
pares well with historical controls treated by repeated 
and prolonged balloon angioplasty alone. The results 
of the first randomized trial of the Gianlurco-Roubin 
in bailout therapy (GRACE) are awaited with inter-
est (26). The principle advantages of the Gianturco-
Roubin stent include its range of lengths and longi-
tudinal flexibility. While the relatively large inlerstrut 
intervals of Imm raise questions over the suitability 
of this stent for the management of friable vein graft 
lesions, the advantages of the Gianturco-Roubin stent 
design include minimal risk of 'jailing' side branch-
es and the potential to perform coronary intervention-
al procedures in side branches through the interslrut 
spaces. While this stent excels in long dissections in 
curved coronary segments, its more generalised use 
was hindered by the high profile of the first genera-
tion. The new generation flex II stent overcome these 
problems with a lower profile and a higher visibility. 
Wiktor stelll 
The available clinical data on the Wiktor stent aris-
es from observational studies and registry data [27-
30], the principle registry of which has been in the 
management of restenotic lesions. Like the Gianturco-
Roubin slent, the Wiktor sten! is a coil sten! which 
offers marked flexibility and thus conformability with 
the vessel curvature. However, also like the Gianturco-
Roubin stent, the Wiktorslent is unlikely to excel in the 
treatment of friable vein grafts on account of the large 
interslrut interval of the Wiktor sten! and subsequent-
ly reduced scaffolding properties. The radiopacity of 
the Wiktor stent allows exquisite positioning of the 
stent in ostial and focal lesions, while the flexibili· 
ty of the stent makes it suitable for short dissections 
on curved coronary segments. The recent introduction 
of the option of a monorail delivery syslem improves 
the user-friendliness of the device. The limitations of 
the initial prototype of the Wiktor stent included the 
availability of only one length and the limited scaf-
folding properties with the potential for the protrusion 
of intimal flaps through the interslrut intervals. These 
limitations have been overcome by the new generation 
short wave form Wiktor sten!, although the radiopacity 
of this tantalum stent can still interfere with on-line 
quantitative angiographic analysis of the stented seg-
ment[3l]. 
Multilillk stellt 
The ACS stent currently has the least clinical expe-
rience of the currently available stents having just 
completed its first 100 patient registry conducted at 
five European centers [32]. The advantages of this 
new stent include the flexibility and low profile of the 
sheathed stent and delivery system. Although the Mul-
tilink sten! design manages to provide remarkable scaf-
folding properties, the metallic burden to the stented 
vessel remains very low by virtue of the small diam-
eter of the corrugated stnlls. The limitations of the 
stent include its radiolucency rendering the position-
ing of non-compliant balloons for post-delivery high 
pressure intrastent inflations very difficult. The current 
availability of only one length of 15mm, means that the 
1st prototype can only be used for very focal lesions. 
Following some minor modifications this stent may 
offer some significant advantages over the earlier gen-
eration of stent designs. The attachment of radiopaque 
tips on the stent would present a significant enhance-
mcnt. 
A FE Micro stell! 
The AVE Micro stent is now undergoing clinical eval-
uation in a large number of countries [33J. ,The high 
degree of radiopacity and baUoon expandable deploy-
ment should render this stent ideal for exquisite posi-
tioning in highly focal and ostial lesions (Figure 3). 
However, by virtue of the longitudinal (axial) orienta-
tion of its eight struts, the 4mm AVE Micro stent units 
may be prone 10 proximal migration and protrusion and 
therefore preferably longer welded AVE Micro stents 
should be deployed in ostial locations. Thecuslomized 
range of short lengths make the AVE Micro sten! ide-
al as an adjunctive complementary device for multi-
ple stenting, filling in the gaps between longer stents 
and improving the inflow or outflow of longer stenls. 
Additionally the high flexibility and low thrombogen-
esity of the AVE micro sten! make it an ideal stent for 
bailout management after failed balloon angioplasty 
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Fig!lr<: 3. (.t1) Short dissection in the origin of th~ left circumflex 
wronary artery following balloon angioplasty. (8) An AVE Micro 
stent is delivered 10 the tBrgel v<,sselthrougb an SF Amplatz guid-
ing C;ltheter. The two radioPJque markers at the extremities of the 
stent are dearly seen. (C) Following deli-,ery of the stent, the thick 
radiopaque stainless sled struts facilitate the preci~e positioning of 
a short non--rompliant balloon (single marker) within the stenl for 
subsequent high prc~ure inflations and optimi7.<ltion of stent deploy-
mcnt(D). 
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[33]. Despite the absence of a protective sheath, the 
low proftle and longitudinal slrut orientation, make the 
AVE micro stent one of the easiest stellt to pass through 
other proximally deployed stents. The monorail deliv-
ery system increases the m;er-friendlinessoflhe device 
which has a short learning curve. The strong radial sup-
port proffered by the thick struts should make the stent 
suitable for the prevention of recoil and rcslenosis. 
Care should be taken, however, to avoid the position-
ing of junctions between the unconnected 4mm units 
at the site of the minimal lumen diameter of lesions 
in order to pre\'ent intimal protrusion. Recent devel-
opments include the heIicoiIdal welding of multiple 
3mm length units (Micro stent - II) to provide multiple 
lengths of up to 36mm. 
Cordis stellt 
The Cordis stent continues to undergo early evaluation 
in the clinical arena [31]. Like the AC.S. stent, the 
Cordis sten! offers some advantages over the first gen-
eration stents by virtue of its low profile, flexibility, and 
comprehensive scaffolding properties. The absence of 
a protective sheath on the delivery system, however, 
increases the possibility of stent dislodgement or dis-
ruption during delivery. The operator should be aware 
of the protrusion of the delivery balloon beyond the 
limits of the Cordis sten! if inflations of higher pres-
sure are considered, While the strongly radiopaque 
tantalum struts allow exquisite positioning (Figure 4) 
of the stent in short dissections in curved coronary 
segments, the radiopacity may pose problems for on-
line quantitative angiographic assessment, particularly 
during assessment of luminal rcnarrowing at 6 month 
angiographic follow-up [31]. The relative merits of this 
stent arc currently being evaluated in a European mul-
ticenter registry and by Dr. Nobuyoshi and colleagues 
in Japan {34]. 
NIR stellt 
The NIR sten! is a recently developed balloon expand-
able stent currently undergoing clinical evaluation in 
some centers in Israel and Europe. Although this sten! 
has a low radiopacity, the stent has a high flexibility and 
comes in a wide range of customized sizes (diameter 2 
to 5mm) and lengths (9 to 32mm). Balloon unmount-
ed model allows to choose various types of balloon 
for the sten! delivery and may spare the usage of an 
additional balloon catheter only for stent delivery. A 
preliminary report indicates a high deployment suc-
cess rate despite most of the lesions were difficult to 
Figure4. (A) Complex lesion of the mid-segment of the right coronary artery. (8) Positioning of the Cordis stent was facilitated by the radiopacity 
of the tantalum struts which are dearly seen during inflation of the contrast-fiUed inlrastent balloon to 12 atmospheres. (C) Angiography post 
stent deployment reveals the sten! struts to Ix: embedded in the vessel wall external to the contour of the contrast-filled lumen. 
treat because of vessel tortuosity, distal location and 
long lesion [35}. The restenosis rate has not yet been 
determined. 
Future stellts 
All currently available stents are composed of met-
al and the long-term effects of their implantation in 
the coronary arteries are still not clear. Because of 
the metallic surface they are thrombogenic, therefore 
rigorous antiplatelet or anticoagulant therapy is theo-
retically required. Furthermore, they have an imperfect 
compromise between scaffolding properties and flexi-
bility, resulting in an unfavourable interaction between 
stent and unstable plaque or thrombus burden. Finally, 
they still induce substantial intimal hyperplasia which 
may result in restenosis. Future stent can be made less 
thrombogenic by modifying the metallic surface, or 
coating it with an antithrombotic agent or a membrane 
eluting an anlithrombotic drug. The unfavourable inter-
action with the unstable plaque and the thrombus bur-
den can be overcome by covering the stent with a bio-
logical conduit such as a vein, or a biodegradable mate-
rial which can be endogenous such as fibrin or exoge-
nous such as a polymer. Finally the problem of persist-
ing induction of intimal hyperplasia may be overcome 
with the usc of either a radioactive stent or a stent 
eluting an antiproliferative drug. 
Coated stellts 
Metal coated 
In vitro work suggests that surface potential may exert 
a substantial effect on both the thrombogenicity and 
antiproliferative effect of metals. High surface pOlen-
tial is associated with pronounced attraction of nega-
tively changed particles such as platelets and plasma 
proteins Ihus resuHing in high thrombogeni~ity. On the 
positive side, however, metals with high surface poten-
tial also have a substantial antiproliferative effect on 
fibroblasts suggesting that by varying surface charge 
we may be able to influence the thrombogenicity and 
neointimal hyperplasia after stent implantation. One 
way of doing this would be by modifying the base 
metal [36}. 
Metals can be modified either by Galvanization or 
by Ion bombardment. Galvanisation involves the elec-
trochemical deposition of metal 3.3 pm in thickness 
on the stent and results in 100% of the stent surface 
being covered prior to sten! expansion. Ion bombard-
ment consists of spluttering a thin metal film onlo the 
stent followed by a bombardment with argon ions. The 
resulting implantation of metal onto the sten! surface 
is 20nm in thickness and 75% stent surface coverage 
is required prior to expansion. 
Preliminary experience suggests that coating steel 
stents with platinum, gold or copper results in high-
er in vitro surface potentials but that the incidence of 
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thrombosis in vivo is increased particularly in stents 
coated using galvanization {36]. Thus in contrast to 
the in vitro suggestion metal charge does not seem 
to playa major role in stent thrombogenicity in vivo. 
Furthermore a low stent charge appeared to correlate 
with an increased neointima formation. Thus modify-
ing stainless steel stents by covering them with gold, 
platinum or copper is unlikely to be the solution to 
either increased Ihrombogenicity of neointimal hyper-
plasia. 
Cell seeding of stellts 
Coating of metallic stents with endothelial cells, partic-
ularly genetically engineered cells with increased cell 
surface fibrinolytic activity may improve their throm-
bogenic nature. Preliminary work has demonstrated 
the feasibility of this approach [37, 38]. More recent-
ly in vitro work suggests that genetically engineered 
endothelial cells woould allow increased fibrinolysis 
to be promoted by the surface localisation of urokinase 
[39]. Questions remain however over the number of 
cells that will remain attached under ftow conditions 
as well as the legal responsibility in case of failure of 
endothelial cell function. 
III/mobilised tirug coatings 
Coating of the stent surface with an antithrombotic 
agent such as heparin {40-42] provides a novel solu-
tion to the problem of increased thrombogenicity of 
metallic stents and the subsequent need for intensive 
anticoagulation resulting in increased morbidity and 
costs. Following encouraging preliminary experience 
with a heparin coated Palmaz Schatz sten! in pig coro-
nary arteries the Beneslent 2 study evaluated the safety 
of. reducing and eliminating anticoagulant therapy in 
patients receiving a heparin coated stent. Initial results 
from the pilot study suggests that subacute stent throm-
bosis does not occur using the heparin coated stenl 
which has virtually eliminated the bleeding complica-
tions following stent implantation and reduced the in 
hospital stay to 3 days [43]. The 6 month angiographic 
follow up also indicates that these coated stents do nod 
induce an excess of intimal hypeplasia [44]. Follow up 
of phase 4 (where coumadin and heparin are replaced 
by tic10dipine and aspirin) are awaited. 
Polymer coated stellts 
The slent metal surface can be rendered less throm-
bogenic by coating it with a thin layer of a synthetic 
polymer. Initial results suggested that although this 
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may protect against acute thrombotic events it does 
not reduce the extent of subsequent neointimaI hyper· 
plasia [45]. The advantage of a polymer coated stent 
however is that it can be loaded with antithrombotic or 
antiproliferative agents directed against the neointimal 
reparative process [46] (Figure 5). 
Fibrin stem 
The fibrin film stent has several theoretical advantages. 
It is a membrane stent and can thus cover the bal. 
loon angioplasty injury site providing a natural healing 
matrix and reducing local thrombus formation. It may 
also be useful in vein grafts where the membrane may 
prevent distal embolisation of friable material. Prelim· 
inary work suggests that the fibrin film stent is both 
bioabsorbable and biocompatible [47]. It also appears 
to be safe in pigs with the use of an antiplatelet agent. 
It had little effect on neointimal proliferation however, 
l~ill coated stellts 
An autologous vein graft coated slen! consisting of a 
conventional slent covered by a vein graft may be the 
ideal conduit for percutaneous revascularisation min· 
imising slent thrombogenicity and local tissue reaction 
sten!. Preliminary experience in 13 patients suggests 
that the technique is feasible and safe resulting in an 
excellent immmediate angiographicresull f481 but fur-
ther studies are warranted to investigate the effect of 
the procedure on subacute thrombosis and long term 
restenosis. 
Nittl/o! stellt 
Nitinol has a number of properties which make it ideal 
for stent composition. It is known to be highly bio· 
compatible and highly malleable allOWing 0.006 inch 
struts without sacrificing flexibility. Furthermore it has 
unique thermoelastic properties which allow for stent 
collapse and removal as well as self expansion [49-52]. 
Finally it is amenable to surface coating for local drug 
delivery and is transmutable into a radioactive emitter 
for local radiation therapy. Preliminary work in a pig 
coronary subacute thrombosis model has confirmed 
some of these theoretical advantages of a nitinol slent 
demonstrating that nilinol stents, particularly polished 
nitinol stents, develop significantly less thrombus (as 
measured by thrombus weight and thrombus grade) in 
comparison to stainless steel stenls of similar design 
[49]. The results on neointimal hyperplasia are still 
a\Vailed although preliminary results from a separate 
Figure 5. Eluting stent consisting of a ~tent sUTTounded by an elastic steeve made of biodegradable polymer loaded with 40% anlilhrombotic 
agent. 
group suggest that a self expanding nilinol stent exerts 
a more favourable effect on vascular remodeling and 
neointimal formation than a balloon expandable tubu-
lar slotted stent [50J. Initial experience in 20 patients 
suggests that a nitinol steD! is safe and effective in the 
treatment of suboptimal results [52J. 
Polymer stellt 
Polymer stenls have several potential advantages. They 
can be loaded with antithrombotic and/or antiproIif-
erative pharmaceutical agents in high concentration 
for sustained local delivery. They lllay have less of 
a mechanical mismatch with the vessel wall than met-
al steuls and may avoid the potential for late stage 
complications. They thus have a synergistic mechani-
cal and local pharmacological therapy providing sus-
tained structural support throughout the healing phase 
to avoid early and late elastic recoil, while local high 
dose drug delivery wiII avoid thrombosis, neointimal 
proliferation and systemic side effects. There is how-
ever only limited strength ifa Jarge% of drug is loaded 
onto the stenl. Initial animal experiments, however, 
have demonstrated a marked inflammatory response 
resulting in substantial luminal encroachment with 
polymer stenls in porcine coronary arteries [53, 54]. 
There is no vascular tissue reaction with HMW PLLA, 
however, and this remains a promising avenue of inves-
tigation. 
Composite (metal augmented) polymer stellts 
Composite polymer stents guarantee a minimal 
mechanical mismatch between the sten! and the vessel 
wall, leaving a delicate metal skeleton after biodegra-
dation. They provides protection of tissues from deep 
slrut laceration and allow large amounts of drug (up 
to 40%) for slow local release without affecting hoop 
strength. Such a composite polymericslent, capable of 
excellent mechanical strength as well high dose local 
drug delivery, has been developed and evaluated in 
porcine coronary arteries. All stenl designs could be 
placed in the selected coronary arteries. Preliminary 
histological analysis showed that neoinlimal hyperpla-
si.a and some degree of inflammatory response was 
present in all groups. Unfortunately implantation of 
bicomponent stents caused a reduction in lumen diam· 
eler for all designs. Further research will be directed 
to the assessment of the relative contribution of slent 
geometry, polymer type and incorporated drug to the 
overall response. 
Radioac/il'c steJlts 
Radiation selectively kills proliferating cells indepen-
dent of any stin1Ulus tor cell growth. As a major com-
ponent of restenosis is neointimal hyperplasia sec-
ondary to vascular smooth muscle cell proliferation 
it seems reasonable to assume that radiation thera-
py may reduce restenosis. Multiple animal studies 
have now confirmed this ability of radiation therapy 
to inhibit neointimal hyperplasia and reduce restenosis 
[55,56]. Radioactive slents have the potential 10 deliv-
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er an appropriate dose of radiotherapy to the area of 
interest thus reducing restenosis, while minimising the 
total dose given to the patient. 
'!\YO methods are currently in use. In the fust 
method conventional Palmaz-Schatz stents were ion 
bombard in a cyclotron to emit low dose beta and gam-
ma radiation from radioisotopes C055, 56, 57, Mn52 
and Fe55 with half lives between 17,5 hours and 2,7 
years [57}. The radiation is predominantly short range 
and homogeneously distributed over the length and cir-
cumference of the stent and being absolutely flxed to 
the metal. Because of this the stents do fiOt require a 
license from the International Atomic Authority. An 
intimal surface dose rate of 4mGray/h results in an 
integral dose of 180mGray after a period of 100 days. 
The low dose radioactive stents were found to 
markedly inhibit neointimal hyperplasia in rabbits, 
Endothelialisation of the radioactive stents was found 
to be delayed with macrophages being located on top of 
the radioactive stent struts until endothelialisation was 
complete. Although the degree of neointimal hyperpla-
sia was reduced it was found, paradoxically, that extra-
cellular matrix production increases after radioactive 
stent implantation [57}. 
The second method is though the use of beta Parti-
cles [58, 59}. Beta particles (free electrons) may rep-
resent the ideal means of local irradiation. P32 is an 
excellent candidate for local delivery as Ihe maximal 
range of beta particles is 3-4mm in tissue. II has a 
desirable half life of 14.3 days and once implanted 
after balloon angiopJasly, there is no detectable radia-
tion by 4 months. P32 or other Beta emitter and also 
be implanted directly onto the sten! wire. 
Such P32 impregnated stents have been now fabri-
cated. In vitro work suggests thatver}' low beta particle 
activity levels inhibit smooth muscle cell growth pref-
erentially within 5-7 mOl of P32 coated stent wires, 
while endothelial cells appear to be much more radio 
resistant. In vivo animal testing in a porcine reslenosis 
model using low dose rate P32 stents have demonstrat-
ed inhibition of neointimal growth [58}. 
A P32 coated stent with doses similar 10 those 
described should be safe in man. Total body dose to the 
patient would be less than 1/1000 that of fluoroscopy 
during angioplasty. Furthermore the radiation would 
be local and would not reach any mediastinal tissues. 
Additionally, the radiation to the interventionalist will 
be much less than fiuoro scalier. 
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Conclusions 
The slen! is the second wind of coronary angioplasty.1t 
is for every physiCian a predictable therapy for bailout, 
improving a suboptimal result and reducing the risk of 
restenosis. As a result of these advantages-over 40% 
of coronary interventional procedures in the current 
year will be by slent implantation. Currently available 
stents, however, have a number of limitations which 
are currently being addressed. Drug eluting stents to 
address the problem of the small vessel and the low 
How situation are on the horizon. Covered stents where 
a membrane acts as an isolating barrier passivating the 
lesion, minimising local thrombus formation anddeIiv-
ering local drug therapy are promising. Radioactive 
stents to inhibit local neointima formation are anoth-
er promising avenue of investigation. Biodegradable 
stents and composite slents are also being actively 
investigated. The future is bright indeed for coronary 
stenling. 
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Chapter 18 
Conclusion 
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Principal findings of the current thesis 
Restenosis after percutaneous coronary revascularisation remains a major problem 
limiting the long term efficacy of these techniques. Accumulated evidence sugge-
sts that intimal thickening secondary to the migration and proliferation of vsmc is 
the main cause. We investigated the problem using a combination of experimental 
and clinical approaches. 
Coronary atherectomy provides a unique opportunity to obtain plaque tissue from 
a wide variety of clinical syndromes. In chapter 2 we used directional coronary 
atherectomy to percutaneously retrieve tissue from patients with clinically and 
angiographically documented coronary artery disease and examined the hypothe-
sis that vsmc cultured from restenotic lesions differ in extracellular matrix synthe-
sis fi'Oln primary atherosclerotic cells. We demonstrated that restenotic cells syn-
thesise significantly more collagen and sulfated aminoglycans than primary cells. 
This would suggest that extracellular matrix synthesis may playa far greater role 
in restenosis than previously thought and may be one potential avenue of treat-
ment. 
Although extracellular matrix production is undoubtedly of importance in defi-
ning the volume of the neointimallesion, the proliferative and migratOlY potential 
of the smooth muscle cell must also playa substantial role. In Chapter 3 we 
investigated the relationship between the clinical and histopathological substrate 
of tissue retrieved during directional coronary atherectomy and the proliferative 
and migratory potential of smooth muscle cells as judged from successful out-
growth during cell culture. We found that although cell outgrowth was not influ-
enced by any of the clinical variables assessed, it was influenced however by the 
presence of organising thrombus in the atherectomy specimen. Thus the presence 
of organising tln'ombus in the retrieved tissue appeared to facilitate smooth muscle 
cell outgrowth suggesting an enhanced proliferative and migratory potential for 
the smooth muscle cell in coronary syndromes where mural tln'ombosis is likely to 
be present. 
One of the limitations of cell culture is that it does not take into account the nor-
mal anatomical relationships of the different cellular components of the vessel 
wall or the cell to cell interactions which may modulate growth. Furthermore cell 
culture from atherectomy specimens has a low yield and it can take a substantial 
amount of tune before adequate numbers of cells can be harvested for further 
investigation. Therefore in chapter 4 an in vitro organ culture of human coronary 
artery subjected to balloon angioplasty was developed. In tlus system intimal 
smooth muscle cell proliferation occurred reproducibly but because of the diffuse 
nature of the disease it was difficult to assess any differential effects balloon an-
gioplasty may have. We were however able to demonstrate quantitatively that bal-
loon angioplasty resultS' in substantial wall damage which recovers after culture. 
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The above in-vitro model relies on the use of serum to maintain tissue viability 
and does not therefore allow us to assess the role that growth factors may play in 
the in-vivo situation. To determine this an in-vivo porcine model of restenosis 
was developed, in which intimal proliferation occurs reproducibly within 4 weeks 
of coronary angioplasty and can be easily quantified (Chapter 5). The integrity of 
the internal elastic lamina appears to be of critical importance in minimising 
neointimal thickening and smooth muscle cell migration and proliferation in tlus 
model. Using this model and a serum fi'ee adaptation of the previously developed 
organ culture technique we were able to show that growth factors may be released 
by the vessel wall, suggesting that growth factor activity by cells intrinsic to the 
angioplasty site may regulate vsmc proliferation in vivo. 
Local dmg delivelY by perfilsion catheters may be a means of delivering high con-
centrations of active drug, such as growth factor antagonists, into the vessel wall. 
Pressure mediated trauma and duration of balloon inflation have, until now, been 
key limitations of these devices. In chapter 6 we investigated a new delivery 
catheter which promises to overcome both these restrictions on normal porcine 
coronary arteries. Inflation duration of up to 60 minutes did not result in any 
signs of ischaemia or haemodynamic compromise. Furthermore intracoronary 
infusion of adenosine with the catheter inflated demonstrated coronary flow velo-
cities similar to controls. Macroscopic examination demonstrated that compounds 
ranging from 0.3-70 kDa could be successfully infused into the coronary wall 
with only localised endothelial damage and an intact internal elastic lamina and 
media. Our data thus suggest that prolonged balloon inflation is feasible with this 
device and that local drug infilsion occurs with minimal trauma to the vessel wall. 
The device may have potential for ameliorating restenosis post coronary interven-
tion. Human studies are currently under way although preliminary data from the 
ITALIC study suggest that local delivery of antisense oligonucleotides, despite 
positive animal results, may not reduce clinical and angiographic restenosis. 
Although experimental models can provide insight into the pathophysiology of 
restenosis they can never however replace the clinical situation. Intracoronary 
ultrasound in13ging allows direct visualisation of the vessel wall in vivo. In the 
second part of tlus thesis we looked at what role this may play in our understan-
ding of the pathophysiological mechanisms involved in the mechanism of acute 
IUlninal gain and subsequent restenosis after coronary intervention. In chapter 8 
we were able to compare the coronary luminal dimensions obtained from intra co-
ronary ultrasound with both geometric and videodensitometric quantitative angio-
graphy (the current gold standard) pre and post intervention. We were able to 
show that intra coronary ultrasound may be better at assessing the complex morp-
hological changes induced by intervention. Chapter 9 summarises our initial cli-
nical experience with a new device combuting intravascular ultrasound imagulg 
with balloon angioplasty thus obviating the need for repeated catheter exchanges 
and allowing on IUle imagulg during the procedure. We were able to show that 
ultra coronary imagulg provides information additional to that provided by contrast 
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angiography in a large proportion of cases and that this information can, on occa-
sion, influence clinical management. In chapter lOwe used intracoronary ultra-
sound to assess the influence of the underlying de-novo vessel remodeling mode 
on the mechanism of acute luminal gain and long term restenosis following coro-
nary balloon angioplasty and directional coronary atherectomy. We were able to 
show that the mode of vessel remodelling may contribute to the efficacy of the 
interventional device (vessel stretch or debulking) and may playa role of the 
mechanism of restenosis. Tltis would be important in the optimal use of new 
devices. For example our study suggests that, in a vessel with paradoxical shrink-
age, stent implantation, to act as a scaffold for the vessel wall and prevent late 
vessel recoil, may be the optimal device to prevent restenosis whereas in a vessel 
with compensatory enlargement, plaque reduction (debulking), during the initial 
interventional procedure and concomitant medical treatment to prevent the growth 
of intimal hyperplasia using local drug delivery or endovascular radiation may be 
the most useful way of reducing restenosis. 
The clinical literature on restenosis is confusing and conflicting because of the 
lack of a readily accepted definition of restenosis and widespread differences in 
the methodology used in different trials. Based on the pioneering work of Serruys 
and Nobuyoslti however it is likely that restenosis is one end of a continuous spec-
tnull and that all lesions deteriorate over time, with around 30% deteriorating to 
such an extent by six months that they are said to have restenosed. A number of 
studies have attempted to define th~.role that patient, lesion and procedural related 
characteristics may play in predisposing to restenosis. These studies are, however, 
flawed by inconsistencies in the definition of restenosis, the angiographic follow 
up rate and the method of angiographic assessment used. For any study to accura-
tely reflect the incidence of restenosis it should involve angiographic follow up of 
all patients, at a predetermined interval, and a well validated system of analysis 
with known accuracy and variability. The logistics, amount of work and expense 
involved however in organising a major restenosis trial are such that no single 
investigator or group of investigators can possibly mount such a study. In the 
third part of the thesis we used data pooled from 4 major restenosis trial with a 
ltigh angiographic follow up rate and where the angiograpltic criteria were stan-
dardised with one central angiographic core lab performing the quantitative angio-
grapltic analysis in all studies to assess what clinical procedural and angiograpltic 
variables may influence restenosis. 
The objective of our study in Chapter II was to examine the relationship between 
senUll cholesterol, a known risk factor for atherosclerosis, and long term resteno-
sis. We found the restenosis rate to be similar in patients with and without hyper-
cholesterolaentia. Additionally there was no difference in either the absolute or 
relative loss, between patients with, and without, hypercholesterolaemia. 
Conversely the total serum cholesterol in patients with restenosis (using the cate-
gorical definition) was similar to those without restenosis. Dividing the popula-
tion into deciles according to total cholesterol and examining the categorical reste-
242 
nosis rate, as well as the absolute and relative loss, again revealed no significant 
differences between deciles. There was also no differences in the categorical res-
tenosis rate, or the absolute or relative loss between deciles according to LDL, 
HDL, or LDL:HDL ratio suggesting no influence by these cholesterol subfractions 
on restenosis. Our results thus indicate that there is no association between cho-
lesterol and restenosis, suggesting that measures aimed at reducing total choleste-
rol, although highly desirable in this high risk group, are unlikely by themselves, 
to significantly influence post angioplasty restenosis. This has been subsequently 
borne out by a number of studies looking at cholesterol lowering therapy post 
angioplasty, including the Flare study, all of which have been negative. 
Another major risk factor for atherosclerosis is smoking. The influence of smo-
king on post angioplasty restenosis, however is unclear. In our study population 
we found substantial differences in the underlying demographic characteristics 
between smokers and non-smokers (Chapter 12). Smokers were less likely to be 
diabetic or hypertensive but were younger, more likely to be male, to have perip-
heral vascular disease, have sustained a previous myocardial infarction and be in a 
worse anginal class. Their lesions were more likely to be located in the right coro-
nary artery and to require a longer duration of inflation at higher pressures. There 
was, however, no significant difference in either categorical or continuous meas-
ures of restenosis at 6 months. Thus smokers require coronary intervention earlier 
than non smokers but their short term, six month outcome is similar to non smo-
kers. 
Our experimental work in Chapter 3 suggested that he presence of organising 
thrombus in retrieved atherectomy tissue facilitates smooth muscle cell outgrowth 
suggesting an enhanced proliferative and migratory potential potential in these 
lesions. Therefore in Chapter 13 we examined whether the presence and subse~' ' 
quent organisation of local thrombus may influence post angioplasty restenosis. 
We found the categorical restenosis rate and both the absolute and relative loss to 
be significantly higher in lesions containing thrombus. The higher restenosis in 
lesions containing thrombus was primarily due to an increased incidence of occlu-
sions at follow up angiography in this group. When these were excluded from the 
analysis the categorical restenosis rate and the absolute and relative loss were 
similar in the two groups. Our results thus indicate that thrombus is associated 
with higher restenosis but that tllis reflects an increased risk of occlusion rather 
than long term luminal renarrowing, suggesting that although thrombus may be of 
importance in this, it is unlikely to play an important role in long term intimal 
hyperplasia after PTCA. 
Total occlusions are an interesting subgroup of the angioplasty population. 
Although a number of factors are known to influence the acute success rate relati-
vely little accurate information is available regarding long term restenosis. In 
chapter 14 we evaluated restenosis in total occlusions and compared this with the 
control population of stenoses. We found restenosis to be significantly higher in 
occlusions using both the categorical and continuous approach. The higher reste-
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nosis in these lesions was again predominantly due to an increased number of 
occlusions at follow up angiography in this group. There were no significant dif-
ferences within the occlusions group between total and functional occlusions, in 
either long tenn restenosis or re-occlusion. These results thus indicate that suc-
cessfully dilated coronary occlusions have a higher rate of angiographic restenosis 
at 6 months, chiefly due to a higher rate of re-occlusion at follow up angiography. 
Measures aimed at reducing restenosis following successful dilatation of coronary 
occlusion should therefore be focused in this direction. 
Experimental and human intravascular ultrasound studies suggest that unfavoura-
ble vascular remodelling may be important in restenosis after coronary angiopla-
sty. In chapter 16 we evaluated whether favourable vascular remodelling, ie lumi-
nal enlargement, may also occur following successful balloon angioplasty and 
which factors may influence this. Within our study population 27.3% of lesions 
underwent luminal enlargement in the angiographic follow up period. 
Multivariate analysis suggested that diuretic therapy, MLD and diameter stenosis 
pre PTCA were positively related whilst age, heparin therapy, number of vessels 
diseased, lesion length, Lad location, total inflation time and relative gain were 
negatively related to luminal enlargement at follow up angiography. Thus luminal 
enlargement may occur after successful coronary angioplasty and can be substan-
tially influenced by clinical, angiographic and procedural variables. 
Future interventional perspectives for these findings 
Restenosis remains a major limitation of percutaneous coronary revascularisation 
detracting from both the clinical and economic advantages of the techniques. In 
this thesis both in-vivo and in-vitro models of intimal hyperplasia after balloon 
angioplasty were developed and the pathophysiological mechanisms involved stu-
died. In addition the epidemiology of restenosis was investigated and lesions with 
a higher rate of angiographic restenosis identified. 
In many ways however the current thesis marks the end of one era and the begin-
ning of another. With the landmark publication of the Benestent/Stress studies 
and subsequent refining of the stents themselves as well as the deployment teclmi-
que, coronary stenting has finally overcome some of the major limitations of coro-
nary angioplasty in terms of both acute occlusion and long term restenosis. 
Coronary stenting has in many ways moved the goal posts further back allowing 
us to dilate lesions previously thought difficult or inlpossible, with relative impu-
nity. Although coron31Y stenting has overcome some of the mechanisms involved 
in restenosis, such as acute/chronic recoil and remodeling, in-stent restenosis still 
occurs and in fact, if we look at absolute loss as a biological marker of intimal 
hyperplasia, is probably greater after stent implantation than it is after balloon 
angioplasty. The basic science factors discussed in the first part of this thesis now 
become even more relevant, as in-stent l'estenosis is predominantly neointimal 
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hyperplasia. Furthermore coronary stenling by encasing the vessel in a metallic 
constraint, may prevent favourable arterial remodeling and hence any long term 
luminal enlargement which, as discussed in Chapter 15, may occur in up to 27% 
of lesions. Thus the interventional cardiologist has finally created the disease he 
initially thought was responsible for a large percentage of restenosis after angio-
plasty and may have inadvertently also minimised any possibility of favourable 
vessel remodeling. 
Balloon angioplasty 
Balloon angioplasty has been left in the doldrums since the widespread uptake of 
coronary stenting. Nonetheless a substantial number of coronary interventions are 
currently being performed with stand alone balloon angioplasty and potentially, by 
using ultrasound guidance for lesion characterisation and selection with subse-
quent optimal balloon sizing excellent long term results can be obtained using 
standalone angioplasty. Another potential avenue for optimising balloon angiopla-
sty is through Doppler flow guidance to achieve a haemodynamically excellent 
acute result. Two further avenues of potential expansion of balloon angioplasty 
are brachytherapy and local drug/therapeutic agent delivery. Ionizing radiation is 
known to have an inhibitory effect on cellular proliferation and is widely used in 
the treatment of both neoplastic and non neoplastic conditions. In addition bra-
chytherapy has also been demonstrated to reduce restenosis in peripheral and 
coronary arteries in animal models and restenosis after stent implantation in 
femoral-popliteal arteries in man. More recently a number of groups have been 
able to demonstrate that coronalY brachytherapy is both feasible and safe in man 
and preliminary analysis suggests a reduction in late loss. The efficacy and safety 
of the different sources and procedures however have still not been well establish-
ed and neither has their long term safety. As more data becomes available, if the 
efficacy and safety of brachytherapy is confirmed it is likely to lead to increasing 
endovascular revascularisation and a resurgence of balloon angioplasty. Brachy 
therapy and, as discussed below, the local delivery of therapeutic agents may thus 
be the second wind of coronary angioplasty. 
Stent implantation 
It is also feasible that coronary stenting which reduces recoil and vascular remo-
deling may also be married to radiotherapy in the form of radioactive stents to 
reduce neointimal proliferation. These would provide endovascular scaffolding to 
the vessel but also deliver velY low dose ionising radiation (up to 10,000 times 
lower than activity levels of sources used for catheter-based vascular brachythera-
py) whilst at the same time allowing uniform dose distribution and precise dosi 
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metry. Initial animal work is encouraging demonstrating potent inhibition of 
neointimal hyperplasia. One caveat however is that stent endothelialisation appe-
ars to be delayed; this may have important clinical implications with regard to 
stent occlusion. 
Intravascular imaging 
Intracoronary ultrasound imaging has seen a major advance in our understanding 
of the mechanisms involved in the acute results of percutaneous revascularisation 
and the long term restenosis. As imaging transducers become smaller, and are 
married with balloonistentiatherectomy devices they are likely to become an 
integral part of the armamentarium of the interventional cardiologist. As well as 
providing tomographic imaging of the vessel wall intravascular ultrasound has 
also been used recently for assessing flow. Using analysis of the intravascular 
radiofrequency echo signals and a decorrelation based method, extraction of cross 
sectional velocity profiles and quantification of volume blood flow is performed 
which allows a unique opportunity to simultaneously assess physiologic and ana-
tomic parameters. What impact this may have on clinical decision making still 
has to be demonstrated. 
Local drug delivery 
Locally deliveredGene therapy is emerging as a potential strategy for the treat-
ment of restenosis after angioplasty. Experimental studies have already demon-
strated that vascular smooth muscle proliferation and lesion formation can be pre-
vented by the blockade of genes regulating cell cycle progression and that thera-
peutic effects can also be achieved by the in vivo transfer of gene(s) whose pro-
duct( s) (eg nitric oxide) exert a paracrine effect on the vessel wall. Adenoviral 
vectors have been recently used to demonstrate that therapeutic genes encoding 
both cytotoxic and cytostatic products successfully inhibit smooth muscle cell pro-
liferation and related intimal hyperplasia. Major teclmical issues however include 
the toxicity of first generation adenoviral vectors, inefficient transduction of athe-
rosclerotic arteries, and the risk of extra-arterial transfection. These issues remain 
to be addressed before gene therapy can be applied to clinical restenosis. 
Therapeutic angiogenesis 
Diffuse coronary disease remains a problem for both the interventional cardiolo-
gist and the cardiac surgeon. A promising approach to the treatment of such 
patients is therapeutic angiogenesis, the induction of new capillaries and other 
blood vessels thereby by-passing the epicardial vessels. The first clinical study on 
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angiogenic therapy for ischaemic tissue was the administration of vascular endot-
helial growth factor to patients with severe peripheral vascular disease demonstra-
ting improved collateral blood flow with a corresponding increase in both resting 
and maximal blood flow in the treated extremity. More recently the first angioge-
nic therapy of human coronary artery disease has been demonstrated. Shumacher 
and colleagues were able to show that neovascularisation occurs, extending out 
from the relevant area, 12 weeks after injection offibroblast growth factor- I 
directly into the myocardium, at the time of coronary artelY bypass grafting. A 
number of issues remain to be clarified however. These include defining what is 
the optimal agent and the optimal route, what is the optimal dosing regimen, what 
is the duration of therapy or action, and whether therapy can be targeted towards 
ischaemic tissues, thus minimising the potential for undesired angiogenesis. 
Transmyocardial revascularisation 
Transmyocardial revascularisation is based on the premise underlying the original 
Vineberg procedure, first proposed more than 40 years ago, that ischaemic myo-
cardium may be directly supplied with oxygenated blood. In the case ofTMR tillS 
is directly from the left ventricle, via the creation of a series of small transmyocar-
dial channels. Although the mechanism of benefit by TMR remains unclear preli-
minary clinical studies have demonstrated clear improvement in anginal sympto-
matology; this however has come at the cost of substantial perioperative mortali-
ty. Wllether the less invasive, percutaneous, methods ofTMR currently under-
going clinical trials will result in equivalent benefit at substantially lower mortali-
ty remains to be answered. 
Final thoughts 
Percutaneous revascularisation has finally come of age, 2 I years after Andreas 
Gruentzig's seminal procedure. We can now tackle almost any lesion in the coro-
nary tree with relative impunity, and even small centres, with a limited selection 
of balloons and stents can offer their patients percutaneous revascularisation with 
little risk and a high chance of long term success. We are finally entering an era 
in which percutaneous revascularisation can replace open heart surgery for the 
majority of patients and lesions. The only cloud on the horizon, is in-stent reste-
nosis. If this can be eliminated by stent coating, local dl1lg therapy, or brachythe-
rapy the fuhll'e will be bright indeed for coronaty revascularisation. 
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Chapter 19 
Samenvatting 
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PTCA is een techniek die wijd verbreid is voor de behandeling van vernauwingen 
in de kransslagaders. Een beperking is echter, dat in 25 tot 30% van de gevallen 
restenose optreedt. Pathologisch-anatoll1isch onderzoek suggereert dat de belang-
rijkste oorzaak van restenose hyperplasie van de intima tengevolge van proliferatie 
van gladde spiercellen in de vaatwand is. Ons inzicht in het probleem wordt 
momenteel beperkt door een gebrek aan adequate laboratioriummodellen waarin 
het proces verder onderzocht kan worden en door een gebrek aan klinische en epi-
demiologische gegevens van goede kwaliteit. Wij onderzochten het restenosepro-
bleem, gebruikll1akend van elkaar aanvullende experimentele en klinische benade-
ringen. 
In het eerste deel (hoofdshlk 2 tim 6) van dit proefschrift worden laboratioriull1-
modellen en -technieken geevalueerd die inzicht kUllllen verschaffen in de onder-
liggende pathologische processen. Bijvoorbeeld synthese van extracellulaire 
matrix door gladde spiercellen (gsc) in de vaatwand kan een belangrijk ll1echanis-
me zijn voor restenose. 
In hoofdshlk 2 onderzochten we het vennogen van gsc om extracellulaire matrix 
te produceren in vitro, waarbij we gsc gebruikten die gekweekt waren uit primaire 
vernauwingen en uit restenose weefsel, dat in vivo verkregen was door middel van 
directional coronary atherectomy (DCA). We toonden aan dat cellen uit resteno-
se-weefsel significant meer collageen en gesulfateerde aminoglycanen syntheti-
seerden dan cellen uit primaire vernauwingen. Dit suggereert dat synthese van 
extracellulaire matrix een veel grotere rol kan spelen bij restenose dan in het ver-
leden werd gedacht. 
In hoofdshlk 3 onderzochten we de relatie hlssen klinische factoren en het histo-
pathologische substraat van via DCA verkregen weefsel aan de ene kant, en het 
proliferatief enmigratorisch verll10gen van gladde spiercellen, zoals bepaald op 
basis van succesvolle groei bij celkweek aan de andere kant. We vonden dat de 
aanwezigheid van een zich organiserende trombus in het verkregen weefsel de 
groei van gladde spiercellen faciIiteert, hetgeen een toegenomen proliferatief en 
migratorisch potentieel suggereert van de gsc in deze lesies. 
Celkweek houdt echter geen rekening met de normale anatomische verbanden van 
de verschillende cellulaire componenten van de vaatwand of de cel-cel interacties 
die de groei kUllllen 1l10duleren. Daarom ontwikkelden we in hoofdstuk 4 een 
orgaankweek van menselijke coronair-arterie die ballon angioplastiek had onder-
gaan teneinde de cellulaire enmoleculaire basis van intima-proliferatie te onder-
zoeken in een opzet die de anatomische verbanden van de vaatwand intact liet. 
We vonden dat intima-proliferatie optrad in orgaanculhmr van menselijke coronair 
arterie die ballon-angioplastiek ondergaan had, en dat de gladde spiercellen in de 
neointimale laag het resultaat zijn van zowel migratie als proliferatie. 
In hoofdstuk 5 gebmikten we een serumvrije aanpassing van de orgaancultuur 
techniek in combinatie met een in vivo varken model van restenose om te bepalen 
of het vrijkomen van groeifactoren van cellen inh'insiek aan de vaatwand een 1'01 
speelt bij de ontwikkeling van restenose. We vonden dat de lamina elastica inter-
na een sleuteh'ol speelt bij het minimaliseren vanneointimale verdikking en smc 
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proliferatie in dit model en vonden direct bewijs voor groeifactor activiteit van 
cellen intrinsiek aan de plaats van angioplastiek, die smc proliferatie kunnen regu-
leren. Karakterisering van deze factoren kan ons helpen de mechanismen te 
begrijpen die een rol spelen bij restenose en richting geven aan de ontwikkeling 
van nieuwe therapieen die tot doel hebben de incidentie ervan te verlagen. 
Een van de manieren waarop men hoopt restenose te kunnen reduceren is lokale 
toediening van geneesmiddelen via perfusie catheters. Trauma door de druk ver-
oorzaakt en duur van de ballon inflatie zijn echter belangrijke beperkingen van 
deze techniek. In hoofdstuk 6 evalueerden we een nieuwe lokale afgifte catheter, 
de Dispatch, die ontworpen is om beide beperkingen te boven te komen. We von-
den dat langdurige ballon-inflatie haalbaar is met dit instrument, en dat lokale 
drug-infusie optreedt met minimale beschadiging van de vaatwand. Het instl1l-
ment biedt dus grote mogelijkheden voor het lokaal toedienen van geneesll1idde-
len die acute occlusie en restenose na corona ire interventie kunnen verll1inderen. 
Hoewel experill1entele 1l10dellen inzicht klllmen verschaffen in de pathofysiologie 
van restenose, kunnen ze nooit de klinische sihmtie vervangen. In het tweede deel 
van dit proefschrift (hoofdstuk 7 tim 10) onderzochten we eennieuwe techniek, 
intravasculair ultrageluid (IVUS), die van revolutionair belang kan zijn voor ons 
begrip van de mechanismen die een rol spelen bij de gebeurtenissen tijdens coro-
nair angioplastiek en de daarop volgende restenose in de klinische sihlatie. 
Hoofdshlk 7 geeft een beknopt overzicht van het onderwerp terwijl hoofdstuk 8 de 
met lVUS aan het vaatlumen verrichte metingen vergeJijkt met de gouden stan-
daard tot nu toe, kwantitatieve coronair angiografie. 
Hoofdshlk 9 geeft een samenvatting van onze eerste klinische ervaringen met een 
nieuw instrument, waarbij beeldvorming door intravasculair ultrageluid gecombi-
neerd wordt met ballon angioplastiek, waardoor on-line beeldvorll1ing gedurende 
de procedure mogelijk wordt en de behoefte aan herhaald verwisselen van cathe-
ters vervalt. We vonden dat intravasculare beeldvorming in meer dan 50% van de 
gevallen extra infofmatie opleverde bovenop de infonnatie die verkregen werd 
door contrast angiografie. Deze informatie speelde in ruill1 10% van de gevallen 
een doorslaggevende rol bij het bepalen van de behandeling van de patient. 
In hoofdstuk 10 gebruikten we intracoronair ultrageluid om te zien wat de rol is 
van het zich aktief oll1vonnen van de vaatwand (vascular remodelling) bij de 
mechanismen van vergroting van het vaatlumen tijdens PTCA en DCA, en bij de 
lange tennijn restenose ema. 
In het laatste deel van dit proefschrift (hoofdshlk II tim 17) werden gegevens van 
vier grote Europese en Amerikaanse trials gebruikt om de invloed van klinische, 
angiografische en procedure-gerelateerde factoren op restenose te onderzoeken. 
Hoofdstuk II onderzoekt de rol van cholesterol en cholesterol subfracties op res-
tenose, terwijl hoofdshlk 12 de invloed van het roker ofex-roker zijn op restenose 
na angioplastiek nagaat. We vonden geen verband tussen cholesterol (inclusief 
subfracties) en restenose bij een categoriale noch bij een continue benadering. Dus 
maatregelen die uitsluitend gericht zijn op het verlagen van het totale cholesterol 
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zullen waarschijnlijk geen significante invloed hebben op het optreden van reste-
nose na PTCA. We vonden geen verband tussen rookgewoonten en restenose, met 
een categoriale noch met een continue benadering, hetgeen suggereert dat maatre-
gelen gericht op het terugdringen van roken waarschijnlijk geen significante 
invloed zullen hebben op restenose na PTCA. 
Hoofdstuk 13 gaat verder in op een aantal van onze bevindingen en bepaalt de rol 
van lokale trombus vonning ell-incorporatie op restenose. We vonden dat trom-
bus geassocieerd is met meer restenose. Het mechallisme hiervoor staat in verband 
met occ1usie tijdens follow-up angiografie, hetgeen suggereert dat maatregelen die 
gericht zijn op het verbeteren van het resultaat bij deze patienten toegespitst moe-
ten worden in deze richting. 
Hoofdstuk 14 gaat in op totale occ1usies en de kans dat bij deze lesies restenose 
optreedt, terwijl hoofdstuk 15 de rol onderzoekt van gunstige vaatwand-omvor-
ming (gedefinieerd als negatiefverlies van lumen) na PTCA. 
Hoofdstuk 16 geeft een kritisch overzicht van de grote multi-centre onderzoeken 
waarop de vorige onderzoeken gebaseerd waren en bespreekt manieren waarop 
sonunige van de beperkingen ervan gereduceerd zouden kunnen worden in toe-
komstige onderzoeken. 
Tenslotte vatten we in hoofdstuk 17 het huidige spectrum van teclmologieen 
samen, dat de interventionele cardioloog ter beschikking staat bij zijn strijd tegen 
restenose. 
Restenose blijft een belangrijke beperking van angioplastiek van de kransvaten, 
die afbreuk doet aan zowel de klinische als economische voordelen van de tech-
niek. In dit proefschrift werden zowel in vivo als in vitro modellen van intima Ie 
hyperplasie na ballon angioplastiek ontwikkeld en de pathofysiologische mecha-
nismen die een rol spelen bestudeerd. Daal'llaast werd de epidemiologie van reste-
nose onderzocht en werden lesies waarbij restenosen vaker optreedt gejdentifi-
ceerd. 
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